{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "d708a6c5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ok\n"
     ]
    }
   ],
   "source": [
    "print(\"ok\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "ee5d7997",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain import PromptTemplate\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain.vectorstores import Pinecone\n",
    "from langchain.document_loaders import PyMuPDFLoader,DirectoryLoader\n",
    "from langchain.document_loaders import DirectoryLoader, PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.llms import CTransformers\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "599eafab",
   "metadata": {},
   "outputs": [],
   "source": [
    "PINECONE_API_KEY = \"pcsk_4BRfYd_Ncdg2tRXmJffVSzo1qLodYV6gvxzcdnr5ZraGeJUAM9xEjjYkRo8Ammwh7gpsHX\"\n",
    "PINECONE_API_ENV = \"us-east-1\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "a4081468",
   "metadata": {},
   "outputs": [],
   "source": [
    "## extract data from pdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "cfa761b4",
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_pdf(data):\n",
    "    loader = DirectoryLoader(data,glob='*.pdf',loader_cls=PyPDFLoader)\n",
    "    documents = loader.load()\n",
    "    return documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "4584e64f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded 356 documents\n",
      "A Treatment \n",
      "Improvement \n",
      "Protocol\n",
      "Medication-Assisted Treatment\n",
      "For Opioid Addiction in \n",
      "Opioid Treatment Programs\n",
      "TIP\n",
      "43\n",
      "U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES\n",
      "Substance Abuse and Mental Health Services Administration\n",
      "Center for Substance Abuse Treatment\n",
      "www.samhsa.gov\n",
      "MEDICATION-\n",
      "ASSISTED\n",
      "TREATMENT\n"
     ]
    }
   ],
   "source": [
    "extracted_data = load_pdf(\"data/\")\n",
    "print(f\"Loaded {len(extracted_data)} documents\")\n",
    "print(extracted_data[0].page_content[:500])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "1ed5abb1",
   "metadata": {},
   "outputs": [],
   "source": [
    "## split create text chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "c782b608",
   "metadata": {},
   "outputs": [],
   "source": [
    "def text_split(extracted_data):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=500,chunk_overlap=20)\n",
    "    text_chunks = text_splitter.split_documents(extracted_data)\n",
    "    return text_chunks\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "7b8d291c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "length of the text chunks: 2358\n"
     ]
    }
   ],
   "source": [
    "text_chunks = text_split(extracted_data)\n",
    "print(\"length of the text chunks:\",len(text_chunks))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "54107a89",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='A Treatment \\nImprovement \\nProtocol\\nMedication-Assisted Treatment\\nFor Opioid Addiction in \\nOpioid Treatment Programs\\nTIP\\n43\\nU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES\\nSubstance Abuse and Mental Health Services Administration\\nCenter for Substance Abuse Treatment\\nwww.samhsa.gov\\nMEDICATION-\\nASSISTED\\nTREATMENT', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 0}),\n",
       " Document(page_content='U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES\\nSubstance Abuse and Mental Health Services Administration\\nCenter for Substance Abuse Treatment\\n1 Choke Cherry Road\\nRockville, MD 20857\\nSteven L. Batki, M.D.\\nConsensus Panel Chair\\nJanice F. Kauffman, R.N., M.P.H., LADC, CAS\\nConsensus Panel Co-Chair\\nIra Marion, M.A.\\nConsensus Panel Co-Chair\\nMark W. Parrino, M.P.A. \\nConsensus Panel Co-Chair\\nGeorge E. Woody, M.D.\\nConsensus Panel Co-Chair\\nA Treatment \\nImprovement \\nProtocol\\nTIP\\n43', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 1}),\n",
       " Document(page_content='Protocol\\nTIP\\n43\\nMedication-Assisted Treatment\\nFor Opioid Addiction in \\nOpioid Treatment Programs', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 1}),\n",
       " Document(page_content='Acknowledgments\\nNumerous people contributed to the \\ndevelopment of this Treatment Improvement\\nProtocol (see pp. xi and xiii as well as\\nAppendixes E and F). This publication was\\nproduced by Johnson, Bassin & Shaw, Inc.\\n(JBS), under the Knowledge Application\\nProgram (KAP) contract numbers 270-99-\\n7072 and 270-04-7049 with the Substance\\nAbuse and Mental Health Services\\nAdministration (SAMHSA), U.S. Department\\nof Health and Human Services (DHHS).\\nChristina Currier served as the Center for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='Substance Abuse Treatment (CSAT)\\nGovernment Project Officer, and Andrea\\nKopstein, Ph.D., M.P .H., served as Deputy\\nGovernment Project Officer. Robert Lubran,\\nM.S., M.P .A., and Alan Trachtenberg, M.D.,\\nserved as CSAT technical experts. Lynne\\nMcArthur, M.A., A.M.L.S., served as \\nthe JBS KAP Executive Project Co-Director.\\nBarbara Fink, R.N., M.P .H., served as \\nthe JBS KAP Managing Project Co-Director.\\nOther JBS KAP personnel included Dennis\\nBurke, M.S., M.A., Deputy Director for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='Product Development; Wendy Caron,\\nEditorial Quality Assurance Manager;\\nFrances Nebesky, M.A., Quality Assurance\\nEditor; Leah Bogdan, Junior Editor; Emily\\nTinkler, Junior Writer; and Pamela Frazier,\\nDocument Production Specialist. Catalina\\nVallejos Bartlett, M.A., Margaret Brooks,\\nJ.D., Jonathan Max Gilbert, M.A., Randi\\nHenderson, and Deborah J. Shuman \\nwere writers. \\nDisclaimer\\nThe opinions expressed herein are the views \\nof the consensus panel members and do not', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='necessarily reflect the official position of CSAT,\\nSAMHSA, or DHHS. No official support of or\\nendorsement by CSAT, SAMHSA, or DHHS\\nfor these opinions or for particular instruments,\\nsoftware, or resources described in this \\ndocument is intended or should be inferred.\\nThe guidelines in this document should not be\\nconsidered substitutes for individualized client\\ncare and treatment decisions.\\nPublic Domain Notice\\nAll materials appearing in this volume except', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='those taken directly from copyrighted sources\\nare in the public domain and may be reproduced\\nor copied without permission from SAMHSA/ \\nCSAT or the authors. Do not reproduce or \\ndistribute this publication for a fee without \\nspecific, written authorization from SAMHSAís\\nOffice of Communications.\\nElectronic Access and Copies\\nof Publication\\nCopies may be obtained free of charge from\\nSAMHSAís National Clearinghouse for Alcohol\\nand Drug Information (NCADI), (800) 729-6686', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='or (301) 468-2600; TDD (for hearing impaired),\\n(800) 487-4889; or electronically through the\\nfollowing Internet World Wide Web site:\\nwww.ncadi.samhsa.gov.\\nRecommended Citation\\nCenter for Substance Abuse Treatment.\\nMedication-Assisted Treatment for Opioid\\nAddiction in Opioid Treatment Programs.\\nTreatment Improvement Protocol (TIP) Series\\n43. DHHS Publication No. (SMA) 05-4048.\\nRockville, MD: Substance Abuse and Mental\\nHealth Services Administration, 2005.\\nOriginating Office', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='Originating Office\\nPractice Improvement Branch, Division of\\nServices Improvement, Center for Substance\\nAbuse Treatment, Substance Abuse and Mental\\nHealth Services Administration, 1 Choke\\nCherry Road, Rockville, MD 20857.\\nDHHS Publication No. (SMA) 05-4048\\nPrinted 2005', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 2}),\n",
       " Document(page_content='Contents\\nWhat Is a TIP? ............................................................................................................ix\\nConsensus Panel ..........................................................................................................xi\\nKAP Expert Panel and Federal Government Participants ..................................................xiii\\nForeword ...................................................................................................................xv', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Executive Summary ...................................................................................................xvii\\nChapter 1óIntroduction ...............................................................................................1\\nPurpose of This TIP .......................................................................................................1\\nKey Definitions..............................................................................................................2', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Audience for This TIP.....................................................................................................2\\nA Decade of Change ........................................................................................................2\\nRemaining Challenges......................................................................................................6\\nThe Future of MAT .......................................................................................................10', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Chapter 2óHistory of Medication-Assisted T reatment for Opioid Addiction...........................11\\nEmergence of Opioid Addiction as a Significant Problem and the Roots of Controversy .................11\\nOrigins of Opioid Maintenance Therapy .............................................................................17\\nRegulatory History........................................................................................................21', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Chapter 3óPharmacology of Medications Used To T reat Opioid Addiction ...........................25\\nPharmacology and Pharmacotherapy ................................................................................28\\nDosage Forms ..............................................................................................................31\\nEfficacy......................................................................................................................32', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Side Effects .................................................................................................................33\\nInteractions With Other Therapeutic Medications.................................................................36\\nSafety ........................................................................................................................42\\nChapter 4óInitial Screening, Admission Procedures, and Assessment Techniques ..................43', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Initial Screening ...........................................................................................................43\\nAdmission Procedures and Initial Evaluation ......................................................................46\\nMedical Assessment .......................................................................................................49\\nInduction Assessment ....................................................................................................53', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='Comprehensive Assessment .............................................................................................53\\nAppendix 4-A. Example of Standard Consent to Opioid Maintenance Treatment ..........................61\\niii', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 3}),\n",
       " Document(page_content='iv\\nChapter 5óClinical Pharmacotherapy ............................................................................63\\nContraindications to Opioid Pharmacotherapy ....................................................................64\\nStages of Pharmacotherapy.............................................................................................65\\nMedically Supervised Withdrawal ....................................................................................78', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Take-Home Medications ................................................................................................81\\nOffice-Based Opioid Therapy...........................................................................................85\\nChapter 6óPatientñT reatment Matching:\\nTypes of Services and Levels of Care ..........................................................................87', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Steps in PatientñTreatment Matching ................................................................................88\\nPatients With Special Needs ............................................................................................91\\nTreatment Planning.......................................................................................................95\\nChapter 7óPhases of T reatment..................................................................................101', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Rationale for a Phased-Treatment Approach and Duration ...................................................101\\nPhases of MAT ...........................................................................................................102\\nTransition Between Treatment Phases in MAT....................................................................119\\nReadmission to the OTP ...............................................................................................120', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Chapter 8óApproaches to Providing Comprehensive Care and \\nMaximizing Patient Retention .................................................................................121\\nCore Services .............................................................................................................121\\nRetaining Patients in MAT.............................................................................................122', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Counseling and Case Management, Behavioral Treatments, and Psychotherapy .........................124\\nBenefits of Family Involvement.......................................................................................133\\nIntegrative Approaches.................................................................................................135\\nRelapse Prevention......................................................................................................136', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Referral to Social Services.............................................................................................138\\nInvoluntary Discharge From MAT...................................................................................138\\nPatient Advocacy ........................................................................................................142\\nChapter 9óDrug T esting as a Tool...............................................................................143', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Purposes of Drug Testing in OTPs...................................................................................143\\nBenefits and Limitations of Drug Tests .............................................................................144\\nDrug-Testing Components and Methods ............................................................................148\\nDevelopment of Written Procedures.................................................................................151', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='Other Considerations in Drug-Testing Procedures ...............................................................154\\nInterpreting and Using Drug Test Results..........................................................................155\\nReliability, Validity, and Accuracy of Drug Test Results........................................................158\\nContents', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 4}),\n",
       " Document(page_content='v\\nChapter 10óAssociated Medical Problems in Patients Who Are Opioid Addicted .................161\\nIntegrated Versus Referral Services .................................................................................162\\nRoutine Testing and Followup for Medical Problems............................................................163\\nAcute, Life-Threatening Infections ..................................................................................163', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Infectious Diseases.......................................................................................................164\\nPatients With Disabilities ..............................................................................................173\\nPain Management........................................................................................................174\\nHospitalization of Patients in MAT ..................................................................................178', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='General Medical Conditions and MAT ..............................................................................178\\nChapter 11óT reatment of Multiple Substance Use..........................................................179\\nPrevalence of Multiple Substance Use in MAT....................................................................180\\nCommon Drug Combinations Used by Patients in MAT ........................................................181', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Effects of Other Substance Use.......................................................................................182\\nManagement of Multiple Substance Use in MAT..................................................................186\\nInpatient Detoxification and Short-Term Stabilization..........................................................188\\nChapter 12óT reatment of Co-Occurring Disorders ........................................................189', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Prevalence of Co-Occurring Disorders..............................................................................190\\nMotivation for Treatment and Co-Occurring Disorders.........................................................191\\nEtiology of Co-Occurring Disorders .................................................................................191\\nScreening for Co-Occurring Disorders..............................................................................192', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Making and Confirming a Psychiatric Diagnosis .................................................................194\\nPrognosis for Patients With Co-Occurring Disorders ...........................................................197\\nTreatment Issues .........................................................................................................199\\nAppendix 12-A. Internet Resources for Accessing Psychiatric Instruments ................................209', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Chapter 13óMedication-Assisted T reatment for Opioid Addiction During Pregnancy............211\\nAcceptance of Methadone Maintenance as the Standard of Care .............................................211\\nDiagnosing Opioid Addiction in Pregnant Patients ..............................................................212\\nMedical and Obstetrical Concerns and Complications ..........................................................212', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Methadone Dosage and Management ................................................................................215\\nPostpartum Treatment of Mothers in MAT ........................................................................218\\nBreast-Feeding ...........................................................................................................218\\nEffects on Neonatal Outcome .........................................................................................218', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='Use of Buprenorphine During Pregnancy..........................................................................220\\nImportance of Integrated, Comprehensive Services .............................................................222\\nNutrition Assessment, Counseling, and Assistance ...............................................................223\\nContents', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 5}),\n",
       " Document(page_content='vi\\nChapter 14óAdministrative Considerations ...................................................................225\\nStaffing.....................................................................................................................225\\nMedication Diversion Control Plans.................................................................................230\\nThe Community Effort .................................................................................................231', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 6}),\n",
       " Document(page_content='OTPs and National Community Education Initiatives ..........................................................236\\nEvaluating Program and Staff Performance.......................................................................238\\nAppendix AóBibliography ..........................................................................................241\\nAppendix BóAbbreviations and Acronyms ....................................................................279', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 6}),\n",
       " Document(page_content='Appendix CóGlossary ................................................................................................283\\nAppendix DóEthical Considerations in MAT ..................................................................297\\nFundamental Ethical Principles......................................................................................297\\nEthics in Practice........................................................................................................298', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 6}),\n",
       " Document(page_content='Ethics: Conclusion.......................................................................................................303\\nAppendix EóResource Panel ......................................................................................305\\nAppendix FóField Reviewers ......................................................................................307\\nIndex ......................................................................................................................317', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 6}),\n",
       " Document(page_content='CSAT TIPs and Publications Based on TIPs ...................................................................331\\nContents', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 6}),\n",
       " Document(page_content='vii\\nExhibits\\n1-1 NIDA Comprehensive Care-Related Principles of Effective Drug Addiction Treatment.............8\\n3-1 Pharmacotherapeutic Medications for Opioid Addiction Treatment ...................................26\\n3-2 Requirements for Physiciansí Waivers To Dispense or Prescribe Buprenorphine and \\nBuprenorphine-Naloxone to Patients Who Are Opioid Addicted .....................................27\\n3-3 Intrinsic Activity of Full Agonist (Methadone), Partial Agonist (Buprenorphine), and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='Antagonist (Naloxone) Therapy ..............................................................................31\\n3-4 Possible Side Effects of Opioid Agonist and Partial Agonist Therapy..................................34\\n3-5 Reported Drug Interactions With Methadone ...............................................................37\\n3-6 Other Inducers and Inhibitors of CYP450 and CYP3A4 ..................................................40', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='4-1 Suicide Risk Factors...............................................................................................45\\n4-2 Recommended Responses to Indicators of Suicidality .....................................................45\\n4-3 Recommended Procedures for Identifying and Addressing Domestic Violence.......................57\\n5-1 Using Signs and Symptoms To Determine Optimal Methadone Levels .................................68', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='5-2 Induction SimulationóModerate to High T olerance .......................................................69\\n5-3 Heroin Use in Preceding 30 Days\\n(407 Methadone-Maintained Patients by Current Methadone Dose) .................................73\\n5-4 Methadone Dose/Mean Plasma Levels .........................................................................74\\n5-5 Blood Plasma Levels Over 4 and 24 Hours With an Adequate and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='Inadequate Methadone Dose ..................................................................................75\\n5-6 SMLs After Single and Split Methadone Dosing in a Fast Metabolizer .................................76\\n5-7 Types of Detoxification From Illicit Opioids .................................................................80\\n6-1 Case Study: PatientñTreatment Planning in MAT ..........................................................97', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='7-1 Acute Phase of MAT .............................................................................................104\\n7-2 Rehabilitative Phase of MAT...................................................................................109\\n7-3 Supportive-Care Phase of MAT ...............................................................................114\\n7-4 Medical Maintenance Phase of MAT .........................................................................116', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='7-5 Tapering Phase of MAT .........................................................................................118\\n8-1 Resource Materials for Psychoeducational, Skill-Building, and \\nGroup Counseling  Sessions..................................................................................127\\n8-2 Strategy for Contingency Management in MAT ............................................................129', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='8-3 Common Strategies for Psychotherapy in MAT............................................................131\\n8-4 Strategies for Psychoeducation in MAT .....................................................................133\\n8-5 Patient Goals in Building Relapse Prevention Skills......................................................137\\n9-1 Typical Testing and Confirmation Cutoff Concentrations and Detection Times for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='Various Substances of Abuse ................................................................................145\\n9-2 Common Immunoassays.........................................................................................150\\n9-3 Sample OTP Guidelines for Monitoring Urine Drug Test Specimen Collection .....................151\\n9-4 Examples of Onsite Analytical Methods for Drug Tests ..................................................156', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='10-1 Classification of TB ..............................................................................................165\\n10-2 Hepatitis C Evaluation Flowchart ............................................................................169\\nContents', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 7}),\n",
       " Document(page_content='viii\\n10-3 Nonpharmacologic Approaches to Managing Chronic Nonmalignant Pain ..........................177\\n11-1 Reported Use of Other Substances by Patients Admitted to OTPs ....................................180\\n11-2 Current Substance Use Disorders in Patients Dependent on Another Substance While\\nAddicted to Opioids and Admitted to OTPs, \\nWith and Without Co-Occurring Disorders (N=716) ...................................................181', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 8}),\n",
       " Document(page_content='11-3 Drug Combinations and Common Reasons for Use .......................................................182\\n12-1 Common Co-Occurring Disorders in Patients Who Are Opioid Addicted............................191\\n12-2 DSM-IV-TR Classification of Diagnoses Associated With \\nDifferent Classes of Substances .............................................................................196\\n12-3 Mutual-Help Groups for People With Co-Occurring Disorders ........................................203', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 8}),\n",
       " Document(page_content='12-4 Topics for Psychoeducational Groups for People With Co-Occurring Disorders...................204\\n12-5 Interactions of Some Medications for Depression and Bipolar Disorder \\nWith Methadone and Recommended Treatment Response in MAT .................................206\\n13-1 Common Medical Complications Among Pregnant Women Who Are Opioid Addicted............213\\n13-2 Laboratory Tests for Pregnant Women Who Are Opioid Addicted....................................214', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 8}),\n",
       " Document(page_content='13-3 Common Obstetrical Complications Among Women Addicted to Opioids ............................215\\nD-1 Case Example......................................................................................................299\\nD-2 AATOD Canon of Ethics ........................................................................................303\\nD-3 Ethical Codes of Selected Treatment-Oriented Organizations and Their Web Sites ...............304\\nContents', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 8}),\n",
       " Document(page_content='What Is a TIP?\\nTreatment Improvement Protocols (TIPs), developed by the Center for\\nSubstance Abuse Treatment (CSAT), part of the Substance Abuse and\\nMental Health Services Administration (SAMHSA), within the U.S.\\nDepartment of Health and Human Services (DHHS), are best-practice\\nguidelines for the treatment of substance use disorders. CSAT draws on\\nthe experience and knowledge of clinical, research, and administrative\\nexperts to produce the TIPs, which are distributed to facilities and indi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 9}),\n",
       " Document(page_content='viduals across the country. The audience for the TIPs is expanding\\nbeyond public and private treatment facilities to include practitioners in\\nmental health, criminal justice, primary care, and other health care and\\nsocial service settings.\\nCSATís Knowledge Application Program (KAP) expert panel, a distin-\\nguished group of experts on substance use disorders and professionals in\\nsuch related fields as primary care, mental health, and social services,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 9}),\n",
       " Document(page_content='works with the State Alcohol and Drug Abuse Directors to generate \\ntopics for the TIPs. Topics are based on the fieldís current needs for\\ninformation and guidance.\\nAfter selecting a topic, CSAT invites staff from pertinent Federal \\nagencies and national organizations to be members of a resource panel\\nthat recommends specific areas of focus as well as resources that should\\nbe considered in developing the content for the TIP . These recommenda-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 9}),\n",
       " Document(page_content='tions are communicated to a consensus panel composed of experts on the\\ntopic who have been nominated by their peers. This consensus panel\\nparticipates in a series of discussions. The information and recommen-\\ndations on which they reach consensus form the foundation of the TIP .\\nThe members of each consensus panel represent substance abuse treat-\\nment programs, hospitals, community health centers, counseling pro-\\ngrams, criminal justice and child welfare agencies, and private practi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 9}),\n",
       " Document(page_content='tioners. A panel chair (or co-chairs) ensures that the contents of the TIP\\nmirror the results of the groupís collaboration.\\nA large and diverse group of experts closely reviews the draft document.\\nOnce the changes recommended by these field reviewers have been\\nincorporated, the TIP is prepared for publication, in print and on line.\\nTIPs can be accessed via the Internet at www.kap.samhsa.gov. The \\nix', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 9}),\n",
       " Document(page_content='online TIPs are consistently updated and pro-\\nvide the field with state-of-the-art information.\\nAlthough each TIP strives to include an \\nevidence base for the practices it recommends,\\nCSAT recognizes that the field of substance\\nabuse treatment is evolving, and research \\nfrequently lags behind the innovations pio-\\nneered in the field. A major goal of each TIP is\\nto convey ìfront-lineî information quickly but\\nresponsibly. For this reason, recommendations', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 10}),\n",
       " Document(page_content='proffered in the TIP are attributed to either\\npanelistsí clinical experience or the literature.\\nIf research supports a particular approach,\\ncitations are provided.\\nThis TIP , Medication-Assisted Treatment for\\nOpioid Addiction in Opioid Treatment\\nPrograms, incorporates the many changes in\\nmedication-assisted treatment for opioid \\naddiction (MAT) that have occurred over the\\nmost active decade of change since the incep-\\ntion of this treatment modality approximately', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 10}),\n",
       " Document(page_content='40 years ago. The TIP describes the nature and\\ndimensions of opioid use disorders and their\\ntreatment in the United States, including basic\\nprinciples of MAT and historical and regulatory\\ndevelopments. It presents consensus panel \\nrecommendations and evidence-based best\\npractices for treatment of opioid addiction in\\nopioid treatment programs (OTPs). It also\\nexamines related medical, psychiatric, sociolog-\\nical, and substance use disorders and their\\ntreatment as part of a comprehensive mainte-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 10}),\n",
       " Document(page_content='nance treatment program. The TIP includes a\\ndiscussion of the ethical considerations that\\narise in most OTPs, and it provides a useful\\nsummary of areas for emphasis in successfully\\nadministering MAT in OTPs.\\nx What Is a TIP?', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 10}),\n",
       " Document(page_content='Chair\\nSteven L. Batki, M.D.\\nProfessor and Director of Research\\nDepartment of Psychiatry\\nSUNY Upstate Medical University\\nSyracuse, New York\\nCo-Chairs\\nJanice F. Kauffman, R.N., M.P.H., \\nLADC, CAS\\nVice President\\nAddiction Treatment Services\\nNorth Charles Foundation, Inc.\\nCambridge, Massachusetts;\\nDirector\\nAddiction Psychiatry Service\\nDepartment of Psychiatry\\nBrigham and Womenís Hospital\\nBoston, Massachusetts;\\nand Assistant Professor of Psychiatry\\nHarvard Medical School\\nBoston, Massachusetts', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 11}),\n",
       " Document(page_content='Ira Marion, M.A.\\nExecutive Director\\nDivision of Substance Abuse\\nAlbert Einstein College of Medicine\\nBronx, New York\\nMark W. Parrino, M.P.A.\\nPresident\\nAmerican Association for the \\nTreatment of Opioid Dependence\\nNew York, New York\\nGeorge E. Woody, M.D.\\nTreatment Research Institute\\nUniversity of Pennsylvania/\\nMIRECC Philadelphia VAMC\\nPhiladelphia, Pennsylvania\\nEditorial Advisory Board\\nJohn D. Crowley\\nCrowley Associates\\nElgin, South Carolina\\nHerbert D. Kleber, M.D.\\nProfessor of Psychiatry', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 11}),\n",
       " Document(page_content='Columbia University College of Physicians \\n& Surgeons\\nNew York, New York\\nStewart B. Leavitt, Ph.D.\\nLeavitt Medical Communications\\nGlenview, Illinois\\nJocelyn Sue Woods, M.A.\\nPresident\\nNational Alliance of Methadone Advocates\\nNew York, New York\\nJoan Zweben, Ph.D.\\nExecutive Director\\n14th Street Clinic & Medical Group, Inc.\\nEast Bay Community Recovery Project\\nBerkeley, California\\nConsensus Panelists\\nPatrick Abbott, M.D.\\nMedical Director\\nCenter on Alcoholism, Substance Abuse, \\nand Addictions', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 11}),\n",
       " Document(page_content='and Addictions\\nUniversity of New Mexico\\nAlbuquerque, New Mexico \\nLeslie Amass, Ph.D.\\nPrincipal Investigator\\nFriends Research Institute, Inc.\\nLos Angeles, California\\nHector D. Barreto, M.D., M.P.H.\\nMedical Director\\nCenter for Drug-Free Living\\nOrlando, Florida \\nxi\\nConsensus Panel', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 11}),\n",
       " Document(page_content='Michael D. Couty\\nDirector\\nDivision of Alcohol and Drug Abuse\\nMissouri Department of Mental Health\\nJefferson City, Missouri\\nVashti Jude Forbes, R.N., BC., M.S.N.,\\nLCDC\\nAssociate Director\\nSubstance Abuse and Specialized Services\\nAustin Travis County Mental Health and\\nMental Retardation Center\\nAustin, Texas\\nRon Jackson, M.S.W.\\nExecutive Director \\nEvergreen Treatment Services\\nSeattle, Washington\\nKarol A. Kaltenbach, Ph.D.\\nDirector\\nMaternal Addiction Treatment Education \\nand Research', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 12}),\n",
       " Document(page_content='and Research\\nJefferson Medical College\\nThomas Jefferson University\\nPhiladelphia, Pennsylvania\\nJudith Martin, M.D., FASAM\\nMedical Director\\n14th Street Clinic & Medical Group, Inc.\\nOakland, California\\nViolanda T. NuÒez, M.S.W.\\nExecutive Director\\nAyudantes, Inc.\\nSanta Fe, New Mexico\\nJ. Thomas Payte, M.D.\\nMedical Director\\nDrug Dependence Associates\\nSan Antonio, Texas\\nNorma J. Reppucci, R.N.\\nDirector\\nOperations for Eastern MA and NH \\nCommunity Substance Abuse Centers\\nMalden, Massachusetts', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 12}),\n",
       " Document(page_content='Yong S. Song, Ph.D.\\nAssistant Clinical Professor and Program \\nDirector\\nOpiate Treatment Outpatient Program\\nUniversity of California, San Francisco \\nSan Francisco, California\\nJo L. Sotheran, Ph.D.\\nAssociate Research Scientist\\nMailman School of Public Health\\nColumbia University\\nNew York, New York\\nTrusandra Taylor, M.D.\\nPhysician Advisor\\nParkside Recovery Methadone Maintenance\\nPhiladelphia, Pennsylvania\\nxii Consensus Panel', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 12}),\n",
       " Document(page_content='Barry S. Brown, Ph.D.\\nAdjunct Professor\\nUniversity of North Carolina at Wilmington\\nCarolina Beach, North Carolina\\nJacqueline Butler, M.S.W., LISW, LPCC, \\nCCDC III, CJS\\nProfessor of Clinical Psychiatry\\nCollege of Medicine\\nUniversity of Cincinnati\\nCincinnati, Ohio\\nDeion Cash\\nExecutive Director\\nCommunity Treatment and Correction \\nCenter, Inc.\\nCanton, Ohio\\nDebra A. Claymore, M.Ed.Adm.\\nOwner/Chief Executive Officer\\nWC Consulting, LLC\\nLoveland, Colorado\\nCarlo C. Di Clemente, Ph.D.\\nChair', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 13}),\n",
       " Document(page_content='Chair\\nDepartment of Psychology\\nUniversity of Maryland Baltimore County\\nBaltimore, Maryland\\nCatherine E. Dube, Ed.D.\\nIndependent Consultant\\nBrown University\\nProvidence, Rhode Island\\nJerry P. Flanzer, D.S.W., LCSW, CAC\\nChief, Services \\nDivision of Clinical and Services Research\\nNational Institute on Drug Abuse\\nBethesda, Maryland\\nMichael Galer, D.B.A., M.B.A., M.F.A.\\nChairman of the Graduate School of Business\\nUniversity of PhoenixóGreater Boston \\nCampus\\nBraintree, Massachusetts', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 13}),\n",
       " Document(page_content='Renata J. Henry, M.Ed.\\nDirector\\nDivision of Alcoholism, Drug Abuse, and\\nMental Health\\nDelaware Department of Health and \\nSocial Services\\nNew Castle, Delaware\\nJoel Hochberg, M.A.\\nPresident\\nAsher & Partners\\nLos Angeles, California\\nJack Hollis, Ph.D.\\nAssociate Director\\nCenter for Health Research\\nKaiser Permanente\\nPortland, Oregon \\nMary Beth Johnson, M.S.W.\\nDirector\\nAddiction Technology Transfer Center\\nUniversity of MissourióKansas City\\nKansas City, Missouri \\nEduardo Lopez\\nExecutive Producer', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 13}),\n",
       " Document(page_content='Executive Producer\\nEVS Communications\\nWashington, D.C.\\nHolly A. Massett, Ph.D.\\nAcademy for Educational Development\\nWashington, D.C.\\nDiane Miller\\nChief\\nScientific Communications Branch\\nNational Institute on Alcohol Abuse\\nand Alcoholism\\nBethesda, Maryland\\nHarry B. Montoya, M.A.\\nPresident/Chief Executive Officer\\nHands Across Cultures\\nEspanola, New Mexico\\nxiii\\nKAP Expert Panel and Federal\\nGovernment Participants', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 13}),\n",
       " Document(page_content='xiv\\nRichard K. Ries, M.D.\\nDirector/Professor\\nOutpatient Mental Health Services\\nDual Disorder Programs\\nSeattle, Washington\\nGloria M. Rodriguez, D.S.W.\\nResearch Scientist\\nDivision of Addiction Services\\nNew Jersey Department of Health and\\nSenior Services\\nTrenton, New Jersey\\nEverett Rogers, Ph.D.\\nCenter for Communications Programs\\nJohns Hopkins University\\nBaltimore, Maryland\\nJean R. Slutsky, P.A., M.S.P.H.\\nSenior Health Policy Analyst\\nAgency for Healthcare Research \\n& Quality\\nRockville, Maryland', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 14}),\n",
       " Document(page_content='Rockville, Maryland\\nNedra Klein Weinreich, M.S.\\nPresident\\nWeinreich Communications\\nCanoga Park, California\\nClarissa Wittenberg\\nDirector\\nOffice of Communications and\\nPublic Liaison\\nNational Institute of Mental Health\\nBethesda, Maryland\\nConsulting Members to the\\nKAP Expert Panel\\nPaul Purnell, M.A.\\nSocial Solutions, L.L.C.\\nPotomac, Maryland\\nScott Ratzan, M.D., M.P.A., M.A.\\nAcademy for Educational Development\\nWashington, D.C.\\nThomas W. Valente, Ph.D.\\nDirector, Master of Public Health Program', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 14}),\n",
       " Document(page_content='Department of Preventive Medicine\\nSchool of Medicine\\nUniversity of Southern California\\nAlhambra, California\\nPatricia A. Wright, Ed.D.\\nIndependent Consultant\\nBaltimore, Maryland\\nKAP Expert Panel and Federal Government Participants', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 14}),\n",
       " Document(page_content='Foreword\\nThe Treatment Improvement Protocol (TIP) series supports SAMHSAís\\nmission of building resilience and facilitating recovery for people with or\\nat risk for mental or substance use disorders by providing best-practices\\nguidance to clinicians, program administrators, and payers to improve\\nthe quality and effectiveness of service delivery and thereby promote\\nrecovery. TIPs are the result of careful consideration of all relevant', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 15}),\n",
       " Document(page_content='clinical and health services research findings, demonstration experience,\\nand implementation requirements. A panel of non-Federal clinical\\nresearchers, clinicians, program administrators, and client advocates\\ndebates and discusses its particular areas of expertise until it reaches \\na consensus on best practices. This panelís work is then reviewed and\\ncritiqued by field reviewers.\\nThe talent, dedication, and hard work that TIPs panelists and reviewers', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 15}),\n",
       " Document(page_content='bring to this highly participatory process have helped bridge the gap\\nbetween the promise of research and the needs of practicing clinicians\\nand administrators who serve, in the most current and effective ways,\\npeople who abuse substances. We are grateful to all who have joined\\nwith us to contribute to advances in the substance abuse treatment field.\\nCharles G. Curie, M.A., A.C.S.W.\\nAdministrator\\nSubstance Abuse and Mental Health Services Administration', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 15}),\n",
       " Document(page_content='H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM\\nDirector\\nCenter for Substance Abuse Treatment\\nSubstance Abuse and Mental Health Services Administration\\nxv', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 15}),\n",
       " Document(page_content='Executive Summary\\nResearch supports the perspective that opioid addiction is a medical \\ndisorder that can be treated effectively with medications when they are\\nadministered under conditions consistent with their pharmacological\\nefficacy and when treatment includes necessary supportive services \\nsuch as psychosocial counseling, treatment for co-occurring disorders,\\nmedical services, and vocational rehabilitation. Medication-assisted', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 17}),\n",
       " Document(page_content='treatment for opioid addiction (MAT) has been effective in facilitating\\nrecovery from opioid addiction for many patients.\\nThis TIP provides a detailed description of MAT, especially in opioid\\ntreatment programs (OTPs). MAT includes optional approaches such as\\ncomprehensive maintenance treatment, medical maintenance treatment,\\ndetoxification, and medically supervised withdrawal. Some or all of\\nthese approaches can be provided in OTPs or other settings. With the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 17}),\n",
       " Document(page_content='approval of buprenorphine for physicianís office-based opioid treat-\\nment, MAT availability is expected to increase.\\nGrowing understanding and acceptance of opioid addiction as a \\ntreatable medical disorder have facilitated advances in MAT. The \\neffectiveness of MAT advanced significantly with the development of\\nmethadone maintenance treatment in the 1960s and the creation and\\nexpansion of publicly funded treatment programs in the 1970s. The first', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 17}),\n",
       " Document(page_content='official Federal use of the term ìmaintenance treatmentî (referring to\\nopioid addiction treatment) occurred in the Narcotic Addict Treatment\\nAct of 1974. Perhaps the most important development in MAT during\\nthe 1990s was publication of recommendations by a National Institutes\\nof Health consensus panel on Effective Medical Treatment of Opiate\\nAddiction. The panel concluded that opioid addiction is a treatable med-\\nical disorder and explicitly rejected notions that addiction is self-induced', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 17}),\n",
       " Document(page_content='or a failure of willpower. The panel called for a commitment to providing\\neffective treatment for opioid addiction and for Federal and State efforts\\nto reduce the stigma attached to MAT and to expand MAT through\\nincreased funding and less restrictive regulation. The implementation of\\nan accreditation system for OTPs further serves to standardize and\\nimprove MAT.\\nxvii', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 17}),\n",
       " Document(page_content='Accompanying these improvements in opioid\\naddiction treatment is an increasing emphasis\\non the concomitant treatment of diseases such\\nas HIV/AIDS, hepatitis, and tuberculosis, all of\\nwhich occur at higher rates among people who\\ninject drugs than in the general population. \\nThis TIP addresses a variety of issues and\\nchallenges in MAT, including\\nï Drug testing for screening and assessmentó\\nhow and when (chapters 4 and 9)\\nï Administrative dischargeóissues of safety\\nand noncompliance (chapter 8)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='ï Use of other substances with opioids and\\nresulting complications for MAT (chapter 11)\\nï Co-occurring mental disorders and their \\ncomplications for MAT (chapter 12)\\nï Administration of staffs and procedures\\n(chapter 14).\\nThe following paragraphs summarize chapters\\nin this TIP .\\nChapter 1, Introduction, introduces MAT and\\nprovides important concepts for understanding\\nthis TIP . It describes opioid addiction as a\\nmedical disorder with similarities to other dis-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='orders. It outlines the main options for MAT,\\nsuch as choices of medication and optional \\nservices. The chapter concludes by summariz-\\ning the greatest challenges facing OTPs and\\noffering a vision of the future.\\nChapter 2, History of Medication-Assisted\\nTreatment for Opioid Addiction, provides the\\nhistorical context for MAT. It details the histo-\\nry of the use of opioids in the United States; the\\npolitical, legal, and regulatory responses to opi-\\noid abuse; treatment trends (including logistics', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='and strategies); and development of modern\\nmedications available in MAT.\\nChapter 3, Pharmacology of Medications \\nUsed To Treat Opioid Addiction, reviews the\\npharmacology and clinical applications of the\\nmedications used for treating opioid addiction.\\nIt focuses on the metabolic activity, dosage\\nforms, efficacy, side effects, drug interactions,\\nsafety considerations, and current availability\\nand restrictions for methadone, levo-alpha\\nacetyl methadol (LAAM), buprenorphine,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='and naltrexone. The information will enable\\ntreatment providers to compare the benefits\\nand limitations of available opioid addiction\\ntreatment medications.\\nChapter 4, Initial Screening, Admission\\nProcedures, and Assessment Techniques,\\ndescribes screening and assessment procedures\\nused with applicants for admission to treat-\\nment and with patients in MAT. The chapter\\ndescribes components of the screening (or\\nintake) process that provides a foundation \\nfor treatment and procedures used during', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='the admissions process to ensure thorough,\\nefficient data collection and to gather informa-\\ntion for ongoing treatment intervention.\\nComponents of substance use, medical, \\nmedication induction, and comprehensive \\npsychosocial assessments are used to determine\\nMAT eligibility, individualize treatment plans,\\nand monitor changes in patient status. The\\nchapter also provides information on manag-\\ning emergency situations during admission and\\ntreatment.\\nChapter 5, Clinical Pharmacotherapy, explains', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='opioid pharmacotherapy, focusing on the \\nclinical use of methadone, buprenorphine,\\nLAAM, and naltrexone. It details the discrete\\nstages of opioid pharmacotherapy, each of\\nwhich requires unique clinical considerations.\\nIt discusses factors that may affect individual\\nresponses to treatment medications and key\\nconsiderations in determining individual\\ndosages. For patients who must leave MAT,\\neither voluntarily or involuntarily, the chapter\\nexplains methods of withdrawal from treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='medications. It also discusses important consid-\\nerations in administering take-home medication.\\nChapter 6, PatientñTreatment Matching: Types\\nof Services and Levels of Care, describes a\\nmultidimensional, clinically driven strategy \\nfor matching patients in MAT with the types \\nof treatment services and levels of care that\\noptimize treatment outcomes, within or in \\nxviii Executive Summary', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 18}),\n",
       " Document(page_content='conjunction with OTPs. Patientñtreatment\\nmatching involves individualizing the choice\\nand application of treatment resources to each\\npatientís needs, abilities, and preferences. The\\nchapter describes alternative types of treat-\\nment programs and settings for identified types\\nof patients and recommends elements that\\nshould be included in patientñtreatment match-\\ning, including ways to accommodate patients\\nwith special needs. The chapter describes \\nelements of a treatment plan and the planning', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='process, including the roles of counselor and\\npatient, the importance of cultural and linguistic\\ncompetence, motivation for treatment, and the\\nneed for a multidisciplinary team.\\nChapter 7, Phases of Treatment, describes\\nphases of treatment for patients in MAT. These\\nphases are conceptualized as parts of a dynam-\\nic continuum of patient progress toward\\nintended treatment outcomes. Each patient\\nprogresses according to his or her capacity and\\nneeds. After an orientation to introduce', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='patients to the program, successive treatment\\nphases include (1) the acute phase, during\\nwhich patients attempt to eliminate illicit-opioid\\nuse and lessen the intensity of other problems\\nassociated with their addiction, (2) the rehabili-\\ntative phase, during which patients continue to\\naddress addiction while gaining control of other\\nmajor life domains, (3) the supportive-care\\nphase, during which patients maintain their\\nabstinence while receiving other interventions', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='when needed, (4) the medical-maintenance\\nphase, during which patients are committed to\\ncontinuing pharmacotherapy for the foresee-\\nable future but no longer rely on other OTP\\nservices, (5) the tapering and readjustment\\nphase, an optional phase in which patients\\ngradually reduce and eliminate opioid treat-\\nment medication, and (6) the continuing-care\\nphase, in which patients who have tapered\\nfrom treatment medication continue regular\\ncontact with their treatment program. Phases', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='of treatment address the therapeutic relation-\\nship, motivation,  patientsí use of alcohol and\\nillicit drugs, their mental and medical disorders,\\nlegal problems, and basic needs (including \\nhousing, education, and vocational training).\\nMost patients need more frequent, intensive\\nservices in the acute phase, careful monitoring\\nand diversified services during rehabilitative\\nand supportive-care phases, and less frequent\\nservices in subsequent phases.\\nChapter 8, Approaches to Providing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='Comprehensive Care and Maximizing Patient\\nRetention, describes the core- and extended-\\ncare services essential to MAT effectiveness in\\nOTPs. It explains how a comprehensive treat-\\nment program improves patient retention in\\ntreatment and the likelihood of positive treat-\\nment outcomes. Patients who receive regular,\\nfrequent, integrated psychosocial and medical\\nservices along with opioid pharmacotherapy\\noften realize better outcomes than those who\\nreceive only limited services. Counseling', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='services are integral to comprehensive mainte-\\nnance treatment and can be behavioral,\\npsychotherapeutic, or family oriented.\\nStrategies that target relapse prevention also\\nshould be part of any comprehensive treatment\\nprogram. The chapter describes ways to\\nincrease patient retention and avoid adminis-\\ntrative discharge. Administrative discharge \\nusually results in rapid relapse and may lead to\\nincarceration or death. Clear communication\\nand awareness on the part of both patients', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='and staff members help avoid administrative\\ndischarge.\\nChapter 9, Drug Testing as a Tool, presents an\\noverview of drug testing in OTPs. Drug testing\\nprovides an objective measure of treatment\\nefficacy and a tool to monitor patient progress,\\nas well as information for quality assurance,\\nprogram planning, and accreditation. OTPs\\nmust ensure the clinical utility of test results\\nand protect patientsí privacy. Several drug-\\ntesting methodologies are available or in devel-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='opment, including tests of urine, oral fluid,\\nblood, sweat, and hair. The chapter describes\\nthe benefits and limitations of these tests. Most\\noften, OTPs use urine drug testing by\\nimmunoassay or thin-layer chromatography\\nbecause these methods are the least costly and\\nbest validated of all options, but the Center for\\nSubstance Abuse Treatment has indicated that\\nxixExecutive Summary', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 19}),\n",
       " Document(page_content='oral-fluid testing may be an alternative\\napproach in OTPs. The chapter describes \\ncriteria that an OTP should use to collect\\nspecimens and how treatment providers\\nshould respond to test results that indicate\\npossible treatment problems.\\nChapter 10, Associated Medical Problems in\\nPatients Who Are Opioid Addicted, focuses\\non diagnosis and treatment of the medical\\nconditions most commonly seen in MAT\\npatients. A primary issue in MAT is deciding\\nwhich medical services patients should receive', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='in house versus through referral to outside\\nproviders. Chapter 10 examines the factors\\nthat influence this determination and reviews\\nthe screening services and protocols OTPs\\nshould have in place to evaluate patientsí\\nacute and chronic medical problems and to\\nperform periodic reassessments.\\nChapter 11, Treatment of Multiple Substance\\nUse, discusses problems associated with\\npatientsí continued abuse of other substances,\\nwhich is likely to affect patientsí participation', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='in MAT, proper use of medication, and mental\\nand physical health. Some substances, such as\\nalcohol and certain sedatives, have a poten-\\ntially lethal effect when combined with an \\nopioid agonist or partial agonist medication. \\nA number of interventions can address the\\ncontinued abuse of other substances, includ-\\ning increased drug testing and the use of \\ndisulfiram, contingency management, dose\\nadjustments, and counseling.\\nChapter 12, Treatment of Co-Occurring', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='Disorders, addresses issues for patients who\\nhave substance use and co-occurring mental\\ndisorders. These patients often exhibit \\nbehaviors or experience emotions that inter-\\nfere with treatment and require special \\ninterventions. The chapter describes the\\nprevalence of co-occurring disorders, \\nscreening and diagnosis of these disorders,\\nand the effects of such disorders on treatment\\noutcomes. It discusses general issues, specific\\npsychiatric diagnoses, and a range of inter-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='ventions (including psychoeducation, \\npsychotherapy, and pharmacotherapy) to\\ntreat co-occurring disorders. The chapter\\nexplores special issues such as acute psychiatric\\ndanger, how to handle emergencies, and the\\neffect of co-occurring disorders on behaviors\\nthat increase the risk of infectious diseases.\\nChapter 13, Medication-Assisted Treatment for\\nOpioid Addiction During Pregnancy, describes\\nthe complications associated with pregnancy\\nand opioid addiction and how pregnancy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='should be addressed during MAT to reduce the\\npotential for harm to a pregnant woman in\\nMAT and her fetus. Among the main concerns\\nare those related to HIV/AIDS and hepatitis C.\\nThe chapter describes how to adjust methadone\\ndosage and manage overdose and withdrawal\\nand addresses the postpartum treatment of\\nmother and child, including topics such as\\nbreast-feeding and neonatal abstinence syn-\\ndrome. The chapter focuses on methadone,\\nwhich has been accepted for treating opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='addiction during pregnancy since the late 1970s.\\nChapter 14, Administrative Considerations,\\ncovers the challenging administrative aspects \\nof managing and staffing the complex and\\ndynamic environment of an OTP . Successful\\ntreatment outcomes depend on the competence,\\nvalues, and attitudes of staff members. To\\ndevelop and retain a stable team of treatment\\npersonnel, program administrators must\\nrecruit and hire qualified, capable, culturally\\nsensitive individuals; offer competitive salaries', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='and benefit packages; and provide good super-\\nvision and ongoing training. Implementing \\ncommunity relations and community education\\nefforts is important for OTPs. Outreach and\\neducational efforts can dispel misconceptions\\nabout MAT and people in recovery. Finally, the\\nchapter provides a framework for gathering\\nand analyzing program performance data.\\nProgram evaluation contributes to improved\\ntreatment services by enabling administrators\\nto base changes in services on evidence of what', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='works. Evaluation also serves as a way to \\neducate and influence policymakers and public\\nand private payers.\\nAppendix D, Ethical Considerations in MAT,\\nexplores ethical issues inherent in MAT and\\nprovides a structure that administrators \\nand clinicians can use in considering how to\\nresolve them.\\nxx Executive Summary', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 20}),\n",
       " Document(page_content='1 Introduction\\n1\\nIn This\\nChapter…\\nPurpose of This\\nTIP\\nKey Definitions\\nAudience for This\\nTIP\\nA Decade of Change\\nRemaining\\nChallenges\\nThe Future of MAT\\nOpioid addiction is a problem with high costs to individuals, families,\\nand society. Injection drug use-associated exposure accounts for approxi-\\nmately one-third of all AIDS cases diagnosed in the United States\\nthrough 2003 (National Center for HIV , STD and TB Prevention 2005)\\nand for many cases of hepatitis C (National Institute on Drug Abuse', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 21}),\n",
       " Document(page_content='2000; Thomas 2001). In the criminal justice system, people who use\\nheroin account for an estimated one-third of the $17 billion spent each\\nyear for legal responses to drug-related crime. Indirect costs from lost\\nproductivity and overdose also are high (Mark et al. 2001), and people\\nwith opioid addictions and their families experience severe reductions in\\ntheir quality of life. The increasing abuse of prescription opioids is\\nanother major concern, both for their damaging effects and as gateway', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 21}),\n",
       " Document(page_content='drugs to other substance use (see chapter 2).\\nPurpose of This TIP\\nThis Treatment Improvement Protocol (TIP) is a guide to medication-\\nassisted treatment for opioid addiction (MAT) in opioid treatment \\nprograms (OTPs). Compared with MAT in other settings, such as physi-\\nciansí offices or detoxification centers, treatment in OTPs provides a\\nmore comprehensive, individually tailored program of medication \\ntherapy integrated with psychosocial and medical treatment and support', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 21}),\n",
       " Document(page_content='services that address most factors affecting each patient. Treatment in\\nOTPs also can include detoxification from illicit opioids and medically\\nsupervised withdrawal from maintenance medications.\\nThis TIP combines and updates TIP 1 (State Methadone Treatment\\nGuidelines, published in 1993), TIP 10 (Assessment and Treatment of\\nCocaine-Abusing Methadone-Maintained Patients, published in 1994),\\nTIP 20 (Matching Treatment to Patient Needs in Opioid Substitution', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 21}),\n",
       " Document(page_content='Therapy, published in 1995), and TIP 22 (LAAM in the Treatment of\\nOpiate Addiction, published in 1995). It incorporates the many changes\\nin MAT that have occurred since the publication of TIP 1, primarily as\\nthey are reflected in OTPs, and discusses the challenges that remain.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 21}),\n",
       " Document(page_content='Key Definitions\\nThe glossary (Appendix C) and list of acronyms\\n(Appendix B) at the back of the book provide\\ndefinitions of key words, terms, acronyms, and\\nabbreviations. Particularly important distinc-\\ntions among selected terms and phrases are \\ndiscussed below.\\nDistinctions between dependence and addiction\\nvary across treatment fields. This TIP uses the\\nterm ìdependenceî to refer to physiological\\neffects of substance abuse and ìaddictionî for\\nphysical dependence on and subjective need', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='and craving for a psychoactive substance either\\nto experience its positive effects or to avoid\\nnegative effects associated with withdrawal\\nfrom that substance.\\nMAT is any treat-\\nment for opioid\\naddiction that\\nincludes a medi-\\ncation (e.g.,\\nmethadone,\\nbuprenorphine,\\nlevo-alpha acetyl\\nmethadol [LAAM],\\nnaltrexone)\\napproved by the\\nU.S. Food and Drug\\nAdministration\\n(FDA) for opioid\\naddiction detoxifica-\\ntion or maintenance\\ntreatment. MAT\\nmay be provided in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='may be provided in\\nan OTP or an OTP medication unit (e.g., phar-\\nmacy, physicianís office) or, for buprenor-\\nphine, a physicianís office or other health care\\nsetting. Comprehensive maintenance, medical\\nmaintenance, interim maintenance, detoxifica-\\ntion, and medically supervised withdrawal\\n(defined under ìTreatment Optionsî below and\\nindividually in the glossary) are types of MAT.\\nAn OTP is any treatment program certified \\nby the Substance Abuse and Mental Health', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='Services Administration (SAMHSA) in \\nconformance with 42 Code of Federal\\nRegulations (CFR), Part 8, to provide super-\\nvised assessment and medication-assisted \\ntreatment for patients who are opioid addicted.\\nAn OTP can exist in a number of settings,\\nincluding, but not limited to, intensive outpa-\\ntient, residential, and hospital settings. Types of\\ntreatment can includemedical maintenance,\\nmedically supervised withdrawal, and detoxifi-\\ncation, either with or without various levels of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='medical, psychosocial, and other types of care.\\nThe term ìabstinenceî in this TIP refers to\\nnonuse of alcohol or illicit drugs (drugs not\\napproved by FDA), as well as nonabuse of \\nprescription drugs. Abstinence does not refer\\nto withdrawal from legally prescribed mainte-\\nnance medications for addiction treatment (for\\nwhich ìmedically supervised withdrawalî is the\\npreferred term).\\nTerminology continues to evolve for describing\\nthe combination of substance use and mental', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='disorders. In this TIP , ìco-occurringî is the\\npreferred term, but others use ìcoexisting,î\\nìdual diagnosis,î and ìcomorbidî to describe\\nthe combination of current or former substance\\nuse disorders and any other Axis I or any \\nAxis II mental disorders recognized by the\\nDiagnostic and Statistical Manual of Mental\\nDisorders, Fourth Edition, Text Revision\\n(American Psychiatric Association 2000). \\n(See also TIP 42, Substance Abuse Treatment\\nfor Persons With Co-Occurring Disorders\\n[CSAT 2005b].)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='[CSAT 2005b].)\\nAudience for This TIP\\nThe intended audience for this TIP is treat-\\nment providers and administrators working in\\nOTPs. Other groups that want to understand\\nthe principles and procedures followed in MAT\\nalso will benefit.\\nA Decade of Change\\nSeveral forces are transforming the MAT field.\\nThe implementation of an accreditation system\\n(Federal Register64:39814) is standardizing\\nand improving opioid addiction treatment (for\\n2 Chapter 1\\nThe intended\\naudience for this\\nTIP is treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='TIP is treatment\\nproviders and\\nadministrators\\nworking in OTPs.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 22}),\n",
       " Document(page_content='details, see 42 CFR, Part 8). Choices of medi-\\ncation, including methadone, buprenorphine,\\nLAAM, and naltrexone (see chapter 3), now are\\navailable to treat opioid addiction. Each has its\\nown benefits and limitations. Continued\\nresearch on opioid addiction and treatment is\\nclarifying what works to improve treatment\\noutcomes, with an emphasis on accelerating the\\nincorporation of evidence-based methods into\\ntreatment. Changes in the health care system\\nnationwide (e.g., the growth of managed care', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='and effects of the Health Insurance Portability\\nand Accountability Act) are having an effect on\\nOTPs and other types of health care programs.\\nUnderstanding and acceptance of opioid addic-\\ntion as a medical disorder by patients, health\\ncare providers, the media, and the public have\\nincreased since the publication of TIP 1.\\nMATóA More Accepted Form\\nof Treatment\\nOpioid addiction as a medical\\ndisorder\\nDiscussions about whether addiction is a medi-\\ncal disorder or a moral problem have a long', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='history. For decades, studies have supported\\nthe view that opioid addiction is a medical dis-\\norder that can be treated effectively with medi-\\ncations administered under conditions consis-\\ntent with their pharmacological efficacy, when\\ntreatment includes comprehensive services,\\nsuch as psychosocial counseling, treatment for\\nco-occurring disorders, medical services, voca-\\ntional rehabilitation services, and case manage-\\nment services (e.g., Dole and Nyswander 1967;\\nMcLellan et al. 1993).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='Dole (1988, p. 3025) described the medical\\nbasis of methadone maintenance as follows:\\nThe treatment is corrective, normaliz-\\ning neurological and endocrinologic\\nprocesses in patients whose endogenous\\nligand-receptor function has been\\nderanged by long-term use of powerful\\nnarcotic drugs. Why some persons who\\nare exposed to narcotics are more \\nsusceptible than others to this derange-\\nment and whether long-term addicts\\ncan recover normal function without\\nmaintenance therapy are questions for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='the future. At present, the most that\\ncan be said is that there seems to be a\\nspecific neurological basis for the com-\\npulsive use of heroin by addicts and\\nthat methadone taken in optimal doses\\ncan correct the disorder.\\nSimilarities to other medical\\ndisorders\\nMcLellan and colleagues (2000) compared basic\\naspects of substance addiction with those of\\nthree disordersóasthma, hypertension, and\\ndiabetesówhich universally are considered\\nìmedicalî and usually chronic and relapsing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='and for which behavioral change is an impor-\\ntant part of treatment. They found that genet-\\nic, personal-choice, and environmental factors\\nplayed comparable roles in the etiology and\\ncourse for these disorders and that rates of\\nrelapse and adherence to medication were simi-\\nlar, although substance addiction often was\\ntreated as an acute, not chronic, illness. Their\\nreview of outcome literature showed that, as\\nwith the other disorders, substance addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='has no reliable cure but that patients who com-\\nply with treatment regimens have more favor-\\nable outcomes. Fewer than 30 percent of\\npatients with asthma, hypertension, or diabetes\\nadhered to their medication regimens, pre-\\nscribed diets, or other changes to increase their\\nfunctional status and reduce their risk of symp-\\ntom recurrence. As a result, 50 to 70 percent\\nexperienced recurrent symptoms each year to\\nthe point of requiring additional medical care\\nto reestablish remission.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='Another similarity found between opioid \\naddiction and these medical disorders was their\\noutcome predictors (McLellan et al. 2000). For\\nexample, patients who were older and\\nemployed with stable families and marriages\\nwere found to be more likely to comply with\\ntreatment and have positive treatment results\\nthan were younger, unemployed patients with\\nless stable family support.\\n3Introduction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 23}),\n",
       " Document(page_content='4 Chapter 1\\nThe concept of opioid addiction as a medical\\ndisorder was supported further by other treat-\\nment followup studies showing that opioid\\naddiction has a reasonably predictable course,\\nsimilar to such conditions as diabetes, hyper-\\ntension, and asthma. For example, Woody and\\nCacciola (1994) found that the risk of relapse\\nfor a person who was opioid addicted was high-\\nest during the first 3 to 6 months after cessa-\\ntion of opioid use. This risk declined for the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='first 12 months after cessation and continued to\\ndecrease but at a much slower rate. Results\\nfrom other posttreatment studies indicated that\\nroughly 80 percent of patients who are opioid\\naddicted but leave MAT resume daily opioid\\nuse within 1 year after leaving treatment (e.g.,\\nMagura and Rosenblum 2001).\\nSimilar to patients with other chronic disorders,\\nmany who are opioid addicted have been found\\nto respond best to treatment that combines\\npharmacological and behavioral interventions.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='As detailed throughout this TIP , treatment of\\nopioid addiction with maintenance medication,\\nalong with other treatment services for related\\nproblems that affect patientsí motivation and\\ntreatment compliance, increases the likelihood\\nof cessation of opioid abuse. Conversely, dis-\\ncontinuation of maintenance medication often\\nresults in dropout from other services and a\\nreturn to previous levels of opioid abuse, with\\nits accompanying adverse medical and psycho-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='social consequences (Ball and Ross 1991). Entry\\ninto comprehensive maintenance treatment pro-\\nvides an opportunity to prevent, screen for, and\\ntreat diseases such as HIV/AIDS, hepatitis B\\nand C, and tuberculosis (see chapter 10) and to\\nincrease compliance with medical, psychiatric,\\nand prenatal care (Chaulk et al. 1995;\\nUmbricht-Schneiter et al. 1994). Recent data on\\nbuprenorphine indicate that treatment with this\\nmedication, like methadone, has similar positive', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='outcomes (CSAT 2004a; Johnson et al. 2000;\\nKakko et al. 2003).\\nViewing opioid addiction as a medical disorder\\nis consistent with the idea that treatment of\\neven severe cases improves outcomes, just as in\\nother chronic and relapsing medical disorders,\\neven before abstinence is achieved. For \\nexample, Metzger and colleagues (1998) found\\nthat substance abuse treatment was associated\\nwith a significantly lower risk of HIV infection \\nthan was nontreatment. Treatment also was', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='associated with a significant reduction, but not\\nnecessarily cessation, of drug use for many\\nindividuals. Similar findings on the positive\\nhealth outcomes associated with maintenance\\ntreatment of opioid addiction, regardless of\\nwhether abstinence was attained, were seen in\\nstudies finding that methadone maintenance\\ndecreases overdose death. Data on benefits of\\npartial responses to maintenance treatment\\nresemble the benefits of treatment for other\\nchronic medical disorders in terms of symptom', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='alleviation. An analogy with MAT would be the\\ndesirability of reducing the risk of HIV infec-\\ntion, overdose, and the many psychosocial\\ncomplications of addiction, which is not as\\ndesirable as the benefits of attaining complete\\nabstinence from opioids but is associated \\nwith significantly improved patient health and \\nwell-being. The goal is always reducing or \\neliminating the use of illicit opioids and other\\nillicit drugs and the problematic use of pre-\\nscription drugs.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='scription drugs.\\nThe medical community recognizes that opioid\\naddiction is a chronic medical disorder that\\ncan be treated effectively with a combination of\\nmedication and psychosocial services. An\\nimportant development in MAT during the\\n1990s was the 1997 publication of recommen-\\ndations by a National Institutes of Health con-\\nsensus panel on effective medical treatment of\\nopiate addiction. After hearing from experts\\nand the public and examining the literature,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='the panel concluded that ì[opioid addiction] is\\na medical disorder that can be effectively treat-\\ned with significant benefits for the patient and\\nsocietyî (National Institutes of Health 1997b,\\np. 18). That panel explicitly rejected the notion\\nìthat [addiction] is self-induced or a failure of\\nwillpower and that efforts to treat it inevitably\\nfailî (p. 18). It called for ìa commitment to\\noffer effective treatment for [opioid addiction]\\nto all who need itî (p. 2). The panel also called', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='for Federal and State efforts to reduce the \\nstigma attached to MAT and to expand MAT\\nthrough increased funding, less restrictive', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 24}),\n",
       " Document(page_content='regulation, and efforts to make treatment avail-\\nable in all States (p. 24). The consensus panel\\nfor this TIP further recommends that access to\\ntreatment with methadone and other FDA-\\napproved medications for opioid addiction be\\nincreased for people who are incarcerated, on\\nparole, or on probation.\\nThe trend toward greater acceptance of MAT\\nas an effective treatment for opioid addiction\\nhas resulted in fewer State-mandated restric-\\ntions for treatment. For example, many States', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='have removed restrictions on the length of time\\nthat patients may remain in treatment.\\nMore Treatment Programs and\\nMore Patients in Treatment\\nIn 1993, when TIP 1 was published, approxi-\\nmately 750 registered OTPs were treating some\\n115,000 patients in 40 States, the District of\\nColumbia, Puerto Rico, and the Virgin Islands\\n(CSAT 1993b, p. 1). At this writing, more than\\n1,100 OTPs operating in 44 States, the District\\nof Columbia, Puerto Rico, and the Virgin', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='Islands are treating more than 200,000 patients\\n(Substance Abuse and Mental Health Services\\nAdministration n.d.b; Nicholas Reuter, personal\\ncommunication, June 2004). As of this writing,\\nmethadone treatment is not available in six\\nStates: Idaho, Mississippi, Montana, North\\nDakota, South Dakota, and Wyoming.\\nMost expansion in the treatment system in the\\npast 10 years has occurred in the proprietary\\nsector. Historically, most OTPs were funded\\npublicly, whereas proprietary programs were', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='in the minority. In the 1980s, public funding\\nfor methadone treatment began to be reduced,\\nalong with State, Federal, and local budgets,\\nand increasingly was replaced by private fee-\\nfor-service treatment programs in which\\npatients bore more of the costs (Knight et al.\\n1996a, 1996b; Magura and Rosenblum 2001).\\nChoices of Medications\\nThe National Institute on Drug Abuse (NIDA)\\nhas been working to broaden the array of effec-\\ntive treatment medications for chronic opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='addiction. Just after the publication of TIP 1,\\nFDA approved the use of LAAM, although its\\nuse has been curtailed\\nsubstantially since\\nthen (see chapter 3).\\nIn October 2002, \\nFDA approved two\\nnew formulations \\ncontaining buprenor-\\nphine for treatment \\nof opioid addiction.\\nBuprenorphine is\\nused to treat individu-\\nals who have been\\nopioid addicted for\\nless than 1 year, as\\nwell as patients for\\nwhom buprenor-\\nphineís unique prop-\\nerties are beneficial\\n(CSAT 2004a). The\\nopioid antagonist nal-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='trexone is available to\\ntreat people who are\\nopioid addicted and have undergone medically\\nsupervised withdrawal. These medications are\\ndiscussed in chapter 3.\\nTreatment Options\\nOTPs can provide several treatment options:\\nï Maintenance treatment combines pharmaco-\\ntherapy with a full program of assessment,\\npsychosocial intervention, and support ser-\\nvices; it is the approach with the greatest like-\\nlihood of long-term success for many patients.\\nï Medical maintenance treatment is provided to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='stabilize patients and may include long-term\\nprovision of methadone, buprenorphine,\\nLAAM, or naltrexone, with a reduction in \\nclinic attendance and other services. A\\npatient can receive medical maintenance \\nat an OTP , after he or she is stabilized \\nfully. The patient usually must complete a\\ncomprehensive treatment program first. The\\ndecision about whether to provide medical\\nmaintenance must be made by a licensed\\npractitioner. A designatedmedication unit\\n5Introduction\\nThe medical com-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='The medical com-\\nmunity recognizes\\nthat opioid addic-\\ntion is a chronic\\nmedical disorder\\nthat can be treated\\neffectively...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 25}),\n",
       " Document(page_content='(e.g., physicianís office, pharmacy, long-term\\ncare facility) affiliated with an OTP can pro-\\nvide some medical maintenance services. To\\nreduce clinic attendanceóa key feature of\\nmedical maintenanceópatients must qualify,\\nsubject to variations in State regulations\\n(which may be more stringent than Federal\\nregulations), to receive 7- to 14-day supplies\\nof methadone for take-home dosing after 1\\nyear of continuous treatment and 15- to 30-\\nday supplies after 2 years of continuous', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='treatment in an OTP (if additional criteria\\nare satisfied [see chapter 5]) (42 CFR, Part 8\\nß 12(h); Federal Register66:4079).\\nï Detoxification from short-acting opioids\\ninvolves medication and, perhaps, counseling\\nor other assistance to stabilize patients who\\nare opioid addicted by withdrawing them in a\\ncontrolled manner from the illicit opioids.\\nï Medically supervised withdrawal treatment\\ninvolves the controlled tapering of treatment\\nmedication for patients who want to remain', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='abstinent from opioids without the assistance\\nof medication.\\nBased on the framework provided by the Drug\\nAddiction Treatment Act of 2000 (21 United\\nStates Code 823(g)),\\nqualified practition-\\ners are authorized to\\nuse Subutex\\nÆand\\nSuboxoneÆ(see\\nchapter 3) to treat\\nchronic opioid\\naddiction in an\\noffice-based opioid\\ntreatment (OBOT)\\nor other health care\\nsetting.\\nThese alternatives\\nare increasing access\\nto care as OTPs\\nbroaden their range\\nof treatment options,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='more physicians offer OBOT and become bet-\\nter trained in MAT principles and methods,\\nand individuals with opioid addiction seek new\\npoints of treatment entry. At this writing, the\\navailability of these options varies, often\\nbecause of individual State regulations.\\nChanges in the Federal\\nRegulatory System\\nOn May 18, 2001, SAMHSA promulgated a\\nnew accreditation oversight system. Its goal \\nis to ìreduce the variability in the quality of\\nopioid treatment services, and reform the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='treatment system to provide for expanded\\ntreatment capacityî (Federal Register\\n64:39814). As OTPs meet these national \\nstandards, treatment improvement is expected\\nto continue along with increased attention to\\nprogram evaluation and quality improvement\\nmechanisms. The consensus panel hopes that\\nthis TIP will contribute to the movement\\ntoward quality-driven treatment standards.\\nRemaining Challenges\\nAlthough important strides have been made,\\nmuch remains to be done to improve and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='expand treatment and to address the stigma\\nthat affects patients and programs.\\nAdministering Appropriate\\nDose Levels\\nThe consensus panel believes that programs\\nshould monitor and adjust patientsí dose levels\\nof methadone and other opioid treatment medi-\\ncations to ensure that they receive therapeutic\\ndosages without regard to arbitrary dose-level\\nceilings that are unsupported by research evi-\\ndence. Dosage decisions should be appropriate\\nand tailored to each patient. Progress has been', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='made to ensure that patients receive the thera-\\npeutic dosage levels they need to remain stabi-\\nlized; however, the panel finds it troubling that\\nsome OTPs still fail to prescribe medication in\\nadequate doses (DíAunno and Pollack 2002).\\n6 Chapter 1\\nDosage decisions\\nshould be appro-\\npriate and tailored\\nto each patient.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 26}),\n",
       " Document(page_content='Treating Patients Who Have\\nMore Complex Problems\\nComplex problems can complicate patientsí\\ndiagnosis and treatment. When TIP 1 was \\npublished, the opioid addiction treatment \\nsystem faced two major challengesóthe spread\\nof HIV/AIDS and the problem of untreated \\nco-occurring disorders. The consensus panel\\nbelieves that the provision of psychiatric ser-\\nvices at or through OTPs has not kept pace\\nwith best practices. It is critical that OTPs be\\nprepared to diagnose and treat co-occurring', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='disorders aggressively, either directly or by\\nreferral. This issue is discussed in chapter 12.\\nThe treatment system is grappling with the\\nimplications of hepatitis C virus (HCV) infec-\\ntion among people who inject drugs, with esti-\\nmates of HCV infection in this group ranging\\nfrom 60 percent on average nationwide\\n(National Institute on Drug Abuse 2000) to 90\\npercent in some regions (Thomas 2001). OTPs\\nface the challenge of how to provide patient\\neducation and HCV testing for people who', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='inject drugs.\\nPatterns of opioid abuse have changed in the\\npast decade. For example, in some areas of the\\ncountry, patients are presenting with addiction\\nto pain management medications as a primary\\nadmission indication (CSAT 2001a; Office of\\nNational Drug Control Policy 2002). OTPs\\nreport that patients addicted to pain manage-\\nment medications require higher therapeutic\\nmethadone levels than other patients. Since the\\nmid-1990s, the prevalence of lifetime heroin', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='use has increased for both youth and young\\nadults. From 1995 to 2002, the rate among\\nyouth ages 12 to 17 increased from 0.1 to 0.4\\npercent; among young adults ages 18 to 25, the\\nrate rose from 0.8 to 1.6 percent (Substance\\nAbuse and Mental Health Services\\nAdministration 2003c).\\nPromoting Evidence-Based\\nTreatment Services\\nThroughout this TIP are many examples of\\ntypes of interventionsócomprehensive MAT ,\\nmedical maintenance, psychosocial interven-\\ntions, and moreóand program characteristics', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='that have been demonstrated to improve reten-\\ntion and outcomes for patients. The consensus\\npanel recommends that program administra-\\ntors and treatment providers compare their\\npractices with these evidence-based practices\\nand make necessary changes where appropri-\\nate. Moreover, OTPs should measure their \\noutcomes continuously, using appropriate pro-\\ngram evaluation tools, to improve treatment\\nquality (see chapter 14). Finally, OTPs may\\nwant to partner with the research community', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='to investigate and adopt new interventions for\\nimproving outcomes.\\nIn addition, SAMHSA has established and\\nfunded the Addiction Technology Transfer\\nCenter (ATTC) Network, which is dedicated to\\nimproving the skills and knowledge of sub-\\nstance abuse treatment providers and increas-\\ning their awareness of research findings.\\nRegional centers in the ATTC Network seek to\\naccomplish this goal by identifying and advanc-\\ning opportunities to improve addiction treat-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='ment through the dissemination of new infor-\\nmation in response to emerging needs and\\ndevelopments in the treatment field. (For more\\ninformation, visit the ATTC Web site at\\nwww.nattc.org.)\\nExpanding the Treatment\\nSystem\\nAlthough the number of patients enrolled in\\nOTPs for addiction treatment has almost dou-\\nbled since 1993, an estimated 898,000 people\\nchronically or occasionally use heroin in the\\nUnited States (Office of National Drug Control\\nPolicy 2003). Only about 20 percent of people', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='who use heroin are being treated. For people\\nwho abuse opioid medications normally\\nobtained by prescription, the percentage in\\ntreatment is even lower. \\nLack of funding for services remains a \\nsignificant barrier to treatment. In many\\nStates, Medicaid does not reimburse MAT \\nservices; accordingly, patients, many of whom\\n7Introduction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 27}),\n",
       " Document(page_content='have limited financial resources, are compelled\\nto finance their treatment. \\nMaking Treatment Available\\nto Criminal Justice Populations\\nCriminal justice populations are in critical need\\nof opioid addiction treatment, yet most do not\\nhave access to MAT (National Center on\\nAddiction and Substance Abuse 1998; National\\nDrug Court Institute 2002; U.S. Department of\\nJustice 1999). Resistance to MAT by many in\\nthe criminal justice system may be rooted in the\\ntraditional view that medical maintenance', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='treatment is substitution of one drug for \\nanother (National Center on Addiction and\\nSubstance Abuse 1998). The Rikers Island jail\\nfacility in New York City has been providing\\ninmates access to methadone treatment since\\n1987 (National Drug Court Institute 2002).\\nRhode Island jail facilities offer a 30-day \\ndose-tapering program. The consensus panel\\nunderstands that few other correctional institu-\\ntions have provided MAT services. \\nPromoting Comprehensive\\nTreatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='Treatment\\nIn its 1999 publication, Principles of Drug\\nAddiction Treatment: A Research-Based Guide,\\nNIDA stressed the importance of comprehen-\\nsive treatment services by devoting 3 of the 13\\nprinciples of effective drug addiction treatment\\nto comprehensive care (see Exhibit 1-1)\\n(National Institute on Drug Abuse 1999).\\nThe consensus panel believes that it is critical\\nto emphasize the central importance of compre-\\nhensive care as more physicians begin to use', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='buprenorphine to treat chronic opioid addic-\\ntion in their private offices. Ideally, a full con-\\ntinuum of care should integrate the services of\\nprimary care physicians who dispense opioid\\ntreatment medications in private offices and\\nother medication units with the services provid-\\ned by counselors, case managers, and other\\nessential staff in OTPs. \\nCombating Stigma\\nFor almost a century, the predominant view of\\nopioid addiction has been that it is a self-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='induced or self-inflicted condition resulting\\nfrom a character disorder or moral failing and\\nthat this condition is best handled as a criminal\\nmatter (see chapter 2). Use of methadone and\\nother therapeutic medications has been viewed\\ntraditionally as substitute therapyómerely\\nreplacing one addiction with another and the\\ntreatment of choice for those too weak to over-\\ncome temptation. The stigma associated with\\n8 Chapter 1', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='8 Chapter 1\\nï Effective treatment attends to multiple needs of the individual, not just his or her\\ndrug use. \\nï Counseling (individual and/or group) and other behavioral therapies are \\ncritical components of effective treatment for addiction.\\nï Medications are an important element of treatment for many patients, \\nespecially when combined with counseling and other behavioral therapies.\\nSource: National Institute on Drug Abuse 1999.\\nExhibit 1-1\\nNIDA Comprehensive Care-Related Principles of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='Effective Drug Addiction Treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 28}),\n",
       " Document(page_content='MAT has been unique in its permeation of com-\\nmunity institutions, affecting the attitudes of\\nmedical and health care professionals; social\\nservices agencies and workers; paraprofession-\\nals; employers, families, and friends of persons\\nwho are opioid addicted; and other people \\nwho formerly abused substances, as well as\\ninfluencing criminal justice policies, creating\\npolitical opposition, and limiting funding and\\nspace for OTPs.\\nAlthough diversion control is an important part', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='of MAT, public policy sometimes has seemed to\\nplace greater emphasis on protecting society\\nfrom methadone than on the addiction, vio-\\nlence, and infectious diseases that these medi-\\ncations help alleviate (Institute of Medicine\\n1995; Joseph et al. 2000; Nadelmann and\\nMcNeeley 1996). The cost-effectiveness of MAT\\noften has been overlooked (see chapter 2).\\nStigma affects patients in various ways. It \\ndiscourages them from entering treatment and\\nprompts them to leave treatment early. It cre-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='ates a barrier for those trying to access other\\nparts of the health care system. A striking\\nexample is the failure of many medical practi-\\ntioners to medicate pain adequately in this\\ngroup. In addition, the refusal of some organ\\ntransplant programs to provide liver trans-\\nplants to patients maintained on methadone\\nmay be a result of stigma, as well as a lack of\\nconvincing data on outcomes for methadone\\npatients who receive transplants.\\nStigma affects programs too. It prevents new', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='programs from opening when community oppo-\\nsition develops. It can affect a programís inter-\\nnal operations. Staff members who work in\\nOTPs sometimes absorb societyís antipathy\\ntoward patients in MAT and may deliver pro-\\ngram services with a punitive or counterthera-\\npeutic demeanor. OTPs must guard against\\nthese attitudes through supervision, education,\\nand leadership efforts (see chapter 14).\\nSeveral factors have made the destructive force\\nof stigma particularly intractable, including the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='isolation of MAT from mainstream medicine,\\nnegative media reports about treatment, and\\nthe public impressions made by poorly run\\nprograms. Fortunately, positive changes are\\noccurring in each area.\\nPositive stories about MAT in the media are\\nsometimes overshadowed by highly charged\\nnegative accounts, for example, stories about\\npatients loitering outside OTPs or diversion of\\ntake-home doses. SAMHSA, recognizing that\\nì[s]ignificant reduction in stigma and changes', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='in attitudes will require a concerted effort\\nbased on systematic researchî (CSAT 2000b, \\np. 4), has undertaken\\na national educational\\ncampaign, titled\\nPartners for\\nRecovery. Many OTP\\nmanagers and staff\\nmembers have isolat-\\ned themselves from\\ntheir communities,\\nwhich contributes to\\nnegative stereotypes\\nand media stories.\\nManagers and staff\\nmembers should\\ndevelop effective skills\\nfor working with the\\nmedia. The consensus\\npanel believes that the\\npatient advocacy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='patient advocacy\\nmovement also can advance a national educa-\\ntional campaign about MAT.\\nStrong efforts are needed to eliminate stigma\\nwithin OTPs as well. Staff members should\\ntreat patients with respect and pay attention \\nto the terms they use. The term ìsubstitution\\ntreatmentî should be avoided because it incor-\\nrectly implies that long-acting opioid medica-\\ntions act like heroin and other short-acting \\nopioids. Terms such as ìdirtyî and ìcleanî in\\nreference to drug-test specimens should be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='replaced by more clinically useful terms such\\nas ìpositiveî and ìnegative,î respectively. The\\nuse of criminal justice terms such as ìproba-\\ntionary treatmentî should be replaced with\\nclinically appropriate language (see chapter 14).\\nFinally, programs should become better neigh-\\nbors. Idle, perhaps intoxicated, patients who\\n9Introduction\\nManagers and\\nstaff members\\nshould develop\\neffective skills for\\nworking with the\\nmedia.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 29}),\n",
       " Document(page_content='remain near an OTP can become, by default,\\nthe programís public representatives and easy\\ntargets for complaints from the community.\\nFrequently, patient loitering is a result of insuf-\\nficient program management. Patient conduct\\nin and around OTPs should be considered both\\na treatment and a community relations concern.\\nThe Future of MAT\\nThis is an exciting and challenging time for the\\nMAT field, as positive changes accelerate and\\nreinforce one another. The consensus panel', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 30}),\n",
       " Document(page_content='hopes that this publication will advance high-\\nquality care in OTPs by providing up-to-date\\ninformation on science-based, best-treatment\\npractices and by highlighting sound ethical\\nprinciples of treatment. Equipped with this\\nTIP , the accreditation standards, and a devel-\\noping alliance with the general medical commu-\\nnity, OTPs should be able to improve and\\nexpand effective opioid addiction treatment\\nthroughout the country.\\n10 Chapter 1', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 30}),\n",
       " Document(page_content='In This\\nChapterÖ\\nLorem ipsum dolor\\nsit\\nSed do\\neiusmod\\nUt enim\\nad minim\\nveniam quis\\nDolore eu\\nfugiat nulla\\n11\\n2 History of Medication-\\nAssisted Treatment for\\nOpioid Addiction\\nIn This\\nChapterÖ\\nEmergence of\\nOpioid Addiction as\\na Significant\\nProblem and the\\nRoots of\\nControversy\\nOrigins of Opioid\\nMaintenance\\nTherapy\\nRegulatory History\\nThis chapter describes the history of opioid use and addiction in the\\nUnited States; changes in the population groups affected by opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 31}),\n",
       " Document(page_content='addiction disorders; and this countryís social, political, legal, and \\nmedical responses. The chapter emphasizes factors affecting the develop-\\nment and course of medication-assisted treatment for opioid addiction\\n(MAT) in opioid treatment programs (OTPs).\\nOpioid addiction has affected different population groups and socio-\\neconomic classes in the United States at different times. Societyís\\nresponse has changed along with changes in the groups or classes most', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 31}),\n",
       " Document(page_content='affected, shifts in social and political attitudes toward opioid addiction,\\nand the accumulation of more and better information about its causes\\nand treatments (Musto 1999). The consensus panel for this TIP believes\\nthat an appreciation for the roots of opioid addiction and treatment is\\nimportant because attitudes and beliefs about opioid use and addiction\\nthat are rooted in U.S. history over the past 150 years continue to \\ninfluence policies governing MAT.\\nEmergence of Opioid Addiction as', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 31}),\n",
       " Document(page_content='a Significant Problem and the\\nRoots of Controversy\\nMany of todayís substances of abuse including the opioidsóprimarily\\nopium, morphine, heroin, and some prescription opioidsógained their\\nearly popularity as curatives provided by physicians, pharmacists, and\\nothers in the healing professions or as ingredients in commercial prod-\\nucts ranging from pain elixirs and cough suppressants to beverages.\\nThese products usually delivered the benefits for which they were used,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 31}),\n",
       " Document(page_content='at least initially, such as pain relief, increased physical and mental ener-\\ngy (or ìrefreshmentî), and reduced anxiety. For example, opioids were\\noften the best available substances to relieve pain on Civil War battle-\\nfields. Unfortunately, the uncontrolled use of opioids either for pre-\\nscribed and advertised benefits or for nonmedicinal effects leads to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 31}),\n",
       " Document(page_content='increased tolerance and addiction. Tolerance\\nincreases the need for larger quantities of opi-\\noids, more frequent use, or combination with\\nother substances to\\nsustain their effects;\\nit also increases the\\nseverity of withdraw-\\nal when addiction is\\nnot satisfied. Recog-\\nnition of this prob-\\nlem has spurred a\\nlong-running debate\\namong patients and\\npeople who use \\nopioids, their fami-\\nlies, physicians,\\nresearchers, commu-\\nnity leaders, patient\\nadvocates, and \\ngovernment officials.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='This debate centers\\non two different\\nviews: (1) opioid addiction is a generally incur-\\nable disease that requires long-term mainte-\\nnance with medication; or (2) opioid addiction\\nstems from weak will, lack of morals, other\\npsychodynamic factors, or an environmentally\\ndetermined predilection that is rectified by\\ncriminalization of uncontrolled use and distri-\\nbution and measures promoting abstinence.\\nThe Changing Face of Opioid\\nAddiction\\nOpioid addiction first emerged as a serious', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='problem in this country during and after the\\nCivil War, when opioids were prescribed widely\\nto alleviate acute and chronic pain, other types\\nof discomfort, and stress. Although a smaller\\npattern of nonmedical opioid use continued as\\nwell, mainly opium smoking among Chinese\\nimmigrants and members of the Caucasian\\nìundergroundî (e.g., prostitutes, gamblers,\\npetty criminals), iatrogenic addiction was much\\nmore common (White 1998). By the late 19th\\ncentury, probably two-thirds of those addicted', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='to opioids (including opium, morphine, and\\nlaudanum) were middle- and upper-class White\\nwomen, a fact Brecher and the Editors of\\nConsumer Reports (1972, p. 17) attribute to\\nìthe widespread medical custom of prescribing\\nopiates for menstrual and menopausal discom-\\nfort, and the many proprietary opiates pre-\\nscribed for ëfemale troubles.í î Civil War veter-\\nans who were addicted by medical procedures\\ncomposed another group, but their numbers\\nwere dwindling. By 1900, an estimated 300,000', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='persons were opioid addicted in the United\\nStates (Brecher and Editors 1972; Courtwright\\n2001; Courtwright et al. 1989).\\nDuring the late 19th and early 20th centuries,\\nU.S. society generally viewed iatrogenic addic-\\ntion among women and disabled war veterans\\nsympatheticallyóas an unfortunate medical\\nconditionóand treated these groups with \\ntolerance and empathy, particularly because\\nneither group presented major social problems\\n(Courtwright 2001). Doctors usually prescribed', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='more opioids for these patients, and sanatori-\\nums were established for questionable ìcuresî\\nof the resulting addictions. The chronic nature\\nof opioid addiction soon became evident, how-\\never, because many people who entered sanato-\\nriums for a cure relapsed to addictive opioid\\nuse after discharge. In Eugene OíNeillís autobi-\\nographical drama ìLong Dayís Journey Into\\nNight,î for example, his father refuses to\\nreturn OíNeillís mother, who is addicted, to a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='sanatorium because he is aware of the addictive\\nqualities of morphine and is resigned to the\\ninevitability of relapse (Courtwright 2001).\\nBy the end of the 19th century, doctors became\\nmore cautious in prescribing morphine and\\nother opioids, and the prevalence of opioid\\naddiction decreased. Small groups still prac-\\nticed opium smoking, but most Americans\\nregarded it as socially irresponsible and\\nimmoral. It is noteworthy, however, that \\nheroin, introduced in 1898 as a cough suppres-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='sant, also began to be misused for its euphoric\\nqualities, gradually attracting new types of\\nusers. This development, along with diffusion\\nof the hypodermic technique of drug adminis-\\ntration, which gained popularity between 1910\\nand 1920, had a profound effect on opioid use\\nand addiction in the 20th century and beyond\\n(Courtwright 2001).\\n12 Chapter 2\\n[O]pioids were \\nprescribed widely\\nto alleviate acute\\nand chronic pain,\\nother types of dis-\\ncomfort, and\\nstress.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 32}),\n",
       " Document(page_content='The size and composition of the U.S. opioid-\\naddicted population began to change in the\\nearly 20th century with the arrival of waves of\\nEuropean immigrants. Courtwright (2001) \\nportrays most users of opioids of this period as\\nyoung men in their 20s: ìdown-and-outsî of\\nrecent-immigrant European stock who were\\ncrowded into tenements and ghettos and\\nacquired their addiction during adolescence or\\nearly adulthood. They often resorted to illegal\\nmeans to obtain their opioids, usually from', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='nonmedical sources and specifically for the\\neuphoric effects. ìGone was the stereotype of\\nthe addicted matron; in its place stood that of\\nthe street criminalî (Courtwright 2001, p. 1).\\nThe initial treatment response in the early 20th\\ncentury continued to involve the prescriptive\\nadministration of short-acting opioids. By the\\n1920s, morphine was prescribed or dispensed\\nin numerous municipal treatment programs\\n(Courtwright et al. 1989).\\nAddictive use of opium, cocaine, and heroin,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='along with drug-related crime, especially in\\npoor urban communities, increasingly con-\\ncerned social, religious, and political leaders.\\nThe tolerance and empathy shown toward Civil\\nWar veterans and middle-aged women evapo-\\nrated; negative attitudes toward and discrimi-\\nnation against new immigrants probably col-\\nored views of addiction. Immigrants and others\\nwho trafficked in and abused drugs were\\nviewed as a threat. As detailed below, societyís\\nresponse was to turn from rudimentary forms', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='of treatment to law enforcement (Brecher and\\nEditors 1972; Courtwright 2001; Courtwright et\\nal. 1989). For more on trends in the 1920s and\\n1930s, see ìEarly treatment effortsî below.\\nMcCoy (n.d.) refers to a forced decline in \\nopioid addiction during World War II, brought\\nabout by restrictions on shipping and strict\\nport security, which produced a marked hiatus\\nin global opium trafficking and caused the U.S.\\nopioid-addicted population to drop to a historic', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='low of about 20,000. Once smuggling resumed\\nafter the war, the population that had used \\nopioids resumed the habit.\\nAnother major change in the U.S. opioid-\\naddicted population occurred after World \\nWar II. As many European immigrants moved\\nfrom crowded cities, Hispanics and African-\\nAmericans moved into areas with preexisting\\nopioid abuse problems, and the more suscepti-\\nble people in these groups acquired the disorder\\n(Courtwright 2001; Courtwright et al. 1989).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='The post-World War II shift in the composition\\nof opioid-addicted groups coincided with hard-\\nening attitudes toward these groups, leading\\nsome researchers to conclude that stigmatiza-\\ntion of people with addiction disorders and\\ntheir substances of abuse reflected, at least in\\npart, class and ethnic biases. A portion of U.S.\\nsociety appeared to view with disdain and fear\\nthe poor White, Asian, African-American, and\\nHispanic people with addiction disorders who', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='lived in the inner-city ghettos (Courtwright et\\nal. 1989).\\nBrecher and the Editors of Consumer Reports\\n(1972) point out that, by the mid-1960s, the\\nnumber of middle-class young White Americans\\nusing heroin was on the rise, as was addiction-\\nrelated crime. By the 1970s, U.S. military\\ninvolvement in Vietnam also was having an\\neffect. From one-fourth (Brecher and Editors\\n1972) to one-half (Courtwright 2001) of\\nAmerican enlisted men in Vietnam were\\nbelieved to have used or become addicted to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='heroin; however, White (1998) points out that\\nthe feared epidemic of heroin addiction among\\nreturning veterans did not materialize fully. He\\nconcludes, ìVietnam demonstrated that a pat-\\ntern of drug use could emerge in response to a\\nparticular environment and that spontaneous\\nremission could occur when the environment\\nwas changedî (p. 303).\\nBy the 1980s, an estimated 500,000 Americans\\nused illicit opioids (mainly heroin), mostly poor\\nyoung minority men and women in the inner', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='cities. Although this number represented a \\n66-percent increase over the estimated number\\nof late 19th-century Americans with opioid\\naddiction, the per capita rate was much less\\nthan in the late 19th century because the \\npopulation had more than doubled\\n13History of Medication-Assisted Treatment for Opioid Addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 33}),\n",
       " Document(page_content='(Courtwright et al. 1989). Nevertheless, \\naddiction became not only a major medical\\nproblem but also an explosive social issue\\n(Courtwright 2001; Courtwright et al. 1989).\\nBy the end of the 1990s, an estimated 898,000\\npeople in the United States chronically or occa-\\nsionally used heroin (Office of National Drug\\nControl Policy 2003), and the number seeking\\ntreatment was approximately 200,000 (almost\\ndouble the number during the 1980s). The\\nabuse of opioids that normally were obtained', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='by prescription was a growing concern because\\nof both their damaging effects and their poten-\\ntial as gateway drugs to other substance use.\\nTreatment admission rates for addiction to opi-\\noid analgesics more than doubled between 1992\\nand 2001 (Substance Abuse and Mental Health\\nServices Administration 2004), and visits to\\nemergency rooms related to opioid analgesic\\nabuse increased 117 percent between 1994 and\\n2001 (Substance Abuse and Mental Health\\nServices Administration 2003b).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='Societyís Changing Response\\nThe Harrison Narcotic Act of\\n1914\\nThe Pure Food and Drug Act of 1906, which\\nrequired medicines containing opioids to say so\\non their labels, was the first national response\\nto the changing image of people with addictions\\n(Brecher and Editors 1972). The Harrison\\nNarcotic Act of 1914 was the earliest significant\\nFederal attempt to place strict controls on opi-\\noids and other substances (Brecher and Editors\\n1972). Although U.S. mercantile and trade', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='interests were also at stake, the widely held\\nperception that people with addictions generally\\nwere members of a White criminal underclass\\nor a Chinese minority has been portrayed as \\nan underlying motivation for the statute\\n(Courtwright 2001; Courtwright et al. 1989).\\nThe Harrison Act was conceived not as a prohi-\\nbition law but as a measure to regulate the\\nmanufacture, distribution, and prescription of\\nopioids, coca, and their derivatives. Under the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='actís provisions, manufacturers, pharmacists,\\nand physicians had to be licensed, keep records\\nfor inspection, and pay modest fees to the U.S.\\nDepartment of the Treasury, referred to here-\\nafter as Treasury. \\nThe act permitted physicians and dentists to\\ndispense or distribute opioids ìto a patient . . .\\nin the course of [the physicianís] professional\\npractice onlyî (38 Stat. 786 [1914]). Although\\nthis provision permitted physicians to prescribe\\nor dispense opioids so long as they kept the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='required records, Treasury interpreted the act\\nas a prohibition on physiciansí prescribing opi-\\noids to persons with addictions to maintain\\ntheir addictions. (Treasury was the agency\\nresponsible for enforcing the Harrison Act as\\nwell as prohibition laws.) Treasuryís position\\nappeared to be that addiction is not a disease\\nand the person with an addiction, therefore,\\nwas not a patient. It followed that any physi-\\ncian prescribing or dispensing opioids to such', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='individuals was not doing so in the ìcourse of\\nhis professional practiceî (White 1998). In\\n1919, the United States Supreme Court upheld\\nTreasuryís interpretation. This interpretation\\nand enforcement of the Harrison Act effectively\\nended, until well into the 1960s, any legitimate\\nrole for the general medical profession in \\nmedication-assisted treatment for Americans\\nwho had drug addictions (White 1998).\\nEarly treatment efforts\\nUntil the 1919 Supreme Court decision uphold-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='ing Treasuryís interpretation of the Harrison\\nAct, numerous municipalities with large num-\\nbers of residents who were opioid addicted\\nwere operating treatment clinics in which \\nmorphine was prescribed or dispensed. Some\\nclinics prescribed heroin and cocaine\\n(Courtwright et al. 1989). These early OTPs\\nvaried in how they functioned; some provided\\ndetoxification treatment and others adopted a\\nmaintenance policy (Courtwright 2001; Gewirtz\\n1969). Perhaps the best known of these early', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='OTPs were the Department of Health program\\nin New York City, where those with addictions\\nwere detoxified with decreasing doses of heroin\\nand morphine, and the program established by\\nDr. Willis Butler in Shreveport, Louisiana,\\n14 Chapter 2', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 34}),\n",
       " Document(page_content='which not only detoxified patients but also\\nmaintained some of them on morphine\\n(Courtwright et al. 1989).\\nCourtwright and others state that Treasury\\nregarded these clinics as a threat to its anti-\\nmaintenance philosophy. By the early 1920s, it\\nhad succeeded in closing them through legal\\npressure, critical inspections, and threats. The\\nlast program to be closed was Dr. Butlerís in\\nShreveport (Courtwright 2001; Courtwright et\\nal. 1989).\\nIn the 1920s, an increase in crime related to the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='acquisition of illicit opioids was reported in\\ncities throughout the country. In 1929,\\nCongress appropriated funds to establish two\\nnew treatment facilities, initially called ìnar-\\ncotics farmsî (White 1998), in Fort Worth,\\nTexas, and Lexington, Kentucky. The\\nLexington facility, which opened to patients in\\n1935, was renamed the U.S. Public Health\\nService Narcotics Hospital in 1936. These insti-\\ntutions detoxified patients with opioid addic-\\ntion who entered voluntarily, and they also', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='served as hospitals for prison inmates who had\\nopioid addictions and were legally committed\\nthrough a Federal court. The prescribed stay\\nwas about 6 months, although some patients\\nstayed longer. Prisoners could stay for up to 10\\nyears. These hospitals offered social, medical,\\npsychological, and psychiatric services in \\naddition to detoxification and had a low\\npatient-to-staff ratio (about 2 to 1), but the\\natmosphere was described as prisonlike, espe-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='cially at the Lexington facility (White 1998).\\nTwo major followup studies showed the pro-\\ngram to be a failure. One reported a relapse\\nrate of 93 percent in 1,881 former patients over\\na 1.0- to 4.5-year followup period (Hunt and\\nOdoroff 1962). The second found a relapse rate\\nof 97 percent in 453 former patients over fol-\\nlowup periods of 6 months to 5 years (Duvall et\\nal. 1963). The Lexington hospital facility was\\nturned over to the Bureau of Prisons in 1974', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='(Courtwright et al. 1989). Despite the failure of\\nthese programs, White credits the research\\nconducted there with providing ìmuch of the\\nfoundation upon which modern treatment\\nadvances were builtî (White 1998, p. 126).\\nThe increase in heroin addiction in New York\\nCity after World War II led, in 1952, to the\\nestablishment of Riverside Hospital for adoles-\\ncents with addiction disorders. This program\\nalso proved to be a failure. A followup study in\\n1956 showed a high posttreatment relapse rate', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='(e.g., at least 86 percent of patients admitted in\\n1955), and the Riverside facility was closed in\\n1961 (Brecher and Editors 1972).\\nExperiment in civil \\ncommitment\\nCivil commitment is portrayed by Brecher and\\nthe Editors of Consumer Reports (1972) and\\nWhite (1998) as legislation enabling those with\\nsubstance addiction and those ìin imminent\\ndanger of becoming addictedî (White 1998, p.\\n250) to be confined in rehabilitation centers\\nwithout having first committed or been convict-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='ed of a crime. Civil commitment was instituted\\nin California and New\\nYork in the 1960s to\\nallay fears about\\naddiction-related\\ncrimes against people\\nand property in the\\ninner cities. People\\nwith addictions could\\nbe committed to \\nfacilities through a\\nvoluntary process \\nthat included a \\nmedical examination\\nto validate the pres-\\nence of an addiction,\\nor they could be \\ncommitted for 3 years\\nwhen arrested on a\\nmisdemeanor charge, as an alternative to a \\njail sentence. The civil commitment program', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='instituted in New York in 1966 turned out to be\\nexceedingly expensive, and the positive results\\nwere minimal (Brecher and Editors 1972;\\nInciardi 1988). The great majority of those\\nadmitted, treated, and paroled to aftercare\\nprograms dropped out of these programs, and\\nthey usually could not be located. A review of\\nCaliforniaís civil commitment experience in the\\n15History of Medication-Assisted Treatment for Opioid Addiction\\nTreasuryís posi-\\ntion appeared to\\nbe that addiction\\nis not a disease...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='and the personÖ\\nnot a patient.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 35}),\n",
       " Document(page_content='1960s showed that five of every six patients\\ncommitted for addictions and subsequently\\nplaced on aftercare relapsed, were rearrested,\\ndropped out of treatment, died, or were\\nremoved from the program by writs of habeas\\ncorpus (Joseph 1988; Joseph and Dole 1970).\\nAlthough statutes permitting involuntary com-\\nmitment might remain on the books in some\\nStates, such laws rarely have been used to com-\\nmit people who abuse substances and who are\\nnot under criminal justice jurisdiction (Anglin', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='1988). Court decisions after the 1960s generally\\nhave required that an individual be a danger to\\nhimself or herself or others before the legal sys-\\ntem can use involuntary commitment (e.g.,\\nOíConnor v. Donaldson, 422 U.S. 563, 1975).\\nThe search for alternatives\\nIn New York, death rates associated with the\\ninjection of heroin increased from 7.2 to 35.8\\nper 10,000 deaths between 1950 and 1961\\n(Frank 2000; Joseph et al. 2000). In the 1960s\\nand 1970s, more than 150,000 names were\\nadded to the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='added to the\\nNarcotics Register\\nin New York City.\\n(The Narcotics\\nRegister, active\\nfrom 1967 to 1974,\\nwas a list of known\\nor suspected persons\\nwith addictions.)\\nBy the middle to\\nlate 1960s,\\nillicitñopioid-related\\nmortality had\\nbecome the leading\\ncause of death for\\nyoung adults from\\nages 15 to 35 in New\\nYork City. The\\nnumber of serum\\nhepatitis (now\\ncalled hepatitis B)\\ncases related to con-\\ntaminated needles\\nalso was increasing.\\nRecord numbers of\\npeople with opioid addictions were arrested for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='drug-related crimes (e.g., possession, sales,\\nrobbery, burglary), and overcrowded jails had\\nno effective method to ease detoxification\\n(Inciardi 1988; Joseph and Dole 1970). By 1968,\\nthe Manhattan County Jail for Men (also known\\nas the Tombs) had been wracked by riots\\nblamed on poor living conditions, severe over-\\ncrowding, and lack of medical care for inmates\\nwith drug addictions.\\nAs the incidence of addiction and related crimi-\\nnal activity rose dramatically in urban areas,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='concern grew in the legal and medical commu-\\nnities because increased incarceration had\\nfailed to stem the tide. The legal and medical\\nprofessions were perturbed by the post-World\\nWar II rise in opioid addiction in the United\\nStates and the ineffectiveness of Federal regula-\\ntory policy. In 1958, a joint committee of the\\nAmerican Bar Association and the American\\nMedical Association (AMA) issued a report \\nrecommending that an outpatient facility \\nprescribing opioids to treat addiction be estab-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='lished on a controlled experimental basis\\n(Brecher and Editors 1972).\\nOther groups voiced support for the concept of\\nopioid maintenance programs. The New York\\nAcademy of Medicine recommended, in 1955\\nand again in 1963, that clinics be established in\\naffiliation with hospitals to dispense opioids in a\\ncontrolled manner to patients addicted to illicit\\nopioids. In 1956, the AMA advocated a\\nresearch project to investigate the feasibility of\\ndispensing opioids in an OTP . In 1963, the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='Kennedy administrationís Advisory Commission\\non Narcotic and Drug Abuse also recommended\\nresearch to determine the effectiveness of out-\\npatient OTPsí dispensing of opioids to people\\naddicted to opioids (Brecher and Editors 1972).\\nIn the early 1970s, faced with increased opioid-\\nrelated drug use and crimes, the Nixon admin-\\nistration greatly increased funding to stem the\\nsupply of illicit opioids, primarily heroin,\\nentering the United States. It also greatly', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='increased funding for methadone maintenance,\\nand the number of patients receiving methadone\\nincreased from 9,000 in 1971 to 73,000 in 1973\\n(Courtwright 2001). Support for opioid \\n16 Chapter 2\\nSupport for opioid\\nmaintenance grew,\\nespecially because\\nno effective \\npsychosocial alter-\\nnative existed to\\ntreat the large\\nnumber of people\\nwith opioid \\naddictions.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 36}),\n",
       " Document(page_content='maintenance grew, especially because no effec-\\ntive psychosocial alternative existed to treat the\\nlarge number of people with opioid addictions.\\nOrigins of Opioid\\nMaintenance Therapy\\nDevelopment of Medications\\nTo Treat Opioid Addiction\\nEarly rationale for\\nmethadone maintenance\\ntreatment\\nIn 1962, Dr. Vincent P . Dole, a specialist in\\nmetabolism at The Rockefeller University,\\nbecame chair of the Narcotics Committee of the\\nHealth Research Council of New York City.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='After studying the scientific, public health, and\\nsocial ramifications of addiction in the city, he\\nreceived a grant to establish a research unit to\\ninvestigate the feasibility of opioid mainte-\\nnance. In preparing for this research, he read\\nThe Drug Addict as a Patient by Dr. Marie E.\\nNyswander (Nyswander 1956), a psychiatrist\\nwith extensive experience treating patients who\\nwere addicted to opioids. She was convinced\\nthat these individuals could be treated within', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='general medical practice. She also believed that\\nmany would have to be maintained on opioids\\nfor extended periods to function because a \\nsignificant number of people who attempted\\nabstinence without medication relapsed, in\\nspite of detoxifications, hospitalizations, and\\npsychotherapy (Brecher and Editors 1972;\\nCourtwright et al. 1989). Dr. Nyswander joined\\nDr. Doleís research staff in 1964. Among others\\njoining the team was clinical investigator Dr.\\nMary Jeanne Kreek.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='Mary Jeanne Kreek.\\nThese researchers realized that morphine,\\nwhich is related to heroin, was not a good\\nchoice as an opioid maintenance drug because\\npatientsí social functioning was impaired by\\nmorphineís sedating effects (White 1998). Also,\\nthe short half-life of morphine required several\\ninjections per day, and, as tolerance developed,\\nincreasing amounts were needed over a short\\ntime for patients to remain stable (Brecher and\\nEditors 1972). Other short-acting opioids, such', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='as heroin, codeine, oxycodone, and meperidine\\n(Demerol\\nÆ), showed similar results (Dole 1980,\\n1988).\\nDevelopment of methadone\\nWith short-acting opioids eliminated as options\\nfor maintenance therapy, research focused on\\nmethadone. Methadone appeared to be longer\\nacting and effective when administered orally.\\nIt also was selected on the basis of observations\\nof its use in patients withdrawing from heroin\\nand as an analgesic in the experimental treat-\\nment of pain (Dole 1980, 1988). In 1964, tech-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='nology was not available to measure blood levels\\nof heroin, morphine, or methadone to assess\\nduration of action. Proof of the efficacy of\\nmethadone maintenance treatment depended\\non observation and recognition by researchers.\\nIn an initial study, methadone was adminis-\\ntered to two patients previously maintained on\\nmorphine. Once tolerance for daily doses of 50\\nto 120 mg was established, patients could func-\\ntion normally without the anxiety associated', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='with drug craving (White 1998). During this\\nresearch, the following important findings\\nabout methadone maintenance were noted, all\\nsupporting its efficacy and benefits (Dole 1980,\\n1988):\\nï Patients did not experience euphoric, tran-\\nquilizing, or analgesic effects. Their affect\\nand consciousness were normal. Therefore,\\nthey could socialize and work normally with-\\nout the incapacitating effects of short-acting\\nopioids such as morphine or heroin.\\nï A therapeutic, appropriate dose of methadone', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='reduced or blocked the euphoric and tran-\\nquilizing effects of all opioid drugs examined\\n(e.g., morphine, heroin, meperidine, and\\nopium), regardless of whether a patient\\ninjected or smoked the drugs.\\nï No change usually occurred in tolerance \\nlevels for methadone over time, unlike for\\nmorphine and other opioids; therefore, a\\ndose could be held constant for extended\\nperiods (more than 20 years in some cases). \\n17History of Medication-Assisted Treatment for Opioid Addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 37}),\n",
       " Document(page_content='ï Methadone was effective when administered\\norally. Because it has a half-life of 24 to 36\\nhours, patients could take it once a day \\nwithout using a syringe.\\nï Methadone relieved the opioid craving or\\nhunger that patients with addiction described\\nas a major factor in relapse and continued\\nillegal use.\\nï Methadone, like most opioid-class drugs,\\ncaused what were considered minimal side\\neffects, and research indicated that\\nmethadone was medically safe and nontoxic.\\nExpansion of methadone', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='maintenance from research\\nproject to public health \\nprogram\\nIn 1965, the initial research project on\\nmethadone safety and efficacy was transferred\\nto Manhattan General Hospital in New York\\nCity (Brecher and Editors 1972). Because Dole\\nand his colleagues knew that an independent\\nevaluation of this new treatment would be \\nnecessary, a team headed by Dr. Frances Rowe\\nGearing was formed at Columbia University\\nSchool of Public Health to evaluate patient', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='progress as this treatment expanded. In general,\\nthe team found that patientsí social functioning\\nimproved with time in treatment, as measured\\nby elimination of illicit-opioid use and better\\noutcomes in employment, school attendance,\\nand homemaking. Most patients were stabilized\\non methadone doses of 80 to 120 mg/day. Most\\npatients who remained in treatment subse-\\nquently eliminated illicit-opioid use. However,\\n20 percent or more of these patients also had', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='entered treatment with alcohol and polysub-\\nstance abuse problems, despite intake screening\\nthat attempted to eliminate these patients from\\ntreatment (Gearing and Schweitzer 1974).\\nMethadone treatment was continued for these\\npatients, along with attempts to treat their \\nalcoholism and polysubstance abuse. Further\\nevaluation, research, and expansion of the \\nprogram ultimately were recommended (Joseph\\nand Dole 1970) and instituted. Methadone\\nmaintenance became a major public health', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='initiative to treat opioid addiction under the\\nleadership of Dr. Jerome Jaffe, who headed the\\nSpecial Action Office for Drug Abuse\\nPrevention in the Executive Office of the White\\nHouse in the early 1970s. Dr. Jaffeís office\\noversaw the creation of a nationwide, publicly\\nfunded system of treatment programs for \\nopioid addiction.\\nDevelopment of LAAM\\nLike methadone, levo-alpha acetyl methadol\\n(LAAM) was classified as a U.S. Drug\\nEnforcement Administration (DEA) schedule II', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='controlled substance (i.e., having a high poten-\\ntial for abuse but also a currently accepted\\nmedical use) that creates a pharmacologic\\ncross-tolerance for other opioids and therefore\\nblocks their euphoric effects while controlling\\nopioid craving. Whereas methadone suppressed\\nopioid withdrawal symptoms for 24 hours or\\nlonger, LAAM achieved this effect for 48 to 72\\nhours or longer.\\nLAAM was first developed in 1948 by German\\nchemists as an analgesic (Finn and Wilcock', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='1997). By the late 1960s, interest arose in\\nLAAM as an alternative to methadone\\n(American Association for the Treatment of\\nOpioid Dependence n.d.). Between 1969 and\\n1981, 27 separate studies of more than 6,000\\npatients established LAAMís safety and efficacy\\n(National Institute on Drug Abuse 1993a). The\\nU.S. Food and Drug Administration (FDA)\\napproved LAAM for use in OTPs in July 1993\\n(National Institute on Drug Abuse 1993a).\\nLater studies continued to confirm that LAAM', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='was an effective alternative to methadone and\\nwas preferred by some patients (Glanz et al.\\n1997). However, in April 2001, based on\\nreported LAAM-related disturbances in cardiac\\nfunction, FDA and Roxane Laboratories, Inc.,\\nmanufacturer of ORLAAM\\nÆ, strengthened the\\nwarnings in LAAM product labeling (Haehl\\n2001). The American Association for the\\nTreatment of Opioid Dependence has issued\\nclinical guidelines for LAAM (American\\nAssociation for the Treatment of Opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='Dependence n.d.). At this writing, only 3 \\n18 Chapter 2', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 38}),\n",
       " Document(page_content='percent of patients enrolled in maintenance\\nprograms in the United States are receiving\\nLAAM (Substance Abuse and Mental Health\\nServices Administration 2002a).\\nIn 2003, Roxane Laboratories announced that\\nit would stop producing LAAM on January 1,\\n2004 (Schobelock 2003), making LAAMís con-\\ntinued availability doubtful. This TIP contin-\\nues to include basic, limited coverage of LAAM\\nin discussions of opioid medications because of\\nits clinical significance and relevance in MAT.\\nDevelopment of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='Development of \\nbuprenorphine\\nInformation on the development of the latest\\nsuccessful maintenance medication, buprenor-\\nphine, is in ìDEA classification of buprenor-\\nphineî below and TIP 40, Clinical Guidelines\\nfor the Use of Buprenorphine in the Treatment\\nof Opioid Addiction(CSAT 2004a).\\nDevelopment of naltrexone\\nNaltrexone is the only pure opioid antagonist of\\nthe medications described here (see chapter 3).\\nIn the early 1980s, the National Institute on', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='Drug Abuse (NIDA) completed initial testing of\\nnaltrexone to treat opioid addiction, and FDA\\napproved naltrexone for this use in 1984. In\\n1995, naltrexone also received FDA approval\\nas a preventive treatment for relapse to alcohol\\nuse among patients dependent on alcohol. Some\\nopioid treatment providers have found that\\nnaltrexone is most useful for highly motivated\\npatients who have undergone detoxification\\nfrom opioids and need additional support \\nto avoid relapse or who desire an expedited', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='detoxification schedule because of external \\ncircumstances. Naltrexone also may benefit\\nsome patients in the beginning stages of opioid\\nuse and addiction. Other patient groups \\nfrequently have demonstrated poor compliance\\nwith long-term naltrexone therapy, mainly\\nbecause naltrexone neither eases craving for\\nthe effects of illicit opioids when used as direct-\\ned nor produces withdrawal symptoms when\\ndiscontinued (Tai et al. 2001).\\nPublic Policy Studies and\\nReports Since 1993', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='Reports Since 1993\\nAnalyses since the publication of TIP 1 have\\nshown that maintenance treatment for opioid\\naddiction is effective in both treatment out-\\ncomes and costs.\\nCalifornia Drug and Alcohol\\nTreatment Assessment\\nIn 1994, the California\\nDepartment of Alcohol\\nand Drug Programs\\npublished the results\\nof a pioneering large-\\nscale study of the\\neffectiveness, benefits,\\nand costs of substance\\nabuse treatment in\\nCalifornia. Using State\\ndatabases, provider\\nrecords, and followup', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='interviews with treat-\\nment participants, the\\nstudy detailed the\\neffects of treatment on\\nparticipant behavior\\nincluding drug and\\nalcohol use, criminal\\nactivity, health, health\\ncare use, and income;\\nthe costs of treatment; and the economic value of\\ntreatment to society (Gerstein et al. 1994). \\nAmong the California Drug and Alcohol\\nTreatment Assessmentís findings were the \\nfollowing:\\nï Treatment was cost beneficial to taxpayers,\\nwith the cost averaging $7 returned for every', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='dollar invested (Gerstein et al. 1994). ìEach\\nday of treatment paid for itself (the benefits\\nto taxpaying citizens equaled or exceeded the\\ncosts) on the day it was received, primarily\\nthrough an avoidance of crimeî (Gerstein et\\nal. 1994, p. iv). ìRegardless of the modality\\nof care, treatment-related economic savings\\noutweighed costs by at least 4 to 1î (Gerstein\\net al. 1994, p. 90).\\n19History of Medication-Assisted Treatment for Opioid Addiction\\nAnalysesÖhave\\nshown that main-\\ntenance treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='tenance treatment\\nfor opioid addic-\\ntion is effective in\\nboth treatment\\noutcomes and\\ncosts.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 39}),\n",
       " Document(page_content='20 Chapter 2\\nï Methadone treatment was among the most\\ncost-effective treatments, yielding savings of\\n$3 to $4 for every dollar spent. This was true\\nfor each major methadone treatment modali-\\nty, but costs were lower in an outpatient OTP\\nthan in a residential or social modality\\n(Gerstein et al. 1994).\\nï Patients in methadone maintenance showed\\nthe greatest reduction in intensity of heroin\\nuse, down by two-thirds, of any type of opi-\\noid addiction treatment studied.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='ï Patients in methadone maintenance showed\\nthe greatest reductions in criminal activity\\nand drug selling, down 84 percent and 86\\npercent, respectively, of any type of opioid\\naddiction treatment studied.\\nï Health care use decreased for all treatment\\nmodalities; participants in methadone main-\\ntenance treatment showed the greatest reduc-\\ntion in the number of days of hospitalization,\\ndown 57.6 percent, of any modality.\\nInstitute of Medicine\\nIn 1995, the Institute of Medicine (IOM) pro-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='duced a study titled Federal Regulation of\\nMethadone Treatment(Institute of Medicine\\n1995). This study\\nconcluded that FDA\\nregulations were\\ninhibiting physicians\\nfrom exercising their\\nprofessional judg-\\nment; isolating\\nmethadone treat-\\nment from main-\\nstream medicine,\\nthereby depriving\\npatients of important\\nancillary services;\\nand discouraging\\nresearch into new\\nmedications. This\\nIOM study recom-\\nmended that the\\nFederal \\nregulatory process\\nbe modified to\\nï Encourage programs to provide comprehen-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='sive services, such as individual and group\\ncounseling and medical care\\nï Emphasize the need for continuing clinical\\nassessment throughout treatment\\nï End arbitrary restrictions on OTP practices.\\nNational Institutes of Health\\nIn 1997, a National Institutes of Health (NIH)\\nconsensus panel called for expansion of\\nmethadone maintenance treatment. It identified\\nsuch barriers as the publicís misperception of\\npersons who are opioid addicted not as individ-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='uals with a disease but as ìotherî or ìdifferent,î\\nthe misperception ìthat [addiction] is self-\\ninduced or a failure of willpower and that\\nefforts to treat it inevitably fail,î and overregu-\\nlation of methadone treatment that limits the\\nflexibility and responsiveness of treatment \\nprograms (National Institutes of Health 1997b).\\nThat panel called for the following:\\nï Federal leadership to inform the public that\\nopioid addiction is a medical disorder that', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='can be treated effectively, with significant\\nbenefits for the patient and society\\nï Access to methadone treatment for persons\\nunder legal supervision (e.g., probation,\\nparole, incarceration)\\nï Increase in funding for methadone mainte-\\nnance treatment\\nï Reduction in unnecessary regulation of MAT,\\nincluding\\nñ Replacement of FDA regulation and \\noversight of MAT with more effective, less\\nexpensive measures, such as accreditation,\\nto improve the quality of methadone \\ntreatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='treatment\\nñ Revision of DEA regulations to eliminate\\nthe extra level of regulation placed on\\nmethadone compared with other schedule\\nII opioids, thereby encouraging more\\nphysicians and pharmacies to prescribe\\nand dispense methadone and making\\nmaintenance treatment available in more\\nlocations\\nFor more than\\nthree decades,\\nmethadoneís use to\\ntreat addiction has\\nbeen subjected to\\nextensive Federal,\\nState, and local\\nregulation.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 40}),\n",
       " Document(page_content='21History of Medication-Assisted Treatment for Opioid Addiction\\nñ Faster approval of new medications for\\nMAT by FDA and the States\\nñ Expansion of the availability of \\nmaintenance pharmacotherapy to States\\nand programs where it is currently\\nunavailable.\\nRegulatory History\\nFor more than three decades, methadoneís use\\nto treat addiction has been subjected to extensive\\nFederal, State, and local regulation. (For a\\ndetailed history of Federal regulation of\\nmethadone treatment, see chapter 5 in the IOM', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='report [1995] edited by Rettig and Yarmolinsky.)\\nLaws Related to Controlled\\nSubstances as Addiction\\nTreatment Medications\\nCongress has enacted several significant\\nstatutes since 1970 to limit and control the\\navailability of psychoactive drugs and their use\\nto treat addiction.\\nControlled Substances Act\\n(1970)\\nThe Controlled Substances Act of 1970 (Public\\nLaw [P .L.] 91ñ513) requires all manufacturers,\\ndistributors, and practitioners who prescribe,\\ndispense, or administer controlled substances', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='to register with DEA. A physician seeking \\nregistration must meet certain standards estab-\\nlished by the Secretary of Health and Human\\nServices and must comply with regulations\\nestablished by the U.S. Attorney General\\nregarding security of opioid stocks and mainte-\\nnance of records.\\nNarcotic Addict Treatment\\nAct (1974)\\nIn passing the Narcotic Addict Treatment Act\\nof 1974 (P .L. 93ñ281), which amended the\\nControlled Substances Act, Congress \\nrecognized the use of an opioid drug to treat', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='opioid addiction as critical and, for the first\\ntime in Federal law, defined ìmaintenance\\ntreatment.î To promote closer monitoring of\\nprograms that use opioids for maintenance\\ntreatment, the law required separate DEA \\nregistration by medical practitioners who dis-\\npense opioid drugs in the treatment of opioid\\naddiction. Previously, any physician with a\\nDEA registration could prescribe methadone\\nfor pain management or addiction treatment.\\nThis act also increased coordination between', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='the U.S. Department of Health and Human\\nServices (DHHS) and DEA. Under its provi-\\nsions, before a practitioner can obtain regis-\\ntration from DEA, DHHS must determine\\nthat the practitioner is qualified according to\\nestablished treatment standards.\\nThe Narcotic Addict Treatment Act also \\nestablished NIDA as an institute independent \\nof the National Institute of Mental Health.\\nAuthority to regulate the treatment of opioid\\naddiction was split between NIDA and FDA.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='NIDA became responsible for determining\\nappropriate standards for medical, scientific,\\nand public health aspects of drug abuse treat-\\nment. FDA received the authority to determine\\nthe safety and effectiveness of drugs and\\napprove new drugs for opioid addiction \\ntreatment.\\nDrug Addiction Treatment\\nAct (2000)\\nThe Drug Addiction Treatment Act of 2000\\n(DATA [P .L. 106ñ310 div. B]) amended that\\nportion of the Controlled Substances Act man-\\ndating separate registration for practitioners', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='who dispense opioids in addiction treatment. It\\nallows practitioners who meet certain qualify-\\ning criteria to dispense or prescribe schedule\\nIII, IV , or V controlled substances specifically\\napproved by FDA for MAT. Chapter 3\\ndescribes the specific requirements that physi-\\ncians must satisfy under DATA provisions,\\nincluding the requirement that physicians must', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 41}),\n",
       " Document(page_content='have the capacity to refer patients for needed\\ncounseling and other ancillary services.\\nDEA classification of\\nbuprenorphine\\nOn October 8, 2002, DEA completed its \\nevaluation of buprenorphine, classifying it as a\\nschedule III drug (i.e., having potential for\\nabuse and a currently accepted medical use in\\ntreatment but less potential for addiction than\\nschedule II drugs). FDA made buprenorphine\\nthe first drug approved for treatment of opioid\\naddiction in physiciansí offices (CSAT 2004a;', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='Substance Abuse and Mental Health Services\\nAdministration 2003a; see also chapter 3).\\nHistory of Methadone\\nRegulation\\nFederal regulation\\nIn 1972, FDA issued regulations governing \\neligibility, evaluation procedures, dosages,\\ntake-home medications, frequency of patient\\nvisits, medical and psychiatric services, coun-\\nseling, support services, and related details for\\nmethadone treatment\\nprograms. Several\\nmodifications were\\nmade to these regula-\\ntions during the\\n1980s. Until 2001,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='1980s. Until 2001,\\nFDA was responsible\\nfor approving these\\nprograms and ensur-\\ning compliance with\\nFDA regulations.\\nAs experience with\\nthe effectiveness of\\nmethadone grew,\\ncriticism of the 1972\\nFDA regulations\\nincreased from\\nphysicians, who \\ncomplained that the\\nregulations placed\\nburdens on their\\npractice of medicine, and from addiction \\ntreatment specialists, who pointed out that \\nproscriptive regulations failed to leave room \\nfor treatment innovation. (See comments on', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='the new rules in their proposed form [Federal\\nRegister 64:39812ñ39814].)\\nThe movement away from a compliance \\norientation and toward an accreditation\\nmodel was supported by a number of reviews,\\nincluding the 1997 NIH consensus develop-\\nment conference on Effective Treatment of\\nOpiate Addiction and the review of 1972 FDA\\nregulations by IOM (Institute of Medicine\\n1995). Interest in accreditation grew because\\nof its emphasis on self-assessment and\\nimprovement and on integration of quality', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='assurance and performance elements devel-\\noped by expert accreditation organizations.\\nIn addition, trends in national health care\\nfueled movement toward accreditation. \\nMany managed care organizations require \\nall accredited health care practitioners to\\ndemonstrate quality care. Several States\\ngrant exemptions from State licensing\\nrequirements (called ìdeemed statusî) to\\naccredited health care facilities.\\nFinal regulations issued by DHHS and the\\nSubstance Abuse and Mental Health Services', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='Administration (SAMHSA) on January 17,\\n2001, effective May 18, 2001, govern the use of\\nmethadone and LAAM in both maintenance\\nand detoxification treatments for opioid addic-\\ntion. The 1972 FDA regulations were repealed,\\nand a new accreditation-based regulatory \\nsystem was created. The new system shifted\\nadministration and oversight from FDA to\\nSAMHSA. The new regulations acknowledged\\nthat addiction is a medical disorder not\\namenable to one-size-fits-all treatment. They', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='recognized that different patients, at different\\ntimes, could need vastly different services.\\nAccreditation itself is a peer-review process\\nthat evaluates a treatment program against\\nSAMHSAís opioid treatment standards and\\naccreditation standards of SAMHSA-approved\\naccrediting bodies (42 Code of Federal\\nRegulations, Part 8). It includes site visits by\\n22 Chapter 2\\nThe new \\nregulations\\nacknowledged that\\naddiction is a \\nmedical disorder\\nnot amenable to\\none-size-fits-all\\ntreatment.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 42}),\n",
       " Document(page_content='23History of Medication-Assisted Treatment for Opioid Addiction\\nspecialists with experience in opioid pharma-\\ncotherapy and related activities.\\nThe new regulations establish an entirely \\ndifferent regulatory and oversight structure for\\nMAT. The DEA role remains the same, but\\nFDAís authority to approve and monitor pro-\\ngrams has been transferred to SAMHSA.\\nInstead of detailed proscriptive rules, the new\\nregulations set forth general certification\\nrequirements and Federal opioid treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 43}),\n",
       " Document(page_content='standards. These are elaborated in best-\\npractice guidelines and in accreditation \\nìelementsî (or standards) developed by the\\nSAMHSA-approved accreditation bodies.\\nSAMHSA has employed a series of expert pan-\\nels to develop guidelines for an accreditation-\\nbased certification system. Placing detailed\\npractice criteria in accreditation standards\\nrather than in regulations permits SAMHSA\\nand the accreditation bodies to update the stan-\\ndards as needed.\\nThe new regulations provide that, once a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 43}),\n",
       " Document(page_content='program is accredited, SAMHSA uses accredi-\\ntation results along with other data to deter-\\nmine whether the program is qualified to\\ncarry out treatment under the standards in\\nthe regulations. SAMHSA maintains oversight\\nof accreditation elements in its review of\\naccreditation bodiesí initial and renewal\\napplications. \\nThe consensus panel for this TIP expects the\\naccreditation process to result in an integrated\\nand individualized approach to services,\\nincreased patient satisfaction, better staff', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 43}),\n",
       " Document(page_content='recruitment, enhanced community confidence\\nand outcomes, and improvements in quality \\nof care. The shift to accreditation enables\\nSAMHSA to focus its oversight efforts on\\nimproving treatment rather than ensuring that\\nprograms are meeting regulatory criteria.\\nStates\\nThe new Federal regulations preserve Statesí\\nauthority to regulate OTPs. Oversight of treat-\\nment medications remains a tripartite system\\ninvolving States, DHHS/SAMHSA, and the\\nU.S. Department of Justice/DEA.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 43}),\n",
       " Document(page_content='States can monitor the same areas as Federal\\nagencies, but State rules do not always echo\\nFederal regulations. Some States have estab-\\nlished medical recertification requirements for\\ncontinuation of comprehensive, long-term MAT\\nafter a specified period. Other State and local\\nrequirements, such as certificates of need, zon-\\ning, and licensure, can affect the number, size,\\nand location of OTPs. These regulations are not\\naffected by the change in Federal regulations.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 43}),\n",
       " Document(page_content='In This\\nChapterÖ\\nLorem ipsum dolor\\nsit\\nSed do\\neiusmod\\nUt enim\\nad minim\\nveniam quis\\nDolore eu\\nfugiat nulla\\n25\\n3 Pharmacology of\\nMedications Used To\\nTreat Opioid Addiction\\nIn This\\nChapter…\\nPharmacology and\\nPharmacotherapy\\nDosage Forms\\nEfficacy\\nSide Effects\\nInteractions With\\nOther Therapeutic\\nMedications\\nSafety\\nThis chapter reviews the pharmacology and clinical applications of the\\nprincipal medications used to treat opioid addiction in opioid treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 45}),\n",
       " Document(page_content='programs (OTPs), including the opioid agonists methadone and levo-\\nalpha acetyl methadol (LAAM), the partial opioid agonist buprenor-\\nphine, and the opioid antagonist naltrexone. Coverage of LAAM is brief\\nbecause its future availability is uncertain. Coverage of buprenorphine is\\nshort because TIP 40, Clinical Guidelines for the Use of Buprenorphine\\nin the Treatment of Opioid Addiction(CSAT 2004a), discusses its phar-\\nmacology in more detail. Coverage of naltrexone is short because its use', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 45}),\n",
       " Document(page_content='in the United States generally has been limited to easing withdrawal\\nsymptoms for a small portion of patients undergoing medically super-\\nvised withdrawal after maintenance treatment. Exhibit 3-1 provides\\ninformation about these and other medications for opioid addiction\\ntreatment, including the year of their U.S. Food and Drug\\nAdministration (FDA) approval and their U.S. Drug Enforcement\\nAdministration (DEA) drug schedule assignment.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 45}),\n",
       " Document(page_content='The most frequently used medication for opioid addiction treatment in\\nOTPs is methadone, and much of this chapter focuses on methadone\\npharmacology. LAAM always has been used much less than methadone,\\nand its use was reduced further in 2001, after it was associated with car-\\ndiac arrhythmia in some patients. That association led FDA to warn that\\nLAAM be used only for patients not responding well to methadone. That\\nwarning and other factors led the manufacturer to cease production of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 45}),\n",
       " Document(page_content='LAAM on January 1, 2004 (Schobelock 2003), making its continued\\navailability uncertain after depletion of existing stocks. Programs were\\nencouraged to transfer patients using LAAM to other treatments.\\nAnother pharmaceutical company may manufacture and distribute\\nLAAM in the future.\\nFDA approved buprenorphine on October 8, 2002, for use in medical\\nmaintenance treatment and medically supervised withdrawal. It is the\\nfirst partial opioid agonist in recent U.S. history available for use by cer-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 45}),\n",
       " Document(page_content='tified physicians outside the traditional opioid treatment delivery system\\nand the strict requirements of the Narcotic Addict Treatment Act of 1974', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 45}),\n",
       " Document(page_content='(see chapter 2). In addition, on May 22, 2003,\\nan interim rule change made buprenorphine\\navailable for use in OTPs that receive certifica-\\ntion from the Substance Abuse and Mental\\nHealth Services Administration (SAMHSA) to\\ndispense buprenorphine. Physicians working in\\nmedical offices or other appropriate settings\\nmust obtain a waiver from SAMHSA to use\\nbuprenorphine to treat opioid addiction (see\\nExhibit 3-2). Qualified physicians may dispense\\nor prescribe buprenorphine products for up to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 46}),\n",
       " Document(page_content='30 patients at a time under the provisions of\\nthe Drug Addiction Treatment Act of 2000\\n(DATA). (More information about DATA and\\nwaivers can be found at www.buprenorphine.\\nsamhsa.gov; also see Boatwright 2002.)\\nThe consensus panel for this TIP expects that\\nthe availability of buprenorphine in multiple\\nsettings will increase the number of patients in\\ntreatment and that its availability in physi-\\nciansí offices and other medical and health\\ncare settings should help move medical mainte-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 46}),\n",
       " Document(page_content='nance treatment of opioid addiction into main-\\nstream medical practice.\\n26 Chapter 3\\nExhibit 3-1 \\nPharmacotherapeutic Medications for Opioid Addiction Treatment\\nProduct Formulations\\nReceptor\\nPharmacology\\nFDA\\nApproval\\nDEA\\nSchedule Treatment Settings\\nMethadone Oral solu-\\ntion, liquid\\nconcentrate,\\ntablet/\\ndiskette,\\nand powder\\nFull mu \\nopioid agonist\\nNever \\nformally\\napproved\\nby FDA\\nII OTP\\nLAAM Oral \\nsolution\\nFull mu \\nopioid agonist\\n1993 II OTP\\nBuprenor-\\nphine\\n(Subutex\\nÆ)\\nSublingual\\ntablet', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 46}),\n",
       " Document(page_content='Sublingual\\ntablet\\nPartial mu\\nopioid agonist\\n2002 III Physicianís office,\\nOTP , or other health\\ncare setting\\nBuprenor-\\nphine-\\nnaloxone\\n(Suboxone\\nÆ)\\nSublingual\\ntablet\\nPartial \\nmu opioid\\nagonist/mu\\nantagonist\\n2002 III Physicianís office,\\nOTP , or other health\\ncare setting\\nNaltrexone Oral tablet Mu opioid\\nantagonist\\n1984 Not \\nscheduled\\nPhysicianís office,\\nOTP , any substance\\nabuse treatment \\nprogram', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 46}),\n",
       " Document(page_content='27Pharmacology of Medications Used To Treat Opioid Addiction\\nì To qualify for a waiver under DATA 2000 a licensed physician (MD or DO) must\\nmeet any one or more of the following criteria: \\nï The physician holds a subspecialty board certification in addiction psychiatry\\nfrom the American Board of Medical Specialties. \\nï The physician holds an addiction certification from the American Society of\\nAddiction Medicine.\\nï The physician holds a subspecialty board certification in addiction medicine', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 47}),\n",
       " Document(page_content='from the American Osteopathic Association. \\nï The physician has, with respect to the treatment and management of opioid-\\naddicted patients, completed not less than eight hours of training (through \\nclassroom situations, seminars at professional society meetings, electronic \\ncommunications, or otherwise) that is provided by the American Society of\\nAddiction Medicine, the American Academy of Addiction Psychiatry, the\\nAmerican Medical Association, the American Osteopathic Association, the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 47}),\n",
       " Document(page_content='American Psychiatric Association, or any other organization that the Secretary\\n[of Health and Human Services] determines is appropriate for purposes of this\\nsubclause.\\nï The physician has participated as an investigator in one or more clinical \\ntrials leading to the approval of a narcotic drug in schedule III, IV , or V for\\nmaintenance or detoxification treatment, as demonstrated by a statement \\nsubmitted to the Secretary by the sponsor of such approved drug.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 47}),\n",
       " Document(page_content='ï The physician has such other training or experience as the State medical \\nlicensing board (of the State in which the physician will provide maintenance or\\ndetoxification treatment) considers to demonstrate the ability of the physician to\\ntreat and manage opioid-addicted patients.\\nï The physician has such other training or experience as the Secretary considers to\\ndemonstrate the ability of the physician to treat and manage opioid-addicted', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 47}),\n",
       " Document(page_content='patients. Any criteria of the Secretary under this subclause shall be established\\nby regulation. Any such criteria are effective only for 3 years after the date on\\nwhich the criteria are promulgated, but may be extended for such additional \\ndiscrete 3-year periods as the Secretary considers appropriate for purposes of\\nthis subclause. Such an extension of criteria may only be effectuated through a\\nstatement published in the Federal Registerby the Secretary during the 30-day', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 47}),\n",
       " Document(page_content='period preceding the end of the 3-year period involved.î\\nSource: www.buprenorphine.samhsa.gov/waiver_qualifications.html.\\nExhibit 3-2 \\nRequirements for Physiciansí Waivers To Dispense or Prescribe\\nBuprenorphine and Buprenorphine-Naloxone to Patients Who\\nAre Opioid Addicted', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 47}),\n",
       " Document(page_content='28 Chapter 3\\nPharmacology and\\nPharmacotherapy\\nMethadone and LAAM\\nThe synthetic opioids methadone and LAAM\\nare the only long-acting full opioid agonists\\napproved for opioid pharmacotherapy at this\\nwriting. Opioid agonists bind to the mu opiate\\nreceptors on the surfaces of brain cells, which\\nmediate the analgesic and other effects of opi-\\noids. Methadone and LAAM produce a range\\nof mu agonist effects similar to those of short-\\nacting opioids. Therapeutically appropriate', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='doses of these agonist medications produce\\ncross-tolerance for short-acting opioids such as\\nmorphine and heroin, thereby suppressing\\nwithdrawal symptoms and opioid craving as a\\nshort-acting opioid is eliminated from the body.\\nThe dose needed to produce cross-tolerance\\ndepends on a patientís level of tolerance for\\nshort-acting opioids.\\nLAAM is longer acting than methadone. Unlike\\nmethadone, it cannot be administered daily\\nbecause its longer duration of action would', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='lead to accumulation of toxic levels in the \\nbody that could result in death (Roxane\\nLaboratories, Inc., 2001). Articles by Oda \\nand Kharasch (2001) and Walsh and colleagues\\n(1998), as well as the manufacturerís package\\ninsert for ORLAAM\\nÆ(Roxane Laboratories,\\nInc., 2001), provide more information on\\nLAAMís pharmacology.\\nWhen given intramuscularly or orally,\\nmethadone suppresses pain for 4 to 6 hours.\\nIntramuscular methadone is used only for\\npatients who cannot take oral methadone,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='for example, patients in medication-assisted\\ntreatment for opioid addiction (MAT) who are\\nadmitted to a hospital for emergency medical\\nprocedures. Methadone should not be given\\nparenterally in an OTP .\\nBecause of its extensive bioavailability and\\nlonger half-life, an adequate daily oral dose of\\nmethadone suppresses withdrawal and drug\\ncraving for 24 to 36 hours in most patients who\\nare opioid addicted. Patients with special needs\\nmay require split methadone doses given more', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='than once daily. Methadone is metabolized\\nchiefly by the cytochrome P3A4 (CYP3A4)\\nenzyme system (Oda and Kharasch 2001),\\nwhich is significant when methadone is co-\\nadministered with other medications that also\\noperate along this metabolic pathway (see\\nìInteractions With Other Therapeutic\\nMedicationsî below).\\nAfter patient induction into methadone \\npharmacotherapy, a steady-state concentration\\n(i.e., the level at which the amount of drug\\nentering the body equals the amount being', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='excreted) of methadone usually is achieved in 5\\nto 7.5 days (four to five half-lives of the drug).\\nMethadoneís pharmacological profile supports\\nsustained activity at the mu opiate receptors,\\nwhich allows substantial normalization of many\\nphysiological disturbances resulting from the\\nrepeated cycles of intoxication and withdrawal\\nassociated with addiction to short-acting \\nopioids. Therapeutically appropriate doses \\nof methadone also attenuate or block the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='euphoric effects of heroin and other opioids.\\nGoodman and Gilmanís Pharmacological \\nBasis of Therapeutics (Hardman et al. 2001)\\nprovides a comprehensive description of\\nmethadoneís pharmacological effects.\\nMethadone is up to 80 percent orally bio-\\navailable, and its elimination half-life ranges\\nfrom 24 to 36 hours. When methadone is\\nadministered daily in steady oral doses, its\\nlevel in blood should maintain a 24-hour\\nasymptomatic state, without episodes of over-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='medication or withdrawal (Payte and Zweben\\n1998). Methadoneís body clearance rate varies\\nconsiderably between individuals. The serum\\nmethadone level (SML) and elimination half-\\nlife are influenced by several factors including\\npregnancy and a patientís absorption,\\nmetabolism and protein binding, changes in\\nurinary pH, use of other medications, diet,\\nphysical condition, age, and use of vitamin and\\nherbal products (Payte and Zweben 1998).\\nMeasuring methadone via SMLs helps', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='determine how much is circulating in patientsí', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 48}),\n",
       " Document(page_content='systems. In a typical 24-hour period after \\ndosing, SMLs should peak after about 2 to 4\\nhours and decline gradually to trough levels\\nthereafter (Payte and Zweben 1998). Although\\nresearchers have noted a strong correlation\\nbetween methadone dosage and serum concen-\\ntrations in some patients, the relationship is \\nnot necessarily linear, and a high degree of\\nvariation exists among patients (reviewed by\\nLeavitt et al. 2000). The rate-of-change ratio\\nbetween peak and trough SMLs can be useful', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='clinically; Payte and Zweben (1998) suggested\\nthat peak SMLs should not exceed twice the\\ntrough levels.\\nResearchers have found that trough SMLs of\\n150 to 600 ng/mL are necessary to suppress\\ndrug craving (reviewed in Leavitt et al. 2000).\\nMany treatment providers consider that trough\\nSMLs of $400 ng/mL provide adequate opioid\\ncross-tolerance, thereby controlling patientsí\\nopioid abuse; however, Eap and colleagues\\n(2002) found no studies that validated these\\nminimum trough levels.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='Methadone has two enantiomeric forms, ì(R)-î\\n(also called levo- or \\nL-) methadone and ì(S)-î\\n(dextro- or D-) methadone, which have the\\nsame chemical formula but different spatial\\narrangements. OTPs in the United States use a\\n50:50 racemic mixture of these two enantiomers.\\nOnly (R)-methadone has clinically significant\\nmu receptor agonist activity, and its potency as\\nan analgesic is 50 times greater than that of (S)-\\nmethadone (Eap et al. 2002). (R)-methadone', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='also has a significantly higher mean clearance\\nrate than (S)-methadone (Eap et al. 1999).\\nMethadone is metabolized into inactive metabo-\\nlites, mainly in the liver by CYP450 enzymes,\\nbut probably also by enzymes in the intestines.\\nThese metabolites are then excreted. Drugs\\nthat induce or inhibit this enzyme activity can\\naffect methadone metabolism. If these enzymes\\nare stimulated by other medications, the dura-\\ntion of methadoneís effect and SMLs may be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='lowered, precipitating withdrawal symptoms. If\\nthese enzymes are inhibited by other medica-\\ntions, methadone metabolism may be slowed,\\nand the SMLs and duration of methadoneís\\neffect in patients may be increased (Eap et al.\\n2002; Leavitt et al. 2000; Payte and Zweben\\n1998).\\nSeveral CYP450 isoforms help metabolize\\nmethadone, including CYP3A4 (the most abun-\\ndant), CYP2B6, CYP2D6, and possibly, but to\\na smaller extent, CYP1A2, CYP2C9, and\\nCYP2C19 (Cozza and Armstrong 2001; Eap et', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='al. 2002; Gerber et al. 2004). Different\\nenzymes metabolize (R)- and (S)-methadone\\ndifferently. Numerous genetic and environmen-\\ntal factors affect these\\nenzymes and account\\nfor variations in\\nmethadone\\nmetabolism among\\nindividuals. Some\\nenzymes also play a\\npart in metabolizing\\nother medications,\\nsuch as benzodi-\\nazepines, antidepres-\\nsants, anticonvul-\\nsants, antibiotics, and\\nantiviral agents (e.g.,\\nHIV protease\\ninhibitors). Through\\ntheir effects on these\\nenzymes, some medi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='enzymes, some medi-\\ncations can raise or\\nlower patientsí SMLs. Especially during initia-\\ntion of methadone maintenance, methadone\\ncan increase CYP3A4 activity, thereby acceler-\\nating its own metabolism in some individuals\\n(Eap et al. 2002; Leavitt et al. 2000).\\nCYP2D6 selectively metabolizes the (R)-\\nmethadone enantiomer. Production of this\\nenzyme is affected by genetic factors. A small\\nportion of the population does not produce\\nmuch CYP2D6, whereas others have very high', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='CYP2D6 activity. The latter group may require\\nmuch higher methadone doses to compensate\\nfor their high rate of (R)-methadone\\nmetabolism (Eap et al. 2002; Leavitt et al.\\n2000). Individuals also differ considerably in\\nCYP3A4 and CYP1A2 activity, accounting in\\npart for the wide variations in methadone\\nmetabolism (Eap et al. 2002).\\n29Pharmacology of Medications Used To Treat Opioid Addiction\\n[A]n adequate\\ndaily oral dose \\nof methadone \\nsuppresses with-\\ndrawal and drug\\ncraving for 24 to\\n36 hours...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 49}),\n",
       " Document(page_content='Buprenorphine\\nBuprenorphine, a derivative of the opium \\nalkaloid thebaine, is a synthetic opioid and \\ngenerally is described as a partial agonist at the\\nmu opiate receptor and an antagonist at the\\nkappa receptor. Research has demonstrated\\nthat buprenorphineís partial agonist effects at\\nmu receptors, its unusually high affinity for\\nthese receptors, and its slow dissociation from\\nthem are principal determinants of its pharma-\\ncological profile (Cowan 2003).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='In the 1990s, researchers determined that, as a\\npartial mu agonist, buprenorphine does not\\nactivate mu receptors fully (i.e., it has low\\nintrinsic activity), resulting in a ceiling effect\\nthat prevents larger doses of buprenorphine\\nfrom producing greater agonist effects (Walsh\\net al. 1994). As a result, there is a greater mar-\\ngin of safety from death by respiratory depres-\\nsion when increased doses of buprenorphine\\nare used, compared with increased doses of full', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='opioid agonists. Buprenorphine overdose is\\nuncommon, although it has been reported in\\nFrance, and it is associated almost always with\\ninjection of buprenorphine coupled with inges-\\ntion of high doses of benzodiazepines, alcohol,\\nor other sedative-type substances (Kintz 2001,\\n2002). Another feature of  buprenorphine is\\nthat it can be used on a daily or less-than-daily\\nbasis. Typically, the interdosing interval is\\nextended by doubling or tripling the daily dose', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='to permit alternate-day or thrice weekly dosing\\n(Amass et al. 2000, 2001), which is possible\\nbecause, although larger doses do not increase\\nbuprenorphineís agonist activity, they do length-\\nen its duration of action (Chawarski et al. 1999).\\nBuprenorphine also may be an excellent agent\\nto facilitate detoxification from illicit opioids\\nand abused prescription opioids. Although it\\nhas a relatively short plasma half-life (about 4\\nto 6 hours), buprenorphine has a long duration', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='of action resulting from its high affinity for and\\ncorrespondingly slow dissociation from the mu\\nreceptor (Cowan 2003). This slow dissociation\\nlikely reduces the magnitude of withdrawal\\nsymptoms during detoxification (Johnson et al.\\n2003b). Some evidence supports a short-term\\ncourse of buprenorphine-naloxone therapy for\\ndetoxification from opioids.\\nBuprenorphine is metabolized in the liver by\\nthe CYP3A4 subgroup of CYP450 enzymes\\n(Kobayashi et al. 1998), and, like methadone', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='and LAAM, its rate of metabolism is affected\\nby coadministration of other medications\\nmetabolized along this pathway.\\nDepending on the dosage, buprenorphine activ-\\nity can be viewed as falling between that of full\\nagonists, such as methadone and LAAM, and\\nantagonists, such as naltrexone (Exhibit 3-3)\\n(Johnson et al. 2003b). Because it is a partial\\nagonist at higher doses, buprenorphine also\\ncan precipitate opioidlike withdrawal symp-\\ntoms in patients with high levels of physical', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='dependence on opioids, making it appear to\\nfunction more like an antagonist under these\\nconditions (see ìInductionî in chapter 5).\\nNaltrexone\\nNaltrexone is a highly effective opioid antago-\\nnist that tightly binds to mu opiate receptors.\\nBecause it has a higher affinity for these recep-\\ntors than has heroin, morphine, or methadone,\\nnaltrexone displaces those drugs from receptors\\nand blocks their effects. It can, therefore, \\nprecipitate withdrawal in patients who have not', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='been abstinent from short-acting opioids for at\\nleast 7 days and have not been abstinent from\\nlong-acting ones, such as methadone, for at\\nleast 10 days (OíConnor and Fiellin 2000).\\nNaltrexone displaces buprenorphine to a lesser\\ndegree, but, in high enough doses, it overrides\\nbuprenorphineís activity as well.\\nBecause naltrexone has no narcotic effect,\\nthere are no withdrawal symptoms when a\\npatient stops using naltrexone, nor does nal-\\ntrexone have abuse potential. Early research', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='concluded that tolerance does not develop for\\nnaltrexoneís antagonist properties, even after\\nmany months of regular use (Kleber et al.\\n1985). A 50 mg tablet markedly attenuates or\\nblocks opioid effects for 24 hours, and a 100 to\\n150 mg dose can block opioid effects for up to\\n72 hours (OíBrien et al. 1975).\\n30 Chapter 3', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 50}),\n",
       " Document(page_content='The FDA approved naltrexone for maintenance\\ntreatment in 1984 based on its pharmacological\\neffects, without requiring proof of its efficacy\\nin clinical trials for opioid addiction treatment.\\nDespite its potential advantages, it has had lit-\\ntle impact on the treatment of opioid addiction\\nin the United States, primarily because of poor\\npatient compliance (OíConnor and Fiellin 2000). \\nDosage Forms\\nMethadone\\nMethadone is provided in various forms,\\nincluding diskettes, tablets, oral solution, liq-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 51}),\n",
       " Document(page_content='uid concentrate, and powder. In the United\\nStates, methadone used in MAT almost always\\n31Pharmacology of Medications Used To Treat Opioid Addiction\\nExhibit 3-3 \\nIntrinsic Activity of Full Agonist (Methadone), Partial Agonist\\n(Buprenorphine), and Antagonist (Naloxone) Therapy\\nSource: Reprinted from Drug and Alcohol Dependence70(Suppl.) Johnson et al.\\nBuprenorphine: How to use it right. S59ñS77, 2003b, with permission from Elsevier.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 51}),\n",
       " Document(page_content='is administered orally in liquid form.\\nParenteral administration is prohibited in\\nOTPs. Parenteral abuse of methadone is not\\nwidespread, and people rarely inject the\\nmethadone dispensed in U.S. OTPs because it\\nis mixed with substances (e.g., flavored drinks)\\nthat make injection unattractive.\\nApproved forms of\\nmethadone for oral\\nadministration are\\nsupplied in various\\ndoses and \\nconcentrations,\\nallowing OTPs to\\nchoose which to dis-\\npense on the basis of\\nclinic and patient\\npreferences, conve-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='preferences, conve-\\nnience, and cost.\\nThe diskette form\\ncomprises scored\\ntablets, which are\\ndissolved in water,\\nmixed with a fla-\\nvored liquid, and\\ntaken orally.\\nAdvantages are easy\\ninventory and the\\nability for patients to\\nsee what they are\\ntaking before water\\nis added. The\\ndiskette is not suited, however, for small dose\\nincrements and decrements. Methadone tablets,\\nwhich dissolve in water, can be used in con-\\njunction with diskettes for small dose changes;', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='however, tablets normally are used only for\\nanalgesic applications; OTPs favor forms less\\nsubject to diversion. The liquid concentrate\\nform offers complete dosing flexibility, particu-\\nlarly with a computer-assisted dispensing pump\\nsystem. The powder form can be mixed with\\nwater into a solution.\\nLAAM\\nLAAM is supplied to OTPs as a colorless liquid\\nto be taken orally. When LAAM was approved,\\nFederal regulations required OTPs to ensure\\nthat ìdosage forms of LAAM and methadone', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='are easily distinguishedî (21 Code of Federal\\nRegulations, Part 291 ß 505). Therefore, OTPs\\ncolor LAAM to distinguish it from methadone.\\nBuprenorphine\\nBuprenorphine is available in sublingual tablets\\ncontaining either buprenorphine alone (some-\\ntimes called monotherapy tablets and marketed\\nunder the name Subutex) or combined with\\nnaloxone (called combination therapy tablets\\nwith the trade name Suboxone). For the combi-\\nnation therapy tablet, the ratio of buprenor-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='phine to naloxone is 4 mg of buprenorphine to\\n1 mg of naloxone. The combination tablet was\\ndeveloped because of problems with injection\\nabuse of buprenorphine reported outside the\\nUnited States, where injection of buprenor-\\nphine is not permitted for treatment. Injected\\nalone, buprenorphine precipitates withdrawal\\nsymptoms in most patients who are opioid\\naddicted, and the addition of naloxone increases\\nthis likelihood. The combination tablet may pre-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='cipitate acute withdrawal. Withdrawal also may\\nbe precipitated if too much or too little\\nbuprenorphine is given or if it is administered\\nwhile the opioid receptors are highly occupied by\\nan opioid agonist. Therefore, physicians need to\\nbe careful when timing the initiation of\\nbuprenorphine induction.\\nNaltrexone\\nNaltrexone was first produced by DuPont\\nunder the trade name Revia\\nÆ. However, it is\\nnow produced by Mallinckrodt under the trade\\nname Depade\\nÆand is supplied in 25, 50, and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='100 mg tablets.\\nEfficacy\\nMethadone\\nMethadone maintenance has been demonstrated\\nrepeatedly to be safe and effective when used\\nwith appropriate safeguards and psychosocial\\n32 Chapter 3\\nIn a...study com-\\nparing the efficacy\\nof LAAM...,\\nbuprenorphine...,\\nand methadone...,\\nall three medica-\\ntions substantially\\nreduced illicit \\nopioid use.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 52}),\n",
       " Document(page_content='services (OíConnor and Fiellin 2000). Mainte-\\nnance treatment typically leads to reduction or\\ncessation of illicit opioid use and its adverse\\nconsequences, including cellulitis, hepatitis,\\nand HIV infection from use of nonsterile injec-\\ntion equipment, as well as criminal behavior\\nassociated with obtaining drugs. Methadone\\npharmacotherapy has been shown to lead \\nto improved overall adjustment, including\\nreductions in psychiatric symptoms, unemploy-\\nment, and family or social problems. Mattick', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='and colleagues (2003) provide complete reviews\\nof the effectiveness of methadone.\\nLAAM\\nControlled clinical trials generally have \\nestablished that LAAM is as effective as\\nmethadone and buprenorphine in reducing\\nillicit-opioid use and retaining patients in treat-\\nment when equipotent doses are compared\\n(e.g., Johnson et al. 2000; White et al. 2002).\\nAppel and colleagues (2001) provide more\\ninformation on LAAMís efficacy.\\nBuprenorphine\\nThe primary efficacy of buprenorphine in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='clinical trials was demonstrated via patient\\nretention and elimination of illicitñopioid-\\npositive drug tests. Compared with equipotent\\ndoses of both methadone and LAAM,\\nbuprenorphine produced similar rates of \\ntreatment retention and abstinence from illicit\\nopioids. In a controlled, randomized study\\ncomparing the efficacy of LAAM (75 to 115\\nmg), buprenorphine sublingual solution (16 to\\n32 mg), and methadone (60 to 100 mg), all\\nthree medications substantially reduced illicit', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='opioid use (Johnson et al. 2000).\\nJohnson and colleagues (2003b) reviewed\\nnumerous studies evaluating the efficacy of\\nbuprenorphine for maintenance treatment last-\\ning up to 1 year. These studies have shown that\\ndaily doses of 8 mg of sublingual solution or 8\\nto 16 mg of the buprenorphine tablet are safe\\nand well tolerated. Most studies comparing\\nbuprenorphine and methadone have shown\\nthat 8 mg of sublingual buprenorphine or 16\\nmg of the tablet per day is equivalent to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='approximately 60 mg of oral methadone per\\nday. A study by Fudala and colleagues (2003)\\ndemonstrated the efficacy and safety of the\\nbuprenorphine-naloxone combination tablet \\nin office-based settings.\\nNaltrexone\\nNaltrexone is highly effective in preventing\\nrelapse when used as directed. However, most\\nstudies have indicated very high (70 to 80 per-\\ncent) dropout rates from naltrexone therapy\\n(Stine et al. 2003). A study by Rothenberg and\\ncolleagues (2002) found especially poor retention', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='levels for patients who had received methadone\\nbefore naltrexone treatment (none of them\\ncompleted 6 months of treatment, compared\\nwith 31 percent of patients who had not\\nreceived methadone before naltrexone therapy).\\nOther studies have demonstrated better compli-\\nance when naltrexone therapy is supported\\nwith payment scheduling and vouchers (e.g.,\\nPreston et al. 1999b).\\nSide Effects\\nLong-term methadone, LAAM, or buprenor-\\nphine therapy is associated with few side', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='effects. Although patients typically have high\\nlevels of medical and mental disorders, most\\nresult from preexisting problems or the conse-\\nquences of addiction, not from the treatment\\nmedication (Institute of Medicine 1995).\\nChapter 10 provides a review of related medical\\nproblems in patients who are opioid addicted.\\nThe most common adverse effects reported by\\npatients receiving methadone or LAAM are\\nconstipation, which is caused by slowed gastric\\nmotility, and sweating; a similar side effect', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='profile is seen for buprenorphine. Other side\\neffects include insomnia or early awakening\\nand decreased libido or sexual performance\\n(Hardman et al. 2001). Possible side effects\\nreported after regular use of these medications\\nare listed in Exhibit 3-4.\\n33Pharmacology of Medications Used To Treat Opioid Addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 53}),\n",
       " Document(page_content='34 Chapter 3\\nExhibit 3-4 \\nPossible Side Effects of Opioid Agonist and Partial Agonist Therapy\\nWhole Body Effects\\nï Weakness, loss of energy (asthenia)\\nï Back pain, chills\\nï Fluid accumulation (edema)\\nï Hot flashes\\nï Flu syndrome and malaise\\nï Weight gain\\nGastrointestinal Effects\\nï Constipation\\nï Dry mouth\\nï Nausea and vomiting\\nï Abdominal pain\\nMusculoskeletal Effects\\nï Joint pain (arthralgia)\\nï Muscle pain (myalgia)\\nNervous System Effects\\nï Abnormal dreams\\nï Anxiety\\nï Decreased sex drive', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 54}),\n",
       " Document(page_content='ï Depression\\nï Euphoria\\nï Headache\\nï Decreased sensitivity to tactile \\nstimulation (hypesthesia)\\nï Insomnia \\nï Nervousness\\nï Somnolence\\nRespiratory Effects\\nï Cough\\nï Rhinitis\\nï Yawning\\nCardiac Effects\\nï Electrocardiogram changes (possible \\nQT prolongation with LAAM or high\\ndoses of methadone)\\nï Postural hypotension\\nï Slowed heart rate (bradycardia)\\nHepatic Effects\\nï Abnormal liver function tests\\nEndocrine Effects\\nï Hyperprolactinemia\\nï Absence of menstrual periods \\n(amenorrhea)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 54}),\n",
       " Document(page_content='(amenorrhea)\\nSkin and Appendage Effects\\nï Sweating\\nï Rash\\nSpecial Sensory Effects\\nï Blurred vision\\nUrogenital Effects\\nï Difficult ejaculation\\nï Impotence', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 54}),\n",
       " Document(page_content='Cardiovascular Effects\\nMethadone\\nMethadone has been shown to increase QT\\nintervals in at least two studies (i.e., Krantz et\\nal. 2003; Martell et al. 2003). A QT interval is\\nthat part of a patientís electrocardiogram read-\\ning that begins at the onset of the QRS complex\\nand extends to the end of the T wave. The QT\\ninterval represents the time between the start\\nof ventricular depolarization and the end of\\nventricular repolarization. The QT interval\\nnormally varies depending on heart rate, age,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='and gender. The QT interval may be influenced\\nby electrolyte balance, medications, and\\nischemia. A prolonged QT interval increases\\nthe risk of developing a cardiac arrhythmia\\ncalled torsade de pointes. \\nCases of torsade de pointes have been reported\\nin patients taking high doses of methadone\\n(mean daily doses of approximately 400 mg).\\nAlthough information about this effect is limit-\\ned, 6 of 17 patients who developed torsade de\\npointes in one study had an increase in their', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='methadone dose during the month preceding\\narrhythmia (Krantz et al. 2003). This finding\\nsupported the possibility that methadone con-\\ntributed to the development of arrhythmia.\\nFurthermore, Martell and colleagues (2003)\\nshowed that, regardless of dose, a statistically\\nsignificant increase occurred in QT intervals\\nduring the first 2 months of treatment.\\nPractitioners should be aware of potential QT-\\nprolonging effects of methadone, especially at\\nhigh doses, and should be aware of interactions', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='with other medications that also have QT-\\nprolonging properties or with medications that\\nslow the elimination of methadone.  \\nLAAM\\nLAAM has been associated with prolonged QT\\ninterval in some patients and, in rare cases,\\nwith death from torsade de pointes arrhythmia.\\nAs a result, it has been taken off the market in\\nEurope, and it has been given a ìblack boxî\\nwarning (i.e., a required warning on the pack-\\nage insert and other product-related materials)\\nin the United States by FDA. These findings', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='have led to discontinuation of LAAM therapy\\nfor new patients by most American OTPs.\\nCurrently, it is labeled for use only when no\\nother treatment option exists or for continuing\\nuse in patients who already have demonstrated\\ntolerability for the medication (Roxane\\nLaboratories, Inc., 2001).\\nBefore a patient is started on LAAM, providers\\nmust follow informed-consent procedures\\nabout QT interval prolongation and provide\\ninformation about the possibility of arrhythmia', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='and sudden death (CSAT 1999b). Patients\\nshould be screened for cardiac risk factors,\\nincluding preexisting prolonged QT intervals or\\nother cardiac problems (Food and Drug\\nAdministration 2001; Schwetz 2001). More\\ninformation about LAAM is available from\\nRoxane Laboratories Technical Product\\nInformation at 800-962-8364 and in chapter 2.\\nSide Effects of Naltrexone\\nApproximately 10 percent of patients receiving\\nnaltrexone have gastrointestinal side effects', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='(e.g., nausea and vomiting) that may necessi-\\ntate stopping the medication. Most patients,\\nhowever, experience only mild, transient \\nstomach upset (Stine et al. 2003). Naltrexone\\nalso can cause anxiety, nervousness, insomnia,\\nheadache, joint or muscle pain, and tiredness\\nin some patients (National Library of Medicine\\n1997).\\nEffects on the Immune\\nSystem\\nShort-acting opioids such as heroin and mor-\\nphine interfere with the normal activity of the\\nimmune system, perhaps through stress hor-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='mones such as cortisol, which are known to sup-\\npress immune function. These effects are not\\nseen with methadone, which does not appear to\\naffect natural killer cell activity, immunoglobu-\\nlin, or T or B cells (Novick et al. 1989). \\nEffects on the Liver\\nMethadone, LAAM, and buprenorphine are\\nmetabolized by the liver, but no evidence exists\\n35Pharmacology of Medications Used To Treat Opioid Addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 55}),\n",
       " Document(page_content='that they are hepatotoxic (Joseph et al. 2000).\\nBecause the liver is a major storage site for\\nthese medications, patients with liver disease\\nshould be expected to metabolize opioid-based\\nmedications more slowly, which might raise\\nblood levels of these medications but lower\\ntheir stores and shorten their duration of\\naction. Abnormal liver functions among\\npatients maintained on these drugs usually \\nare caused by viral infections, most commonly\\nhepatitis C acquired from contaminated', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='needles, or by cirrhosis secondary to alcoholism\\n(Marray 1992). Chapter 10 provides informa-\\ntion on medical conditions commonly seen in\\npatients who are opioid addicted.\\nAlthough the presence of liver disease is not a\\nreason to exclude patients from MAT, severe\\npersistent liver disease in these patients indi-\\ncates the need to monitor liver functions regu-\\nlarly and to use caution in dosage adjustment.\\nSevere liver impairment might result in toxic\\nserum levels of an opioid medication. Symptoms', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='of toxic levels include poor concentration,\\ndrowsiness, dizziness when standing, and exces-\\nsive anxiety (sometimes called feeling ìwiredî).\\nThese effects usually can be managed by dose\\nreduction. The consensus panel and the FDA\\nlabels on Subutex and Suboxone recommend\\nbaseline and periodic liver function testing for\\npatients receiving buprenorphine.\\nIn evaluating naltrexone to treat alcoholism, \\na Center for Substance Abuse Treatment con-\\nsensus panel (CSAT 1998a) recommended cau-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='tion in using naltrexone for patients who have\\nhigh (three times normal) serum transaminase\\nlevels. OTPs should perform liver function tests\\nbefore naltrexone therapy and periodically\\nthereafter to ensure healthy liver function. For\\nthe relatively few cases in which liver toxicity\\noccurs, treatment should be discontinued after\\ndetermining that the liver problem has no \\nother cause.\\nSide Effects of Buprenorphine\\nJohnson and colleagues (2003b) reported that', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='buprenorphine in solution or tablet and the\\ncombination buprenorphine-naloxone tablet\\nwere well tolerated. Few serious side effects\\nhave been reported in studies involving more\\nthan 5,000 patients, although, like other opi-\\noids, buprenorphine can produce constipation,\\nheadache, nausea and vomiting, and dizziness\\n(Fudala et al. 2003; Ling et al. 1998). Increases\\nin liver enzymes (aspartate aminotransferase\\nand alanine aminotransferase) were observed\\nin individuals receiving buprenorphine who', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='also were positive for hepatitis C (Petry et \\nal. 2000). At this writing, 53 cases of \\nbuprenorphine-associated hepatitis have been\\nreported in France since 1996 (Auriacombe et\\nal. 2003). One report suggested an association\\nbetween injection buprenorphine misuse and\\nliver toxicity, possibly from buprenorphineís\\nincreased bioavailability when administered\\nparenterally (Berson et al. 2001). The direct\\nrole of buprenorphine in these abnormalities \\nis unclear because many individuals in these', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='studies might have had hepatitis B or C.\\nAdditional studies are needed to clarify this issue.\\nInteractions With\\nOther Therapeutic\\nMedications \\nBecause methadone, LAAM, and buprenor-\\nphine are metabolized chiefly by the CYP3A4\\nenzyme system (a part of the CYP450 system),\\ndrugs that inhibit or induce the CYP450 system\\ncan alter the pharmacokinetic properties of\\nthese medications. Drugs that inhibit or induce\\nthis system can cause clinically significant', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='increases or decreases, respectively, in serum\\nand tissue levels of opioid medications. \\nDrugs that induce the CYP450 enzyme system\\ncan precipitate withdrawal in patients receiving\\nmethadone, LAAM, or buprenorphine. Most\\nnotable are certain medications used to treat\\nHIV infection, such as nelfinavir (McCance-\\nKatz et al. 2000), efavirenz (Clarke, S.M., et al.\\n2001b), and nevirapine (Clarke, S.M., et al.\\n2001a; Otero et al. 1999). Other common\\ninducers are carbamazepine, phenytoin, and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='phenobarbital (Michalets 1998).\\nPsychiatric medications sharing the same\\nmetabolic pathways as methadone and LAAM\\n36 Chapter 3', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 56}),\n",
       " Document(page_content='include some selective serotonin reuptake\\ninhibitors (SSRIs), which inhibit the isoenzymes\\nthat metabolize methadone and might increase\\nSMLs (Nemeroff et al. 1996). Hamilton and \\ncolleagues (2000), who examined SMLs in\\npatients who were depressed, receiving the\\nSSRI sertraline, and undergoing methadone\\npharmacotherapy, found that sertraline pro-\\nduced modest increases in SMLs during the\\nfirst 6 weeks of treatment. They concluded that\\npatients who are methadone maintained and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 57}),\n",
       " Document(page_content='receiving SSRIs should be monitored for\\naltered SMLs. However, because clinical expe-\\nrience with patients in MAT who take SSRIs\\nhas not indicated that these alterations are \\nclinically significant, the consensus panel rec-\\nommends careful monitoring of these patients\\nbut not routine testing of their SMLs. Of all the\\nSSRIs, fluvoxamine likely has the most poten-\\ntial to cause excessive SMLs while patients are\\nreceiving it and decreased SMLs after patients', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 57}),\n",
       " Document(page_content='discontinue it (Alderman and Frith 1999).\\nFluvoxamine has been implicated in overseda-\\ntion and respiratory depression when combined\\nwith methadone (Alderman and Frith 1999).\\nEarlier studies showed that methadone increased\\nserum levels of tricyclic antidepressants, indicat-\\ning that the oral doses required for a therapeutic\\nresponse to tricyclics might be lower than those\\nneeded for a positive response in patients not\\naddicted to opioids (Maany et al. 1989).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 57}),\n",
       " Document(page_content='Finally, rifampin, carbamazepine, pheno-\\nbarbital (used occasionally for the treatment of\\nseizure disorders), and some medications to\\ntreat HIV infection (see chapter 10) also may\\ninduce liver enzymes that speed the bodyís\\ntransformation of methadone. Patients taking\\nthese medications might need increases in \\ntheir methadone dosage or split doses to \\nmaintain stability. \\nExhibit 3-5 summarizes other reported drug\\ninteractions with methadone.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 57}),\n",
       " Document(page_content='37Pharmacology of Medications Used To Treat Opioid Addiction\\nExhibit 3-5 \\nReported Drug Interactions With Methadone\\nAgent Effect on Methadone Possible Mechanism Remarks\\nAmitriptyline Decreased clearance Inhibition of one or\\nseveral CYP\\nisozymes (1A2, 2C9,\\n2C19, 2D6, 3A4)\\nClinical relevance unclear\\nAmprenavir Decreased serum \\nlevels; possible\\ndecreased opioid\\neffects\\nInduction of CYP3A Median 65% decrease of\\nSMLs in five patients;\\nassociation of amprenavir\\nand abacavir, with ampre-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 57}),\n",
       " Document(page_content='navir the likeliest inducing\\nagent\\nAmylobarbitone Increased clearance Induction of CYP3A Clearance determined in\\npatients receiving\\nmethadone for cancer pain\\n(continued on following page)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 57}),\n",
       " Document(page_content='38 Chapter 3\\nExhibit 3-5 \\nReported Drug Interactions With Methadone (continued)\\nAgent Effect on Methadone Possible Mechanism Remarks\\nCiprofloxacin Increased opioid\\neffects\\nInhibition of\\nCYP1A2 and/or\\nCYP3A4\\nOne case report of sedation,\\nconfusion, and respiratory\\ndepression\\nDiazepam Increased opioid\\neffects\\nMechanism unclear;\\nprobably not a \\npharmacokinetic\\ninteraction\\nClinical relevance unclear\\nEfavirenz Decreased plasma\\nlevels and opioid\\neffects\\nInduction of CYP3A Mean 57% decrease of AUC*', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 58}),\n",
       " Document(page_content='in 11 patients; 1 case report\\nof reduction of both \\nenantiomers of methadone\\nEthanol Increased opioid\\neffects and added\\nsedation\\nMechanism unclear Clinical relevance unclear\\nFluconazole Decreased\\nmethadone clearance\\nand increased SMLs\\nInhibition of\\nCYP3A4\\nIncreased AUC by 35% in 13\\npatients after 200 mg/day for\\n14 days\\nFluoxetine Increased SMLs Inhibition of CYP2D6\\n(stereoselectivity for\\n(R)-methadone)\\nIncreased plasma \\nlevels (mean increase 32%)\\nfor (R)- but not (S)-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 58}),\n",
       " Document(page_content='methadone in seven patients\\nFluvoxamine Increased SMLs and\\nincreased opioid\\neffects\\nInhibition of one or\\nseveral CYP isozymes\\n(1A2, 2C19, 3A4,\\n2C9)\\nOne case report of hypoven-\\ntilation, severe hypoxemia,\\nand hypercapnia; two case\\nreports of withdrawal symp-\\ntoms when fluvoxamine\\nstopped; one case report of\\nfluvoxamine use to decrease\\nmethadone metabolism\\ninduced by barbiturate\\nFusidic acid Decreased opioid\\neffects\\nInduction of CYP3A\\nand CYP2C\\nReports of withdrawal symp-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 58}),\n",
       " Document(page_content='toms after 4-week therapy\\nMoclobemide Increased opioid\\neffects\\nInhibition of\\nCYP2D6 and/or\\nCYP1A2\\nOne case report of withdraw-\\nal symptoms when moclobe-\\nmide stopped\\n*Area under the concentration-time curve.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 58}),\n",
       " Document(page_content='39Pharmacology of Medications Used To Treat Opioid Addiction\\nExhibit 3-5 \\nReported Drug Interactions With Methadone (continued)\\nAgent Effect on Methadone Possible Mechanism Remarks\\nNelfinavir Decreased SMLs Induction of CYP3A;\\npossible induction of\\nP-glycoprotein\\nMean decrease about 55% in\\ntwo patients\\nNevirapine Decreased SMLs and\\nopioid effects\\nInduction of CYP3A Case reports of very important\\ndecrease in SMLs and severe\\nwithdrawal symptoms\\nParoxetine Increased SMLs Inhibition of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 59}),\n",
       " Document(page_content='CYP2D6 (stereoselec-\\ntivity for (R)-\\nmethadone)\\nIncreased (R)-methadone \\nplasma levels in eight CYP2C6\\nextensive metabolizers (32%) but\\nnot in poor metabolizers (3%)\\nPheno-\\nbarbital\\nDecreased SMLs and\\nopioid effects\\nInduction of CYP3A One case report with a 31%\\nreduction of trough SMLs\\nPhenytoin Decreased SMLs and\\nopioid effects\\nInduction of CYP3A Mean 2.4-fold decrease of SMLs\\nwith moderately severe opioid\\nwithdrawal symptoms\\nRifampin Decreased SMLs and\\nopioid effects', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 59}),\n",
       " Document(page_content='opioid effects\\nInduction of CYP3A Cases of severe withdrawal\\nsymptoms\\nRitonavir Decreased SMLs and\\nopioid effects\\nInduction of CYP3A,\\npossible induction of\\nP-glycoprotein; induc-\\ntion of CYP2C19\\nand/or CYP2B6 sug-\\ngested to explain\\ngreater induction of\\nmetabolism of (S)-\\nthan (R)-methadone\\nMean 36% decrease of the AUC\\nin 11 patients after a 14-day\\ntreatment; high interindividual\\nvariability of decrease in SMLs\\nSertraline Increased SMLs Inhibition of one or\\nseveral CYP\\nisozymes (3A4, 2D6,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 59}),\n",
       " Document(page_content='isozymes (3A4, 2D6,\\n1A2, 2C9, 2C19)\\nNo side effects from excess\\ndosage recorded\\nSpirono-\\nlactone\\nIncreased clearance Induction of CYP3A Clearance determined in\\npatients receiving methadone\\nfor cancer pain\\nAdapted from Eap et al. 2002, by permission of Adis International.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 59}),\n",
       " Document(page_content='40\\nExhibit 3-6 provides a list of other substances\\nthat are known to induce or inhibit CYP3A4\\nand potentially could affect levels of\\nmethadone, LAAM, and buprenorphine.\\nLittle information is available on the interac-\\ntion of naltrexone with other medications.\\nLethargy and somnolence have been reported\\nwhen naltrexone is used along with Thorazine\\nÆ\\n(chlorpromazine) or MellarilÆ(thioridazine),\\nand caution should be taken when naltrexone \\nis used with other antipsychotic drugs. Patients', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 60}),\n",
       " Document(page_content='taking naltrexone experience significant block-\\nade of opioid effects from medications taken for\\nanalgesia. However, this blockade is present\\nonly when naltrexone is taken regularly; it will\\ncease 24 to 72 hours after naltrexone is discon-\\ntinued (OíConnor and Fiellin 2000).\\nStrategies To Prevent or\\nMinimize Harmful Drug\\nInteractions in MAT\\nTo control patientsí vulnerability to adverse\\ncardiac and other harmful effects of drug \\ninteractions with methadone or LAAM, the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 60}),\n",
       " Document(page_content='consensus panel recommends obtaining a \\nthorough drug and medication history, includ-\\ning results of drug and other laboratory tests.\\nIn some cases, particularly when patients are\\ntreated in multiple settings, consolidating this\\ninformation can be a challenge.\\nTreatment providers should rely on their \\nexperience, intuition, and common sense to\\nanticipate and circumvent negative drug inter-\\nactions. The traditional advice when adding\\ndrugs to a therapeutic regimen is to start with\\nChapter 3', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 60}),\n",
       " Document(page_content='Chapter 3\\nExhibit 3-6\\nOther Inducers and Inhibitors of CYP450 and CYP3A4\\nCYP3A4 Inducers Expected To Reduce Opioid Medication Levels\\nCarbamazepine\\nDexamethasone\\nEthosuximide\\nPrimidone\\nRifabutin\\nTroglitazone\\nCYP3A4 Inhibitors Expected To Increase Opioid Medication Levels*\\nAmiodarone\\nCannabinoids\\nClarithromycin\\nErythromycin\\nGrapefruit juice\\nIndinavir\\nItraconazole\\nKetoconazole\\nMetronidazole\\nMibefradil\\nMiconazole\\nNefazodone\\nNorfloxacin\\nOmeprazole (slight)\\nQuinine\\nSaquinavir\\nTroleandomycin', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 60}),\n",
       " Document(page_content='Troleandomycin\\nZafirlukast\\n*Although clarithromycin and erythromycin are CYP3A4 inhibitors, azithromycin does not\\ninhibit CYP3A4.\\nAdapted from Michalets 1998, from Pharmacotherapywith permission; with additional\\ninformation from Gourevitch and Friedland 2000 and McCance-Katz et al. 2000.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 60}),\n",
       " Document(page_content='41\\nlow doses, increase slowly, and monitor closely.\\nIn many cases, medication dosages lower than\\nthose recommended by the manufacturer may\\nbe sufficient for the desired therapeutic effect\\n(Cohen 1999). This is especially prudent for\\npatients receiving agonist medications who have\\na positive diagnosis for cardiac risk factors.\\nEducating patients about the risks of drug\\ninteraction is essential. The following informa-\\ntion should be emphasized:\\nï During any agonist-based pharmacotherapy,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='abusing drugs or medications that are respi-\\nratory depressants (e.g., alcohol, other opioid\\nagonists, benzodiazepines) may be fatal.\\nï Current or potential cardiovascular risk \\nfactors may be aggravated by opioid agonist\\npharmacotherapy, but certain treatment\\nstrategies reduce cardiovascular risk (and\\nshould be included as needed in patientsí\\ntreatment plans).\\nï Other drugsóillicit, prescribed, or over \\nthe counteróhave potential to interact with\\nopioid agonist medications (specific, relevant', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='information should be provided).\\nï Patients should know the symptoms of\\narrhythmia, such as palpitations, dizziness,\\nlightheadedness, syncope, or seizures, and\\nshould seek immediate medical attention\\nwhen they occur.\\nï Maintaining and not exceeding dosage \\nschedules, amounts, and other medication\\nregimens are important to avoid adverse drug\\ninteractions.\\nResearchers (e.g., Cohen 1999; Levy et al.\\n2000; Piscitelli and Rodvold 2001) have provid-\\ned other suggestions for treatment providers to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='minimize harmful drug interactions in MAT:\\nï When possible, substitute alternative \\nmedications that do not interact with opioid\\ntreatment medications (e.g., azithromycin for\\nerythromycin [because the latter is a strong\\nCYP3A4 inhibitor] or divalproex for carba-\\nmazepine [because the latter is a potent\\nCYP3A4 inducer]).\\nï When other medications must be coadminis-\\ntered with opioid treatment medications,\\nselect those that have the least potential for\\ninteraction.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='interaction.\\nï Consider whether significant adverse drug\\ninteractions might be ameliorated by admin-\\nistering a medication with or without food or\\nby altering dosing schedules.\\nï Be aware that, the more complicated the\\nmedication regimen, the less likely patients\\nwill adhere to it, necessitating increased \\nvigilance on the part of treatment providers\\nas the complexity of medication treatment\\nincreases.\\nï When potentially interactive medications are\\ncoadministered, adjust the agonist or partial', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='agonist dosage based on patient response,\\nrather than prophylactically basing the\\ndosage on expected interaction, because\\ndegrees of interaction vary dramatically; \\nprejudging the amount of a necessary dosage\\nadjustment is unlikely to work.\\nï When opioid medication dosage must be\\nadjusted to compensate for the effects of\\ninteracting drugs, observe patients for \\nsigns or symptoms of opioid withdrawal or\\nsedation to determine whether they are\\nundermedicated or overmedicated.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='ï When a potentially interactive drug combina-\\ntion must be used and concerns exist about\\nadverse effects if opioid medication is\\nincreased, for example, in patients with \\npreexisting cardiovascular conditions, closely\\nmonitor drug serum concentrations or\\nincrease testing frequency. Advise patients of\\nthe physical signs or symptoms of adverse\\ninteractions, and tell them what to do if these\\nindicators occur.\\nï Be aware of concomitant preexisting diseases', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='(e.g., diseases that decrease renal or hepatic\\nfunction) and preexisting cardiovascular \\nconditions that might influence the potential\\nfor adverse drug interactions.\\nKnowledge about medication interactions \\nwith methadone and other medications used in\\nthe treatment of opioid addiction is changing\\nPharmacology of Medications Used To Treat Opioid Addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 61}),\n",
       " Document(page_content='42\\nconstantly. The reader is advised to check for\\nthe most current information on a regular\\nbasis. A useful Web site is\\nmedicine.iupui.edu/flockhart.\\nSafety\\nMethadone and LAAM\\nThe safety profiles of methadone and LAAM\\nare excellent when these drugs are taken as\\ndirected by the manufacturer and, for LAAM,\\nwhen patients are screened carefully for any\\ncardiac risk factors. However, because both\\nmethadone and LAAM are full mu opioid ago-\\nnists, overdose and death can occur if they are', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 62}),\n",
       " Document(page_content='taken in larger amounts than directed and in\\namounts exceeding patientsí tolerance levels.\\nUnintended, possibly lethal respiratory depres-\\nsant effects also can occur if these medications\\nare used in combination with substances that\\ndepress the central nervous system, such as\\nalcohol and benzodiazepines.\\nBuprenorphine\\nLike methadone, buprenorphine generally is\\nsafe and well tolerated when used as recom-\\nmended by the manufacturer, and buprenor-\\nphineís partial agonist characteristics reduce the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 62}),\n",
       " Document(page_content='risk of respiratory depression from overdose.\\nBuprenorphine overdose deaths reported in\\nFrance generally have been attributed to the\\nconcurrent parenteral abuse of buprenorphine\\nand benzodiazepines (Kintz 2001; Reynaud et\\nal. 1998; Tracqui et al. 1998a, 1998b). Only\\ntwo overdose deaths have been attributed to\\nbuprenorphine alone (Kintz 2002). The poten-\\ntial for injection abuse with buprenorphine is\\nbelieved lower than with full agonists because,\\nas a partial agonist, buprenorphine can precip-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 62}),\n",
       " Document(page_content='itate withdrawal in individuals who are opioid\\naddicted. Moreover, use of combination\\nbuprenorphine-naloxone tablets in the United\\nStates should mitigate further the risk of abuse.\\nAs with any agonist-based pharmacotherapy,\\nhowever, it is extremely important to educate\\npatients about the potential lethality of abusing\\ntreatment medication alone or in combination\\nwith respiratory depressants, especially \\nbenzodiazepines.\\nNaltrexone\\nNaltrexone generally is safe when used', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 62}),\n",
       " Document(page_content='according to the manufacturerís directions.\\nHall and Wodak (1999) cautioned that over-\\ndose rates for patients on naltrexone who\\nrelapse to heroin use might be higher than\\namong patients receiving other treatments \\nfor opioid addiction. Further investigation \\nis needed to validate this concern.\\nChapter 3', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 62}),\n",
       " Document(page_content='43\\n4 Initial Screening,\\nAdmission Procedures,\\nand Assessment\\nTechniques\\nIn This\\nChapterÖ\\nInitial Screening\\nAdmission\\nProcedures and\\nInitial Evaluation\\nMedical Assessment\\nInduction\\nAssessment\\nComprehensive\\nAssessment\\nInitial screening or intake procedures determine an applicantís eligibility\\nand readiness for medication-assisted treatment for opioid addiction\\n(MAT) and admission to an opioid treatment program (OTP). Ongoing\\nassessment should begin as soon as a patient is admitted to an OTP . It', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 63}),\n",
       " Document(page_content='provides a basis for individualized treatment planning and increases the\\nlikelihood of positive outcomes.\\nNo single tool incorporates all the important elements for assessing\\npatients in MAT. The Addiction Severity Index (ASI) (McLellan et al.\\n1992), although not comprehensive, can guide collection of the basic\\ninformation needed to measure patient conditions and progress objec-\\ntively. Recent research (e.g., Bovasso et al. 2001) continues to support', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 63}),\n",
       " Document(page_content='the validity of ASI composite scores. The consensus panel recommends\\nthat OTPs develop tools and methods for more extensive assessment.\\nThis chapter describes screening and assessment procedures and \\nimportant considerations that might be made during and shortly after\\nadmission to an OTP , as well as assessment techniques and considera-\\ntions that are important to ongoing MAT.\\nInitial Screening\\nFirst Contact\\nThe screening process begins when an applicant or family member first', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 63}),\n",
       " Document(page_content='contacts an OTP , often via telephone or a visit to the OTP . This contact\\nis the first opportunity for treatment providers to establish an effective\\ntherapeutic alliance among staff members, patients, and patientsí fami-\\nlies. Careful planning for and interaction with new applicants and their\\nfamilies contribute to positive MAT outcomes. Staff members should be\\nprepared to provide immediate, practical information that helps poten-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 63}),\n",
       " Document(page_content='tial applicants make decisions about MAT, including the approximate\\nlength of time from first contact to admission, what to expect during the\\nadmission process, and types of services offered. A brief exploration of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 63}),\n",
       " Document(page_content='44\\napplicantsí expectations and circumstances can\\nreveal other information they need for consid-\\nering MAT.\\nGoals of Initial Screening\\nThe consensus panel recommends the following\\ngoals for initial screening:\\nï Crisis intervention.Identification of and\\nimmediate assistance with crisis and emergen-\\ncy situations (see ìScreening of Emergencies\\nand Need for Emergency Careî below)\\nï Eligibility verification.Assurance that an\\napplicant satisfies Federal and State regula-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='tions and program criteria for admission to\\nan OTP\\nï Clarification of the treatment alliance.\\nExplanation of patient and program \\nresponsibilities\\nï Education.Communication of essential \\ninformation about MAT and OTP operations\\n(e.g., dosing schedules, OTP hours, treat-\\nment requirements, addiction as a brain \\ndisease) and discussion of the benefits and\\ndrawbacks of MAT to help applicants make\\ninformed decisions about treatment\\nï Identification of treatment barriers.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='Determination of factors that might hinder\\nan applicantís ability to meet treatment\\nrequirements, for example, lack of childcare\\nor transportation.\\nAlong with these primary goals, initial screen-\\ning can begin to identify other medical and \\npsychosocial risk factors that could affect \\ntreatment, including factors related to mental\\ndisorders; legal difficulties; other substance\\nuse; and vocational, financial, transportation,\\nand family concerns. Cultural, ethnic, and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='spiritual factors that affect communication and\\nmight affect treatment planning should be\\nnoted as early as possible. Staff members\\nshould obtain enough information from appli-\\ncants to accommodate needs arising from any\\nof these factors if necessary.\\nScreening of Emergencies and\\nNeed for Emergency Care\\nThe consensus panel recommends that\\nproviders develop medically, legally, and \\nethically sound policies to address patient\\nemergencies. Emergencies can occur at any', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='time but are most common during induction \\nto MAT and the acute treatment phase (see\\nchapter 7). In particular, patients who exhibit\\nsymptoms that could jeopardize their or othersí\\nsafety should be referred immediately for inpa-\\ntient medical or psychiatric care. If possible,\\nstaff members who conduct initial screening\\nand assessment should make appropriate refer-\\nrals before applicants are admitted to an OTP .\\nIdentifying and assessing emergencies may', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='require staff familiarity with the components of\\na mental health status examination (see\\nìPsychosocial Assessmentî below).\\nSuicidality\\nIn a study of population data from the U.S.\\nNational Comorbidity Survey, a significant\\nassociation was found between opioid addiction\\nand increased risk of suicide (Borges et al.\\n2000). Initial screening and periodic assess-\\nments should help determine whether those\\nindicating risks of suicide need additional \\nservices (e.g., hospitalization for protection or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='treatment, outpatient mental treatment, or\\nevaluation for antidepressant medication).\\nExhibit 4-1 lists some indicators of suicidality.\\nExhibit 4-2 lists recommended responses.\\nHomicidality and threats of\\nviolence\\nThreats should be taken seriously. For exam-\\nple, if an individual with knowledge of OTP\\nprocedures and schedules makes a threat, pat-\\nterns of interaction between staff and this indi-\\nvidual should be shifted. It might be necessary\\nto change or stagger departure times, imple-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='ment a buddy system, or use an escort service\\n(National Institute for Occupational Safety and\\nHealth 1996). Counseling assignments can be\\nchanged, or patients can be transferred to\\nanother OTP .\\nChapter 4', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 64}),\n",
       " Document(page_content='45Initial Screening, Admission Procedures, and Assessment Techniques\\nExhibit 4-1\\nSuicide Risk Factors\\nBehavioral and Circumstantial Indicators of Suicide Risk\\nï Talk about committing suicide \\nï Trouble eating or sleeping \\nï Drastic changes in behavior \\nï Withdrawal from friends or social activities \\nï Loss of interest in hobbies, work, or school \\nï Preparations for death, such as making a\\nwill or final arrangements\\nï Giving away prized possessions \\nï History of suicide attempts', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 65}),\n",
       " Document(page_content='ï Unnecessary risk taking \\nï Recent severe losses \\nï Preoccupation with death and dying \\nï Loss of interest in personal appearance \\nï Increased use of alcohol or drugs\\nExpressed Emotions That May Indicate Suicide Risk\\nï Canít stop the pain \\nï Canít think clearly \\nï Canít make decisions \\nï Canít see any way out \\nï Canít sleep, eat, or work \\nï Canít get out of depression \\nï Canít make the sadness go away \\nï Canít see a future without pain \\nï Canít see oneself as worthwhile', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 65}),\n",
       " Document(page_content='ï Canít get someoneís attention \\nï Canít seem to get control\\nExhibit 4-2 \\nRecommended Responses to Indicators of Suicidality\\nï Be direct. Talk openly and matter-of-factly about suicide. \\nï Be willing to listen. Allow expressions of feelings. Accept the feelings. \\nï Be nonjudgmental. Donít debate whether suicide is right or wrong or feelings are good or\\nbad. Donít lecture on the value of life. \\nï Get involved. Become available. Show interest and support. \\nï Donít dare an individual to do it.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 65}),\n",
       " Document(page_content='ï Donít act shocked. This puts distance between the practitioner and the individual. \\nï Donít be sworn to secrecy. Seek support. \\nï Offer hope but not glib reassurances that alternatives are available. \\nï Take action. Remove means, such as guns or stockpiled pills.\\nï Get help from persons or agencies specializing in crisis intervention and suicide prevention.\\nSource: Adapted from American Association of Suicidology n.d.\\nSource: Adapted from American Association of Suicidology n.d.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 65}),\n",
       " Document(page_content='46 Chapter 4\\nThe consensus panel recommends that OTP\\nstaff members receive training in recognizing\\nand responding to the signs of potential patient\\nviolence. OTPs should develop policies and\\nprocedures for homicide and other violent \\nsituations. The OTPís policy on violence and\\nthreats of violence should be explained at the\\nbeginning of treatment. Emergency screening\\nand assessment procedures should include \\nthe following:\\nï Asking the patient questions specific to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='homicidal ideation, including thoughts, \\nplans, gestures, or attempts in the past year;\\nweapons charges; and previous arrests,\\nrestraining orders, or other legal procedures\\nrelated to real or potential violence at home\\nor the workplace.\\nï Documenting violent incidents and diligent\\nmonitoring of these records to assess the\\nnature and magnitude of workplace violence\\nand to quantify risk. When a threat appears\\nimminent, all legal, human resource, employ-\\nee assistance, community mental health, and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='law enforcement resources should be readied\\nto respond immediately (National Institute\\nfor Occupational Safety and Health 1996).\\nAdmission Procedures\\nand Initial Evaluation\\nAfter initial applicant screening, the admission\\nprocess should be thorough and facilitate timely\\nenrollment in the OTP . This process usually\\nmarks patientsí first substantial exposure to the\\ntreatment system, including its personnel, other\\npatients, available services, rules, and require-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='ments. The admission process should be\\ndesigned to engage new patients positively while\\nscreening for and assessing problems and needs\\nthat might affect MAT interventions. \\nTimely Admission, Waiting\\nLists, and Referrals\\nThe longer the delays between first contact, \\ninitial screening, and admission and the more\\nappointments required to complete these proce-\\ndures, the fewer the applicants who actually\\nenter treatment. Prompt, efficient orientation\\nand evaluation contribute to the therapeutic', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='nature of the admission process.\\nIf a program is at capacity, admitting staff\\nshould advise applicants immediately of a \\nwaiting list and provide one or more referrals\\nto programs that can meet their treatment\\nneeds more quickly. A centralized intake pro-\\ncess across programs can facilitate the admis-\\nsion process, particularly when applicants must\\nbe referred. For example, if an applicant\\naccepts referral to another provider, telephone\\ncontact by the originating program often can', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='facilitate the applicantís acceptance into the\\nreferral program. If an applicant goes willingly\\nto another program for immediate treatment\\nbut prefers admission to the original OTP , the\\nadmission process should be completed and the\\napplicantís name added to the waiting list.\\nPatients who prefer to await treatment at the\\noriginal site should be added to the waiting list\\nand contacted periodically to determine\\nwhether they want to continue waiting or be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='referred. For individuals who are ineligible,\\nstaff should assess the need for other acute ser-\\nvices and promptly make appropriate referrals.\\nThe consensus panel recommends that each\\nOTP establish criteria to decide which prequal-\\nified patients should receive admission priority,\\nespecially when a program is near capacity. For\\nexample, some programs offer high-priority\\nadmission to pregnant women, addicted spouses\\nof current patients, applicants with HIV infec-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='tion or other serious medical conditions, or \\nformer patients who have tapered off mainte-\\nnance medication but subsequently require\\nrenewed treatment.\\nInterim Maintenance\\nTreatment\\nFor eligible individuals who cannot be \\nadmitted to a public or nonprofit program for\\ncomprehensive maintenance services within a\\nreasonable geographic area and within 14 days\\nof applying, 42 Code of Federal Regulations\\n(CFR), Part 8 ß 12(j), provides for ìinterim\\nmaintenance treatment,î in which medication', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 66}),\n",
       " Document(page_content='47Initial Screening, Admission Procedures, and Assessment Techniques\\nis administered to patients at an OTP for up to\\n120 days without formal screening or admission\\nand with only minimal drug testing, assuming\\nthe existence of reasonable criteria at the OTP\\nto prioritize admissions.\\nDenial of Admission\\nDenial of admission to an OTP should be \\nbased on sound clinical practices and the best\\ninterests of both the applicant and the OTP .\\nAdmission denial should be considered, for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='example, if an applicant is threatening or vio-\\nlent. Continuity of care should be considered,\\nand referral to more suitable programs should\\nbe the rule. Due process and attention to \\napplicant rights (see CSAT 2004b) minimize \\nthe possibility that decisions to deny admission\\nto an OTP are abusive or arbitrary.\\nAdmission Team\\nOTPs should have qualified, compassionate,\\nwell-trained multidisciplinary teams (see \\nchapter 6) that efficiently collect applicantsí', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='information and histories, evaluate their needs\\nas patients, and orient them to MAT. Team\\nmembers should be cross-trained in treating\\naddiction and co-occurring disorders. Those\\nconducting admission interviews should be \\nculturally competent, and their interactions\\nwith applicants should not be stigmatizing.\\nThey also should be able to communicate \\nOTP policies and services and make \\nappropriate referrals.\\nInformation Collection and\\nDissemination\\nCollection of patient information and dissemi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='nation of program information occur by vari-\\nous methods, such as by telephone; through a\\nreceptionist; and through handbooks, informa-\\ntion packets, and questionnaires. Medical\\nassessments (e.g., physical examinations, blood\\nwork) and psychosocial assessments also are\\nnecessary to gather specific types of informa-\\ntion. Although collection procedures differ\\namong OTPs, the consensus panel recommends\\nthat the following types of information be \\ncollected, documented, or communicated to\\npatients:', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='patients:\\nï Treatment history. An OTP should obtain \\na new patientís substance abuse treatment\\nhistory, preferably\\nfrom previous treat-\\nment providers,\\nincluding informa-\\ntion such as use of\\nother substances\\nwhile in treatment,\\ndates and durations\\nof treatment, pat-\\nterns of success or\\nfailure, and reasons\\nfor discharge or\\ndropout. Written\\nconsent from a\\npatient is required to\\nobtain information\\nfrom other programs\\n(see CSAT 2004b).\\n(See below for\\ndetails on other com-\\nponents to include in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='this history.)\\nï Orientation to MAT.\\nAll patients should receive an orientation to\\nMAT, generally extending over several ses-\\nsions and including an explanation of treat-\\nment methods, options, and requirements\\nand the roles and responsibilities of those\\ninvolved. Each new patient also should\\nreceive a handbook (or other appropriate\\nmaterials), written at an understandable level\\nin the patientís first language if possible, that\\nincludes all relevant program-specific infor-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='mation needed to comply with treatment\\nrequirements. Patient orientation should be\\ndocumented carefully for medical and legal\\nreasons. Documentation should show that\\npatients have been informedof all aspects \\nof the multifaceted MAT process and its\\ninformation requirements, including (1) \\nthe consent to treatment (CSAT 2004b), (2)\\nprogram recordkeeping and confidentiality\\nrequirements (e.g., who has access to records\\nand when, who can divulge information \\nThe admission\\nprocess should be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='process should be\\ndesigned to engage\\nnew patients \\npositively while\\nscreening for and\\nassessing problems\\nand needs...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 67}),\n",
       " Document(page_content='48 Chapter 4\\nwithout patient con-\\nsent [see CSAT\\n2004b]), (3) program\\nrules, including\\npatient rights,\\ngrievance proce-\\ndures,and circum-\\nstances under which\\na patient can be dis-\\ncharged involuntari-\\nly, and (4) facility\\nsafety instructions\\n(e.g., emergency exit\\nroutes). OTPs\\nshould require\\npatients to sign or\\ninitial a form docu-\\nmenting their partic-\\nipation in the orien-\\ntation process. Also, patients must receive\\nand sign a written consent to treatment form', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='(see Appendix 4-A; see also CSAT 2004b),\\nwhich is kept on file by the OTP .\\nï Age of applicant. Persons younger than age\\n18 must meet specific Federal and State\\nrequirements (at this writing, some States\\nprohibit MAT for this group), and an OTP\\nmust secure parental or other guardian \\nconsent to start adolescents on MAT (see \\ndiscussion below of exemptions from the\\nSubstance Abuse and Mental Health Services\\nAdministrationís [SAMHSAís] 1-year \\ndependence duration rule).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='ï Recovery environment. A patientís living \\nenvironment, including the social network,\\nthose living in the residence, and stability of\\nhousing, can support or jeopardize treatment.\\nï Suicide and other emergency risks.(See\\nabove.)\\nï Substances of abuse. A patientís substance\\nabuse history should be recorded, focusing\\nfirst on opioid use, including severity and age\\nat onset of physical addiction, as well as use\\npatterns over the past year, especially the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='previous 30 days. A baseline determination of\\ncurrent addiction should meet, to the extent\\npossible, accepted medical criteria. Many\\npeople who are opioid addicted use other\\ndrugs and alcohol; this multiple substance use\\nhas definite implications for treatment out-\\ncomes (see ìSubstance Use Assessmentî below\\nand chapter 11). Therefore, screening and\\nmedical assessment also should identify and\\ndocument nonopioid substance use and deter-\\nmine whether an alternative intervention', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='(e.g., inpatient detoxification) is necessary \\nor possible before an applicant is admitted to\\nthe OTP .\\nï Prescription drug and over-the-counter \\nmedication use. All prescription drug and\\nover-the-counter medication use should be\\nidentified. Procedures should be in place to\\ndetermine any instances of misuse, overdose,\\nor addiction, especially for psychiatric or\\npain medications. The potential for drug\\ninteractions, particularly with opioid treatment\\nmedications, should be noted (see chapter 3).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='ï Method and level of opioid use.The general\\nfrequency, amounts, and routes of opioid use\\nshould be recorded. If opioids are injected,\\nthe risk of communicable diseases (e.g.,\\nHIV/AIDS, hepatitis C, endocarditis) in-\\ncreases. Patient reporting helps providers\\nassess patientsí substance addiction and tol-\\nerance levels, providing a starting point to\\nprescribe appropriate treatment medication\\nfor stabilization (American Psychiatric\\nAssociation 2000; Mee-Lee et al. 2001a).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='ï Pattern of daily preoccupation with opioids.\\nA patientís daily pattern of opioid abuse\\nshould be determined. Regular and frequent\\nuse to offset withdrawal is a clear indicator of\\nphysiological dependence. In addition, people\\nwho are opioid addicted spend increasing\\namounts of time and energy obtaining, using,\\nand responding to the effects of these drugs.\\nï Compulsive behaviors. Patients in MAT\\nsometimes have other impulse control disor-\\nders. A treatment provider should assess', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='behaviors such as compulsive gambling or\\nsexual behavior to develop a comprehensive\\nperspective on each patient.\\nï Patient motivation and reasons for seeking\\ntreatment. Prospective patients typically \\npresent for treatment because they are in\\nwithdrawal and want relief. They often are\\n[A]ddressing \\nconcerns about\\nand stressing the\\nbenefits of MAT\\n...are essential to\\nlong-term treat-\\nment retention...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 68}),\n",
       " Document(page_content='49Initial Screening, Admission Procedures, and Assessment Techniques\\npreoccupied with whether and when they can\\nreceive medication. Because successful MAT\\nentails not only short-term relief but a\\nsteady, long-term commitment, applicants\\nshould be asked why they are seeking treat-\\nment, why they chose MAT, and whether they\\nfully understand all available treatment\\noptions and the nature of MAT. Negative atti-\\ntudes toward MAT may reduce patient moti-\\nvation. However, concerns about motivation', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='should not delay admission unless applicants\\nclearly seem ambivalent. In such cases, treat-\\nment providers and applicants can discuss\\nthe pros and cons of MAT. The consensus\\npanel believes that identifying and addressing\\nconcerns about and stressing the benefits of\\nMAT as early as possible are essential to\\nlong-term treatment retention and maintain-\\ning patient motivation for treatment.\\nï Patient personal recovery resources. A\\npatientís comments also can identify his or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='her recovery resources. These include com-\\nments on satisfaction with marital status and\\nliving arrangements; use of leisure time;\\nproblems with family members, friends, \\nsignificant others, neighbors, and coworkers;\\nthe patientís view of the severity of these\\nproblems; insurance status; and employment,\\nvocational, and educational status. Identifi-\\ncation of patient strengths (e.g., stable\\nemployment, family support, spirituality,\\nstrong motivation for recovery) provides a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='basis for a focused, individualized, and \\neffective treatment plan (see chapter 6).\\nï Scheduling the next appointment. Unless \\nthe program can provide assessment and\\nadmission on the same day, the next visit\\nshould be scheduled for as soon as possible.\\nTo facilitate an accurate diagnosis of opioid\\naddiction and prompt administration of the\\ninitial dose of medication when other docu-\\nmentation of a patientís condition is unavail-\\nable, the applicant should be instructed to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='report to the OTP while in mild to moderate\\nopioid withdrawal.\\nMedical Assessment\\nMedical assessment plays a substantial role in\\ndetermining MAT eligibility. Some assessment\\ntools and methods mentioned briefly in this\\nchapter are explained further in chapter 10.\\nThe results of medical assessment, including\\ntoxicology tests, other laboratory results, and\\npsychosocial assessment, usually are reviewed\\nby a program physician and then submitted to\\nthe medical director in preparation for phar-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='macotherapy. Programs should minimize delay\\nin administering the first dose of medication\\nbecause, in most cases, applicants will present\\nin some degree of opioid withdrawal.\\nDetermination of Opioid\\nAddiction and Verification of\\nAdmission Eligibility\\nFederal regulations on \\neligibility\\nFederal regulations state that, in general, \\nopioid pharmacotherapy is appropriate for\\npersons who currently are addicted to an opi-\\noid drug and became addicted at least 1 year', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='before admission (42 CFR, Part 8 ß 12(e)).\\nDocumentation of past addiction might include\\ntreatment records or a primary care physi-\\ncianís report. When an applicantís status is\\nuncertain, admission decisions should be based\\non drug test results and patient consultations.\\nExemptions from SAMHSAís\\n1-year dependence duration\\nrule\\nIf appropriate, a program physician can invoke\\nan exception to the 1-year addiction history\\nrequirement for patients released from correc-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='tional facilities (within 6 months after release),\\npregnant patients (program physician must \\ncertify pregnancy), and previously treated\\npatients (up to 2 years after discharge) (42\\nCFR, Part 8 ß 12(e)(3)).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 69}),\n",
       " Document(page_content='50 Chapter 4\\nA person younger than 18 must have under-\\ngone at least two documented attempts at\\ndetoxification or outpatient psychosocial \\ntreatment within 12 months to be eligible for\\nmaintenance treatment. A parent, a legal\\nguardian, or an adult designated by a relevant\\nState authority must consent in writing for an\\nadolescent to participate in MAT (42 CFR,\\nPart 8 ß 12(e)(2)). Patients younger than 18\\nshould receive age-appropriate treatments, \\nideally with a separate treatment track (e.g.,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='young adult groups). \\nCases of uncertainty\\nWhen absence of a treatment history or with-\\ndrawal symptoms creates uncertainty about an\\napplicantís eligibility, OTP staff should ask the\\napplicant for other means of verification, such\\nas criminal records involving use or possession\\nof opioids or knowledge of such use by a proba-\\ntion or parole officer. A notarized statement\\nfrom a family or clergy member who can attest\\nto an individualís opioid abuse might be feasible.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='The consensus panel does not recommend use\\nof a naloxone (Narcan\\nÆ) challenge test (see\\nchapter 5) in cases of uncertainty. Physical\\ndependence on opioids can be demonstrated by\\nless drastic measures. For example, a patient\\ncan be observed for the effects of withdrawal\\nafter he or she has not used a short-acting \\nopioid for 6 to 8 hours. Administering a low\\ndose of methadone and then observing the\\npatient also is appropriate. Administering\\nnaloxone, although effective, can initiate severe', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='withdrawal, which the consensus panel believes\\nis unnecessary. It also requires invasive injec-\\ntion, and the effects can disrupt or jeopardize\\nprospects for a sound therapeutic relationship\\nwith the patient. The panel recommends that\\nnaloxone be reserved to treat opioid overdose\\nemergencies.\\nHistory and Extent of\\nNonopioid Substance Use and\\nTreatment\\nThe extent and level of alcohol and nonopioid\\ndrug use and treatment also should be deter-\\nmined, and decisions should be made about', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='whether these disorders can be managed safely\\nduring MAT (see ìSubstance Use Assessmentî\\nbelow and chapter 11). \\nMedical History\\nA complete medical history should include\\norgan system diagnoses and treatments and\\nfamily and psychosocial histories. It should\\ncover chronic or acute medical conditions such\\nas diabetes, liver or renal diseases, sickle cell\\ntrait or anemia, and chronic pulmonary \\ndisease. Documentation of infectious diseases,\\nincluding hepatitis, HIV/AIDS, tuberculosis', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='(TB), and sexually transmitted diseases\\n(STDs), is especially important. Staff should\\nnote patientsí susceptibility to vaccine-\\npreventable illnesses and any allergies and\\ntreatments or medications received for other\\nmedical conditions. Womenís medical histories\\nalso should document previous pregnancies;\\ntypes of delivery; complications; current preg-\\nnancy status and involvement with prenatal\\ncare; alcohol and drug use, including over-the-\\ncounter medications, caffeine, and nicotine,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='before and during any pregnancies; and \\nincidences of sudden infant death syndrome.\\nComplete Physical\\nExamination\\nEach patient must undergo a complete, fully\\ndocumented physical examination by the pro-\\ngram physician, a primary care physician, or\\nan authorized health care professional under\\nthe direct supervision of the program physi-\\ncian, before admission to the OTP . The full\\nmedical examination, including the results of\\nthe serology and other tests, must be docu-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='mented in the patientís record within 14 days\\nfollowing admission. States may have addition-\\nal requirements, and OTPs must comply with', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 70}),\n",
       " Document(page_content='these requirements. The examination should\\ncover major organ systems and the patientís\\noverall health status and should document indi-\\ncations of infectious diseases; pulmonary, liver,\\nand cardiac abnormalities; dermatologic seque-\\nlae of addiction; vital signs; general appearance\\nof head, eyes, ears, nose, throat, chest,\\nabdomen, extremities, and skin; and physical\\nevidence of injection drug use and dependence,\\nas well as the physicianís clinical judgment of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='the extent of physical dependence. Women\\nshould receive a pregnancy test and a gyneco-\\nlogical examination at the OTP site or by \\nreferral to a womenís health center. Again, the\\nresults of all tests, laboratory work, and other\\nprocesses related to the initial medical exami-\\nnation are to be contained in the patientís file\\nwithin 14 days following admission.\\nLaboratory Tests\\nAlthough Federal regulations no longer require\\nOTPs to conduct a full panel of laboratory', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='tests, some States do. The consensus panel rec-\\nommends that laboratory tests include routine\\ntests for syphilis, hepatitis, TB, and recent\\ndrug use. SAMHSA regulations stipulate ìat\\nleast eight random drug abuse testsî annually\\nper patient, performed according to accepted\\nOTP practice (CFR 42, Part 8 ß 12(f)(6)).\\nGiven that some drugs are metabolized exten-\\nsively and excreted quickly, it is important that\\nanalytic procedures provide the highest sensi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='tivity for substances of interest, such as breath\\ntesting for alcohol use.\\nTB testing\\nThe risk of TB infection and disease is high\\namong individuals involved with drugs (Batki\\net al. 2002). Rates of active TB among people\\nwho use substances and are HIV infected are\\nhigh (Gourevitch et al. 1999), and cases of \\nmultidrug-resistant TB in this group are\\nincreasing. All patients should undergo screen-\\ning and medical examination for TB every 12\\nmonths. Anergy panel tests should be adminis-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='tered to anergic patients (those with diminished\\nreactivity to certain antigens). Patients who are\\nimmune system compromised might have a \\nnegative purified protein derivative test, even\\nwith active infection. A chest x ray or sputum\\nanalysis should be done if there is doubt. If a\\npatient has a positive TB test, medical staff\\nshould treat the patient accordingly (see chap-\\nter 10) or refer him or her to a primary care\\nclinic for treatment.\\nHepatitis testing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='Hepatitis testing\\nPeople who inject drugs are at high risk for\\nhepatitis virus infection (see chapter 10) and\\nshould be tested at\\nadmission to an OTP .\\nHepatitis A is an\\nimportant liver \\ninfection that affects\\npeople who abuse\\ndrugs at higher rates\\nthan people who do\\nnot. Most patients in\\nOTPs are seropositive\\nfor surface antigen or\\nantibody to hepatitis\\nB virus (HBV) core\\nantigen, and some\\nexhibit signs of \\nchronic hepatitis. Any\\npatients whose tests\\nare negative for hep-\\natitis A virus or HBV', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='infection should be vaccinated for these \\ninfections at the OTP or by referral.\\nHepatitis C virus (HCV) accounts for most new\\nhepatitis cases among people who inject drugs,\\ninfects between 70 and 96 percent of this popu-\\nlation, and is the countryís leading cause of\\nchronic liver disease (Sylvestre 2002b). The\\nconsensus panel strongly recommends that\\nHCV diagnosis and referral be an integral com-\\nponent of initial MAT assessment. Programs\\nthat do not offer onsite HCV antibody testing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='should provide appropriate referrals. (A simple\\nblood test for hepatitis C antibodies is avail-\\nable; a positive result does not necessarily \\nsignal current infections, only that antibodies\\nhave developed.)\\n51Initial Screening, Admission Procedures, and Assessment Techniques\\n[R]esults of...the\\nmedical examina-\\ntion are to beÖin\\nthe patientís file\\nwithin 14 days fol-\\nlowing admission.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 71}),\n",
       " Document(page_content='HIV testing\\nOTPs are required to provide adequate medi-\\ncal services, and the program sponsor must be\\nable to document\\nthat these services\\nare fully and reason-\\nably available to\\npatients. HIV testing\\non site or by refer-\\nral, with pretest and\\nposttest counseling,\\nis a recommended\\nmedical service.\\nOTPs should make\\nHIV testing part of\\ntheir medical ser-\\nvices as recommend-\\ned by the Centers\\nfor Disease Control\\nand Prevention\\n(2001a). Medical\\ncare and other sup-\\nportive services can', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='be offered if patientsí HIV and HCV statuses\\nare known early in treatment and monitored\\ncontinuously.\\nRapid HIV tests have been approved by the\\nU.S. Food and Drug Administration (FDA) and\\nare recommended by the U.S. Public Health\\nService to facilitate early diagnosis of HIV\\ninfection among at-risk populations involved in\\nsubstance abuse (Centers for Disease Control\\nand Prevention 2002a). Rapid tests can detect\\nantibodies to HIV in blood obtained by', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='fingerstick or venipuncture, or in oral fluid and\\nprovide reliable and valid results in 20 minutes\\nor less. Thus, the rapid HIV test provides a\\nmeasure of exposure to HIV and requires con-\\nfirmatory testing for a diagnosis of HIV infec-\\ntion. In studies by the manufacturer,the blood\\nantibody test correctly identified 99.6 percent\\nof people infected with HIV and 100 percent of\\nthose not infected, which is comparable to the\\nresults of FDA-approved enzyme immunoassays.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='FDA expects clinical laboratories to obtain sim-\\nilar results (Centers for Disease Control and\\nPrevention 2003b). OTPs performing rapid\\nHIV tests should comply with the guidelines\\nprovided in SAMHSAís Rapid HIV Testing\\nInitiative (www. samhsa.gov/HIVHep/\\nrhti_factsheet.aspx). As a preliminary positive\\ntest, positive results should be confirmed by sup-\\nplemental HIV testing. In addition,some States\\nhave other requirements for laboratory testing\\nin general and HIV testing specifically.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='STD testing\\nEarly testing for STDs in patients receiving\\nMAT usually is a State health requirement.\\nPersons who inject drugs are at higher risk of\\nSTDs, primarily from increased likelihood of\\ninvolvement in sex trading to finance drug use\\nand the disinhibiting effects of psychoactive\\nsubstances (Sullivan and Fiellin 2004).\\nTherefore, all patients in MAT should receive\\nserologic screening for syphilis and, for women\\nand symptomatic men, genital cultures for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='gonorrhea and chlamydia (Sullivan and Fiellin\\n2004). In the early stages of admission and\\ntreatment, patients should be educated about\\nthe effects of STDs and their correlation with\\nother communicable diseases, such as HIV/AIDS\\nand hepatitis C, to increase patientsí knowledge\\nof the ways they can avoid these risks. \\nFor many patients who are opioid addicted,\\nsexual activities are intertwined with drug use\\nbehaviors (Calsyn et al. 2000b). Documenting', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='the sexual histories of heterosexual and lesbian,\\ngay, and bisexual (LGB) patients, in terms of\\ntiming of sexual encounters and partners, is\\nessential to determine their potential exposure\\nto HCV , HIV , and other STDs, as well as the\\nrisk of infection for other sexual partners.\\nSeveral studies have pointed to increased high-\\nrisk sexual behavior among populations that\\nare substance addicted, homeless, and mentally\\nill, in addition to higher levels of psychological', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='distress and psychiatric symptoms (McKinnon\\net al. 2002; Stoskopf et al. 2001).\\nAdditional drug testing\\nAfter initial drug testing, subsequent assessment\\nshould include further review of urine, blood,\\noral fluid, or other drug test results. Ideally,\\ndrug tests should be conducted regularly and\\n52 Chapter 4\\nClinical examina-\\ntion and an \\napplicantís medi-\\ncal history are\\nkeys to determine\\nthe appropriate-\\nness of MAT.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 72}),\n",
       " Document(page_content='randomly during treatment. The first test is\\nespecially important because it is part of the\\ninitial evaluation and may serve as documenta-\\ntion of current opioid use. As noted in Federal\\nregulations, the presence of opioids in test\\nresults does not establish a diagnosis of opioid\\naddiction, and the absence of opioids does not\\nrule it out. Clinical examination and an appli-\\ncantís medical history are keys to determine the\\nappropriateness of MAT. Chapter 9 discusses', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='drug-testing procedures and Federal regulations\\ngoverning these procedures.\\nWomenís Health\\nWomen in MAT should receive information on\\ntheir particular health needs, for example,\\nfamily planning, gynecological health, and\\nmenopause (see the forthcoming TIP Substance\\nAbuse Treatment: Addressing the Specific\\nNeeds of Women[CSAT forthcoming f]).\\nWomen of childbearing age should be counseled\\non pregnancy testing during admission before\\nmaking decisions about detoxification (42 CFR,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='Part 8 ß 12(e)(3)). Pregnancy testing, along\\nwith onsite access to or referral for family \\nplanning services, should be available in all\\nOTPs as part of an overall womenís health \\ninitiative (see chapter 13). \\nInduction Assessment\\nInduction is the riskiest stage of MAT (see\\nchapter 5), and proper medical assessment dur-\\ning induction requires an understanding of the\\npharmacology of treatment medication (see\\nchapter 3). A patient should be assessed at least', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='daily during induction for signs of overmedica-\\ntion or undermedication, and dose adjustments\\nshould be made accordingly.\\nComprehensive\\nAssessment\\nCompletion of induction marks the beginning \\nof stabilization and maintenance treatment \\nand ongoing, comprehensive medical and \\npsychosocial assessment conducted over \\nmultiple sessions. This assessment should\\ninclude, but not be limited to, patient \\nrecollections of and attitudes about previous\\nsubstance abuse treatment; expectations and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='motivation for treatment; level of support for\\na substance-free lifestyle; history of physical\\nor sexual abuse; military or combat history;\\ntraumatic life events; and the cultural, reli-\\ngious, and spiritual basis for any values and\\nassumptions that might affect treatment. This\\ninformation should be included in an integrated\\nsummary in which data are interpreted,\\npatientsí strengths and problems are noted,\\nand a treatment plan is developed (see chapter', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='6) that matches each patient to appropriate \\nservices.\\nData should be collected in a respectful way,\\ntaking into consideration a patientís current\\nlevel of functioning. Motivational interviewing\\ntechniques (Miller and Rollnick 2002) can help\\nengage applicants early. The information col-\\nlected depends on program policies, proce-\\ndures, and treatment criteria; State and\\nFederal regulations; and the patientís stability\\nand ability to participate in the process. The', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='psychosocial history can reveal addiction-\\nrelated problems in areas that might be over-\\nlooked, such as strengths, abilities, aptitudes,\\nand preferences. Most information can be ana-\\nlyzed by using standardized comprehensive\\nassessment instruments tailored to specific pop-\\nulations or programs, such as those described\\nby Dodgen and Shea (2000).\\nSAMHSA regulations require that patients\\nìaccepted for treatment at an OTP shall be\\nassessed initially and periodically by qualified', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='personnel to determine the most appropriate\\ncombination of services and treatmentî (42\\nCFR, Part 8 ß 12(f)(4) [Federal Register\\n66(11):1097]). Treatment plans should be\\nreviewed and updated, initially every 90 days\\nand, after 1 year, biannually or whenever\\nchanges affect a patientís treatment outcomes.\\nOngoing monitoring should ensure that services\\nare received, interventions work, new problems\\nare identified and documented, and services\\nare adjusted as problems are solved. Patientsí', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='views of their progress, as well as the treatment\\nteamís assessment of patientsí responses to\\n53Initial Screening, Admission Procedures, and Assessment Techniques', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 73}),\n",
       " Document(page_content='treatment, should be documented in the \\ntreatment plan.\\nPatient Motivation and\\nReadiness for Change\\nPatient motivation to engage in MAT is a pre-\\ndictor of early retention (Joe et al. 1998) and is\\nassociated with increased participation, positive\\ntreatment outcomes, improved social adjust-\\nment, and successful treatment referrals (CSAT\\n1999a).\\nStarting with initial contact and continuing\\nthroughout treatment, assessment should focus\\non patient motivation for change (CSAT', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='1999a). OTP staff members help patients move\\nbeyond past experiences (e.g., negative relation-\\nships with staff, inadequate dosing) by focusing\\non making a fresh start, letting go of old\\ngrievances, and identifying current realities,\\nambivalence about change, and goals for the\\nfuture. It often is helpful to enlist recovering\\npatients in motivational enhancement \\nactivities. TIP 35, Enhancing Motivation for\\nChange in Substance Abuse Treatment (CSAT\\n1999a), provides extensive information about', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='stages of change, the nature of motivation, \\nand current guidelines for enhancing patient\\nmotivation to change.\\nSubstance Use Assessment\\nAs discussed previously, a patientís lifetime\\nsubstance use and treatment history should be\\ndocumented thoroughly. The following areas\\nshould be assessed:\\nï Periods of abstinence (e.g., number, duration,\\ncircumstances)\\nï Circumstances or events leading to relapse\\nï Effects of substance use on physical, \\npsychological, and emotional functioning', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='ï Changing patterns of substance use, with-\\ndrawal signs and symptoms, and medical\\nsequelae.\\nReports of psychiatric symptoms during absti-\\nnence help treatment providers differentiate\\ndrug withdrawal from mental disorder \\nsymptoms and can reveal important clues \\nto effective case management, for example, \\nthe need to refer patients for treatment of \\nco-occurring disorders.\\nChapter 11 discusses treatment methods and\\nconsiderations for patients with histories of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='multiple substance abuse. Most of these\\npatients fall into one of three groups, which\\nshould be determined during assessment: those\\nwho use multiple substances (1) to experience\\ntheir psychoactive effects, (2) to self-medicate\\nfor clinically evident reasons (e.g., back pain,\\ninsomnia, headache, co-occurring disorders),\\nor (3) to compensate for inadequate treatment\\nmedication (Leavitt et al. 2000). Multiple sub-\\nstance use should be identified and addressed', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='as soon as possible because of the risk of possi-\\nble overdose for patients who continue to abuse\\ndrugs or alcohol during treatment. Continued\\nsubstance abuse while in MAT might indicate\\nthat another treatment option is more appro-\\npriate. A challenge in treating patients who\\nabuse substances for clinically evident reasons\\nis to determine whether the patients are\\nattempting to medicate undiagnosed, misdiag-\\nnosed, or undertreated problems. If so, then', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='effectively addressing these related problems\\nmay reduce or eliminate continuing drug or\\nalcohol abuse and improve outcomes.\\nCultural Assessment\\nA comprehensive assessment should include\\npatientsí values and assumptions; linguistic\\npreferences; attitudes, practices, and beliefs\\nabout health and well-being; spirituality and\\nreligion; and communication patterns that\\nmight originate partly from cultural traditions\\nand heritage (Office of Minority Health 2001).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='Staff knowledge about diverse groups is \\nimportant for effective treatment services. Of\\nparticular importance are experiences and \\ncoping mechanisms related to assimilation and\\nacculturation of groups into mainstream\\nAmerican culture that may affect how they \\nperceive substance abuse and MAT. Gathering\\npertinent information often must rely on \\nsubjective sources (e.g., interviews and \\n54 Chapter 4', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 74}),\n",
       " Document(page_content='questionnaires). Even so, staff members\\ninvolved in screening and assessment should \\nbe cautioned against making value judgments\\nabout cultural or ethnic preferences or\\nassumptions about ìaverageî middle-class\\nAmerican values and beliefs. (See the forth-\\ncoming TIP Improving Cultural Competence \\nin Substance Abuse Treatment[CSAT \\nforthcoming b].)\\nA shared staffñpatient cultural identity is\\nattractive to some patients entering treatment.\\nTo the extent possible, patient preferences for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='staff members who share their cultural identity\\nshould be honored. Multilingual educational\\nmaterials and displays of culturally diverse\\nmaterials in the OTP help patients feel more at\\nease when English is not their primary language.\\nPsychosocial Assessment\\nThe components and objectives of psychosocial\\nassessment also are applicable to patients in\\nMAT. A psychosocial assessment typically iden-\\ntifies the relevant dynamics of patientsí lives\\nand functioning both before the onset of illness', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='(e.g., depression, anxiety) and currently. It\\nidentifies patientsí specific strengths and\\nresources (e.g., employment, supportive family\\nrelationships) as a basis for focused, individu-\\nalized, effective treatment planning. \\nHistory of co-occurring \\ndisorders and current mental\\nstatus\\nMental status assessments identify the threshold\\nsigns of co-occurring disorders and require\\nfamiliarity with the components of a mental\\nstatus examination (i.e., general appearance,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='behavior, and speech; stream of thought,\\nthought content, and mental capacity; mood\\nand affect; and judgment and insight) as out-\\nlined in Diagnostic and Statistical Manual of\\nMental Disorders, Fourth Edition, Text\\nRevision (American Psychiatric Association\\n2000). A mental status assessment also should\\nlook for perceptual disturbances and cognitive\\ndysfunction.\\nQualified professionals should train all staff\\nmembers involved in screening and assessment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='to recognize signs and symptoms of change in\\npatientsí mental sta-\\ntus. This training\\nshould be ongoing.\\nAfter reviewing their\\nobservations with the\\nprogram physician,\\nstaff members should\\nrefer all patients still\\nsuspected of \\nhaving co-occurring\\ndisorders for psychi-\\natric evaluation. This\\nevaluation should\\nidentify the types of\\nco-occurring disor-\\nders and determine\\nhow they affect\\npatientsí comprehen-\\nsion, cognition, and\\npsychomotor func-\\ntioning. Persistent\\nneuropsychological', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='neuropsychological\\nproblems warrant for-\\nmal testing to diag-\\nnose their type and severity and to guide treat-\\nment. Consultations by psychologists or physi-\\ncians should be requested or referrals made for\\ntesting. (See chapter 12 for typical methods of\\npsychiatric screening and diagnosis in an OTP .)\\nSociodemographic history\\nSociodemographic data about an applicant\\nshould include employment, educational, legal,\\nmilitary, family, psychiatric, and medical histo-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='ries, as well as current information, and should\\nbe supplemented by documents for identifica-\\ntion, such as a driverís license, birth or bap-\\ntismal certificate, passport, Social Security\\ncard, Medicaid card, public assistance card, or\\nidentification card from another substance\\nabuse treatment program.\\n55Initial Screening, Admission Procedures, and Assessment Techniques\\nA psychosocial\\nassessmentÖ\\nidentifies the \\nrelevant dynamics\\nof patientsí lives\\nand functioning\\nboth before the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='both before the\\nonset of illness and \\ncurrently.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 75}),\n",
       " Document(page_content='Family and cultural back-\\nground, relationships, and\\nsupports\\nThe effect of substance use on a patientís \\nfamily cannot be overestimated, and family\\nproblems should be expected for most patients\\nentering treatment. The comprehensive assess-\\nment should include questions about family\\nrelationships and problems, including any \\nhistory of domestic violence, sexual abuse, and\\nmental disorders (see below). When possible,\\nthe assessment should include input from rela-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='tives and significant others. Because families\\nwith members who abuse substances have\\nproblems directly linked to this substance\\nabuse, at least one staff member should be\\ntrained in family therapy or in making appro-\\npriate referrals for this intervention. \\nDuring assessment, program staff should be\\nsensitive to various family types represented in\\nthe patient population. For example, programs\\ntreating significant numbers of single parents\\nshould consider onsite childcare programs.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='Structured childcare services also enable OTP\\nstaff to observe and assess a patientís family\\nfunctioning, which can be valuable in treat-\\nment planning.\\nAny counselor or treatment provider who\\nmight confront emergencies related to child or\\nspousal abuse should be trained in how to iden-\\ntify and report these problems. TIP 25,\\nSubstance Abuse Treatment and Domestic\\nViolence(CSAT 1997b), provides screening,\\nassessment, and response guidance when\\ndomestic violence is suspected. TIP 36,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='Substance Abuse Treatment for Persons With\\nChild Abuse and Neglect Issues(CSAT 2000d),\\nfocuses on screening and assessment when\\npatients are suspected of being past victims or\\nperpetrators of child abuse. Staff members\\nshould be trained to listen and prepared to\\nhear traumatic stories and handle these situa-\\ntions, for example, by monitoring any intense\\nsymptoms and seeking special assistance when\\nnecessary (CSAT 2000d). Staff should be able\\nto identify individuals who exhibit certain signs', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='and symptoms associated with abuse (e.g.,\\nposttraumatic stress disorder [PTSD]) and\\nprovide or coordinate immediate services to\\naddress it (CSAT 1997b, 2000d).\\nChild abuse. All States require mandatory\\nreporting of child abuse by helping professionals\\nincluding OTP staffóparticularly State-\\nlicensed physicians, therapists, nurses, and\\nsocial workers (CSAT 2000d). Most States\\nrequire that this reporting be immediate and\\noffer toll-free numbers. Most also require that', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='reports include the name and address of a par-\\nent or caretaker, the type of abuse or neglect,\\nand the name of the alleged perpetrator.\\nFailure to report indications of abuse that\\nresults in injury to a child can lead to criminal\\ncharges, a civil suit, or loss of professional\\nlicensure. Mandated reporters generally are\\nimmune from liability for reports made in good\\nfaith that later are found to be erroneous\\n(CSAT 2000d).\\nStaff members who suspect domestic violence', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='should investigate immediately whether a\\npatientís children have been harmed. Inquiries\\ninto possible child abuse can occur only after\\nnotice of the limitations of confidentiality in\\nMAT (42 CFR, Part 8 ß 12(g)) has been given\\nto the patient, who must acknowledge receipt of\\nthis notice in writing. Patients also must be\\ninformed, during orientation and when other-\\nwise applicable, that substance abuse treatment\\nproviders are required to notify a childrenís', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='protective services agency if they suspect child\\nabuse or neglect.\\nSpousal or partner abuse. Generally, if a\\npatient believes that she or he is in imminent\\ndanger from a batterer, the treatment provider\\nshould respond to this situation before address-\\ning any others and, if necessary, suspend the\\nscreening or assessment interview to do so.\\nExhibit 4-3 summarizes the steps a treatment\\nprovider should follow. He or she should refer\\na patient to a shelter, legal services, or a domes-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='tic violence program if indicated. Providers\\nshould be familiar with relevant Federal, State,\\nand local regulations on domestic violence (e.g.,\\nthe 1994 Violence Against Women Act [visit\\nwww.ojp.usdoj.gov/vawo/laws/vawa/vawa.htm])\\n56 Chapter 4', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 76}),\n",
       " Document(page_content='and the legal resources available (e.g., restrain-\\ning orders, duty to warn, legal obligation to\\nreport threats and past crimes, confidentiality).\\nRomans and colleagues (2000) identified the\\nfollowing methods for exploring potential\\ndomestic violence situations, which can be\\nincorporated into effective assessment tools:\\nï Always interview patients in private about\\ndomestic violence.\\nï Begin with direct, broad questions and move\\nto more specific ones; inquire how disagree-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 77}),\n",
       " Document(page_content='ments or conflicts are resolved (e.g., ìDo you\\nwant to hit [him or her] to make [him or her]\\nsee sense?î); ask whether patients have trou-\\nble with anger or have done anything when\\nangry that they regret; combine these ques-\\ntions with other types of lifestyle questions.\\nï Ask about violence by using concrete exam-\\nples and specific hypothetical situations\\nrather than vague, conceptual questions.\\nï Display information about domestic violence\\nin public (e.g., waiting room) and private', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 77}),\n",
       " Document(page_content='(e.g., restroom) locations.\\nï Use opportunities during discussions (e.g.,\\ncomments about marital conflict situations or\\npoor communication with partners) to probe\\nfurther.\\nï Obtain as complete a description as possible\\nof the physical, sexual, and psychological \\nviolence perpetrated by or on a patient\\nrecently; typically, those who commit domes-\\ntic violence minimize, deny, or otherwise\\nobscure their acts.\\nHistory of physical or sexual\\nabuse\\nSome patients enter an OTP with a history of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 77}),\n",
       " Document(page_content='physical or sexual abuse, which frequently\\ncauses additional psychological distress (Schiff\\net al. 2002). Information about these types of\\nabuse is important in treatment planning but\\nnot always easily accessible using specific\\nassessment tools, especially early in treatment.\\n57Initial Screening, Admission Procedures, and Assessment Techniques\\nExhibit 4-3\\nRecommended Procedures for Identifying and\\nAddressing Domestic Violence*', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 77}),\n",
       " Document(page_content='ï Look for physical injuries, especially patterns of untreated injuries to the face, neck,\\nthroat, and breasts, which might become apparent during the initial physical examination.\\nï Pay attention to other indicators: history of relapse or treatment noncompliance; inconsis-\\ntent explanations for injuries and evasiveness; complications in pregnancy; possible stress-\\nand anxiety-related illnesses and conditions; sad, depressed affect; or talk of suicide.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 77}),\n",
       " Document(page_content='ï Fulfill legal obligations to report suspected child abuse, neglect, and domestic violence.\\nï Never discuss a patient without the patientís permission; understand which types of sub-\\npoenas and warrants require that records be turned over to authorities.\\nï Convey that there is no justification for battering and that substance abuse is no excuse. \\nï Contact domestic violence experts when battery has been confirmed.\\n*State laws may include other requirements.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 77}),\n",
       " Document(page_content='Some patients with abuse histories might deny\\ntheir victimization. Many women are less likely\\nto admit abuse to male counselors. Male staff\\nshould know when to request a staff change for\\ncounseling about physical or sexual abuse.\\nPatients might not be ready to address the\\nproblem, think it is unrelated to substance\\nabuse, or be ashamed. Gathering information\\nfrom them about abuse, therefore, requires\\nextreme care and respect during screening and\\nassessment. Once patients are stabilized and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='their practical needs are addressed, counseling\\nby qualified treatment providers can focus on\\nthis problem.\\nPeer relations and support\\nThe extent of social deterioration, interpersonal\\nloss, and isolation that patients have experi-\\nenced should be documented thoroughly during\\nscreening and assessment. Assessment of a\\npatientís support systems, including past \\nparticipation in mutual-help groups (e.g.,\\nAlcoholics Anonymous, Methadone Anonymous\\n[MA]), is critical to identifying peer support', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='networks that provide positive relationships\\nand enhance treatment outcomes. Some 12-\\nStep groups are ill-informed about MAT and\\nmay be unaware of the treatment goals of MAT\\nand less than sup-\\nportive; in these\\ncases, providers\\nshould help patients\\nidentify other\\nsources of support\\n(e.g., MA groups)\\nand encourage con-\\ntinued development\\nof some type of peer\\nsupport network. In\\nareas with limited\\nresources, patients\\nmay be able to over-\\ncome initial discrimi-\\nnatory behavior in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='natory behavior in\\nexisting groups by\\nincreasing their\\nknowledge of MAT\\nand their ability to\\nself-advocate.\\nHousing status and safety\\nconcerns\\nBased on year 2000 estimates, approximately\\n10 percent of patients in MAT are homeless or\\nliving as transients when admitted to treatment\\n(Joseph et al. 2000). Moreover, those who are\\nnot homeless often live with people who are\\naddicted or in areas where substance use is\\ncommon. In the opinion of the consensus panel,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='early intervention to arrange safe, permanent\\nshelter for these patients should be a high pri-\\nority, and a patientís shelter needs should be\\nascertained quickly during screening and\\nassessment. OTPs should establish special \\nsupport services to help patients secure \\nappropriate living arrangements, such as refer-\\nral agreements with housing agencies or other\\nprograms to locate housing that addresses the\\nspecial needs of homeless patients. \\nCriminal history and legal\\nstatus', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='status\\nAnother purpose of screening and assessment is\\nto identify legal issues that might interrupt\\ntreatment, such as outstanding criminal\\ncharges or ongoing illegal activity to support\\nsubstance use; however, pending or unresolved\\ncharges are not a contraindication for MAT.\\nAssessment may involve exploring personal \\ncircumstances such as child custody and related\\nobligations. In the consensus panelís experi-\\nence, many patients ignore legal problems \\nduring periods of substance use, but these', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='problems pose a serious threat to recovery. In\\naddition, a patientís arrest record, including\\nage at first arrest, arrest frequency, nature of\\noffenses, criminal involvement during child-\\nhood, and life involvement with the criminal\\njustice system, should be clarified.\\nInsurance status\\nPatientsí resources to cover treatment costs\\nshould be determined during screening and\\nassessment. Often they are uninsured or have\\nnot explored their eligibility for payment assis-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='tance. The consensus panel believes that OTPs\\nare responsible for helping patients explore\\n58 Chapter 4\\n[A]ssessment and\\ntreatment...\\nshould focus on\\nstopping the \\nsubstance abuse\\nthat interferes\\nwith patientsí \\nwell-being.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 78}),\n",
       " Document(page_content='payment options so that they have access to a\\nfull range of treatment services, including med-\\nical care, while ensuring payment to the OTP .\\nIn situations of inadequate funding or patient\\nineligibility for funds, another source of pay-\\nment should be identified. OTP staff can assist\\npatients in applying for public assistance or\\ninquiring whether personal insurance will reim-\\nburse MAT costs. Counselors can help patients\\nmake decisions about involving their insurance', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='companies and address fears that employers\\nwill find out about their substance use or that\\nbenefits for health care will be denied.\\nEmployment history\\nAnother important component of psychosocial\\nassessment is a patientís employment history.\\nBased on year 2000 estimates, only 20 percent of\\npatients in MAT were employed when admitted\\nto an OTP (Joseph et al. 2000). Until they are\\nstabilized, employed patients often experience\\nsubstance-related difficulties at the workplace,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='including lack of concentration, tardiness and\\nabsences, inability to get along with coworkers,\\non-the-job accidents, and increased claims for\\nworkersí compensation. Early identification of\\nthese difficulties can help staff and patients \\ncreate a more effective treatment plan. \\nPatients who are employed often are reluctant\\nto enter residential treatment or take the time\\nto become stabilized on medication; however,\\nmost of these patients would take medical or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='other leave time if they were hospitalized for\\nother illnesses, and they should be encouraged\\nto take their addiction as seriously. A physi-\\ncianís note recommending time off work for\\nsome period might help, but it should be on let-\\nterhead that does not reference drug treatment.\\nMilitary or other service \\nhistory\\nA patientís military or other service history can\\nhighlight valuable areas in treatment planning.\\nIn particular, was military service generally a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='positive or negative experience? If the former,\\ntreatment providers can help patients identify\\nareas of strength or personal achievement,\\nsuch as the ability to cope under stress, receipt\\nof medals for service accomplishments, and\\nhonorable discharge; patients can learn to\\nbuild on past strengths in current challenging\\nsituations and to progress in treatment. If the\\nlatter, providers should review patientsí nega-\\ntive military experiences, including loss of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='friends and loved ones, onset of substance use,\\nwar-related injuries, chronic pain, PTSD, and\\nco-occurring disorders (e.g., depression). This\\ninformation might indicate patterns of behavior\\nthat continue to affect recovery.\\nPatientsí military history also might reveal\\ntheir eligibility for medical and treatment\\nresources through U.S. Department of\\nVeterans Affairs programs and hospitals or\\nsocial service agencies.\\nSpirituality\\nìSpiritualityî in this TIP refers to willing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='involvement in socially desirable activities or\\nprocesses that are beyond the immediate details\\nof daily life and personal self-interest. Attention\\nto the ethics of behavior, consideration for the\\ninterests of others, community involvement,\\nhelping others, and participating in organized\\nreligion are expressions of spirituality.\\nA patientís spirituality can be an important\\ntreatment resource, and persons recovering\\nfrom addiction often experience increased', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='interest in the spiritual aspects of their lives. A\\nstudy by Flynn and colleagues (2003) of 432\\npatients admitted to 18 OTPs found that those\\nwho remained in recovery for 5 years credited\\nreligion or spirituality as one factor in this out-\\ncome. Staff should assess patientsí connections\\nwith religious institutions because these institu-\\ntions often provide a sense of belonging that is\\nvaluable in the rehabilitative process. \\nMiller (1998) found a lack of research explor-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='ing the association between spirituality and\\naddiction recovery but concluded that spiritual\\nengagement or reengagement appeared to be\\ncorrelated with recovery. In studies reviewed\\nby Muffler and colleagues (1992), individuals\\nwith a high degree of spiritual motivation to\\n59Initial Screening, Admission Procedures, and Assessment Techniques', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 79}),\n",
       " Document(page_content='recover reported that treatment programs that\\nincluded spiritual guidance or counseling were\\nmore likely to produce positive outcomes than\\nprograms that did not. OTPs should assess\\nspiritual resources adequately. Counselors and\\nother mental health professionals could benefit\\nfrom training in patient spirituality if it is \\ndifficult for them to explore.\\nSexual orientation and \\nhistory\\nThe assessment and treatment needs of hetero-\\nsexual and LGB populations are similar and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 80}),\n",
       " Document(page_content='should focus on stopping the substance abuse\\nthat interferes with patientsí well-being.\\nAssessment of risk factors associated with sexual\\nencounters and partners is essential. What\\noften differs for an LGB population is the\\nimportance of assessing patientsí sexual or gen-\\nder orientation concerns, such as their feelings\\nabout their sexual orientation (CSAT 2001b).\\nOTP staff should pay strict attention to confi-\\ndentiality concerns for LGB patients because', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 80}),\n",
       " Document(page_content='they may be at increased risk of legal or other\\nactions affecting employment, housing, or child\\ncustody. Treatment modalities and programs\\nshould be accessible to all groups, and pro-\\ngrams providing ancillary services should be\\nsensitive to the special needs of all patients\\nregardless of sexual orientation (CSAT 2001b).\\nPatientsí ability to manage\\nmoney\\nFinancial difficulties are common among\\npatients in MAT, who often have spent \\nconsiderable money on their substance use that', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 80}),\n",
       " Document(page_content='otherwise would have paid for rent, food, and\\nutilities. Financial status and money manage-\\nment skills should be assessed to help patients\\nunderstand their fiscal strengths and weakness-\\nes as they become stabilized. Patients often\\nneed assistance to adjust to loss of income\\ncaused by reduced criminal activity and develop\\nskills that enhance their legitimate earning\\npower. Once financial factors are clarified,\\npatients may be better prepared to devise', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 80}),\n",
       " Document(page_content='realistic strategies to achieve short- and long-\\nterm goals.\\nRecreational and leisure\\nactivities\\nRecreational and leisure activities are impor-\\ntant in recovery; therefore, assessment should\\ndetermine any positive activities in which\\npatients have participated before or during\\nperiods of substance use. Identifying existing\\nrecreational and leisure time preferences and\\ngaining exposure to new ones can be significant\\nsteps in developing a recovery-oriented lifestyle.\\n60 Chapter 4', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 80}),\n",
       " Document(page_content='Appendix 4-A. Example of Standard Consent to\\nOpioid Maintenance Treatment\\nConsent to Participation in Opioid Pharmacotherapy Treatment\\nPatient’s Name:________________________________Date: _________________________\\nI hereby authorize and give voluntary consent to the Division and its medical personnel to dispense\\nand administer opioid pharmacotherapy (including methadone or buprenorphine) as part of the\\ntreatment of my addiction to opioid drugs. Treatment procedures have been explained to me, and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 81}),\n",
       " Document(page_content='I understand that this will involve my taking the prescribed opioid drug at the schedule determined\\nby the program physician, or his/her designee, in accordance with Federal and State regulations.\\nIt has been explained that, like all other prescription medications, opioid treatment medications\\ncan be harmful if not taken as prescribed. I further understand that opioid treatment medications\\nproduce dependence and, like most other medications, may produce side effects. Possible side', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 81}),\n",
       " Document(page_content='effects, as well as alternative treatments and their risks and benefits, have been explained to me.\\nI understand that it is important for me to inform any medical provider who may treat me for any\\nmedical problem that I am enrolled in an opioid treatment program so that the provider is aware\\nof all the medications I am taking, can provide the best possible care, and can avoid prescribing\\nmedications that might affect my opioid pharmacotherapy or my chances of successful recovery\\nfrom addiction.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 81}),\n",
       " Document(page_content='from addiction.\\nI understand that I may withdraw voluntarily from this treatment program and discontinue the\\nuse of the medications prescribed at any time. Should I choose this option, I understand I will be\\noffered medically supervised tapering.\\nFor Female Patients of Childbearing Age:There is no evidence that methadone pharmaco-\\ntherapy is harmful during pregnancy. If I am or become pregnant, I understand that I should', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 81}),\n",
       " Document(page_content='tell my medical provider right away so that I can receive appropriate care and referrals. I under-\\nstand that there are ways to maximize the healthy course of my pregnancy while I am in opioid\\npharmacotherapy.\\n_____________________________________    _________________________ ____________\\nSignature of Patient Date of Birth Date\\nWitness:_______________________________________________________________________', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 81}),\n",
       " Document(page_content='Adapted with permission from Department of Psychiatry and Behavioral Sciences, Albert Einstein\\nCollege of Medicine, Division of Substance Abuse, Bronx, NY.\\n61Initial Screening, Admission Procedures, and Assessment Techniques', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 81}),\n",
       " Document(page_content='In This\\nChapterÖ\\nLorem ipsum dolor\\nsit\\nSed do\\neiusmod\\nUt enim\\nad minim\\nveniam quis\\nDolore eu\\nfugiat nulla\\n63\\n5 Clinical\\nPharmacotherapy\\nThis chapter describes pharmacotherapy in opioid treatment programs\\n(OTPs), in particular the clinical use of methadone, with limited discus-\\nsion of levo-alpha acetyl methadol (LAAM) and buprenorphine. More\\nlimited coverage is provided on the opioid antagonist naltrexone, which\\nis not used widely for opioid addiction treatment in the United States. As', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 83}),\n",
       " Document(page_content='explained in chapter 3, at this writing most OTPs have discontinued the\\nuse of LAAM for new patients, and its continued availability is uncer-\\ntain. TIP 40, Clinical Guidelines for the Use of Buprenorphine in the\\nTreatment of Opioid Addiction(CSAT 2004a), provides more detailed\\ninformation about buprenorphine.\\nIn general, the choice of medication used in medication-assisted treat-\\nment for opioid addiction (MAT) is based on safety and efficacy, patient', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 83}),\n",
       " Document(page_content='preferences, and treatment goals. Methadone maintenance treatment has\\nthe longest successful track record in patients addicted to opioids for\\nmore than a year and has been shown to control withdrawal symptoms,\\nstabilize physiologic processes, and improve functionality. Studies also\\nhave found that methadone maintenance treatment reduces criminality,\\nnoncompliance with HIV/AIDS therapy, seroconversion to HIV/AIDS,\\nand mortality associated with opioid addiction (Appel et al. 2001; Ball', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 83}),\n",
       " Document(page_content='and Ross 1991). Since 2001, LAAM, although effective in opioid pharma-\\ncotherapy, has carried a restrictive label precluding its use as the initial\\nmedication for MAT. As reviewed in chapter 3, the effectiveness of\\nbuprenorphine has been found to be similar to that of methadone and\\nLAAM (Johnson et al. 2000). Sublingual buprenorphine formulations\\nhave been approved for use in OTPs and by physicians in office-based\\nand other health care settings. Some patients prefer buprenorphine', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 83}),\n",
       " Document(page_content='maintenance in an office-based opioid treatment (OBOT) setting to the\\ndaily observed dosing that is part of methadone maintenance in an OTP .\\nHowever, patients who progress in MAT while in an OTP eventually may\\nqualify for take-home medication lasting up to 30 days at a time, as\\ndetailed below, and patients desiring ongoing buprenorphine pharma-\\ncotherapy now can receive buprenorphine on a less-than-daily basis in\\neither an OTP or OBOT setting. For some patients, these options may', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 83}),\n",
       " Document(page_content='reduce the attendance requirements for MAT in an OTP .\\nIn This\\nChapter…\\nContraindications\\nto Opioid\\nPharmacotherapy\\nStages of\\nPharmacotherapy\\nMedically\\nSupervised\\nWithdrawal\\nTake-Home\\nMedications\\nOffice-Based Opioid\\nTherapy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 83}),\n",
       " Document(page_content='For patients who do not qualify for or do not\\nprefer opioid maintenance treatment (see\\nìContraindications to Opioid Pharmacotherapyî\\nbelow), a primary issue during treatment is\\nwhat to do about withdrawal symptoms.\\nNaturally occurring opioid withdrawal is almost\\nnever life threatening, but it can produce dis-\\ncomfort severe enough to warrant urgent inter-\\nvention. Treatment for withdrawal symptoms\\nusually involves administration of a long-acting\\nopioid medication such as methadone or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='buprenorphine, which can be followed by grad-\\nual tapering of the medication as withdrawal\\nsymptoms diminish.\\nControl of withdrawal symptoms often is insuf-\\nficient treatment to prevent a relapse to opioid\\nabuse, and detoxification alone may yield only\\nshort-term benefits. Research has shown that\\nretention in treatment over an extended period\\nis key to successful outcomes for opioid addic-\\ntion in many patients, just as it is for other\\nchronic diseases like hypertension, diabetes,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='and asthma (McLellan et al. 2000). Therefore,\\nwhen detoxification from short-acting opioids is\\nprovided, the consensus panel recommends\\nlinkage to ongoing psychosocial treatment, with\\nor without additional maintenance therapy\\nwith an opioid antagonist such as naltrexone.\\nComprehensive, long-term opioid agonist main-\\ntenance remains the treatment with the best\\ntrack record of controlling opioid use and sav-\\ning lives, although opioid partial agonist thera-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='py is promising. Access and easy transfer to\\nthis care should remain available as part of any\\ndetoxification program.\\nContraindications \\nto Opioid\\nPharmacotherapy\\nThe consensus panel believes that few psychi-\\natric or medical diagnoses categorically should\\nrule out admission to an OTP or access to opi-\\noid pharmacotherapy. Inclusion rather than\\nexclusion should be the guiding principle.\\nTypes of people who possibly should not be\\nadmitted to an OTP and should receive other\\ninterventions include', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='ï Individuals who abuse opioids but whose \\nconditions do not meet criteria for opioid\\ndependence outlined in the Diagnostic and\\nStatistical Manual of Mental Disorders,\\nFourth Edition, Text Revision(DSM-IV-TR)\\n(American Psychiatric Association 2000). If a\\nclear history of opioid abuse or addiction\\nexists but a person currently is not addicted,\\nregulations allow admission to an OTP in two\\ncases in which a person might relapse without\\ntreatment: pregnancy and release from incar-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='ceration (42 Code of Federal Regulation\\n[CFR], 8 Part ß 12(e)(3)).\\nï Individuals with less than 1 year of opioid\\naddiction and no addiction treatment history,\\nexcept patients receiving OBOT with\\nbuprenorphine. Detoxification might be\\nattempted with applicants who have a shorter\\nhistory of addiction. Applicants receiving\\nbuprenorphine may be admitted to an OTP\\nfor either medically supervised withdrawal or\\nmaintenance treatment.\\nï Applicants who cannot attend treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='sessions regularly, especially for medication\\ndosing (unless a clinical exception can be\\nobtained [see chapter 7]); this requirement is\\nless of a hindrance for patients receiving\\nOBOT with buprenorphine.\\nï Previous patients who have had allergic reac-\\ntions to methadone, LAAM, or buprenorphine.\\nï For LAAM, applicants with cardiac abnor-\\nmalities such as prolonged QT interval.\\nIn addition, people who are opioid addicted\\nand meet DSM-IV-TR criteria for alcohol or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='sedative dependence might be problematic can-\\ndidates for opioid pharmacotherapy because\\nthe combined effects of alcohol or sedatives\\nthat depress the central nervous system (CNS)\\ncan cause serious adverse events during MAT\\n(see discussion of drug interactions in chapter\\n3). Some treatment providers require detoxifi-\\ncation from alcohol and sedatives before opioid\\npharmacotherapy, followed by careful monitor-\\ning such as daily BreathalyzerJ tests, ongoing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='drug tests, and reduction or withholding of\\nmedication if a test is positive. The consensus\\npanel endorses this strategy, provided that \\nadequate alcohol or sedative detoxification\\n64 Chapter 5', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 84}),\n",
       " Document(page_content='65Clinical Pharmacotherapy\\nfacilities are readily available. If not, both opi-\\noid addiction and alcohol or sedative depen-\\ndence should be treated concurrently at the\\nOTP site with a combination of psychosocial\\nand pharmacological interventions.\\nStages of\\nPharmacotherapy\\nThe stages of pharmacotherapy with methadone,\\nLAAM, or buprenorphine include induction,\\nstabilization, and maintenance. The stages of\\nnaltrexone pharmacotherapy may differ.\\nInduction\\nInduction procedures for methadone, LAAM,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='and buprenorphine depend on the unique\\npharmacologic properties of each medication,\\nprevailing regulatory requirements, and patient\\ncharacteristics. Regardless of the medication\\nused, safety is key during the induction stage. \\nGeneral considerations\\nTiming.When to begin the first dose of opioid\\ntreatment medication is important. Most treat-\\nment providers begin treating new patients\\nwhen there are no signs of opioid intoxication\\nor sedation and some beginning signs of opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='withdrawal. Administration of the first dose\\nalso should await a physical assessment to rule\\nout any acute, life-threatening condition that\\nopioids might mask or worsen (see chapter 4\\nfor more information on medical assessment).\\nFor naltrexone, patients should be abstinent\\nfrom all short-acting opioids for at least 7 days\\nand from long-acting opioids, such as\\nmethadone, for at least 10 days before begin-\\nning the medication to prevent potentially\\nsevere withdrawal symptoms (OíConnor and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='Fiellin 2000).\\nOther substance use.The presence of sedatives\\nsuch as benzodiazepines or alcohol should be\\nruled out before induction to minimize the \\nlikelihood of oversedation with the first dose.\\nOTP staff should ensure that patients known \\nto abuse sedatives, tranquilizers, tricyclic\\nantidepressants, benzodiazepines, alcohol, or\\nother CNS depressants are told in clear lan-\\nguage of the dangers of adverse effects if they\\ntake these substances while being stabilized or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='maintained on methadone, LAAM, or\\nbuprenorphine.\\nObserved dosing. Observed dosing with\\nmethadone, LAAM, or buprenorphine should\\nbe part of the medical safety procedure and\\ndiversion control plan in an OTP and is recom-\\nmended during induction with buprenorphine.\\nObserved dosing is the only way to ensure that\\na patient ingests a\\ngiven dose and to\\nmonitor a patientís\\nresponse. In observed\\ndosing, staff members\\nwho dispense medica-\\ntion first carefully\\nidentify patientsó\\nsometimes by requir-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='ing them to remove\\nhats or dark glasses,\\nfor exampleóand\\nthen provide the \\nmedication.\\nTo ensure that patients swallow oral doses of\\nmethadone or LAAM, they should be required\\nto speak before and after ingesting at least 2\\nounces of liquid in which an appropriate dose\\nof medication is dissolved. For buprenorphine,\\na sublingual tablet should be observed to have\\ndissolved completely under the tongue. After\\nthe first dose, patients should wait in an obser-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='vation area and be checked 30 to 60 minutes\\nlater for acute adverse effects. If same-day \\ndosing adjustments must be made, patients\\nshould wait 2 to 4 more hours after the addi-\\ntional dosing, for further evaluation when peak\\neffects are achieved. The consensus panel rec-\\nommends that patients be observed for several\\nhours after the first dose of any opioid treat-\\nment medication. This observation is particu-\\nlarly important for patients at higher risk of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='overdose, including those naive to methadone,\\nLAAM, and buprenorphine; those receiving\\nother CNS-depressant medications or known to\\nabuse CNS depressants; and severely medically\\nRegardless of the\\nmedication used,\\nsafety is key \\nduring the\\ninduction stage.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 85}),\n",
       " Document(page_content='66 Chapter 5\\nill, frail, or elderly patients. Naltrexone \\ntypically is prescribed without observed dosing,\\nbut poor patient compliance with ongoing \\nnaltrexone therapy has led some investigators\\nto look at using family members to ensure that\\npatients take their medication (Fals-Stewart\\nand OíFarrell 2003).\\nInitial dosing.The first dose of any opioid\\ntreatment medication should be lower if a\\npatientís opioid tolerance is believed to be low,\\nthe history of opioid use is uncertain, or no', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='signs of opioid withdrawal are evident. Some\\nformer patients who have been released from\\nincarceration or are pregnant and are being\\nreadmitted because they have a history of\\naddiction might have lost their tolerance. Loss\\nof tolerance should be considered for any\\npatient who has abstained from opioids for\\nmore than 5 days. In general, the safety princi-\\nple ìstart low and go slowî applies for early\\nmedication dosages in an outpatient OTP . The\\namount of opioid abuse estimated by patients', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='usually gives only a rough idea of their toler-\\nance and should not be used as a dosing guide\\nfor induction, nor should initial dosages be\\ndetermined by previous treatment episodes or\\npatient estimates of dollars spent per day on\\nopioids. Patients\\ntransferred from\\nother treatment pro-\\ngrams should start\\nwith medication\\ndosages identical to\\nthose prescribed at\\ntheir previous OTPs.\\nDosage adjustments\\nin the first week of\\ntreatment should be\\nbased on how\\npatients feel at the\\npeak period for their', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='medication (e.g., \\n2 to 4 hours after a\\ndose of methadone is\\nadministered), not\\non how long the\\neffects of a medica-\\ntion last. As stores \\nof medication accumulate in body tissues (see\\nbelow), the effects begin to last longer.\\nSteady state. Initial dosing should be followed\\nby dosage increases over subsequent days until\\nwithdrawal symptoms are suppressed at the\\npeak of action for the medication. Methadone,\\nLAAM, and buprenorphine are stored in body\\ntissues, including the liver, from which their', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='slow release keeps blood levels of medication\\nsteady between doses. It is important for physi-\\ncians, staff members, and patients to under-\\nstand that doses of medication are eliminated\\nmore quickly from the bloodstream and medi-\\ncation effects wear off sooner than might be\\nexpected until sufficient levels are attained in\\ntissues. During induction, even without dosage\\nincreases, each successive dose adds to what is\\npresent already in tissues until steady state is', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='reached. Steady state refers to the condition in\\nwhich the level of medication in a patientís\\nblood remains fairly steady because that drugís\\nrate of intake equals the rate of its breakdown\\nand excretion.\\nSteady state is based on multiples of the elimi-\\nnation half-life. Approximately four to five\\nhalf-life times are needed to establish a steady\\nstate for most drugs. For example, because\\nmethadone has a half-life of 24 to 36 hours, its\\nsteady stateóthe time at which a relatively', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='constant blood level should remain present in\\nthe bodyóis achieved in 5 to 7.5 days after\\ndosage change for most patients. However,\\nindividuals may differ significantly in how long\\nit takes to achieve steady state.\\nPatients should stay on a given dosage for a\\nreasonable period before deciding how it will\\nìhold.î During induction, patients should be\\ninstructed to judge their doses by how they feel\\nduring the peak period (the point of maximum\\nconcentration of medication in the blood [for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='methadone, 2 to 4 hours after taking a dose]),\\nrather than during the trough period (the low\\npoint of medication concentration in blood just\\nbefore the next dose [for methadone, approxi-\\nmately 24 hours after ingestion]). Patients who\\nwake up sick during the first few days of opioid\\npharmacotherapy might become convinced that\\n[T]he safety \\nprinciple ìstart\\nlow and go slowî\\napplies for early\\nmedication\\ndosages in an \\noutpatient OTP .', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 86}),\n",
       " Document(page_content='they need a dose increase, when in fact they\\nneed more time for tissue stores to reach steady\\nstate. In contrast, patients who wake up sick\\nafter the first week of treatmentówhen tissue\\nstores have reached steady-state levelsómight\\nindeed need higher doses.\\nIn closely monitored settings such as inpatient\\nprograms, multiple split doses can be adminis-\\ntered per day based on patientsí symptoms at\\npeak blood levels. Outpatient programs are\\nlimited in this approach because patients can', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='be monitored only when they are at the OTP\\nsite. (Split dosing is discussed further below.)\\nBecause buprenorphineís safety profile makes\\noverdose less of a concern, some providers opt\\nto give even new patients receiving buprenor-\\nphine some take-home medication for multiple\\ndosing during induction (CSAT 2004a).\\nInduction with methadone\\nand LAAM\\nBecause methadone overdose deaths have\\noccurred in the first few days of treatment\\n(Caplehorn and Drummer 1999; Zador and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='Sunjic 2000), it is important to adjust\\nmethadone dosage carefully until stabilization\\nand tolerance are established. Federal regula-\\ntions require that methadone initially be given\\ndaily under observation for either 6 or 7 days\\nper week. (A take-home dose is allowed for all\\npatients when the OTP is closed on Sunday.)\\nLAAM must continue to be given under obser-\\nvation and administered no more than every 2\\nto 3 days.\\nInitial dosing. For a patient actively abusing', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='opioids, a typical first dose of methadone is 20\\nto 30 mg (Joseph et al. 2000) and is limited by\\nregulations to no more than 30 mg. If with-\\ndrawal symptoms persist after 2 to 4 hours, the\\ninitial dose can be supplemented with another 5\\nto 10 mg (Joseph et al. 2000). The total first-\\nday dose of methadone allowed by Federal reg-\\nulations is 40 mg unless a program physician\\ndocuments in the patient record that 40 mg was\\ninsufficient to suppress opioid withdrawal', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='symptoms (42 CFR, Part 8 ß 12(h)(3)(ii)).\\nSince 2001, LAAM has carried a restriction\\nthat precludes its use as an initial medication\\nfor pharmacotherapy because of concerns\\nabout its cardiovascular effects. Although\\ndirect induction with LAAM can be accom-\\nplished with an initial dose of 20 to 40 mg every\\n48 hours, LAAM has been used almost exclu-\\nsively in cases involving transfer of patients\\nfrom methadone maintenance. LAAM must\\nnever be given on 2 consecutive days because', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='its extended duration of action can result in\\ntoxic blood levels leading to fatal overdose.\\nVariations in individual response and optimal\\ndosing.Most differences in patient response to\\nmethadone can be explained by variations in\\nindividual rates of absorption, digestion, and\\nexcretion of the drug, which in turn are caused\\nby such factors as body weight and size, other\\nsubstance use, diet, co-occurring disorders and\\nmedical diseases, and genetic factors. Because', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='variation in response to methadone is consider-\\nable, the consensus panel believes that the\\nnotion of a uniformly suitable dosage range \\nor an upper dosage limit for all patients is\\nunsupported scientifically. Whereas 60 mg of\\nmethadone per day may be adequate for some\\npatients, it has been reported that some\\npatients require much more for optimal effect.\\nTreatment providers should avoid thinking of\\nìhigh dosageî as being above a certain uniform\\nthreshold; however, there are few data on the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='safety of methadone doses above 120 mg/day.\\nFor example, diversion of very high doses can\\nbe associated with significant risk because the\\ntolerance of the person taking the diverted dose\\nmay be insufficient to avoid overdose.\\nThe way a person presents at the OTP is often\\nthe best indicator for determining optimal\\ndosage. Looking for clinical signs and listening\\nto patient-reported symptoms related to daily\\ndoses or changes in dosage can lead to adjust-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='ments and more favorable outcomes (Leavitt et\\nal. 2000). Exhibit 5-1 illustrates the use of signs\\nand symptoms to determine optimal methadone\\ndosages. Generally, the disappearance of opioid\\nwithdrawal symptoms indicates adequate dos-\\ning and serum methadone levels (SMLs) within\\nthe therapeutic comfort zone.\\n67Clinical Pharmacotherapy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 87}),\n",
       " Document(page_content='68 Chapter 5\\nResearch indicates that patients diagnosed with\\nmental disorders or hepatitis C along with sub-\\nstance addiction may need increases of 50 per-\\ncent or more in methadone dosage to achieve\\nstabilization (Leavitt et al. 2000; Maxwell and\\nShinderman 2002).\\nExhibit 5-2 illustrates how blood levels of\\nmethadone rise with repeated dosing until steady\\nstate is reached. It is important to understand\\nthat steady state is achieved after a dosage\\nchange. In Exhibit 5-2, because the last change', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 88}),\n",
       " Document(page_content='(to 100 mg) occurred on day 5, steady state was\\nnot achieved until approximately day 10.\\nInduction with buprenorphine\\nBecause buprenorphine has lower abuse poten-\\ntial than methadone or LAAM and is less likely\\nto produce respiratory depression if diverted\\nor misused, qualified practitioners can pre-\\nscribe buprenorphine without the control\\nstructure of an OTP when they meet Drug\\nAddiction Treatment Act of 2000 requirements.\\nNo stated requirement exists for observed dos-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 88}),\n",
       " Document(page_content='ing with buprenorphine, although guidelines\\nstrongly recommend dosage monitoring early in\\ntreatment (CSAT 2004a).\\nExhibit 5-1 \\nUsing Signs and Symptoms To Determine Optimal Methadone Levels\\nAdapted from Leavitt et al. (2000), modified with permission from Mount Sinai Journal\\nof Medicine.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 88}),\n",
       " Document(page_content='69\\nInitial dosing. Awaiting signs of withdrawal\\nbefore administering the first dose is especially\\nimportant for buprenorphine induction\\nbecause, as explained in chapter 3, buprenor-\\nphine can precipitate withdrawal in some cir-\\ncumstances (Johnson and Strain 1999).\\nPrecipitated withdrawal usually is more sudden\\nand can be more severe and uncomfortable\\nthan naturally occurring withdrawal. The \\ntypical first dose of buprenorphine is 4 mg. If\\nwithdrawal symptoms persist after 2 to 4 hours,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 89}),\n",
       " Document(page_content='the initial dose can be supplemented with up to\\n4 mg for a maximum dose of 8 mg of buprenor-\\nphine on the first day (Johnson et al. 2003b).\\nThree national evaluations of the \\nbuprenorphine-naloxone combination tablet\\nfound that direct induction with buprenor-\\nphine alone was effective for most people who\\nwere opioid addicted. However, buprenorphine\\ntablets without naloxone (sometimes called\\nmonotherapy tablets) are recommended during\\nthe first 2 days of induction for patients', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 89}),\n",
       " Document(page_content='attempting to transfer from a longer acting \\nopioid such as sustained-release morphine or\\nmethadone (Amass et al. 2000, 2001) because\\nmost of these patients will experience with-\\ndrawal effects from the naloxone in the \\ncombination tablets. When patientsí tissue \\nlevels of a full agonist are a factor and the\\nbuprenorphine-naloxone tablet is adminis-\\ntered, it may be difficult to determine whether\\nprecipitated withdrawal is caused by the par-\\ntial agonist buprenorphine or small amounts of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 89}),\n",
       " Document(page_content='absorbed naloxone.\\nFor most patients who are appropriate \\ncandidates for induction with the combination\\ntablet, the initial target dose after induction\\nshould be 12 to 16 mg of buprenorphine in \\nClinical Pharmacotherapy\\nExhibit 5-2\\nInduction SimulationóModerate to High Tolerance\\nAdapted from Payte 2002, with permission.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 89}),\n",
       " Document(page_content='a 4-to-1 ratio to naloxone (i.e., 12/3 to 16/4 mg\\n[buprenorphine/naloxone]). Bringing patients\\nto this target dosage may be achieved over the\\nfirst 3 days of treatment by doubling the dose\\neach successive day after initial administration.\\nAn initial dose of 4/1 mg (buprenorphine/\\nnaloxone) is recommended, followed in 2 to 4\\nhours with an additional 4/1 mg if indicated.\\nThe dosage should be increased on subsequent\\ndays to the target dosage (ranging from 12/3 to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='16/4 mg per day). During dose induction,\\npatients may need to visit their OTP or physi-\\ncianís office daily for dose adjustments and\\nclinical monitoring. Further information and\\nguidelines for buprenorphine induction and use\\ncan be found in TIP 40, Clinical Guidelines for\\nthe Use of Buprenorphine in the Treatment of\\nOpioid Addiction (CSAT 2004a).\\nInduction with naltrexone\\nThe standard procedure for induction to nal-\\ntrexone therapy is first to make certain that', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='there is an absence of physiological dependence\\non opioids. This often is done by using a\\nNarcan challenge after a 7- to 10-day period\\nduring which opioids are not used. Then the\\npatient is given 25 mg of naltrexone initially,\\nfollowed by 50 mg the next day if no withdrawal\\nsymptoms occur after the first 25 mg dose.\\nThereafter, the patient is given 50 mg per day\\nor up to 350 mg per week in three doses during\\nthe week. The first dose usually is smaller to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='minimize naltrexoneís side effects, such as nau-\\nsea and vomiting, and to ensure that patients\\nhave been abstinent from opioids for the \\nrequisite time (Stine et al. 2003).\\nStabilization\\nThe terms ìsteady stateî and ìstabilizationî\\nshould be differentiated. Steady state is\\nachieved when a treatment medication is elimi-\\nnated from the blood at the exact rate that\\nmore is added. In contrast, a patient is stabi-\\nlized when he or she no longer exhibits drug-\\nseeking behavior or craving. The correct', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='(steady-state) medication dosage contributes to\\na patientís stabilization, but it is only one of\\nseveral factors, as discussed elsewhere in this\\nTIP . The stabilization stage of opioid pharma-\\ncotherapy focuses on finding the right dosage\\nfor each patient. The potential for undermedi-\\ncation or overmedication can be avoided by a\\nflexible approach to dosing, which sometimes\\nrequires higher dosages of treatment medica-\\ntion than expected, and by taking into account', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='patient-reported symptoms (Leavitt et al. 2000).\\nDosage determination\\nIt is critical to successful patient management in\\nMAT to determine a medication dosage that will\\nminimize withdrawal symptoms and craving\\nand decrease or eliminate opioid abuse. Dosage\\nrequirements for methadone, LAAM, and\\nbuprenorphine must be determined on an indi-\\nvidual basis. There is no single recommended\\ndosage or even a fixed range of dosages for all\\npatients. For many patients, the therapeutic', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='dosage range of methadone may be in the\\nneighborhood of 80 to 120 mg per day (Joseph\\net al. 2000), but it can be much higher, and\\noccasionally it is much lower.\\nThe desired responses to medication that \\nusually reflect optimal dosage include (Joseph\\net al. 2000)\\nï Prevention of opioid withdrawal for 24 hours\\nor longer, including both early subjective\\nsymptoms and objective signs typical of \\nabstinence\\nï Elimination of drug hunger or craving\\nï Blockade of euphoric effects of self-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='administered opioids (This is not a true\\nblockade like that achieved by naltrexone but\\nreflects cross-tolerance for other opioids,\\nattenuating or eliminating desired sensations\\nwhen illicit or prescription opioids are self-\\nadministered in usual ìstreet doses.î The\\nincreasing purity of heroin and availability of\\nhighly potent prescription opioids have made\\nit increasingly difficult to achieve complete\\nblockade in patients through cross-tolerance;\\nconsequently, some patients require dosages', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='considerably greater than 120 mg per day to\\nachieve this effect.)\\n70 Chapter 5', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 90}),\n",
       " Document(page_content='ï Tolerance for the sedative effects of treatment\\nmedication, creating a state in which patients\\ncan function normally without impairment of\\nperception or physical or emotional response\\nï Tolerance for most analgesic effects produced\\nby treatment medication (see ìPain\\nManagementî in chapter 10).\\nUnfortunately, no exact way exists to determine\\noptimal dosage for each patient. However, the\\nconsensus panel recommends that OTPs avoid\\nexclusive reliance on drug test results and pre-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='conceived notions of correct dosage; instead,\\nOTPs should determine dosage based primarily\\non patient response. Even when a medication\\ndosage is controlled for body weight (Leavitt et\\nal. 2000), patient responses, such as absence of\\nwithdrawal symptoms without oversedation and\\nremission from illicit-opioid use, are the best\\nindicators of appropriate dosage. In addition,\\nthe extent of other drug use and alcohol con-\\nsumption should be considered when determin-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='ing dosage adequacy. Finally, a patientís com-\\nplaints (or lack thereof) are also important\\nindicators of dosage adequacy. A patient can\\nexperience opioid craving or withdrawal but\\nmanage to abstain from illicit opioids. \\nMethadone. Strong evidence supports the use\\nof daily methadone doses in the range of 80 mg\\nor more for most patients (Strain et al. 1999),\\nbut considerable variability exists in patient\\nresponses. Some do well on dosages below 80 to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='120 mg per day, and others require significant-\\nly higher dosages (Joseph et al. 2000). OTPs\\nshould exercise additional caution with higher\\ndosages, guarding against diversion of take-\\nhome methadone to individuals who are opioid\\nintolerant because higher dosages can be lethal\\nfor such individuals.\\nBuprenorphine. Buprenorphine dosage should\\nbe determined in a manner similar to that used\\nfor methadone or LAAM. The recommended\\ndosage of buprenorphine to begin stabilization', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='is 12 to 16 mg per day for most patients, with\\nincreases provided thereafter as applicable\\n(Johnson et al. 2003b). As reviewed by Johnson\\nand colleagues (2003b), if patients continue to\\nshow evidence of opioid abuse or withdrawal,\\nthe dosage should be increased using the same\\ntypes of guidelines as for methadone. For\\nexample, if the goal is to suppress opioid with-\\ndrawal symptoms, then dose increases can be\\nless frequent (e.g., weekly or biweekly) because', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='the desired therapeutic response likely will\\nbecome detectable more slowly.\\nMost patients are likely to remain stable on 12\\nto 24 mg per day, although some might need\\ndosages of up to 32 mg per day. Increasing the\\nbuprenorphine dosage\\nto 24 mg per day or\\nhigher has been\\nshown to prolong the\\nduration of its effects\\nand usually is neces-\\nsary if patients are to\\nbe dosed every other\\nday, which is an\\noption with buprenor-\\nphine; however, such\\nan increase usually\\ndoes not increase\\nbuprenorphineís', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='buprenorphineís \\nopioid agonist effects\\nto the same degree\\nbecause of its partial\\nagonist properties\\n(Johnson et al.\\n2003b). Because\\nbuprenorphine is a\\npartial agonist,\\npatients who continue\\nto abuse opioids after sufficient exposure to\\nbuprenorphine treatment and ancillary psycho-\\nsocial services or who experience continued\\nsymptoms of withdrawal at optimal daily doses\\nof buprenorphine (12 to 32 mg) should be \\nconsidered for therapy with methadone or\\nLAAM (CSAT 2004a; Johnson et al. 2003b).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='As with all medications used for MAT, when\\nbuprenorphine dosage changes are contemplat-\\ned, the intensity and frequency of other avail-\\nable psychosocial services (see chapter 8) affect\\npatientsí ability to refrain from opioid abuse\\n(Bickel et al. 1997) and should be considered.\\n71Clinical Pharmacotherapy\\nDosage require-\\nments for\\nmethadone,\\nLAAM, and\\nbuprenorphine\\nmust be deter-\\nmined on an indi-\\nvidual basis.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 91}),\n",
       " Document(page_content='LAAM. Most patients who begin LAAM are\\nbeing transferred from methadone and should\\nhave been screened for cardiac risk. Equiv-\\nalency dosing tables for methadone and LAAM\\nare available in the ORLAAM\\nÆpackage insert\\n(Roxane Laboratories, Inc., 2001), and trans-\\nfer can be done easily. Because of the long-\\nacting nature of LAAM, a patientís reaction\\nshould be monitored closely during the first \\n2 weeks of treatment and adjustments in dosage\\nmade accordingly.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='made accordingly.\\nPatients may request transfer from methadone\\nto LAAM for various reasons: (1) to avoid the\\nhardship of methadoneís daily observed dosing,\\n(2) to provide negative drug test results at work\\n(LAAM is less likely to show up on screening\\ntests), (3) because they are not doing well on\\nmethadone (Borg et al. 2002), (4) because\\nLAAM can be less sedating, and (5) because the\\npatients are rapid metabolizers of methadone\\nand would benefit from LAAM because it is\\nlonger acting.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='longer acting.\\nLAAM can be given every other day if an OTP\\nis open all week or three times per week (i.e.,\\ntwo 48-hour doses and one 72-hour dose) if\\nthat is more convenient. Although some\\npatients take the same dose on Monday,\\nWednesday, and Friday, most benefit from an\\nincrease on Friday (i.e., 10 to 40 percent more\\nthan the Monday and Wednesday doses) with\\nor without an additional small dose of\\nmethadone to be taken home and used on\\nSunday. For stable patients, the best option is a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='regular LAAM dose on Friday and a full\\nmethadone dose (80 percent of the LAAM dose)\\nas a take-home dose for Sunday. The efficacy\\nof LAAM dosing is determined clinically and by\\npatient history and examination; an affordable\\nmeans to determine blood levels of LAAM and\\nits metabolites is unavailable at this writing.\\nNaltrexone. Naltrexone can be administered\\neither daily (usually at a dosage of 50 mg per\\nday) or thrice weekly. For the latter, the usual\\npractice is to give 100 mg on Monday and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='Wednesday and 150 mg on Friday (Stine et al.\\n2003).\\nStudies of the importance of\\ndosing\\nMuch evidence shows a positive correlation\\nbetween medication dosage during MAT and\\ntreatment response (e.g., Strain et al. 1999).\\nHigher dosages in some studies probably pro-\\nduced greater cross-tolerance. Cross-tolerance\\noccurs when medication diminishes or prevents\\nthe euphoric effects of heroin or other short-\\nacting opioids so that patients who continue to\\nabuse opioids no longer feel ìhigh.î The medi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='cation dosage needed for this result depends on\\nhow long and how recently a patient has\\nabused heroin or other opioids and how much\\nhe or she has used, along with individual differ-\\nences in the level of brain receptor adaptation\\ninduced by chronic opioid use.\\nAn Australian study connected the importance\\nof dosage with patient retention in MAT\\n(Caplehorn and Bell 1991). The importance of\\nretention for successful treatment outcomes is\\ndiscussed further in chapter 8. In addition to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='the benefits of eliminating illicit opioids (see\\nbelow), reductions in the threats of HIV and\\nhepatitis B and C make adequate dosing and\\ntreatment retention high priorities and justify\\nadditional studies on the safety and efficacy of\\nmethadone doses exceeding 120 mg.\\nIn their classic study, Ball and Ross (1991)\\nclearly demonstrated an inverse relationship\\nbetween frequency of recent heroin use and\\nmethadone dosage. The data in Exhibit 5-3 are\\nbased on their study of 407 patients who', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='received methadone maintenance treatment.\\nThese data support the premise that lower\\nmethadone dosages are less effective than high-\\ner or adequate dosages in facilitating absti-\\nnence from heroin among patients in MAT. The\\nlow end of the effective range has been accept-\\ned widely as about 60 mg for most patients\\n(reviewed in Faggiano et al. 2003).\\nAnother study (Maxwell and Shinderman 2002)\\nmonitored 144 patients who were not doing well\\nat 100 mg of methadone per day and reported', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='excellent results after raising dosages based on\\nclinical signs and symptoms. Patients receiving\\n72 Chapter 5', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 92}),\n",
       " Document(page_content='more than 200 mg per day (mean 284.9 mg per\\nday) had improved responses with no apparent\\nincrease in adverse events. However, additional\\ncontrolled research is needed to determine the\\nsafety of very high doses of methadone or other\\nmedications used in MAT.\\nWith the increased availability of blood testing\\nin OTPs, measurements of blood concentra-\\ntions of methadone at peak and trough are\\nused more commonly as aids to determine \\nindividual methadone dosage requirements. A', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 93}),\n",
       " Document(page_content='study in England (Wolff et al. 1991) showed a\\npositive correlation between methadone\\ndosages and concentrations in serum (Exhibit\\n5-4). Moreover, mean SMLs near or above \\n400 ng/mL are gaining increasing consensus as\\nideal levels for treatment effectiveness (Payte \\net al. 2003). Although mean SMLs of 400 ng/mL\\n73Clinical Pharmacotherapy\\nExhibit 5-3 \\nHeroin Use in Preceding 30 Days \\n(407 Methadone-Maintained Patients by Current Methadone Dose)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 93}),\n",
       " Document(page_content='Adapted from Ball and Ross, The Effectiveness of Methadone Maintenance Treatment:\\nPatients, Programs, Services, and Outcome, Appendix B, p. 248, with permission from\\nSpringer-Verlag \\uf6d9 1991.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 93}),\n",
       " Document(page_content='generally are considered to be sufficient to\\nblock the effects of illicit opioids and prevent\\nwithdrawal symptoms, some patients may\\nrequire higher SMLs for stabilization. More\\nresearch is needed to understand better the\\nrelationship between methadone blood levels\\nand cessation of opioid abuse. SML results\\nshould continue to be considered along with\\npatient symptoms. For example, a patient with\\nan SML below 400 ng/mL with no symptoms \\nof discomfort would not require a dosage', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 94}),\n",
       " Document(page_content='increase, whereas a patient with an SML of \\n600 ng/mL but with persisting withdrawal\\nsymptoms would.\\nOkruhlica and colleagues (2002) investigated \\n69 patients receiving methadone dosages of \\n10 to 270 mg per day and found a significant\\npositive relationship between dosage and mean\\nSMLs, although, at each dosage level, patientsí\\nresulting SMLs differed widely. Some had \\nrelatively low (subtherapeutic) SMLs, even at\\ndaily doses considerably above 100 mg, which', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 94}),\n",
       " Document(page_content='would be expected to affect treatment negative-\\nly (Leavitt et al. 2000). Given these and similar\\ndata, it is incorrect to conclude that a particu-\\nlar methadone dosage causes a specific SML;\\nmany other factors are likely to affect SMLs for\\nindividual patients. However, measuring SMLs\\ncan be useful to determine why a relatively\\nhigh methadone dosage does not appear to ben-\\nefit a patient. In such cases, a blood test may\\nshow that a patientís SML remains low and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 94}),\n",
       " Document(page_content='that he or she requires a higher dose.\\nIn their review, Leavitt and colleagues (2000)\\nnoted a broad range of SMLs among patients in\\nMAT. They suggested that individual differ-\\nences in metabolic enzyme activity and other\\nfactors may lead to higher or lower serum \\n74 Chapter 5\\nExhibit 5-4 \\nMethadone Dose/Mean Plasma Levels\\nAdapted from Wolff et al. (1991) by permission of the AACC.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 94}),\n",
       " Document(page_content='levels of the (R)-methadone enantiomer,\\nexplaining some of the variation in dosage\\nranges needed for clinical effectiveness. In one\\nstudy of the clinical uses of methadone blood\\nlevel measurements, it was suggested that the\\npeak level should be no more than twice the\\ntrough level and that, if it is more, the patient\\nshould be considered a ìfast metabolizerî and\\nbe administered split dosing. When split dosing\\nis used, patients receive two or three doses per', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 95}),\n",
       " Document(page_content='day to achieve the targeted peak-to-trough\\nratio in blood level measurements and to avoid\\nwithdrawal symptoms for 24 hours (Payte et al.\\n2003). Exhibit 5-5 shows 24-hour SML curves\\nat both inadequate and adequate dosages.\\nThese curves include peak SMLs at roughly 4\\nhours after dose ingestion (0 hour) and trough\\nSMLs at 24 hours after ingestion. Data were\\nderived by averaging a series by Inturrisi and\\nVerebely (1972) and another one by Kreek\\n(1973). Exhibit 5-6 shows an example of plasma', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 95}),\n",
       " Document(page_content='levels in a fast metabolizer, illustrating that\\nwhen a dayís dose is split into two (lower curve),\\nthe peak SML achieved after each of the two\\nsplit doses is lower than the peak achieved after\\na single daily dose (upper curve), and the\\ntrough SML reached just before the next split\\ndose is higher than the trough level reached just\\nbefore the next single dose.\\nThe consensus panel recommends that a main-\\ntenance dosage of methadone not be predeter-\\nmined or limited by policy if that policy does', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 95}),\n",
       " Document(page_content='not allow adjustments for individual patients. \\nOther common dosing issues\\nSigns and symptoms associated with lesser\\ndegrees of withdrawal and acute opioid over-\\ndose are well known, but patient changes \\nassociated with overmedicating and undermedi-\\ncating are less dramatic and often more \\nsubjective.\\n75Clinical Pharmacotherapy\\nExhibit 5-5 \\nBlood Plasma Levels Over 4 and 24 Hours With an Adequate and\\nInadequate Methadone Dose', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 95}),\n",
       " Document(page_content='76 Chapter 5\\nCertain medical factors may cause a patientís\\ndosage requirements to change, including (but\\nnot limited to) starting, stopping, or changing\\nthe dosage of other prescription medications;\\nonset and progression of pregnancy; onset of\\nmenopause; progression of liver disease; signifi-\\ncant increase or decrease in weight; or aging\\n(elderly patients are sometimes more sensitive\\nto drugs such as opioids). Patient complaints of\\nopioid craving, withdrawal symptoms, medica-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 96}),\n",
       " Document(page_content='tion side effects, or intoxication always should\\nbe investigated and never should be dismissed.\\nOvermedication.. Mildly to moderately over-\\nmedicated patients might show ìnoddingî \\nand closing of the eyes or might fall asleep at\\ninappropriate times. These patients might\\nscratch their faces continuously, especially their\\nnoses. In some cases, sedation might occur but\\nbe unapparent, and some overmedicated\\npatients might feel mildly stimulated. Nausea', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 96}),\n",
       " Document(page_content='also can occur, particularly in newer patients.\\nPatients should be told when overmedication \\nis suspected, and their dosage should be\\nreduced. Patients also might report feeling high\\nor ìloadedî and ask for a reduced dosage.\\nSuch a reduction can be helpful for patients\\ncommitted to abstinence rather than ongoing\\nmedication maintenance because they may find\\nphysical reminders of intoxication discouraging,\\nfrightening, or relapse triggering.\\nVomited doses. Patients who report that they', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 96}),\n",
       " Document(page_content='have vomited their medication pose special\\nproblems. The consensus panel recommends\\nthat only doses lost to witnessed emesis be\\nreplaced. Emesis 30 minutes after dosing can be\\nhandled by reassuring patients that the full\\ndose has been absorbed. Emesis at 15 to 30\\nminutes after dosing can be handled by replac-\\ning half the dose, and the whole dose should be\\nreplaced if emesis occurs within 15 minutes of\\ndosing. If vomiting persists, it is important to\\nremember that only a portion of the gut is', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 96}),\n",
       " Document(page_content='emptied with forceful emesis; therefore, the\\nrisk of accumulated toxicity increases with\\nrepeated dose replacements. Causes of emesisó\\nincluding pregnancyóshould be explored.\\nExhibit 5-6 \\nSMLs After Single and Split Methadone Dosing in a Fast Metabolizer', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 96}),\n",
       " Document(page_content='77Clinical Pharmacotherapy\\nIngestion of smaller amounts of medication\\nover a few minutes can be helpful and prudent,\\nas can the occasional use of antiemetic\\nmedicines.\\n“Triggered” withdrawal. Environmental cues,\\nincluding people, places, things, and feelings\\nassociated with drug taking, can be associated\\nstrongly with opioid craving and withdrawal.\\nSuch reactions may be identical to opioid with-\\ndrawal symptoms and can stimulate drug crav-\\ning and relapse long after opioid use has', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='stopped and physical dependence has been con-\\ntrolled (Self and Nestler 1998). Environmental\\nchanges and other stressors can cause patients\\nto perceive that a dose on which they were sta-\\nbilized is no longer adequate and to experience\\nincreased drug craving. Events that increase\\nthe availability of substances of abuse, such as\\nanother person who uses drugs moving into a\\npatientís home or new sources of illicit drugs,\\ncan intensify craving. When their discomfort', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='resumes after a period of abstinence, patients\\nmight feel that they are weak willed. They need\\nreassurance that this reaction is a condition of\\ntheir brain chemistry, not a weakness of will. In\\nanimal models, withdrawal symptoms have\\nbeen conditioned to appear with environmental\\ncues after months of abstinence from opioids\\n(Self and Nestler 1998). The consensus panel\\nbelieves that increased medication dosages are\\nappropriate in such cases, although efforts also', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='should focus on resolving the troublesome situ-\\nations such as developing ways to avoid people,\\nplaces, and things that trigger opioid craving or\\nrelapse. Conversely, diminished triggers and\\nreduced drug availability can diminish drug\\ncraving and might indicate the possibility of\\ndecreasing medication dosage if a patient prefers.\\nContingent use of dosage. The consensus panel\\nbelieves that any manipulation of dosage as\\neither a positive or a negative consequence of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='behavior is inappropriate and has no place in\\nMAT. The only type of contingency contracting\\nrelated to medication that should be supported\\nin MAT is that associated with take-home medi-\\ncation. Take-home medication is controlled by\\nFederal regulations, and access is based on sev-\\neral factors, including drug abstinence, OTP\\nattendance, length of time in treatment, and\\noverall functioning. An increase in medication\\ndosage should not be a reward for positive', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='behavior change, although not everyone in the\\nMAT field shares this viewpoint. For example,\\nextensive work has demonstrated the effective-\\nness of using increased dosage (as well as extra\\ntake-home doses) as an incentive to decrease\\nsubstance abuse and increase treatment pro-\\ngram attendance (e.g., Stitzer et al. 1986, 1993;\\nsee also Petry 2000). Although the consensus\\npanel acknowledges important behavioral\\naspects of addiction and the value of contingen-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='cy management as an aid to behavioral change,\\nusing medication dosage as a reward or punish-\\nment is considered inappropriate.\\nMaintenance\\nPharmacotherapy\\nThe maintenance stage of opioid pharma-\\ncotherapy begins when a patient is responding\\noptimally to medication treatment and routine\\ndosage adjustments are no longer needed.\\nPatients at this stage have stopped abusing \\nopioids and other substances and have resumed\\nproductive lifestyles away from the people,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='places, and things associated with their addic-\\ntions. These patients typically receive scheduled\\ntake-home medication privileges. Patients who\\ncontinue to abuse substances, do not seek\\nemployment, or remain connected to their drug-\\nusing social networks have not reached this\\nstage. Along with continued observed medication\\ntreatment, these latter patients are candidates\\nfor intensified counseling and other services to\\nhelp them reach the maintenance stage.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='During the maintenance stage, many patients\\nremain on the same dosage of treatment medi-\\ncation for many months, whereas others\\nrequire frequent or occasional adjustments.\\nPeriods of increased stress, strenuous physical\\nlabor, negative environmental factors, greater\\ndrug availability, pregnancy, or increased drug\\nhunger can reawaken the need for increased\\ndosages over short or extended periods. Serious\\nemotional crises may require long-term or \\ntemporary dosage adjustments. Although the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='counseling relationship and patient interview', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 97}),\n",
       " Document(page_content='78 Chapter 5\\nare paramount, drug test reports and medica-\\ntion blood levels are useful for dosage determi-\\nnation and adjustment during and after transi-\\ntion from stabilization to the maintenance stage.\\nMedically Supervised\\nWithdrawal\\nWhen stable patients in the maintenance stage\\nask for dosage reductions, it is important to\\nexplore their reasons. They might believe that\\nthey can get by on less medication, or they\\nmight be responding to external pressures.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='Patients often perceive that those on lower\\ndosages are ìbetter patients.î These situations\\nrequire physicians or other staff members to\\neducate patients and their significant others\\nabout the importance of adequate dosage and\\nhow individual differences in absorption, body\\nweight, metabolism, and tolerance can affect\\nthe dosage necessary to achieve stability\\n(Leavitt et al. 2000).\\nVoluntary Tapering and\\nDosage Reduction\\nFor various reasons, some patients attempt', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='reduction or cessation of maintenance medica-\\ntion. Some studies indicate high relapse rates,\\noften 80 percent or more, for this group,\\nincluding patients judged to be rehabilitated\\nbefore tapering (e.g., Magura and Rosenblum\\n2001). However, the likelihood of successful\\ndose tapering also depends on individual fac-\\ntors such as motivation and family support.\\nThe possibility of relapse should be explained\\nto patients who want to dose taper, especially\\nthose who are not stable on their current', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='dosage, as part of the informed-consent pro-\\ncess. Patients who choose tapering should be\\nmonitored closely and taught relapse preven-\\ntion strategies. They and their families should\\nbe aware of risk factors for relapse during and\\nafter tapering. If relapse occurs or is likely,\\nadditional therapeutic measures can be taken,\\nincluding rapid resumption of MAT when\\nappropriate (American Society of Addiction\\nMedicine 1997).\\nIdeally, withdrawal should be attempted when', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='it is desired strongly by a stable patient who\\nhas a record of abstinence and has adjusted\\npositively on MAT. However, sometimes dose\\ntapering is necessary for administrative rea-\\nsons, such as a response to extreme antisocial\\nbehavior, noncompliance with minimal pro-\\ngram standards, or a move to a location where\\nMAT is unavailable. In such cases, providers\\nshould refer patients to other programs that\\nare more reasonable and practical in terms of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='the patientsí overall situation (e.g., motivation,\\nresource availability, ability to pay).\\nIn a review of research on withdrawal from\\nMAT, Magura and Rosenblum (2001) noted\\nthat many treatment providers lacked effective\\nways to improve outcomes for patients who\\nundertook planned withdrawal and that opioid\\ncraving remained prevalent in this group, even\\nafter successful physiological withdrawal. They\\nconcluded, therefore, that planned withdrawal\\nfrom opioid pharmacotherapy should be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='undertaken conservatively.\\nRelapse prevention techniques should be \\nincorporated into counseling and other support\\nservices both before and during dosage reduc-\\ntion. Such structured techniques can be useful\\nsafeguards in preventing and preparing for\\nrelapse. Use of mutual-help techniques (see\\nchapter 8) is recommended highly, especially\\nduring dosage reduction.\\nAlthough most data about outcomes after\\ntapering from opioid medication come from\\nstudies of methadone maintenance, the consen-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='sus panel believes that success rates are likely\\nto be similar for patients who taper from\\nbuprenorphine or LAAM, and similar cautions\\nand monitoring processes should be in place.\\nMethadone dosage reduction\\nThe techniques and rates of graded methadone\\nreduction vary widely among patients. One\\ncommon practice is to reduce daily doses in\\nroughly 5- to 10-percent increments with 1 to 2\\nweeks between reductions, adjusting as needed\\nfor patient conditions. Because reductions', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 98}),\n",
       " Document(page_content='79\\nbecome smaller but intervals remain about the\\nsame, many months may be spent in such grad-\\ned reductions. The rate of withdrawal can be\\nincreased or decreased based on individual\\npatient response. A slow withdrawal gives\\npatients and staff time to stop the tapering or\\nresume maintenance if tapering is not working\\nand relapse seems likely.\\nRegardless of the rate of withdrawal from\\nmethadone, a point usually is reached at which\\nsteady-state occupancy of opiate receptors is no', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='longer complete and discomfort, often with\\ndrug hunger and craving, emerges. This point\\nmay occur at any dosage but is more common\\nwith methadone when the dosage is below 40\\nmg per day. Highly motivated patients with\\ngood support systems can continue withdrawal\\ndespite these symptoms. Some patients appear\\nto have specific thresholds at which further\\ndosage reductions become difficult.\\nPhysicians and other staff members should be\\nalert to the possibility of patients attempting', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='dose tapering by substituting other psychoac-\\ntive substances, such as alcohol, cocaine, \\nsedatives-hypnotics, or other nonopioid \\nsubstances for their maintenance medication.\\nSome patients might request blind dosage\\nreduction, that is, withdrawal from medication\\nwithout their awareness of dose reductions at\\neach step. Blind dosage reduction is appropri-\\nate only if requested by a patient. It should be\\ndiscussed and agreed on before it is implement-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='ed. It is inappropriate, clinically and ethically,\\nto withdraw a patient from maintenance medi-\\ncation without his or her knowledge and con-\\nsent. The consensus panel recommends that\\nOTP staff always disclose dosing information\\nunless patients have given specific informed\\nconsent and have requested that providers not\\ntell them their exact dosages.\\nWithdrawal and termination\\nfrom LAAM maintenance\\nFew studies have addressed medically super-\\nvised withdrawal from LAAM. Because LAAM', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='is longer acting than methadone, withdrawal\\nshould be expected to have a delayed onset and\\nprotracted course,\\nalthough symptoms\\nmight be less intense\\nthan with other opi-\\noids. Patients tend to\\ndislike longer periods\\nof withdrawal,\\nregardless of symptom\\nintensity. Special\\ncounseling might be\\nneeded to address \\nthis aspect of with-\\ndrawal from LAAM.\\nFor patients on\\nLAAM who wish to be\\nmedication free,\\ndosage can be\\nreduced gradually at\\na rate determined by', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='their response. Patients who prefer less \\nprotracted withdrawal can be converted to and\\nthen tapered from methadone. As with tapering\\nfrom methadone (Moolchan and Hoffman\\n1994), tapering from LAAM should take into\\naccount a patientís level of stability, past\\nfunctioning without medication, and fear \\nof withdrawal.\\nMedically Supervised\\nWithdrawal After\\nDetoxification\\nFor patients who neither qualify for nor desire\\nopioid maintenance treatment, methadone or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='buprenorphine may be used to control with-\\ndrawal from illicit opioids or from abuse of\\nprescription opioids (detoxification) and then\\ncan be tapered gradually (medically supervised\\nwithdrawal). Regulations specify two kinds of\\ndetoxification with methadone: short-term\\ntreatment of less than 30 days and long-term\\ntreatment of 30 to 180 days. These regulations\\nspecify that patients who fail two detoxification\\nattempts in 12 months must be evaluated for a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='different treatment (42 CFR, Part 8 ß 12(e)(4)). \\nClinical Pharmacotherapy\\nPatients who\\nchoose tapering\\nshould be moni-\\ntored closely and\\ntaught relapse pre-\\nvention strategies.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 99}),\n",
       " Document(page_content='80 Chapter 5\\nDosing decisions in medically supervised \\nwithdrawal are related to the intended \\nsteepness of tapering. Patients undergoing\\nshort-term withdrawal may never achieve\\nsteady state, and tapering from methadone\\nmay be too steep if it begins at a dose greater\\nthan about 40 mg. In long-term withdrawal,\\nstabilization of dosage at a therapeutic range \\nis followed by more gradual reduction (see\\nExhibit 5-7).\\nInvoluntary Tapering or\\nDosage Reduction\\nWhen patients violate program rules or no', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 100}),\n",
       " Document(page_content='longer meet treatment criteria, involuntary\\ntapering might be indicated although it should\\nbe avoided if possible (see chapter 8). For\\nexample, if many days of dosing are missed and\\nrepeated attempts to help a patient comply with\\ndaily dosing requirements have failed, mainte-\\nnance pharmacotherapy no longer may be \\npossible. Treatment decisions should be made\\nin the patientís best interest. If patient progress\\nis unsatisfactory at a particular level of care,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 100}),\n",
       " Document(page_content='the physician should explore the possibility of\\nincreasing that patientís care while maintaining\\nhim or her on methadone. Involuntary taper-\\ning and discontinuation of maintenance medi-\\ncation may be necessary if a patient is unwilling\\nto comply with treatment or tapering or discon-\\ntinuation of medication appears to be in the\\npatientís best interest.\\nIf a patient is intoxicated repeatedly with alco-\\nhol or sedative drugs, the addition of an opioid\\nmedication is unsafe, and any dose should be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 100}),\n",
       " Document(page_content='withheld, reduced, or tapered. Disruptive or\\nviolent behavior or threats to staff and other\\npatients might be reasons for dismissal without\\nExhibit 5-7 \\nTypes of Detoxification From Illicit Opioids', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 100}),\n",
       " Document(page_content='tapering or for immediate transfer to another\\nfacility where a patient may be treated under\\nsafer conditions.\\nAdministrative tapering for nonpayment of fees\\nmay be part of the structure to which patients\\nagree on admission. It should be noted that, in\\naddiction treatment, a patientís sudden lack of\\nfunds is a marker of possible relapse.\\nLAAM\\nWhen involuntary withdrawal from LAAM is\\nunavoidable, patients can be transferred to\\nmethadone before withdrawal because clinical', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='experience with methadone withdrawal is more\\nextensive.\\nIncarceration\\nWhen patients know that they must serve time\\nin jail or prison, planned withdrawal is the best\\ncourse of action. At this writing, few correc-\\ntional institutions offer methadone mainte-\\nnance to nonpregnant inmates (National Drug\\nCourt Institute 2002). Many jails do not pro-\\nvide methadone for detoxification. When a\\npatient in MAT is arrested, program staff\\nshould make every effort to communicate with', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='the criminal justice authorities involved and to\\nrecommend that the patient be withdrawn\\ngradually from medication. Regardless of\\nwhich opioid medication is used, maintenance\\nor medically supervised withdrawal is prefer-\\nable to sudden discontinuation of the medica-\\ntion. The consensus panel recommends that\\nopioid pharmacotherapy be made available\\nduring incarceration for patients who are\\nalready in MAT when incarcerated.\\nTake-Home\\nMedications\\nTake-home medication refers to unsupervised', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='doses. Any OTP patient may receive a single\\ntake-home dose for a day when the OTP is\\nclosed for business, including Sundays and\\nState and Federal holidays. Beyond this, \\ndecisions on dispensing take-home medication\\nare determined by the medical director in\\naccordance with eight criteria for take-home\\nmedication specified in Federal regulations \\n(42 CFR, Part 8 ß 12(i)): \\n1. Absence of recent drug and alcohol abuse\\n2. Regular OTP attendance\\n3. Absence of behavioral problems at the OTP', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='4. Absence of recent criminal activity\\n5. Stable home environment and social \\nrelationships\\n6. Acceptable length of time in comprehensive\\nmaintenance treatment\\n7. Assurance of safe storage of take-home \\nmedication\\n8. Determination that rehabilitative benefits of\\ndecreased OTP attendance outweigh the\\npotential risk of diversion.\\nOnce these clinical criteria are met, maximum\\ntake-home doses must be further restricted\\nbased on length of time in treatment as follows:', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='ï First 90 days (months 1 through 3): one \\ntake-home dose per week\\nï Second 90 days (months 4 through 6): two\\ntake-home doses per week\\nï Third 90 days (months 7 through 9): three\\ntake-home doses per week\\nï Fourth 90 days (months 10 through 12): 6\\ndaysí supply of take-home doses per week\\nï After 1 year of continuous treatment: 2\\nweeksí supply of take-home medication \\nï After 2 years of continuous treatment: 1\\nmonthís supply of take-home medication, but\\nmonthly OTP visits are still required.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='Additional restrictions are imposed in some\\nStates. No take-home doses are permitted for\\npatients in short-term detoxification or interim\\nmaintenance treatment.\\n81Clinical Pharmacotherapy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 101}),\n",
       " Document(page_content='82 Chapter 5\\nSpecific Clinical Considerations\\nin Take-Home Status\\nDemands of a concurrent\\nmedical disorder\\nThe existence and severity of a concurrent\\nmedical disorder (see chapter 10) are additional\\nconsiderations in determining whether take-\\nhome medication is appropriate. For patients\\nwith concurrent diseases causing impaired\\nambulation, reduced OTP attendance might \\nbe required to aid recovery and prevent \\ncomplications. In these cases, OTPs should\\nconsider seeking medical exceptions for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='patients who would not otherwise be permitted\\nto receive take-home doses of medication.\\nThese patient exceptions should be requested\\non Substance Abuse and Mental Health\\nServices Administration (SAMHSA) form \\nSMA-168, Exception Request and Record of\\nJustification. Form SMA-168 is available at\\ndpt.samhsa.gov/Exception168Final.htm.\\nWhen a new medica-\\ntion treatmentósuch\\nas rifampin, highly\\nactive antiretroviral\\ntherapy (HAART),\\nor phenytoinóthat\\nis known to interact\\nwith an opioid treat-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='ment medication is\\nintroduced, a MAT\\npatient might need a\\ndosage adjustment\\n(see chapter 3 for\\nfurther discussion of\\nmedications that\\ninteract with opioid\\ntreatment medica-\\ntions). Take-home\\nmedication should be\\navoided until a\\npatient is stable on\\nthese new medica-\\ntions and the risks of an undesirable outcome\\nhave diminished. In these instances, more \\nfrequent observations are important to monitor\\nconcurrent disease, to avoid methadone-related\\ncomplications of a concurrent medical disor-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='der, and to ensure that the pharmacological\\nbenefits of administering methadone are main-\\ntained during the course and treatment of the\\nconcurrent disease.\\nEnhancement of rehabilitative\\npotential\\nAnother important issue in take-home \\nmedication involves reviewing whether it is \\nlikely to help rehabilitate a patient. Take-home\\nmedication may enable patients to engage in\\nemployment, education, childcare, or other\\nimportant endeavors.\\nEmergency circumstances', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='During emergency situations or unforeseen \\ncircumstances such as personal or family\\ncrises; bereavement; or medical, family, or\\nemployment hardships, the need may arise for\\nunscheduled take-home medication. An OTP\\ncan facilitate emergency or hardship access to\\nmedication for a patient by submitting SAMHSA\\nform SMA-168. The OTPís policies should\\nexplain who can request exceptions and how \\nit is done. Courtesy dosing at a distant OTP\\nusually can be arranged if unstabilized patients\\nare traveling.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='are traveling.\\nPositive drug tests, diversion\\ncontrol, and take-home \\nmedications\\nThe consensus panel believes that take-home\\nmedications are inadvisable for patients who\\ncontinue to abuse illicit drugs or misuse pre-\\nscription medications, as evidenced by drug\\ntesting or other assessment information, and\\nfor those whose drug tests do not reflect medi-\\ncation ingestion. Under the disinhibiting effects\\nof other substances, patients might be unable\\nto safeguard or adequately store their take-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='home doses. They should be encouraged to\\nkeep their medication in a locked cabinet away\\nfrom food or other medicines and out of the\\nreach of children. Some programs require\\nNo take-home\\ndoses are \\npermitted for\\npatients in \\nshort-term detoxi-\\nfication or interim\\nmaintenance \\ntreatment.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 102}),\n",
       " Document(page_content='83Clinical Pharmacotherapy\\npatients to bring a locked container to the OTP\\nwhen they pick up their take-home medication\\nto hold it while in transit. This policy should be\\nconsidered carefully because most such con-\\ntainers are large and visible, which might serve\\nmore to advertise that a patient is carrying\\nmedication than to promote safety. \\nMethadone is stable and does not need refriger-\\nation when in diskette or tablet form. However,\\nwhen methadone diskettes are reconstituted or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='liquid methadone oral concentrate is used and\\ndiluted with juice or some other sugar-based\\nliquid, the mixture may not remain stable\\nbeyond a few days without refrigeration.\\nManufacturer instructions call for adding a\\nminimum of 30 mL or 1 fluid ounce of liquid\\nper dose when reconstituting methadone. \\nAlthough methadone has a significant street\\nvalue, a National Institutes of Health consensus\\nstatement refers to it as ìa medication that is\\nnot often diverted to individuals for recreation-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='al or casual use but rather to individuals with\\nopiate dependence who lack access to\\n[methadone maintenance treatment] pro-\\ngramsî (National Institutes of Health 1997b, p.\\n20). Nevertheless, reported deaths attributed\\nto methadone have increased significantly in\\nsome States. According to data from the Drug\\nAbuse Warning Network, more than 10,000\\nemergency room visits related to methadone\\nwere reported in 2001 compared with more\\nthan 5,000 in 1999 (Crane 2003). This increase', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='has occurred in the context of overall increases\\nin abuse of prescription opioids, in particular\\nhydrocodone and oxycodone. Local reports\\nindicate that most diverted methadone comes\\nfrom medical prescriptions because it has\\ngained acceptance as an excellent chronic pain\\ntreatment (Belluck 2003). Although the slow\\nonset of methadone makes it less attractive\\nthan prescription opioids to potential abusers,\\nit also makes methadone more dangerous\\nbecause respiratory depression can become', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='significant hours after ingestion. To guard\\nagainst the possibility of methadone-related\\nrespiratory depression, the consensus panel\\nrecommends the following diversion control\\npolicies for take-home medication:\\nï Require patients to return all empty dose \\nbottles on their next OTP visit after take-\\nhome dosing. Staff members who accept these\\nbottles should inspect them to ensure that\\nthey are coming from the indicated patient\\nduring the appropriate period.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='ï Institute procedures for responding to\\npatients who frequently fail to return or \\nhave unverified reasons for failing to return\\nempty take-home bottles. Staff should \\nconsider discontinuing take-home medication\\nfor these patients. \\nï Stay open 7 days a week for dispensing. In\\nthis way, take-home doses can be provided\\nonly to stable patients with a record of\\nadherence to treatment, rather than to all\\npatients regardless of their status with the\\nprogram.\\nBehavior, social stability, and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='take-home medications\\nPatients appearing intoxicated; demonstrating\\naggressive, seriously impaired, or disordered\\nbehavior; or engaging in ongoing criminal\\nbehavior are poor candidates for take-home\\nmedication. Their home environments also are\\nkeys to the safety and storage of medication.\\nWhere social relationships are unstable, a \\nsignificant risk exists that methadone take-\\nhome doses will be secured inadequately from\\ndiversion or accidental use (e.g., by children).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='If patients with take-home privileges develop\\naltered mental competency, such as in demen-\\ntia, frequent loss of consciousness, or delusional\\nstates, then take-home privileges should be\\nreevaluated.\\nMonitoring Patients Who\\nReceive Take-Home\\nMedications\\nMonitoring should ensure that patients with\\ntake-home medication privileges are free of\\nillicit drug use and consume their medication as\\ndirected. This goal can be met through random\\ndrug testing and periodic interdisciplinary', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='assessment of continuing eligibility. OTPs', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 103}),\n",
       " Document(page_content='84 Chapter 5\\nshould consider carefully whether to use pill\\ncounts or callbacks of dispensed take-home\\ndoses to verify adherence to program rules. In\\na pill count or callback, the patient receives an\\nunannounced phone call and must show up at\\nthe OTP within a reasonable period (e.g., 24 to\\n36 hours) with all MAT medications. The num-\\nber of pills remaining must correspond to the\\nnumber expected based on prescribed inges-\\ntion. A physician should review periodically the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='status of every patient provided with take-home\\nmedication. When these strategies are followed,\\nprograms should state their policies clearly to\\npatients. Callbacks should be used selectively,\\nnot be applied across the board, and focus on\\nhigh-risk patients who have given OTP staff\\nmembers reason to be concerned.\\nIssues for review\\nThe rationale for providing take-home \\nmedication should be reviewed regularly \\nand documented to determine whether initial', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='justifications continue to apply. For example, if\\nemployment was a reason for take-home medi-\\ncation, the patientís continued employment\\nshould be verified. If a concurrent medical \\ndisorder was the basis, a medical reassessment\\nis necessary to determine whether the clinical\\nstatus of the concurrent medical disease still\\nwarrants reduced OTP attendance.\\nReviewing the original rationale for take-home\\nmedication is a necessary but insufficient \\ncondition for increased patient monitoring. The', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='monitoring process also should include an\\nassessment of whether medical, psychological,\\nor social reasons exist to rescind these privileges.\\nTreatment interruptions\\nMany circumstances, such as work-related\\ntravel, illness, funerals, planned vacations, \\nand emergencies, might require patients to miss\\nOTP visits. Some unstable patients might miss\\ndays because of chaotic social situations. OTPs\\nshould have policies to address treatment \\ninterruptions.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='interruptions.\\nDisability or illness.When disability or illness\\nprevents patients from coming to the OTP ,\\nauthorized staff may use home delivery and\\nobserved-dosing procedures to ensure treat-\\nment continuity. OTPs should evaluate the\\nneed for continuity of other support services,\\nas well as medication, in these circumstances.\\nHospitalization.OTPs are responsible for\\nensuring continuity of treatment when patients\\nare hospitalized for medical or psychiatric', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='problems (see chapters 10 and 12). The best\\npractice is for OTP staff to educate and stay in\\ntouch with a patientís hospital clinicians about\\nMAT. For example, hospital staff might be\\nunaware that certain drugs, such as partial\\nagonists or mixed agonists and antagonists for\\npain management, should be avoided for\\npatients receiving LAAM or methadone for \\nopioid addiction (pain management is discussed\\nin chapter 10). It usually is helpful to provide\\npsychiatric consultation to medical or surgical', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='staff members, especially for patients with co-\\noccurring disorders. Written patient consent is\\nnecessary for this kind of program-to-hospital\\ncommunication; however, if a medical emergen-\\ncy poses a threat to a patientís health, the OTP\\nshould use the medical emergency exception \\nfor treatment when it lacks patient consent. A\\npublication by the Center for Substance Abuse\\nTreatment (CSAT 2004b) provides a description\\nof the confidentiality regulationsí medical \\nemergency exception.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='Hospitalization, particularly of unconscious\\npatients, raises the issue of using identification\\n(ID) cards. Patients can get OTP-specific Medic\\nAlert ID Cards from Advocates for Recovery\\nThrough Medicine (www.methadonetoday.org/\\narmhelp.htm; telephone 615-354-1320), which\\ncan include a patientís name, OTP contact\\ninformation, and a list of contraindicated medi-\\ncations. Some large urban OTPs provide\\npatients with a photographic ID card to gain\\nadmittance to the OTP . Their experience has', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='been that some patients use their OTP cards as\\ngeneric photographic IDs in lieu of a driverís\\nlicense; for example, they use them to cash\\nchecks, despite the fact that the cards identify\\nthem as being in treatment. Smart cards con-\\ntaining a complete medical history are already\\nin use in the United States, Israel, and the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 104}),\n",
       " Document(page_content='85\\nNetherlands and may be useful in OTPs. These\\ncards contain electronically encoded informa-\\ntion needed to identify and monitor a patient\\nwithout outwardly identifying the cardholder as\\na patient.\\nMissed doses.When doses are missed, it is crit-\\nical to evaluate patientsí presenting condition.\\nConcerns should include whether a patient has\\nbeen using illicit drugs or taking other medica-\\ntions, has lost tolerance for previous doses (i.e.,\\nwhether a previously tolerated dosage is still', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 105}),\n",
       " Document(page_content='safe to administer), or is intoxicated.\\nOne dose missed.For patients who miss one\\nscheduled dose and come to the OTP the next\\ndayófor example, 3 to 4 days after the last\\nLAAM or 2 days after the last methadone\\ndoseóthe dosage can remain unchanged, and\\ndosing should resume on schedule. For patients\\non LAAM who miss a dose and come to the\\nOTP 2 days later (i.e., 4 to 5 days after their\\nlast LAAM dose), the scheduled dose still is\\nusually well tolerated.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 105}),\n",
       " Document(page_content='More than 5 days missed.For patients who are\\nout of treatment for a significant time and\\nmight have lost tolerance, dosage reduction or\\nreinduction is advisable. Thereafter, increases\\nof 5 to 10 mg per dose up to the previous level\\ncan be ordered because it is unlikely that the\\ndosage needed to maintain stability will change\\nin 1 week. Patients might have to be reminded\\nabout steady state and that they may not feel\\nback to normal until tissue stores have built \\nup as well.\\nOffice-Based Opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 105}),\n",
       " Document(page_content='Office-Based Opioid\\nTherapy\\nOTPs should consider assisting with transfer\\narrangements for long-term methadone-\\nmaintained patients who prefer to use a \\nphysician in the community for ongoing care.\\nVarious forms of this treatment have been stud-\\nied in the United States and found to be safe\\nand efficacious (King et al. 2002; Schwartz et\\nal. 1999).\\nPatient selection for this treatment option\\nshould focus on a history of negative drug tests,\\na required length of stability in treatment (at', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 105}),\n",
       " Document(page_content='least 1 year), social stability, and minimal need\\nfor psychosocial services. Methadone can be\\nordered by private physicians, through an affil-\\niation or other arrangement with an OTP , and\\npatients can obtain their medication at special-\\nly registered pharmacies under a SAMHSA-\\napproved protocol. Under this arrangement,\\npatients on extended take-home-dosing sched-\\nules (up to 1 month) no longer must ingest their\\ndoses under observation. Outcomes have been', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 105}),\n",
       " Document(page_content='uniformly positive, with few relapses and little\\nor no diversion reported (King et al. 2002;\\nSchwartz et al. 1999). Patient satisfaction has\\nbeen found to be significantly better compared\\nwith OTP dosing (Fiellin et al. 2001) but not\\nsignificantly different from a comparable \\nOTP-based monthly medical maintenance and\\ntake-home schedule (King et al. 2002).\\nClinical Pharmacotherapy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 105}),\n",
       " Document(page_content='6 PatientñTreatment\\nMatching: Types of\\nServices and \\nLevels of Care\\nIn This\\nChapterÖ\\nSteps in\\nPatientñTreatment\\nMatching\\nPatients With\\nSpecial Needs\\nTreatment Planning\\nThis chapter describes a multidimensional, clinically driven strategy for\\nmatching patients in medication-assisted treatment for opioid addiction\\n(MAT) with the types of treatment services and levels of care that opti-\\nmize treatment outcomes, primarily within or in conjunction with opioid', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 107}),\n",
       " Document(page_content='treatment programs (OTPs). Level of care refers to the intensity of a\\ntreatment (in terms of frequency, type of serviceóindividual, group,\\nfamilyóand medication) and the type of setting needed for treatment\\ndelivery. For information on criteria and methods to determine levels of\\ncare in substance abuse treatment, see the American Society of\\nAddiction Medicine (ASAM) patient placement criteria (Mee-Lee et al.\\n2001b). As explained by Mee Lee and colleagues (2001b), the ASAM', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 107}),\n",
       " Document(page_content='model conceptualizes opioid pharmacotherapy as a service that can be\\nprovided at any level of care, although it is delivered most often in an\\noutpatient setting (i.e., ASAM level I).\\nThe chapter also provides information on developing a treatment plan\\nwith short- and long-range goals for each patient. In some cases,\\npatientñtreatment matching and treatment planning involve changes that\\ncan move a patient out of comprehensive MAT to a setting that better', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 107}),\n",
       " Document(page_content='meets the patientís needs. Because this TIP is primarily about outpatient\\nMAT in OTPs, other settings and programs are discussed only briefly.\\nIn general, patientñtreatment matching involves individualizing, to the\\nextent possible, the choice and application of treatment resources to\\neach patientís needs. The chapter explains recommended elements of a\\npatientñtreatment-matching process, including ways to accommodate\\nspecial populations with distinct needs and orientations that affect their', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 107}),\n",
       " Document(page_content='responses to specific treatments and settings.\\nPatients enter OTPs at various points along a continuum of substance\\nabuse and addiction. Many also have co-occurring medical and mental\\nhealth conditions that can be lifelong. Because of the complexity of\\npatientsí circumstances and needs and the range of services required to\\naddress these needs, MAT includes not only opioid pharmacotherapy\\nbut also other forms of treatment in a comprehensive treatment program\\n87', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 107}),\n",
       " Document(page_content='88 Chapter 6\\ndesigned to address multiple disorders and\\nneeds (see chapter 8).\\nThe consensus panel believes that OTPs not\\nalready offering comprehensive MAT services\\nand those lacking resources to adjust levels of\\ncare to patient needs either should augment\\nbasic opioid pharmacotherapy with services\\nthat meet the mental health, medical, and\\nsocial needs of patients who are opioid addict-\\nedóat the level of care each patient needsóor\\nshould provide referrals to programs that pro-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='vide such services.\\nSteps in\\nPatientñTreatment\\nMatching\\nPatient Assessment\\nPatientñtreatment matching begins with a thor-\\nough assessment to determine each patientís\\nservice needs (see chapter 4); then these needs\\nare matched to appropriate levels of care and\\ntypes of services. Assessment should include\\nthe extent, nature, and duration of patientsí\\nopioid and other substance use and their treat-\\nment histories, as well as their medical, psychi-\\natric, and psychosocial needs and functional', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='status. A comprehensive assessment should\\ninclude a patientís gender, culture, ethnicity,\\nlanguage, motivation to comply with treatment,\\nand recovery support outside the OTP .\\nType and Intensity of\\nTreatment Services Needed \\nPsychosocial treatment \\nservices \\nIn a comprehensive MAT setting, patients often\\nhave access to a variety of psychosocial ser-\\nvices, including individual, family, and group\\ncounseling, as well as case management (see\\nchapter 8). Some programs may provide psy-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='chosocial services to patients in other settings.\\nBoth residential and outpatient programs may\\noffer intensive individual and group counseling\\nor counseling on a periodic or as-needed basis\\n(De Leon 1994; Margolis and Zweben 1998).\\nIdeally, service intensity should depend on the\\nlevel of care required to help patients achieve\\nand maintain successful treatment outcomes.\\nMost patients in the acute phase of treatment\\nneed to see a counselor daily for counseling or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='case management, just to become stabilized,\\nwhereas others, who may be highly functioning\\nwith less severe addiction-related psychosocial\\nproblems, require fewer counseling services.\\nMutual-help programs \\nAlthough not a form of treatment, mutual-help\\nprograms (e.g., 12-Step programs, Secular\\nOrganization for Sobriety groups, Women for\\nSobriety groups) offer effective reinforcement\\nand motivation for individuals during and after\\ndiscontinuation of active treatment. Such pro-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='grams provide social support from others who\\nare in recovery from addiction (Washton 1988).\\nMany patients in MAT participate in mutual-\\nhelp groups. However, patients with opioid\\naddiction who are maintained on treatment\\nmedication can feel out of place in some group\\nsettings where continued opioid pharmacother-\\napy may be misunderstood. Researchers have\\ndescribed a variety of specialized groups and\\ninventive strategies for mutual-help programs\\nthat meet the support needs of patients in MAT', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='(Zweben 1991). Chapter 8 presents some of\\nthese strategies.\\nMatching Treatment Service\\nNeeds to Settings\\nAfter the types and intensities of services that\\npatients need are defined, the next crucial step\\nin patientñtreatment matching is to identify the\\nmost appropriate available setting or settings\\nfor these services. MAT has been offered \\nprimarily in a dedicated outpatient OTP .\\nHowever, as the importance of treating\\npatientsí varied medical, psychological, social,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='and behavioral needs as part of addiction\\nrecovery has become evident, more varied \\nprograms and settings have emerged.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 108}),\n",
       " Document(page_content='Throughout this TIP , the consensus panel rec-\\nommends that OTPs lacking the resources to\\naccommodate all their patientsí needs develop\\ncooperative relationships with and refer\\npatients to other treatment providers as appro-\\npriate. However, OTPs should coordinate these\\nservices. Based on its assessments of patients,\\nthe treatment team should collaborate with\\npatients to determine the most appropriate\\ntreatment services, intensities of services, and\\nsettings needed to meet patient needs. This', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='collaboration should continue throughout\\nMAT, and patient progress should be the basis\\nfor adjustments in treatment services and\\nintensities.\\nPatientsí service needs may change throughout\\nMAT. For example, one patient may need refer-\\nral to an inpatient program for detoxification\\nfrom alcohol or benzodiazepines and then\\nreturn to the OTP setting. Another may need\\nthe environment of a residential treatment \\nprogram while continuing MAT. Therefore,\\ntreatment matching in some cases can lead to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='multiple settings for an individualís treatment.\\nIn most cases, the originating OTP should \\nprovide case management and liaison for all\\ntreatment services.\\nTypes of settings and \\nprograms offering opioid\\naddiction treatment services\\nThe following are examples of treatment pro-\\ngrams and settings that offer some or all of the\\ncomprehensive services recommended in MAT.\\nOutpatient OTPs.Outpatient OTPs ideally\\ntreat patients who are opioid addicted during', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='all phases of treatment and at most levels of\\ncare. In reality, many OTPs have capacity or\\nresource limitations or payment requirements\\nthat cause them to refer at least some patients\\nto other specialized treatment providers and\\nsettings, such as those described below, for ser-\\nvices that match patient needs. Either on site\\nor through other care providers, OTPs offer a\\nwide spectrum of treatment services and levels\\nof care for diverse patients.\\nAppropriate patients for treatment in outpa-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='tient OTPs are those who meet Federal and\\nState requirements for opioid addiction treat-\\nment (e.g., 42 Code of Federal Regulations,\\nPart 8), those who have done poorly in other\\ntypes of programs (e.g., medically supervised\\nwithdrawal or residential treatment programs),\\nand those who require opioid pharmacothera-\\npy for long-term stabilization.\\nOTPs in hospital-based outpatient settings may\\nprovide a more enhanced continuum of care\\nthan freestanding\\nOTPs because access\\nto medical and psy-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='to medical and psy-\\nchosocial services is\\nreadily available. This\\navailability, in turn,\\nincreases the likeli-\\nhood that patients in\\nMAT will engage in\\nand adhere to other\\nmedical and psy-\\nchosocial treatment\\nregimens. \\nHospital-based MAT\\nprograms are appro-\\npriate for some\\npatients who also are\\nmedically ill and\\nrequire coordinated\\nservices or care by\\nspecial teams. In\\naddition, because hos-\\npitals can provide a one-stop-shopping model\\nof care by incorporating some primary care', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='services with MAT, some patients with histories\\nof poor treatment compliance may be more\\nlikely to adhere to medical treatment. For\\nexample, one report from a 16-month prospec-\\ntive study of nearly 500 persons in a hospital-\\nbased outpatient methadone program found\\nthat 81 percent also used onsite primary care\\nservices (Selwyn et al. 1993). At this writing,\\nthe number of hospital-based programs offer-\\ning MAT is limited in the United States.\\nResidential treatment programs. Residential', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='treatment programs offer cooperative living\\n89PatientñTreatment Matching\\n[S]ervice intensity\\nshould depend on\\nthe level of care\\nrequired to help\\npatients achieve\\nand maintain \\nsuccessful treat-\\nment outcomes.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 109}),\n",
       " Document(page_content='arrangements for patients in recovery, but they\\nvary in their willingness or ability to accept\\nMAT patients\\n(Margolis and\\nZweben 1998). A\\nresidential treatment\\nsetting is indicated\\nfor patients who\\nrequire residential\\nplacement to sup-\\nport treatment and\\nensure their physical\\nor psychological\\nsafety and who are\\nunlikely to continue\\nMAT otherwise.\\nSuch patients gener-\\nally exhibit high\\nrelapse potential,\\nevidenced by an\\ninability to control\\nsubstance use\\ndespite active partic-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='ipation in less inten-\\nsive outpatient pro-\\ngrams (Margolis and\\nZweben 1998). On\\ncompletion of treat-\\nment in these settings, patients should return to\\nan outpatient setting to continue MAT.\\nIf a patient in an OTP is referred to a residen-\\ntial program that does not offer or allow onsite\\nopioid pharmacotherapy (i.e., when other resi-\\ndential options are unavailable) or methadone\\nor buprenorphine dispensing or administra-\\ntion, some programs allow resident patients to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='travel to the OTP for medication. Some States\\nallow exceptions to regulations governing OTP\\nattendance and take-home medications so that\\nconcurrent treatment is possible. \\nMobile treatment units. The success of mobile\\ntreatment unitsóthat is, mobile vansóin such\\ncities as Baltimore, Boston, San Francisco, and\\nSeattle (Greenfield et al. 1996; Schmoke 1995)\\nhighlights the importance of program accessibil-\\nity as a factor affecting length of stay in treat-\\nment and positive treatment outcomes', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='(Greenfield et al. 1996). Mobile substance abuse\\ntreatment programs either offer comprehensive\\nmaintenance services (with medication, collec-\\ntion of samples for drug testing, and counseling\\nprovided in one or several mobile units) or\\nwork in conjunction with fixed-site outpatient\\nprograms that offer medical care and counsel-\\ning and other psychosocial services, while \\nmedication is delivered via the mobile units. \\nAppropriate patients for treatment in mobile', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='treatment units are those in locations where\\nfixed-site programs are unavailable, those with\\nambulatory disabilities, and those initially sta-\\nbilized in an OTP and then transferred to a\\nmobile unit for continued treatment. Mobile\\nunits not staffed on weekends are appropriate\\nonly for patients who meet State and Federal\\nregulations for weekend take-home medications.\\nOffice-based opioid treatment settings. After\\nachieving biomedical and psychosocial stabi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='lization in an OTP , some patients might be eligi-\\nble for referral to less intensive physicianís\\noffice-based opioid treatment (OBOT) for medi-\\ncal maintenance. In these settings, patients\\nreceive the same level of monitoring and inter-\\nvention as patients receiving other types of\\nhealth care. When available, OBOT programs\\noffer several advantages (Fiellin and OíConnor\\n2002), including\\nï Less intensive service requirements for stable\\npatients (e.g., less restrictive environments,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='focus on maintenance with stable doses of\\nopioid medication, provision of only those\\npsychosocial services needed to prevent\\nrelapse)\\nï Minimized stigma associated with addiction\\ntreatment\\nï Increased opportunity for new treatment\\nadmissions to OTPs\\nï Expansion of treatment to geographic areas\\nwhere there are no OTPs or there are waiting\\nlists for admission to OTPs.\\nCriminal justice settings. At this writing, rela-\\ntively few jails or prisons offer comprehensive', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='MAT or selected MAT services, but these num-\\nbers are likely to increase (for information\\nabout substance abuse treatment in criminal\\n90 Chapter 6\\nThe success of\\nmobile treatment\\nunits...highlights \\nthe importance \\nof program \\naccessibility as a\\nfactor affecting...\\npositive treatment \\noutcomes.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 110}),\n",
       " Document(page_content='justice settings, see TIP 44, Substance Abuse\\nTreatment for Adults in the Criminal Justice\\nSystem [CSAT 2005a]). As a result, MAT \\nservices are often interrupted or discontinued\\nwhen patients are incarcerated. Rikers Island,\\nNew York Cityís central jail facility, is an exam-\\nple of a model program that provides compre-\\nhensive MAT for this patient group (Magura et\\nal. 1993). Patients who receive MAT there are\\nguaranteed a slot at a community-based pro-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='gram in New York City after their incarcera-\\ntion. Other corrections facilities provide rapid\\nmedically supervised withdrawal from mainte-\\nnance medication to patients. When this with-\\ndrawal is the only option, OTPs should work\\nwith criminal justice institutions to ensure that\\nappropriate dose-tapering procedures are fol-\\nlowed. Patients released from a criminal justice\\nsetting should be offered referral to an OTP\\nwhen referral is desirable and feasible.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='Other treatment settings. Numerous other set-\\ntings and specialized programs offer some ser-\\nvices and levels of care needed by patients who\\nare opioid addicted. Any of these programs can\\nbe sources of referral by OTPs or can function\\nas satellite OTPs to ensure that patients receive\\nservices and levels of care they need.\\nChoice of Medications\\nThe consensus panel recommends that OTPs\\noffer a variety of treatment medications.\\nChapters 3 and 5 provide more details about', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='the pharmacology and appropriate use of\\nmethadone, levo-alpha acetyl methadol,\\nbuprenorphine, and naltrexone.\\nPatients With Special\\nNeeds\\nEffective treatment for opioid addiction should\\naddress the unique needs of each patient\\n(OíConnor and Fiellin 2000; Rowan-Szal et al.\\n2000a). Culturally competent and creative\\ntreatment planning, implementation, and \\nreferrals should address the distinct needs of\\npatients from different backgrounds. More\\nstaff training and research are required on the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='unique constellations of treatment needs for\\nvarious populations served by OTPs. Findings\\nfor particular groups are summarized below.\\nOther treatment groupings may be identified,\\nfor example, high-profile persons for whom\\nunique treatment schedules and settings may \\nbe needed to protect confidentiality (CSAT\\nforthcoming e).\\nPatients With Serious Medical\\nDisorders\\nIf a serious medical condition is discovered\\nduring medical evaluation or patient assess-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='ment, the patient should receive appropriate\\nmedical treatment either on site or by referral\\nto a medical center. Chapter 10 describes \\nmedical conditions commonly encountered\\namong patients in MAT and provides treatment\\nrecommendations. Most OTPs offer only basic\\nmedical services. OTPs should develop and\\nmaintain referral networks for patients who\\npresent for MAT and have other medical condi-\\ntions. Moreover, OTP staff should coordinate\\nreferrals and follow up as needed to ensure', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='compliance with medical treatments and to act\\nas consultants about MAT and medication\\ninteractions.\\nPatients With Serious \\nCo-Occurring Disorders\\nMany studies have focused on the co-\\noccurrence of substance use and mental \\ndisorders (see chapter 12). The existence of \\nco-occurring disorders should not prevent\\npatientsí admission to an OTP; however, \\ndiagnosis of these disorders is critical to match\\npatients with appropriate services and settings.\\nTherefore, OTPs should include professional', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='staff trained to screen for the presence of co-\\noccurring disorders, develop appropriate \\nreferrals to services (e.g., psychopharmacology\\nor psychotherapy) for these disorders, and pro-\\nvide coordination of care (CSAT 2005b). Most\\nstaff members can be trained to recognize and\\nflag major symptoms of co-occurring disorders.\\nThe OTP should maintain communication and\\nfollowup with referral resources.\\n91PatientñTreatment Matching', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 111}),\n",
       " Document(page_content='Patients With Housing, Family,\\nor Social Problems\\nThe following psychosocial problems should be\\naddressed during or directly after admission to\\nincrease the likelihood that patients will engage\\nsuccessfully in treatment:\\nï Lack of stable housing\\nï Broken ties with family members; nonexistent\\nor dysfunctional family relationships\\nï Poor social skills and lack of a supportive\\nsocial network\\nï Unemployment; lack of employable skills.\\nOnce these needs are identified during assess-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='ment, referrals can be made. Although some\\nOTPs have social workers on site to manage the\\nassessment and referral processes, most OTPs\\nrely on counselors to assume this role. Case\\nmanagement duties should include arrange-\\nments for provision of psychosocial care when\\nindicated. Family members need education\\nabout MAT, including information on how to\\nsupport a partner or loved one in recovery,\\nself-care of family members, signs and symp-\\ntoms of active addiction, and support and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='assistance from family members willing to \\nparticipate in family counseling. Programs can\\noffer monthly classes to patients, their families,\\nand the community, which can reduce the \\nstigma connected with MAT.\\nPatients With Disabilities\\nOTPs should try to provide access for patients\\nwith physical disabilities. Treatment interven-\\ntions for these patients usually include voca-\\ntional rehabilitation, physical therapy, and\\nsocial services that help procure prosthetic', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='limbs, wheelchairs, and other assistive devices\\n(CSAT 1998c). Alternative approaches in MAT,\\nspecifically those that reduce OTP visits,\\ninclude take-home dosing and requests for\\nmedical exceptions through visiting-nurse \\nservices to provide equal access to treatment\\nfor persons with disabilities (see chapter 10).\\nMobile medication units and office-based or\\nhome-nursing services may offer viable \\ntreatment options for patients with disabilities\\n(Fiellin and OíConnor 2002; Greenfield et al.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='1996). OTP staff should address these chal-\\nlenges with patients so that barriers to treat-\\nment are overcome.\\nThe consensus panel recommends that OTPs\\nengage in discussions with their Federal and\\nState agencies to develop solutions for treating\\npatients with disabilities. Such discussions\\nshould balance the medical needs of these\\npatients and the safety issues involved in pro-\\nviding take-home medications for patients with\\ndisabilities who continue to engage in substance', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='abuse or create a risk of medication diversion.\\nAdolescents and Young Adults\\nAdolescents and young adults present a unique\\nchallenge for MAT. Often, ethnic background,\\npeer affiliations, and aspects of the ìyouth \\ncultureî require staff training and special\\nexpectations from both staff and patients.\\nDifferences in routes of administration for\\nheroin or prescription opioids and in treatment\\nneeds between adolescents or young adults and\\nolder adults who are opioid addicted might be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='attributable in part to generational characteris-\\ntics and life experiences. For example, older\\nadults typically present for treatment after\\nyears (sometimes decades) of chronic substance\\nabuse accompanied by loss of family, health,\\nand employment and deterioration in other\\npsychosocial domains. Youth who are opioid\\naddicted tend to present after only a few years\\nof addiction and with different attitudes toward\\naddiction and the recovery process and distinct', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='treatment needs. These youth may be more dif-\\nficult to evaluate, because, as a result of other\\nmodes of administration (i.e., intranasally and\\nby smoking), they do not exhibit some physical\\nmarkers of opioid use (e.g., track marks).\\nTreatment for adolescents and young adults\\nshould integrate knowledge of their specific\\ndevelopmental and psychosocial concerns and\\nneeds. Some needs are related to identity for-\\nmation and peer group preoccupation (e.g., the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='strong desire to be viewed as fearless or to feel\\ninvincible), legal complications regarding \\n92 Chapter 6', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 112}),\n",
       " Document(page_content='consent for treatment (see CSAT 2004b), and,\\noften, factors leading them to run away from\\ntheir homes. TIP 32, Treatment of Adolescents\\nWith Substance Use Disorders(CSAT 1999d),\\nprovides background information.\\nOther risk factors for this group include possi-\\nble sexual and physical abuse, young age at\\nfirst sexual experience, incidents of trading sex\\nfor drugs (Astemborski et al. 1994; Fullilove et\\nal. 1990), and co-occurring disorders (Fuller \\net al. 2002; Hawkins et al. 1992). These risk', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='factors also can contribute to increased risk \\nfor HIV infection (Doherty et al. 2000; Fuller\\net al. 2001) and other sexually transmitted \\ndiseases (STDs).\\nThe interaction of developmental and psy-\\nchosocial factors affects the ability of adoles-\\ncents and young adults to engage in MAT and\\ntherefore complicates the recovery process.\\nOTPs should provide psychosocial services that\\naddress the unique needs of this age group,\\nespecially those needs that affect their sub-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='stance use and recovery, or they should estab-\\nlish referrals and links to youth-oriented psy-\\nchosocial counseling services.\\nBuprenorphine may be a particularly satisfac-\\ntory treatment for some adolescents. Because\\nbuprenorphine can be administered in an\\nOBOT setting, it should become more widely\\navailable and offer more privacy and less \\nstigma for young patients (see CSAT 2004a).\\nWomen\\nPregnancy\\nThe special needs of women who are opioid\\naddicted and pregnant should be assessed', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='thoroughly through a comprehensive medical\\nevaluation, as discussed in chapter 13.\\nTreatment matching for pregnant patients in\\nMAT should provide optimal, comprehensive,\\nand intensive services related to pregnancy and\\nbirth including prenatal care, maternal nutri-\\ntion, and psychosocial rehabilitation, along\\nwith MAT. The integration of a womenís overall\\nhealth initiative into MAT improves an OTPís\\ncapacity to meet the special needs of these\\npatients, to address potential biomedical and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='obstetrical complications, and to avoid adverse\\neffects of substance use on the fetus (Finnegan\\nand Kandall 1992). Chapter 13 offers a\\ndetailed overview of MAT for pregnant women\\n(also see CSAT forthcoming f).\\nOTPs are required by\\nregulation or accredi-\\ntation standards to\\ntest for pregnancy,\\nbut the provision of\\nprenatal care and\\nancillary services for\\npregnant women\\nvaries depending on\\nthe treatment setting.\\nHospital-based pro-\\ngrams may be better\\nsuited for pregnant\\nwomen in some cases', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='women in some cases\\nbecause hospitals\\noffer easy access to\\nreferrals and links to\\nspecialty care (on or\\noff site).\\nSexual or physical abuse\\nPatientsí risks of ongoing abuse in their \\ncurrent relationships should be addressed, \\nand appropriate plans or referrals made. Co-\\noccurring disorders such as posttraumatic\\nstress disorder can occur among both women\\nand men who have experienced sexual or phys-\\nical abuse. The best treatment settings to\\naddress womenís needs in these cases include', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='OTPs with onsite care provided by psychia-\\ntrists, psychologists, licensed social workers, or\\nmental health professionals with special train-\\ning in this area. In lieu of onsite services, OTPs\\nshould establish referral links to programs\\noffering such services. Many social service\\nagencies, as well as agencies responsible for\\ndomestic violence, offer training and support to\\nOTP staff. TIP 36, Substance Abuse Treatment\\nfor Persons With Child Abuse and Neglect', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='Issues (CSAT 2000d), provides further details.\\n93PatientñTreatment Matching\\nCase management\\n...should include\\narrangements \\nfor... \\npsychosocial care\\nwhen \\nindicated.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 113}),\n",
       " Document(page_content='Complex medical problems\\nThe complex medical problems commonly \\ndiagnosed in women in MAT include gynecolog-\\nical infections, amenorrhea, hypertension, and\\npneumonia (Brown et al. 1992). It is optimal to\\nprovide primary care services on site; hospital-\\nbased programs and OTPs with formalized\\nmedical referral systems are best equipped to\\ndeliver such services. Chapter 10 of this TIP\\nand the forthcoming TIP Substance Abuse\\nTreatment: Addressing the Specific Needs', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='of Women (CSAT forthcoming f) provide \\nadditional information.\\nParents\\nBecause many patients in MAT are parents, the\\nlack of adequate childcare services is often a\\nbarrier to OTP attendance and successful\\ntreatment. One solution is supervised onsite\\nchildcare services,\\nwhich also may pro-\\nvide opportunities to\\nobserve how patients\\nrelate to their chil-\\ndren. Problems in\\nparenting skills \\ncan be addressed \\nin treatment plan-\\nning and through\\nparenting groups \\nfor patients with\\nchildren. However,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='children. However,\\nonsite childcare \\nservices are available\\nin few programs\\nbecause of limited\\nresources and licens-\\ning and insurance\\nrequirements. These\\nobstacles might\\ncause missed appointments or lack of privacy\\nand concentration for parents who must bring\\ntheir children to treatment and counseling \\nsessions. Insufficient treatment may result.\\nThe consensus panel recommends that OTPs\\nseek opportunities and funding for onsite child-\\ncare where appropriate and feasible to help', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='patients with children engage successfully in\\npsychosocial services. Where childcare is\\nunavailable, program staff should offer refer-\\nrals to community daycare agencies.\\nIn most States, OTPs are mandated reporters\\nof child abuse and neglect. When children are\\nat imminent risk of harm or appear neglected,\\nOTPs are required to notify local childrenís\\nprotective services (CPS) agencies so that an\\ninvestigation can be conducted. This require-\\nment can create conflict between an OTP and a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='patient, and the OTP should try to address this\\nissue in a supportive way. Programs and treat-\\nment providers should not discriminate against\\npatients because they have entered into pre-\\ntreatment agreements or have difficulties with\\nCPS agencies (see chapter 13).\\nLesbian, Gay, and Bisexual\\nPatients\\nJust as important as sensitivity to cultural dif-\\nferences based on race or ethnicity is providing\\na treatment climate that is available and sensi-\\ntive to lesbian, gay, or bisexual (LGB) patients', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='by openly acknowledging their heterogeneity\\nand variations in sexual orientation and treat-\\ning these individuals with dignity and respect\\n(CSAT 2001b; Lombardi and van Servellen\\n2000). OTP staff should be prepared to assist\\nLGB patients in coping with problems related\\nto their sexual orientation and the need for\\nHIV/AIDS and STD risk avoidance. Providers\\nshould help patients obtain appropriate medi-\\ncal care and secure their safety if, for example,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='they are threatened. OTPs also should acknowl-\\nedge the unique social support structures of\\nLGB patients, which can provide a way to \\ncounteract isolation and separation from com-\\nmunity, peers, and immediate and extended\\nfamily members (Hughes and Eliason 2002; also\\nsee CSAT 2001b). Finally, the consensus panel\\nrecommends that OTPs identify and refer LGB\\npatients to community counseling, support, and\\nspiritual and religious organizations that are\\nsensitive to these groups and address any', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='sexual- or gender-orientation concerns these\\npatients have that could affect treatment.\\n94 Chapter 6\\nMost patients can\\nbe maintained \\non their MAT\\ndosage while \\ntaking short-acting \\nopioids for pain\\nrelief...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 114}),\n",
       " Document(page_content='Aging Patients\\nMAT treatment planners should consider the\\nstressors common to the aging patient, such as\\nloss of family, retirement, loneliness, and bore-\\ndom, which can contribute to high risk of self-\\novermedication and addiction to alcohol and\\nmedications. The consensus panel recommends\\nthat OTPs focus on the following areas when\\nworking with elderly patients:\\nï Monitoring the increased risk for dangerous\\ndrug interactions; elderly patients often are\\nprescribed multiple medications.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='ï Differentiating between co-occurring disorders\\nand symptoms and disorders associated with\\naging (including dementia) (Lawson 1989).\\nï Differentiating between depression and\\ndementia.\\nï Screening for and treating physical and \\nsexual abuse (see chapter 4).\\nï Developing referral sources that meet the\\nneeds of elderly patients. Relationships with\\nskilled nursing facilities and nursing homes\\nare particularly important (Lawson 1989).\\nï Training staff to be sensitive to the elderly', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='patient population.\\nï Providing psychosocial treatment for age-\\nassociated stressors and medical screening\\nand referral for common medical conditions\\naffected by the aging process (see CSAT\\n1998b).\\nï Assessing and adjusting dosage levels of \\nmedication for the slowed metabolism of\\nmany elderly patients.\\nPatients With Pain\\nPatients in MAT often are undertreated or\\ndenied medication for acute or chronic pain\\nmanagement (Compton and Athanasos 2003).\\nHealth care workers may misperceive pain', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='medication requests by patients in MAT as\\ndrug-seeking behavior, in part because of\\npatientsí higher tolerance for opioids and, usu-\\nally, their need for higher doses. Many physi-\\ncians who treat pain do not have the necessary\\neducation to treat pain in this population\\n(Prater et al. 2002). MAT providers should\\nevaluate patient treatment needs for pain \\nmanagement and assist patients directly in\\nobtaining optimal pain treatment. Medical\\nproviders in MAT should work collaboratively', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='with primary care providers and pain and \\npalliative-care clinicians to ensure establish-\\nment of appropriate pain interventions for\\npatients in MAT. Providers need education\\nabout maintaining current opioid levels while\\nadding sufficient immediate-release treatment\\nagents to manage acute or chronic pain. More\\nfrequent dosing and short-term increased\\ndemand for pain treatment medication should\\nbe expected. Referrals to specialty pain clinics\\noften provide patients a full spectrum of pain', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='care, including pharmacological and psycholog-\\nical or behavioral treatments to alleviate pain\\nsymptoms. These services most often are acces-\\nsible through hospital-based programs or refer-\\nral linkages. Most patients can be maintained\\non their MAT dosage while taking short-acting \\nopioids for pain relief; however, individualized\\npain treatment is usually necessary.\\nTreatment Planning\\nAfter patientsí individual needs are assessed\\nand the best available treatment services and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='most appropriate levels of care are determined,\\na treatment plan should be developed with the\\npatient, as required by accreditation guidelines\\n(CSAT 1999b).\\nDeveloping a Treatment Plan\\nTreatment planning for MAT should involve a\\nmultidisciplinary team, including physicians,\\ncounselors, nurses, case managers, social work-\\ners, and patients. Based on a thorough patient\\nhistory and assessment, a treatment plan\\nshould be realistic and tailored to each\\npatientís needs, strengths, goals, and objec-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='tives. Good treatment plans contain both short-\\nand long-term goals and specify the actions\\nneeded to reach each goal. Treatment plans\\nshould indicate which goals and objectives\\nrequire referral to and followup with outside\\n95PatientñTreatment Matching', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 115}),\n",
       " Document(page_content='resources and which are provided by the OTP\\nitself. Treatment plans should contain specific,\\nmeasurable treatment objectives that can be\\nevaluated for degree of accomplishment.\\nRole of the counselor in plan\\nformulation\\nCounselors should ensure that treatment plans\\nincorporate strategies to develop therapeutic\\nrelationships with patients, based on respect\\nfor patientsí autonomy and dignity, while \\nmotivating patients to become willing partners\\nin the change process (CSAT 1999a). This role,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='which places great responsibility on the coun-\\nselor, usually incorporates cognitive behavioral\\napproaches in which providers strive to\\nenhance patient motivation for change by\\nfocusing on patient strengths and respecting\\npatient decisions (CSAT 1999a). To engage\\npatients in the process of treatment planning,\\ncounselors should encourage the inclusion of\\nmotivational enhancement strategies that high-\\nlight appropriate, realistic treatment goals (Di\\nClemente 1991). Research has shown that con-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='frontational counseling or the use of negative\\ncontingencies often predicts treatment failure\\n(Miller and Rollnick 2002). \\nRole of the patient in plan\\nformulation\\nA patient in MAT should be an integral mem-\\nber of the treatment team with his or her needs\\nand expectations considered respectfully and\\nincorporated into the treatment plan. Patients\\nwho agree with the treatment rationale or ther-\\napeutic approach tend to experience increased\\ndetermination to improve (Hubble et al. 1999).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='A patientís participation in treatment planning\\ncan enhance motivation to adhere to change\\nstrategies, leading to positive treatment out-\\ncomes such as higher rates of abstinence and\\nbetter social adjustment (CSAT 1999a). When\\npossible, the treatment plan should be written\\nin a patientís own words to describe his or her\\nunique strengths, needs, abilities, and prefer-\\nences as well as his or her challenges and \\nproblems. The plan also should contain', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='mutually approved goals that reflect awareness\\nof and sensitivity to a patientís informed \\nchoices, cultural background, age, and medical\\nstatus or disability. \\nOther factors in plan \\nformulation\\nTreatment plans should incorporate an \\nassessment of linguistic and cultural factors\\nthat might affect treatment and recovery either\\npositively or negatively (U.S. Department of\\nHealth and Human Services 2001). Treatment\\nproviders should work collaboratively with', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='patients to identify health-related cultural\\nbeliefs, values, and practices and to decide how\\nto address these factors in the treatment plan\\n(U.S. Department of Health and Human\\nServices 2001).\\nMotivation for treatment\\nPatient motivational strategies should be incor-\\nporated throughout the treatment plan. As part\\nof this process, the treatment team can benefit\\nfrom an understanding of stages of change and\\ntheir effects on patient progress. Prochaska\\nand colleagues (1982, 1986, 1992), who formu-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='lated a useful model that explains how people\\nchange, observed five stages of readiness for\\nchange during addiction treatment: contempla-\\ntion, determination, action, maintenance, and\\nrelapse. An earlier stage (precontemplation)\\nalso plays a role. Patients and treatment\\nproviders ideally should develop recommended\\ntreatment options in the plan based on each\\npatientís readiness for treatment, which can be\\ndetermined by identifying the patientís stage-of-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='change readiness. The stages-of-change model\\nand corresponding counseling responsibilities\\nare described in TIP 35, Enhancing Motivation\\nfor Change in Substance Abuse Treatment\\n(CSAT 1999a).\\nElements of a Treatment Plan\\nBecause some patients require assistance in\\nmany functional areas, treatment plans should\\naddress measurable, achievable goals relevant\\nto the patientís current situation. Short-term\\ngoals, such as vocational rehabilitation \\n96 Chapter 6', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 116}),\n",
       " Document(page_content='assessment or computer training, can evolve\\nfrom a long-term goal, such as full-time\\nemployment. However, treatment plans should\\nbe simple and not so comprehensive that they\\noverpower a patient with the tasks that must be\\nachieved. Although both short- and long-term\\ngoals should be considered, the patientís\\ninvolvement in defining measurable, achievable\\ngoals is important. Treatment plans should be\\nmodified periodically when progress can be\\nassessed. Most OTPs have forms to use for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='treatment planning, many of which were devel-\\noped to meet regulatory and accreditation\\nrequirements, specifying goals, actions, respon-\\nsible parties, and measurable outcomes. The\\npanel urges that these forms not be overly com-\\nplex or overwhelming to the patient. Patients\\nshould receive a copy of the plan. Exhibit 6-1\\nprovides a case study and an example of a treat-\\nment plan.\\n97PatientñTreatment Matching', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='Patient is a 30-year-old Hispanic mother of two children who has been divorced for 3 years.\\nShe dropped out of high school at age 15 when she became pregnant. As a single mother on\\npublic assistance, she first began using heroin intranasally at age 17 and began injecting 1\\nyear later.\\nPatient was born in Puerto Rico, and her family came to the United States when she was 10\\nyears old. She is the youngest of five children. Her father was an unemployed painter and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='alcoholic who physically abused her mother. He died in Puerto Rico from cirrhosis of the\\nliver. Patientís relationship with her mother always has been strained. Her mother has had\\nnumerous relationships that the patient resented. Patient stated that, as the youngest child,\\nshe feels that she never received enough attention or love from her mother. \\nTo support her lifestyle, which includes alcohol, cocaine, and heroin use, patient earned', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='money through prostitution, which led to selling drugs, theft, and other criminal activities.\\nPatient married after giving birth to her second child. Patient has an arrest history and a\\npending case for selling cocaine. After a divorce, patient lived with her mother. An anony-\\nmous call was made to CPS reporting her chronic drug abuse and criminal history. As a\\nresult, her children were placed in foster care. After the patientís arrest and the removal', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='of her children, patientís mother asked her to move out of the house; she then lived with\\nwhomever she could.\\nPatient has enrolled in an OTP , motivated by her desire to regain custody of her children.\\nShe considers cessation of her cocaine habit secondary to cessation of her heroin abuse. \\nShe initially stated that she wanted to change her life, including having her own permanent\\nhousing, and she wanted to stop prostituting. Although stabilized on methadone, she', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='continued to use cocaine on a regular basis during her first 6 months in treatment. While \\nin the program, she tested positive for HIV infection. She was assessed as having severe\\ndepression, with suicidal ideation, and escalation of cocaine abuse.\\nAlthough attempts have been made to motivate patient to stop cocaine use, these attempts\\nhave been unsuccessful. \\nPatientís treatment plan might include the following short- and long-term goals:\\nExhibit 6-1', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='Exhibit 6-1 \\nCase Study: PatientñTreatment Planning in MAT\\n(continued on following page)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 117}),\n",
       " Document(page_content='98 Chapter 6\\nExhibit 6-1\\nCase Study: PatientñTreatment Planning in MAT (continued)\\nShort-term goals\\n1.Address imminent danger of suicide by developing a service plan in conjunction with\\nmental health provider.\\nï Objective: To rule out suicide; to overcome patientís depression and assess need for \\nmedication.\\nï Action: Have patient sign a consent form for a psychiatric evaluation and communication\\nbetween provider and OTP staff; set up appointment with psychiatrist; obtain evaluation,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 118}),\n",
       " Document(page_content='diagnosis, and treatment recommendations from the psychiatrist.\\nï Target date: Immediately for suicidal ideation; within 1 month for ongoing mental \\nhealth needs.\\nï Responsible persons: Patient, counselor or caseworker, and psychiatrist.\\nï Measurable outcome: Patient is stable and no longer at high risk; medication needs \\nare assessed.\\nï Long-term goal: Stable mental health status with ongoing treatment plan. \\n2.Obtain housing for patient, with long-term goal of stable permanent housing.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 118}),\n",
       " Document(page_content='ï Objective: To refer to a shelter.\\nï Action: Make appointment to apply for housing assistance program. \\nï Target date: Immediately.\\nï Responsible persons: Patient, counselor or caseworker, and housing staff.\\nï Measurable outcome: Copy of lease, patient self-report, or both.\\nï Long-term goal: Access to stable housing.\\n3.Obtain HIV counseling.\\nï Objective: To provide support and education about HIV status.\\nï Action: Provide education, resources, and counseling about safe sex and spread of HIV .', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 118}),\n",
       " Document(page_content='ï Target date: 4 to 6 months.\\nï Responsible persons: Medical staff, counselor, and patient.\\nï Measurable outcome: Patient has obtained and integrated accurate information; myths\\nare dispelled; patient reports readiness to explore treatment options.\\nï Long-term goal: Initiation of antiretroviral treatment.\\n4.Address cocaine abuse.\\nï Objective: To educate the patient on the psychological and physiological effects of cocaine\\nabuse; to develop a recovery intervention.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 118}),\n",
       " Document(page_content='99PatientñTreatment Matching\\nExhibit 6-1 \\nCase Study: PatientñTreatment Planning in MAT (continued)\\nï Action: Assess level of use and readiness for change; develop plan with patient to address\\nuse (e.g., motivational groups, Cocaine Anonymous, skill-building interventions, drug\\ntesting).\\nï Target date: 2 to 4 months.\\nï Responsible persons: Patient, counselor, group leader, and medical staff members.\\nï Measurable outcome: Patient decreases cocaine use, based on self-report, observable', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 119}),\n",
       " Document(page_content='behavior, drug testing, and attendance to counseling plan.\\nLong-term goals\\n1.Manage or eliminate depression.\\nï Objective: To stabilize depression; to increase self-esteem and motivation to work on\\ntreatment goals.\\nï Action: Provide regular psychiatric treatment on site or by referral; communicate with\\nproviders.\\nï Target date: 6 months.\\nï Responsible persons: Patient, counselor, and psychiatric providers.\\nï Measurable outcomes: Patient regularly attends to psychiatric treatment plan, adherence', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 119}),\n",
       " Document(page_content='to medication regimen if prescribed, elimination of or reduction in depression (as assessed\\nby patient report, depression assessment tools, observed behavior).\\n2.Regain custody of children once in stable housing situation.\\nï Objective: To reconcile the patient with her family; to maintain a stable living situation.\\nï Action: Assist patient in obtaining public assistance to ensure stable, safe, appropriate\\nenvironment for children; access legal assistance for custody issues; obtain permission to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 119}),\n",
       " Document(page_content='communicate with CPS; assist patient in remaining abstinent from substance use.\\nï Target date: 1 year.\\nï Responsible persons: Patient, counselor or caseworkers, internal or external social \\nservices worker, and lawyer.\\nï Measurable outcomes: Patient self-report, family and CPS agency reports, rent receipts,\\nprogress toward obtaining custody of children.\\n3.Continue HIV medical care.\\nï Objective: To obtain ongoing HIV education and treatment.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 119}),\n",
       " Document(page_content='ï Action: Provide access and communication with HIV and primary care providers; \\nprovide referral to support group meetings for individuals who are HIV positive.\\nï Target date: Ongoing.\\nï Responsible persons: Patient, health care providers, counselor and caseworkers, and\\ngroup counselor or facilitator.\\nï Measurable outcomes: Patient self-report, health care providersí report, laboratory\\nreports, and group leader reports about adherence to health care needs.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 119}),\n",
       " Document(page_content='Chapter 6100\\nThe Multidisciplinary Team\\nApproach\\nThe complexities of treatment planning for\\npatients who receive MAT require a multi-\\ndisciplinary treatment team, the composition \\nof which varies with OTP resources and the\\npopulation being treated. The consensus panel\\nrecommends that the treatment team consist of\\nthe following:\\nï A physician trained in addiction psychiatry,\\nwho provides leadership, health care, and\\nmedical stabilization; conducts detailed', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 120}),\n",
       " Document(page_content='evaluations of the patient; monitors medica-\\ntions; and provides needed substance abuse\\ninterventions when indicated\\nï Nonphysician medical staff members (e.g.,\\nregistered nurse, nurse practitioner, physi-\\ncianís assistant), who administer medications,\\nassist in medical evaluations, maintain\\nrecords, and facilitate referrals for medical\\nand psychiatric treatments\\nï A pharmacist or pharmacy assistant, who \\ndispenses (and sometimes administers) \\nmedications, orders controlled substances,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 120}),\n",
       " Document(page_content='maintains records, and consults with program\\nstaff on all aspects of patient care, particularly\\ndrug interactions\\nï Nonmedical professional staff members (e.g.,\\ncase coordinator, social worker, psychologist,\\nvocational and educational specialist), who\\nprovide a range of psychosocial services,\\nincluding counseling and case management,\\npsychotherapy and family therapy, psycholog-\\nical testing and evaluation, health education,\\nand vocational skills assessment and training', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 120}),\n",
       " Document(page_content='ï A certified or licensed addiction specialist or\\ndrug counselor \\nï Nontreatment and administrative staff mem-\\nbers (e.g., office manager, clerical staff,\\nreceptionist, secretary), who often provide\\ninformation to treatment teams and whose\\nresponsibilities include operational manage-\\nment, billing, receipt of payments, review of\\nrecords, observation of patient interactions,\\nand telephone coverage\\nï Security personnel, who ensure the safety\\nand well-being of patients and staff on site.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 120}),\n",
       " Document(page_content='More information on the multidisciplinary team\\napproach is presented in chapter 14.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 120}),\n",
       " Document(page_content='101\\n7 Phases of Treatment\\nThe consensus panel recommends that medication-assisted treatment for\\nopioid addiction (MAT) as provided in opioid treatment programs\\n(OTPs) be conceptualized in terms of phases of treatment so that inter-\\nventions are matched to levels of patient progress and intended outcomes.\\nThe sequential treatment phases described in this chapter apply primari-\\nly to comprehensive maintenance treatment, rather than other treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 121}),\n",
       " Document(page_content='options such as detoxification or medically supervised withdrawal. When\\nMAT is organized in phases, patients and staff better understand that it\\nis an outcome-oriented treatment approach comprising successive, inte-\\ngrated interventions, with each phase built on another and directly related\\nto patient progress. Such a model helps staff understand the complex\\ndynamics of MAT and the potential sticking points and helps counselors\\norganize interventions based on patient needs.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 121}),\n",
       " Document(page_content='The model described in this chapter comprises either five or six patient-\\ncentered phases for planning and providing MAT services and evaluating\\ntreatment outcomes in an OTP , including the (1) acute, (2) rehabilitative,\\n(3) supportive-care, (4) medical maintenance, (5) tapering (optional),\\nand (6) continuing-care phases.\\nRationale for a Phased-Treatment\\nApproach and Duration\\nResearch on the effectiveness of organizing MAT into phases is limited,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 121}),\n",
       " Document(page_content='partly because MAT is a relatively long-term process, often with no fixed\\nendpoint and with a variety of possible approaches, and partly because\\npatients often leave and then return to MAT, which makes systematic\\nstudies difficult. Although research is limited, the consensus panel\\nbelieves that the notion of phased progression is implicit in treatment\\nand underlies most of a patientís time in MAT. Many OTPs operate\\naccording to an informal phased-treatment model, and others use phases', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 121}),\n",
       " Document(page_content='at least to develop treatment plans.\\nIn This\\nChapter…\\nRationale for a\\nPhased-Treatment\\nApproach and\\nDuration\\nPhases of MAT\\nTransition Between\\nTreatment Phases\\nin MAT\\nReadmission to the\\nOTP', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 121}),\n",
       " Document(page_content='Hoffman and Moolchan (1994) recognized the\\nvalue of treatment phases in OTPs and described\\na highly structured model. This chapter builds\\non, adapts, and\\nextends their model\\nas part of an overall\\nstrategy for matching\\npatients with treat-\\nments. The phases\\ndescribed below are\\nsuggested as guide-\\nlinesóa way of\\norganizing treatment\\nand looking at\\nprogress on a care\\ncontinuumóand \\nas an adjunct to \\nthe levels of care\\nspecified by the\\nAmerican Society of\\nAddiction Medicine\\nin its patient place-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='ment criteria (Mee-Lee et al. 2001a) and\\nreferred to by accreditation agencies.\\nThe model is not one directional; at any point,\\npatients can encounter setbacks that require a\\nreturn to an earlier treatment phase. Therefore,\\nthe chapter includes strategies for addressing\\nsetbacks and recommendations for handling\\ntransitions between phases, discharge, and\\nreadmission. In terms of medication, the model\\nincludes two distinct tracks, one of continuing\\nmedication maintenance and the other of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='medication tapering (medically supervised\\nwithdrawal). The implications of both tracks\\nare discussed. Although most patients would\\nprefer to be medication free, this goal is diffi-\\ncult for many people who are opioid addicted.\\nMaintaining abstinence from illicit opioids and\\nother substances of abuse, even if that requires\\nongoing MAT, should be the primary objective.\\nVariations Within Treatment\\nPhases\\nThe phase model assumes that, although many\\npatients need long-term MAT, the types and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='intensity of services they need vary through-\\nout treatment and should be determined by\\nindividual circumstances. For many patients,\\nMAT is the entry point for diagnosis and treat-\\nment of, or referral for, other health care and\\npsychosocial needs. In general, most patients\\nneed more intensive treatment services at entry,\\nmore diversified services during stabilization,\\nand fewer, less intensive services after bench-\\nmarks of recovery begin to be met (McLellan et', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='al. 1993; Moolchan and Hoffman 1994).\\nThe consensus panel emphasizes that treatment\\nphases should not be viewed as fixed steps with\\nspecific timeframes and boundaries but regard-\\ned as a dynamic continuum that allows patients\\nto progress according to individual capacity.\\nSome patients progress rapidly and some \\ngradually. Some progress through only some\\nphases, and some return to previous phases.\\nTreatment outcomes should be evaluated not\\nonly on how many phases have been completed', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='or whether a patient has had to return to an\\nearlier phase but also on the degree to which\\nthe patientís needs, goals, and expectations\\nhave been met. As described in chapter 4,\\nassessment of patient readiness for a particular\\nphase and assessment of individual needs\\nshould be ongoing.\\nDuration of Treatment Within\\nand Across Phases\\nDecisions concerning treatment duration (time\\nspent in each phase of treatment) should be\\nmade jointly by OTP physicians, other members', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='of the treatment team, and patients. Decisions\\nshould be based on accumulated data and \\nmedical experience, as well as patient partici-\\npation in treatment, rather than on regulatory\\nor general administrative policy. \\nPhases of MAT\\nAcute Phase\\nPatients admitted for \\ndetoxification\\nAlthough the phases of treatment model is struc-\\ntured for patients admitted for comprehensive\\n102 Chapter 7\\n[T]reatment\\nphases should not\\nbe viewed as fixed\\nsteps with specific\\ntimeframes and\\nboundaries...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 122}),\n",
       " Document(page_content='103Phases of Treatment\\nmaintenance treatment, some patients may be\\nadmitted specifically for detoxification from opi-\\noids (see 42 Code of Federal Regulations[CFR],\\nPart 8 ß 12(e)(4)). These patients usually do\\nnot wish to be admitted for or do not meet\\nFederal or State criteria for maintenance treat-\\nment. Patients admitted for detoxification may\\nbe treated for up to 180 days in an OTP . The\\ngoals of detoxification are consistent with those\\nof the acute treatment phase as described', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='below, except that detoxification has specific\\ntimeframes and MAT endpoints. Detoxification\\nfocuses primarily on stabilization with medica-\\ntion (traditionally using methadone but\\nbuprenorphine-naloxone tablets are now \\navailable), tapering from this medication, and\\nreferral for continuing care, usually outside \\nthe OTP . During this process, patientsí basic\\nliving needs and their other substance use, co-\\noccurring, and medical disorders are identified', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='and addressed. Patients also may be educated\\nabout the high-risk health concerns and prob-\\nlems associated with continued substance use.\\nThey usually are referred to community\\nresources for ongoing medical and mental\\nhealth care.\\nPatients admitted for detoxification should\\nhave access to maintenance treatment if their\\ntapering from treatment medication is unsuc-\\ncessful or they change their minds and wish to\\nbe admitted for comprehensive MAT. If these', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='patients meet Federal and State admission cri-\\nteria, their medically supervised withdrawal\\nfrom treatment medication should end, their\\nmedication should be restabilized at a dosage\\nthat eliminates withdrawal and craving, and\\ntheir treatment plans should be revised for\\nlong-term treatment.\\nPatients admitted for \\ncomprehensive maintenance\\ntreatment\\nThe acute phase is the initial period, ranging\\nfrom days to months, during which treatment\\nfocuses on eliminating use of illicit opioids and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='abuse of other psychoactive substances while\\nlessening the intensity of the co-occurring \\ndisorders and medical, social, legal, family, and\\nother problems associated with addiction. The\\nconsensus panel believes that front-loading\\nhighly intensive services during the acute\\nphase, especially for patients with serious \\nco-occurring disorders or social or medical\\nproblems, engages patients in treatment and\\nconveys that the OTP is concerned about all\\nthe issues connected to patientsí addiction.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='Exhibit 7-1 summarizes the main treatment\\nconsiderations, strategies, and indicators of\\nprogress during the acute phase.\\nGoals of the acute phase\\nA major goal during the acute phase is to \\neliminate use of illicit opioids for at least 24\\nhours, as well as inappropriate use of other\\npsychoactive substances. This process involves\\nï Initially prescribing a medication dosage that\\nminimizes sedation and other undesirable\\nside effects\\nï Assessing the safety and adequacy of each', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='dose after administration \\nï Rapidly but safely increasing dosage to \\nsuppress withdrawal symptoms and cravings\\nand discourage patients from self-medicating\\nwith illicit drugs or alcohol or by abusing\\nprescription medications \\nï Providing or referring patients for services to\\nlessen the intensity of co-occurring disorders\\nand medical, social, legal, family, and other\\nproblems associated with opioid addiction\\nï Helping patients identify high-risk situations', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='for drug and alcohol use and develop alterna-\\ntive strategies for coping with cravings or\\ncompulsions to abuse substances.\\nChapter 5 details the procedures for determin-\\ning medication dosage.\\nIndications that patients have reached the goals\\nof the acute phase can include\\nï Elimination of symptoms of withdrawal, \\ndiscomfort, or craving for opioids and \\nstabilization', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 123}),\n",
       " Document(page_content='104 Chapter 7\\nExhibit 7-1 \\nAcute Phase of MAT\\nTreatment Issue Strategies To Address Issue\\nIndications for Transition to\\nRehabilitative Phase\\nAlcohol and drug use ï Schedule weekly drug and\\nalcohol testing\\nï Educate about effects of alco-\\nhol and drugs; discourage their\\nconsumption\\nï Ensure ongoing patient dialog\\nwith staff\\nï Intensify treatment when \\nnecessary\\nï Meet with program physician \\nto ensure adequate dosage of\\ntreatment medication\\nï Elimination of opioid-\\nwithdrawal symptoms,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 124}),\n",
       " Document(page_content='including craving\\nï Sense of well-being\\nï Ability to avoid situations\\nthat might trigger or per-\\npetuate substance use\\nï Acknowledgment of \\naddiction as a problem and\\nmotivation to effect lifestyle\\nchanges\\nMedical concerns\\nï Infectious diseases (e.g.,\\nHIV/AIDS, hepatitis,\\ntuberculosis [TB])\\nï Sickle cell disease\\nï Surgical needs, such as\\nskin or lung abscesses\\nï Refer patients immediately to\\nmedical providers \\nï Vaccinate as appropriate (e.g.,\\nfor hepatitis A and B)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 124}),\n",
       " Document(page_content='ï Resolution of acute medical\\ncrises\\nï Established, ongoing care\\nfor chronic medical \\nconditions\\nCo-occurring disorders \\nï Psychotic, anxiety,\\nmood, or personality \\ndisorders\\nï Identify acute co-occurring \\ndisorders that may need imme-\\ndiate intervention\\nï Identify chronic disorders that\\nneed ongoing therapy\\nï Resolution of acute mental\\ncrises\\nï Established, ongoing care \\nfor chronic disorders\\nBasic living concerns\\nï Legal and financial \\nconcerns\\nï Threats to personal \\nsafety', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 124}),\n",
       " Document(page_content='safety\\nï Inadequate housing\\nï Lack of transportation\\nï Childcare needs\\nï Pregnancy\\nï Advocacy\\nï Assess needs\\nï Refer patient to appropriate\\nservices \\nï Work cooperatively with \\ncriminal justice system\\nï Explore transportation options\\nï Link to legal advocate, case-\\nworker, or social worker\\nï Identify financial resources\\nï Provide ongoing case \\nmanagement\\nï Satisfaction of basic food,\\nclothing, shelter, and safety\\nneeds\\nï Stabilization of living \\nsituation \\nï Stabilization of financial', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 124}),\n",
       " Document(page_content='assistance\\nï Resolution of transportation\\nand childcare needs', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 124}),\n",
       " Document(page_content='ï Expressed feelings of comfort and wellness\\nthroughout the day\\nï Abstinence from illicit opioids and from\\nabuse of opioids normally obtained by \\nprescription, as evidenced by drug tests\\nï Engagement with treatment staff in \\nassessment of medical, mental health, and\\npsychosocial issues\\nï Satisfaction of basic needs for food, shelter,\\nand safety.\\n105Phases of Treatment\\nExhibit 7-1 \\nAcute Phase of MAT (continued)\\nTreatment Issue Strategies To Address Issue\\nIndications for Transition to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 125}),\n",
       " Document(page_content='Rehabilitative Phase\\nTherapeutic relationship\\nï Establishing trust and \\nfeeling of support\\nï Addressing myths about\\nMAT\\nï Advocate adequate dosage\\nï Remain consistent, flexible,\\nand available; minimize\\nwaiting times\\nï Provide incentives and\\nemphasize benefits of\\ntreatment\\nï Dispel myths about MAT\\nï Educate patient about\\ngoals of MAT\\nï Build support system\\nï Build trust\\nï Regular attendance at \\ncounseling sessions\\nï Positive interaction with\\ntreatment providers\\nï Focus on treatment goals', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 125}),\n",
       " Document(page_content='Motivation and readiness for\\nchange \\nï Ambivalent attitudes\\nabout substance use\\nï Avoidance of counseling \\n(noncompliance)\\nï Negative relationships with\\nstaff\\nï Inadequate dosage\\nï Negative attitude about\\ntreatment\\nï Involuntary discharge\\nï Ensure adequate dosage\\nï Address ambivalence\\nï Empower patient\\nï Emphasize treatment \\nbenefits\\nï Emphasize importance of\\nmaking a fresh start\\nï Commitment to treatment\\nprocess\\nï Acknowledgment of \\naddiction as a problem\\nï Lifestyle changes and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 125}),\n",
       " Document(page_content='addressing addiction-\\nrelated issues', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 125}),\n",
       " Document(page_content='106\\nAlcohol, opioid, and other\\ndrug abuse\\nDuring the acute phase, OTP staff members\\nshould pay attention both to patientsí continuing\\nopioid abuse and to their use of other addictive\\nand psychoactive substances. Patients should\\nreceive information about how other drugs,\\nnicotine, and alcohol interact with treatment\\nmedications and why medication must be\\nreduced or withheld when intoxication is evi-\\ndent. When substance abuse continues during\\nthe acute phase, the treatment team should', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='review patientsí presenting problems and revise\\nplans to address them, including changes in\\ndosage, increased drug testing, or other intensi-\\nfied interventions. Chapter 11 discusses treat-\\nment options to address multiple substance use.\\nIn addition, the consensus panel believes that\\nfrequent contact with knowledgeable and car-\\ning staff members who can motivate patients to\\nbecome engaged in program activities, especial-\\nly in the acute phase, facilitates the elimination', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='of opioid abuse. Engaging the patient by\\nscheduling extra individual or group counseling\\nsessions provides additional support and com-\\nmunicates staff concern for the patient.\\nIntensified treatment in the OTP is an effective\\nresponse and provides improved outcomes\\nwhen compared with more infrequent counsel-\\ning sessions (Woody 2003).\\nCo-occurring disorders\\nMany people entering OTPs have mental disor-\\nders. Persistent, independent co-occurring \\ndisorders (i.e., mental disorders that arise from', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='causes other than substance use and need \\nongoing therapy) and substance-induced co-\\noccurring disorders (i.e., mental disorders\\ndirectly related to substance use and addiction\\nthat probably will improve as the addiction is\\ncontrolled) should be identified during initial\\nassessment and the acute phase of treatment so\\nthat appropriate treatment or referral can be\\narranged. Patients should be monitored closely\\nfor symptoms that interfere with treatment\\nbecause immediate intervention might prevent', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='patient dropout. Such disorders can be \\ndisruptive at the start of MAT and require\\nimmediate treatment. The course of recovery\\nfrom substance-induced co-occurring disorders\\nusually follows that of the substance use dis-\\norder itself, and these co-occurring disorders\\ntypically do not require ongoing treatment after\\nthe acute phase. Some patients may require\\nfocused, short-term pharmacotherapy, psycho-\\ntherapy, or both. However, many patients \\nmay have co-occurring disorders requiring a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='thorough psychiatric evaluation and long-term\\ntreatment to improve their quality of life. (See\\nchapters 4 and 12 for more information on\\nassessing these conditions and chapter 12 for\\nmore information on psychiatric diagnosis and\\ntreatment in MAT.)\\nMedical and dental problems\\nPatients often present with longstanding,\\nneglected medical problems. These problems\\nmight require hospitalization or extensive \\ntreatment and could incur substantial costs for\\npeople often lacking financial resources. In', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='addition, many patients in MAT have neglected\\ntheir dental health (Titsas and Ferguson 2002).\\nOnce opioid abuse is stopped, these patients\\noften experience pain because the analgesic\\neffects of the opioids have been removed. Such\\nconditions must be recognized, assessed, and\\ntreated, either within an OTP or via referral.\\n(See chapter 10 for discussion of the diagnosis\\nand treatment of medical problems for patients\\nin MAT.)\\nLegal problems\\nMost correctional systems do not allow MAT.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='The consensus panel believes that sudden,\\nsevere opioid withdrawal caused by precipitous\\nincarceration can endanger health, especially\\nthat of patients already experiencing comorbid\\nmedical illness, and can increase the risk of sui-\\ncide in individuals with co-occurring disorders.\\nTherefore, it is critical to address patientsí\\nlegal problems and any ongoing criminal activi-\\nty as soon as possible, preferably in the acute\\nphase. On behalf of those on probation or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='parole or referred by drug courts, program\\nstaff members should work cooperatively with\\nChapter 7', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 126}),\n",
       " Document(page_content='107\\ncriminal justice agencies, educating them about\\nMAT and, with patientsí informed consent (see\\nCSAT 2004b), reporting patient progress and\\nincorporating continuing addiction treatment\\ninto the probation or parole plan. OTPs should\\nwork with local prisons and jails to provide as\\nmuch support and consultation as possible.\\nWhen medical care is provided in jails or \\nprisons by contracted health agencies, OTPs\\nshould establish contacts directly with these', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='medical providers to improve the care of incar-\\ncerated patients in MAT. (See TIP 44, Substance\\nAbuse Treatment for Adults in the Criminal\\nJustice System[CSAT 2005a].)\\nBasic needs\\nThe consensus panel recommends that\\npatientsí basic needs such as food, clothing,\\nhousing, and safety be determined during the\\nacute phase, if possible, as discussed in chapter\\n4, and that referrals be made to appropriate\\nagencies to address these needs.\\nPatientsí living situations should be relatively', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='stable and secure so that treatment can move\\nbeyond the acute phase. Before they transition\\nto the rehabilitative phase, patients should\\nbegin to develop the coping skills needed to\\nremove themselves from situations of inevitable\\nsubstance use. A patientís inability to gain this\\ncontrol may necessitate revision of the treat-\\nment plan to assist the patient in moving past\\nthe acute phase. The process often includes\\nmeeting directly with the patient to assess moti-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='vation and adequacy of dosage and to define\\ntreatment goals clearly.\\nTherapeutic relationships\\nPositive reinforcement of a patientís treatment\\nengagement and compliance, especially in the\\nacute phase, is important to elicit a commit-\\nment to therapy. Chapter 8 addresses the\\nimportance of the therapeutic bond between\\npatients and treatment providers and reviews\\npractical techniques to address common \\nproblems in counseling.\\nFurthermore, participation in peer support', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='services and mutual-help groups (provided that\\nthese groups support MAT) can be helpful to\\npatients. OTPs can provide information about\\nappropriate meetings and peer support.\\nThe consensus panel recommends that patients\\nbe introduced to key OTP staff members as\\nearly as possible during the acute phase to \\nfoster an atmosphere of safety, trust, and\\nfamiliarity. Patients consistently report that a\\nstrong therapeutic relationship is one of the\\nmost critical factors\\ninfluencing treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='outcomes and that\\ntherapistsí warmth,\\npositive regard, and\\nacceptance are major\\nelements in relation-\\nship development\\n(Metcalf et al. 1996).\\nTreatment providers\\nshould minimize wait-\\ning times during\\nscheduled appoint-\\nments to demonstrate\\nthat they value\\npatientsí time. In\\naddition, when\\nproviders remain flex-\\nible and available\\nduring the acute\\nphase, they contribute\\nto patientsí sense of\\nsecurity. Knowing how\\nto reach staff in an emergency can foster\\npatientsí trust in treatment providers.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='Motivation and patient \\nreadiness\\nAs discussed in chapter 4, patient motivation \\nto engage in treatment is a predictor of reten-\\ntion and should be reassessed continually.\\nCounselors should explore and address\\npatientsí negative treatment experiences. It\\nmight help to acknowledge the weaknesses of\\npast staff efforts and to focus on future actions\\nto move treatment forward. Counseling and\\nmotivational enhancement are discussed in\\ndetail in chapter 8.\\nPhases of Treatment\\nPatients...report', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='Patients...report\\nthat a strong \\ntherapeutic \\nrelationship is one\\nof the most critical\\nfactors influencing\\ntreatment \\noutcomes...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 127}),\n",
       " Document(page_content='The level of patient engagement during the\\nacute phase is critical. Research has shown that\\npatient motivation, staff engagement, and the\\ntrust developed during orientation and the\\nacute phase are linked more closely to treat-\\nment outcomes than patientsí initial reasons for\\nentering an OTP (Kwiatkowski et al. 2000;\\nMarlowe et al. 2001).\\nTransition to the rehabilitative\\nphase\\nThe panel recommends the following criteria for\\ntransition from the acute to the rehabilitative\\nphase:', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='phase:\\nï Amelioration of signs of opioid withdrawal\\nï Reduction in physical drug craving\\nï Elimination of illicit-opioid use and reduction\\nin other substance use, including abuse of\\nprescription drugs and alcohol\\nï Completion of medical and mental health\\nassessment\\nï Development of a treatment plan to address\\npsychosocial issues such as education, voca-\\ntional goals, and involvement with criminal\\njustice and child welfare or other social \\nservice agencies as needed', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='ï Satisfaction of basic needs for food, clothing,\\nshelter, and safety.\\nRehabilitative Phase\\nThe primary goal of the rehabilitative phase of\\ntreatment is to empower patients to cope with\\ntheir major life problemsódrug or alcohol\\nabuse, medical problems, co-occurring disor-\\nders, vocational and educational needs, family\\nproblems, and legal issuesóso that they can\\npursue longer term goals such as education,\\nemployment, and family reconciliation.\\nStabilization of dosage for opioid treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='medication should be complete, although\\nadjustments might be needed later, and patients\\nshould be comfortable at the established dosage\\nfor at least 24 hours before the rehabilitative\\nphase can proceed. Exhibit 7-2 summarizes \\nthe treatment issues addressed during the \\nrehabilitative phase, strategies for addressing\\nthem, and indicators for subsequent transition\\nto the supportive-care phase.\\nAs stated for the acute phase, during the \\nrehabilitation phase treatment, providers', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='should continue to assist or provide referrals\\nfor patients who need help with legal, educa-\\ntional, employment, medical, and financial\\nproblems that threaten treatment retention\\n(Condelli 1993).\\nThroughout this phase, efforts should increase\\nto promote participation in constructive activi-\\nties such as full- or part-time employment, \\neducation, vocational training, child rearing,\\nhomemaking, and volunteer work. As patients\\nattend to other life domains, requirements for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='frequent OTP attendance or group participa-\\ntion should not become barriers to employment,\\neducation, or other constructive activities or\\nmedical regimens. Consequently, program poli-\\ncies in areas such as take-home medications and\\ndosing hours should be more flexible in the\\nrehabilitative phase, especially when patients\\nmust travel long distances to their OTP or\\nreceive medication at restricted hours.\\nThe consensus panel recommends that informa-\\ntion about outside support groups, including', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='faith-based, community, and 12-Step groups,\\nbe reviewed with patients in the rehabilitative\\nphase and that patients be urged to participate\\nin such groups, assuming that these groups sup-\\nport MAT. As discussed in chapter 14, OTPs\\nalso should cultivate direct relationships with\\norganizations that might lend support for\\npatient recovery. Faith-based organizations\\ncan provide spiritual assistance, a sense of\\nbelonging, and emotional support, as well as', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='opportunities for patients to contribute to their\\ncommunities, and in the process can educate\\ncommunity members about MAT.\\nRelapse triggers or cues such as boredom, \\ncertain locations, specific individuals, family\\nproblems, pain, or symptoms of co-occurring\\ndisorders might recur during the rehabilitative\\nphase and trigger the use of illicit drugs or\\nabuse of prescription drugs or alcohol. Helping\\n108 Chapter 7', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 128}),\n",
       " Document(page_content='109Phases of Treatment\\nExhibit 7-2 \\nRehabilitative Phase of MAT\\nTreatment Issue Strategies To Address Issue\\nIndications for Transition \\nto Supportive-Care Phase\\nAlcohol and drug use\\nï Continued opioid use \\nï Continued abuse of\\nother substances (e.g.,\\nalcohol, cocaine, \\nnicotine)\\nï Begin behavioral contracting \\nï Start short-term inpatient \\ntreatment \\nï Introduce disulfiram for alco-\\nhol abuse \\nï Provide pharmacotherapy and\\ncessation groups for tobacco\\nuse\\nï Intensify treatment services', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 129}),\n",
       " Document(page_content='ï Introduce positive incentives:\\ntake-home medication, recog-\\nnition of progress \\nï Adjust dosage as necessary to \\nprevent continued opioid use \\nï Encourage participation in\\nsupport groups and family\\ntherapy\\nï Ability to identify and \\nmanage relapse triggers \\nï Repertoire of coping skills \\nï Demonstrated changes \\nin life circumstances to \\nprevent relapse \\nï Discontinuation of opioid\\nand other drug use \\nï Absence of problem \\nalcohol use \\nï Smoking cessation plan\\nMedical concerns', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 129}),\n",
       " Document(page_content='Medical concerns \\nï Chronic diseases (e.g.,\\ndiabetes, hypertension,\\nseizure disorders, car-\\ndiovascular disease) \\nï Infectious diseases (e.g.,\\nHIV/AIDS, TB, hepati-\\ntis B and C, sexually\\ntransmitted diseases)\\nï Susceptibility to \\nvaccine-preventable\\ndiseases \\nï Dental problems, \\nnicotine dependence\\nï Womenís health issues\\n(e.g., pregnancy, family\\nplanning services)\\nï Ensure onsite primary care or\\nlink to other services \\nï Provide integrated treatment\\napproach\\nï Provide routine TB testing as', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 129}),\n",
       " Document(page_content='appropriate\\nï Provide education on diet, \\nexercise, smoking cessation\\nï Provide vaccinations as \\nindicated\\nï Adjust other medications that\\ninterfere with treatment medi-\\ncation or adjust dosage of\\ntreatment medication\\nï Assess need and refer patient\\nfor pain management \\nï Compliance with treat-\\nment for chronic diseases \\nï Improved overall health\\nstatus \\nï Improved dental health\\nand hygiene \\nï Regular prenatal care \\nï Stable medical and mental\\nhealth status \\n(continued on following page)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 129}),\n",
       " Document(page_content='110 Chapter 7\\nExhibit 7-2 \\nRehabilitative Phase of MAT (continued)\\nTreatment Issue Strategies To Address Issue\\nIndications for Transition\\nto Supportive-Care Phase\\nCo-occurring \\ndisorders\\nï Psychotic, anxiety,\\nmood, posttraumat-\\nic stress, or person-\\nality disorders\\nï Evaluate status\\nï Teach coping skills \\nï Ensure early identification and refer-\\nral for co-occurring disorders \\nï Refer for psychotropic medication or\\npsychotherapy as indicated \\nï Stable mental status \\nand compliance with', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 130}),\n",
       " Document(page_content='psychiatric care\\nVocational and \\neducational needs \\nï Unemployment/\\nunderemployment \\nï Low reading skills \\nï Illiteracy \\nï Learning disabilities\\nï Identify education deficiencies \\nï Provide onsite general equivalency\\ndiploma (GED) counseling or referral \\nï Provide literacy and vocational train-\\ning with community involvement \\nï Provide training on budgeting of \\npersonal finances \\nï Provide employment opportunities\\nor referral to a job developer\\nï Stable source of income \\nï Active employment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 130}),\n",
       " Document(page_content='ï Active employment\\nsearch\\nï Involvement in produc-\\ntive activity: school,\\nemployment, volunteer\\nwork \\nFamily issues \\nï Absence of family \\nsupport system \\nï Emergence of family\\nproblems (e.g.,\\ntraumatic family\\nhistory, divorce,\\nother problem \\nsituations) \\nï Involve community or faith-based,\\nfellowship, recreation, or other peer\\ngroup \\nï Increase involvement in family life\\n(in absence of family dysfunction\\nthat impedes progress) \\nï Provide for well-child care \\nï Social support system\\nin place', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 130}),\n",
       " Document(page_content='in place \\nï Absence of major \\nconflict within support\\nsystem \\nï Increased responsibil-\\nity for dependents \\nLegal problems \\nï Criminal charges \\nï Custody battles \\nï Ongoing illegal\\nactivities \\nï Provide access to legal counsel \\nï Encourage patient to take responsi-\\nbility for legal problems \\nï Identify obstacles to eliminating illegal\\nactivities and replace them with con-\\nstructive activities \\nï Resolution of, or \\nongoing efforts to\\nsolve, legal problems \\nï Absence of illegal \\nactivities', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 130}),\n",
       " Document(page_content='patients develop skills to cope with triggers\\nshould be emphasized in this phase (Sandberg\\nand Marlatt 1991) and might involve individu-\\nal, group, or family counseling or participation\\nin groups focused on relapse prevention. (For a\\ndiscussion of relapse prevention, see chapter 8.)\\nMany factors that receive emphasis in the acute\\nphase should continue to be addressed in the\\nrehabilitative phase:\\nï Continued alcohol and prescription drug\\nabuse and use of illicit drugs\\nï Ongoing health concerns', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='ï Acute and chronic pain management\\nï Employment, formal education, and other\\nincome-related areas\\nï Family relationships and other social supports\\nï Legal problems\\nï Co-occurring disorders\\nï Financial problems.\\nContinued alcohol and \\nprescription drug abuse and\\nuse of illicit drugs\\nThe consensus panel recommends that elimina-\\ntion of alcohol abuse, illicit-drug use, and inap-\\npropriate use of other substances be required\\nto complete the rehabilitative phase. Evidence', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='of heavy alcohol use might warrant that a\\npatient return to the acute phase. If a patient is\\nusing medications, particularly drugs of poten-\\ntial abuse prescribed by a nonprogram physi-\\ncian, the patient should be counseled to advise\\nhis or her OTP physician of these prescriptions\\nand should sign an informed consent statement\\npermitting OTP staff and the outside physician\\nto discuss these prescriptions. If drug use is\\nillicit or unapproved by the OTP physician,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='then group, family, and individual counseling\\nshould continue, and the patient should remain\\nin the rehabilitative phase. Patients who con-\\ntinue to use illicit drugs or demonstrate alcohol\\nuse problems are not eligible for take-home\\nmedication. Take-home medication should \\nnot be considered until these patients have\\ndemonstrated a period of abstinence. Patients\\nalso should receive information on the risks of\\nsmoking, both for their own recovery and for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='the health of those around them. (See chapter\\n11 for techniques to treat continued substance\\nuse during MAT and chapter 8 for counseling\\nand behavior modification strategies.) \\nThe frequency of drug testing during the \\nrehabilitative phase and all subsequent phases\\nshould depend on a patientís progress in treat-\\nment. The consensus panel recommends that,\\nonce a patient is progressing well and has con-\\nsistently negative drug tests, the frequency of\\nrandom testing be decreased to once or twice', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='per month. The criteria for this should be part\\nof the treatment plan. (See chapter 9 for a\\ndetailed discussion of drug testing.)\\nOngoing health concerns\\nAs patients advance in the rehabilitative phase,\\nthey should attend to other medical problems,\\nand OTP staff should help them navigate the\\nmedical- and dental-care systems, while edu-\\ncating practitioners about MAT. Onsite primary\\nhealth care is optimal and has been instituted\\nsuccessfully in many OTPs and can result in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='better outcomes for patients (Weisner et al.\\n2001), although it requires careful coordination\\nof activities and staff (Herman and Gourevitch\\n1997). When lack of resources precludes onsite\\nmedical services in an OTP , referral arrange-\\nments with other service providers should be\\nin place.\\nThe consensus panel recommends a more \\nintegrated approach to patient health in the\\nrehabilitative phase. A patientís health needs\\nshould be diagnosed and treated immediately.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='Education about topics with longer term bene-\\nfits, such as nutrition, exercise, personal\\nhygiene, sleep, and smoking cessation, can be\\nstarted. Eventually, patients should demon-\\nstrate adherence to medical regimens for their\\nchronic conditions and address any acute \\nconditions before they are considered for tran-\\nsition from the rehabilitative phase to subse-\\nquent treatment phases.\\n111Phases of Treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 131}),\n",
       " Document(page_content='Acute and chronic pain \\nmanagement\\nPatients in OTPs are at high risk of under-\\ntreatment for pain (Jamison et al. 2000;\\nRosenblum et al. 2003; Scimeca et al. 2000).\\nChapter 10 provides recommendations for pain\\nmanagement. Because acute pain treatment\\nusually involves opioid medications, programs\\nshould work with patients to recognize the risk\\nof relapse and provide supports to prevent it\\n(Jamison et al. 2000). \\nEmployment, formal \\neducation, and other \\nincome-related issues', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='The consensus panel believes that some of the\\nmost difficult obstacles to a stable life for MAT\\npatients include unemployment and inadequate\\nfunds to live comfortably and safely. Most such\\nlimitations should be addressed during the\\nrehabilitative phase. (See chapter 8 for detailed\\ndiscussion.)\\nIndividuals who need access to high-quality\\nsocial services should be identified during the\\nrehabilitative phase for educational, literacy,\\nand vocational programs that will equip them', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='with the skills needed to function independently.\\nChapters 6 and 8 discuss such assistance. TIP\\n38, Integrating Substance Abuse Treatment and\\nVocational Services (CSAT 2000c), provides\\nmore information on this topic.\\nIdeally, OTPs should provide onsite GED\\ncounseling and assistance or make referrals to\\nlocal adult education programs that are sensitive\\nto the needs of patients in MAT. Efforts can \\nbe made to encourage business, industry, and\\ngovernment leaders to create income-generating', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='enterprises that provide patients with job skills\\nand opportunities for entry into the job market\\nand to preclude employment discrimination \\nfor patients.\\nPatients in MAT face unique employment \\nchallenges, especially as employers increasingly\\nimpose preemployment drug testing and\\npatients must wrestle with whether to disclose\\ntheir status. The panel recommends that \\nvocational training provided in an OTP include\\nbasic education about drug testing, including', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='the fact that methadone may be detected.\\nPatients should be advised to answer all job\\napplication questions honestly and should be\\ncounseled on ways to manage disclosure of their\\ntreatment status. Patients with disabilities\\nshould be educated about the basics of the\\nAmericans with Disabilities Act and any local\\nantidiscrimination legislation and enforcement.\\nBy the end of the rehabilitative phase, patients\\nshould be employed, actively seeking employ-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='ment, or involved in a productive activity such\\nas school, child rearing, or regular volunteer\\nwork. They should have a stable source of legal\\nincome, whether from employment, disability\\nbenefits, or other legitimate sources, ensuring\\nthat they can avoid drug dealing or other \\ncriminal activities to obtain money.\\nFamily relationships and\\nother social supports\\nBroken trust, disappointment, anger, and \\nconflict with family members and acquain-\\ntances are realities that patients should face', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='during the rehabilitative phase. Many need to\\nreconcile with their families, reunite with or\\nregain custody of their children, and handle\\nother family issues. Some patients have had \\nlittle or no family contact during the period of\\ntheir opioid addiction. Counselors need to help\\npatients improve their social supports and rela-\\ntionships and begin to rebuild and heal severely\\ndamaged family relationships. Chapter 8\\nexpands on these goals for patients in MAT.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='Transition from the rehabilitative phase should\\nrequire that patients have a social support sys-\\ntem in place that is free of major conflicts and\\nthat they assume increased responsibility for\\ntheir dependents (e.g., by reliably providing\\nchild support).\\nLegal problems\\nThe stress associated with patientsí legal \\nproblems can precipitate relapse to illicit drug\\n112 Chapter 7', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 132}),\n",
       " Document(page_content='use or abuse of alcohol or prescription drugs.\\nCounselors should probe patientsí legal circum-\\nstances, such as child custody obligations, and\\npatients should be encouraged to take responsi-\\nbility for their actions; however, counselors\\nshould help patients remain in treatment while\\nresolving pending legal problems. During the\\nrehabilitative phase, counselors should help\\npatients overcome guilt, fear, or uncertainty\\nstemming from their legal problems. In addi-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='tion, OTP staff should ensure that patients have\\naccess to adequate legal counsel, for instance,\\nthrough a public defender. All major legal prob-\\nlems should be in the process of resolution\\nbefore patients move beyond the rehabilitative\\nphase. Drug courtsí referrals of patients can\\nresult in reporting requirements and specialized\\nprotocols (see CSAT 2005a).\\nCo-occurring disorders\\nThe consensus panel recommends that, before\\npatients move beyond the rehabilitative phase,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='co-occurring disorders be alleviated or stabi-\\nlized. Although symptoms might continue to\\narise, patients should have adequate coping\\nskills to avoid relapse to opioid abuse. Chapter\\n12 provides specific information about co-\\noccurring disorders in MAT.\\nSupportive-Care Phase\\nAfter meeting the criteria for transition from\\nthe rehabilitative phase, patients should\\nprogress to the supportive-care phase, in which\\nthey continue opioid pharmacotherapy, partici-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='pate in counseling, receive medical care, and\\nresume primary responsibility for their lives.\\nDuring this phase, patients should begin to\\nreceive take-home medication for longer periods\\nand be permitted to make fewer OTP visits.\\nDepending on regulations (State regulations\\noften are more stringent than Federal), these\\npatients might visit their OTP as infrequently as\\nevery other week. Often, supportive care pro-\\nvided in an OTP can be augmented by support-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='ive activities through mutual-help, community,\\nfaith-based, peer, and acculturation groups.\\nExhibit 7-3 summarizes the treatment issues\\nthat should be addressed during the supportive-\\ncare phase, strategies for addressing them, and\\nindicators for the subsequent transition from\\nthe supportive-care phase to medical mainte-\\nnance or tapering.\\nPatients should have discontinued alcohol and\\nprescription drug abuse and all illicit-drug use,\\nas well as any involvement in criminal activities,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='before entering the supportive-care phase.\\nHeavy or problem substance use should result\\nin patientsí return to the acute phase. Patients\\nin supportive care should be employed, actively\\nseeking employment, or involved in other pro-\\nductive activities, and they should have legal,\\nstable incomes. Even though all treatment\\nplans and patientsí progress should be assessed\\nindividually, if any requirements largely are\\nunmet, counselors should consider returning', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='these patients to the rehabilitative phase to\\naddress areas of renewed concern rather than\\nadvancing them to the medical maintenance or\\ntapering phase.\\nAfter patients in supportive care are abstinent\\nfrom illicit drugs or are no longer abusing \\nprescription drugs (as confirmed by treatment\\nobservation and nega-\\ntive drug tests) for a\\nspecified period, they\\nshould be considered\\nfor transition to either\\nthe medical mainte-\\nnance or the tapering\\nphase. Opinions vary\\non the length of time', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='patients should be\\nfree from illicit-drug\\nuse and abuse of pre-\\nscription drugs before\\nbeing allowed to move\\nto the next phase.\\nHowever, to receive\\nthe maximum 30-day\\nsupply of take-home\\nmedication, a patient must be demonstrably\\nfree from illicit substances for at least 2 years\\nof continuous treatment (42 CFR, Part 8 ß\\n12(i)(3)(vi)). The consensus panel believes that\\n113Phases of Treatment\\nHeavy or problem\\nsubstance use\\nshould result in\\npatientsí return to\\nthe acute phase.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 133}),\n",
       " Document(page_content='114 Chapter 7\\na period of treatment compliance lasting\\nbetween 2 and 3 years usually is appropriate.\\nHowever, the length of time a patient remains\\nin supportive care should be based entirely on\\nhis or her needs and progress, not on an\\nimposed timetable. Patientsí progress in coping\\nwith their life domains should be assessed at\\nleast quarterly to determine whether patients\\nare eligible and ready for transition from sup-\\nportive care to either the medical maintenance\\nor tapering phase.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 134}),\n",
       " Document(page_content='or tapering phase.\\nIn some cases, patients who stop opioid abuse\\nand demonstrate compliance with program\\nrules do not make progress in other life\\ndomains. Although such patients might do well\\nin MAT, they still need the ongoing support and\\npharmacotherapy provided by the OTP and, in\\nthe opinion of the consensus panel, should be\\ndeemed ineligible or inappropriate candidates\\nfor either medical maintenance or tapering.\\nInstead, these patients should continue to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 134}),\n",
       " Document(page_content='receive take-home medication for brief periods\\n(e.g., 1 to several days) along with other services\\nas needed.\\nThe criteria for transitioning to the next phase\\nof treatment depend on whether the patient is\\nentering the medical maintenance phase or the\\ntapering and readjustment phase.\\nMedical Maintenance Phase\\nIn the medical maintenance phase, stabilized\\npatients who continue to require medication to\\nremain stable are allowed longer term (up to\\n30-day) supplies of take-home medication and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 134}),\n",
       " Document(page_content='further reductions in the frequency of treat-\\nment visits, generally without the suite of ser-\\nvices included in comprehensive MAT. Medical\\nExhibit 7-3 \\nSupportive-Care Phase of MAT\\nTreatment\\nIssue Strategies To Address Issue\\nIndications for Transition\\nto Next Phase\\nAlcohol and\\ndrug use\\nï Monitor use\\nï Increase frequency of drug screening\\nï Discontinued drug use\\nand no problems with\\nalcohol use\\nMedical and\\nmental health\\nconcerns\\nï Monitor compliance with medical/psychiatric\\nregimens', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 134}),\n",
       " Document(page_content='regimens\\nï Maintain communication with patientsí\\nhealth care and mental health care providers\\nï Stability\\nVocational\\nand educa-\\ntional needs\\nï Monitor vocational status and progress\\ntoward educational goals\\nï Assist in addressing workplace problems\\nï Stable source of income\\nFamily issues ï Monitor family stability and relationships\\nï Refer for family therapy as needed\\nï Stability\\nLegal issues ï Monitor ongoing legal issues\\nï Provide needed support \\nï Resolution', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 134}),\n",
       " Document(page_content='115Phases of Treatment\\nmaintenance with methadone can be adminis-\\ntered through an OTP or through the office of\\na qualified physician who operates under\\nSubstance Abuse and Mental Health Services\\nAdministration (SAMHSA) approval as a \\nìmedication unitî (42 CFR, Part 8 ß 11(h)) and\\nis linked formally to an OTP . Federal regula-\\ntions (42 CFR, Part 8 ß 12(i)(3)(vi); 42 CFR,\\nPart 8 ß 11(h)) permit various levels of take-\\nhome medication for unsupervised use, with the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='amount linked to the length of time that\\npatients have been abstinent from illicit opioids\\nor have stopped abusing prescription opioids\\nand to other specified conditions. Some State\\nregulations (e.g., New York) further restrict the\\namount of take-home opioid treatment medica-\\ntion and supersede Federal regulations. \\nThe consensus panel recommends the following\\ncriteria to determine a patientís eligibility for\\nthe medical maintenance phase of treatment:\\nï 2 years of continuous treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='ï Abstinence from illicit drugs and from abuse\\nof prescription drugs for the period indicated\\nby Federal and State regulations (at least 2\\nyears for a full 30-day maintenance dosage)\\nï No alcohol use problem\\nï Stable living conditions in an environment\\nfree of substance use\\nï Stable and legal source of income\\nï Involvement in productive activities (e.g.,\\nemployment, school, volunteer work)\\nï No criminal or legal involvement for at least \\n3 years and no current parole or probation\\nstatus', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='status\\nï Adequate social support system and absence\\nof significant unstabilized co-occurring \\ndisorders. \\nDuring the medical maintenance phase, OTPs\\nmay play various roles in patientsí primary\\nmedical and mental health care. OTPs that\\nprovide only limited health care services should\\nintegrate their services with those of other\\nhealth care providers (see chapters 10 and \\n12 about related medical problems and co-\\noccurring disorders, respectively). Exhibit 7-4', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='summarizes treatment issues and strategies in\\nthe medical maintenance phase of MAT and\\nprovides indicators for transition to physicianís\\noffice-based opioid treatment (OBOT) or the\\ntapering or continuing-care phases.\\nIn addition, evaluation of life domains \\nincluding substance use, co-occurring medical\\nand mental problems, vocational and educa-\\ntional needs, family circumstances, and legal\\nissues should continue during the medical\\nmaintenance phase, regardless of the setting.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='Although patients in medical maintenance may\\nnot require psychological services, they may\\nneed occasional dosage adjustments based on\\ntheir use of other prescription medication or on\\nsuch factors as a change in metabolism of\\nmethadone (see chapter 5).\\nThe consensus panel recommends random drug\\ntesting and callbacks of medication during the\\nmedical maintenance phase to make sure that\\npatients are adhering to their medication\\nschedules (see chapter 9). Patients in medical', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='maintenance should be monitored for risk of\\nrelapse. Positive drug test results should be\\naddressed without delay, and patients should\\nbe returned to the rehabilitative phase when\\nappropriate.\\nThe consensus panel recommends that, as part\\nof the diversion control plan required for all\\nOTPs by SAMHSA (see chapters 5 and 14), \\nevidence of medication diversion by a patient in\\nmedical maintenance result in reclassification of\\nthat patient to the most appropriate previous', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='phase of treatment and in adjustment of \\ntreatment, other services, and privileges.\\nReinstatement into medical maintenance\\nshould occur only after the phase-regressed\\npatient is observed over a reasonable period \\n(at least 3 to 6 months) and has demonstrated\\nrequired progress.\\nConsiderations for OBOT with\\nmethadone\\nOBOT may be considered for patients receiving\\nmethadone in MAT in an OTP who have\\ndemonstrated stability in all domains for at', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 135}),\n",
       " Document(page_content='116\\nleast 2 consecutive years of treatment. If a\\npatient in medical maintenance who is receiving\\ntreatment through OBOT relapses (to opioid,\\nother drug, or alcohol abuse) or needs the\\nstructure of an OTP for psychosocial reasons,\\nthe treating physician is responsible for \\nreferring the patient back to an OTP . There\\nare some exceptions in which patients, early in\\ntreatment, can be transferred from an OTP to\\nOBOT with methadone (e.g., when travel to an', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 136}),\n",
       " Document(page_content='OTP is impossible or there are medical reasons),\\nbut these exceptions must be preapproved by\\nSAMHSA (see chapter 5).\\nCoordination of care is critical in the OBOT\\nmodel so that patients get the full range of ser-\\nvices needed to remain abstinent. Treatment\\nissues listed in Exhibits 7-1, 7-2, and 7-3 also\\nare applicable to patients who receive OBOT.\\nRegardless of the opioid treatment medication\\nused, treatment of opioid addiction requires a\\ncomprehensive and individualized treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 136}),\n",
       " Document(page_content='approach that includes medication and coun-\\nseling services. Even for patients who are \\nrehabilitated and stable enough to qualify for\\nmedical maintenance, medication alone often is\\ninadequate to treat their opioid addiction\\n(Joseph et al. 2000).\\nTapering and Readjustment\\nPhase\\nì Taperingî and ìmedically supervised with-\\ndrawalî are terms commonly used to describe\\nthe gradual reduction and elimination of main-\\ntenance medication during opioid addiction', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 136}),\n",
       " Document(page_content='treatment. (The term ìdetoxificationî in this\\nTIP refers to tapering from illicit drugs, from\\ninappropriate use of prescription drugs, or\\nfrom alcohol abuse, not to tapering from treat-\\nment medication, to avoid the implication that\\ntreatment medications are toxic.) Studies show\\nthat most patients who are opioid addicted try \\nChapter 7\\nExhibit 7-4 \\nMedical Maintenance Phase of MAT\\nTreatment Issue Strategies To Address Issue\\nIndications for Transition\\nto OBOT or Tapering or', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 136}),\n",
       " Document(page_content='Continuing-Care Phases\\nAlcohol and drug use ï Monitor use\\nï Perform drug testing\\nï Continuous stability for\\n2 years\\nMedical and mental\\nhealth concerns\\nï Monitor compliance\\nï Maintain communication\\nï Stability\\nVocational and edu-\\ncational needs\\nï Monitor progress\\nï Remain available to address work-\\nplace problems\\nï Stability\\nFamily issues ï Monitor family stability\\nï Refer to family therapy as needed\\nï Stability\\nLegal issues ï Monitor ongoing legal issues\\nï Provide support as needed\\nï Stability', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 136}),\n",
       " Document(page_content='117\\nto taper from treatment medication one or\\nmore times after reaching and maintaining sta-\\nbility. With proper support systems and skills,\\nmany patients succeed in remaining abstinent\\nfrom opioids without treatment medication for\\nyears or even life, but studies have shown that\\nsome relapse to opioid abuse (Condelli and\\nDunteman 1993; Hubbard et al. 1989; Kreek\\n1987). Chapter 5 describes procedures and\\nother key considerations in tapering. In the\\nphased model presented here, tapering is con-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='sidered an optional branch.\\nIt is important that any decision to taper from\\nopioid treatment medication be made without\\ncoercion and include careful consideration of a\\npatientís wishes and preferences, level of moti-\\nvation, length of addiction, results of previous\\nattempts at tapering, family involvement and\\nstability, and disengagement from activities\\nwith others who use substances. A patient con-\\nsidering dose tapering should understand that\\nthe chance of relapse to drug use remains', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='(Magura and Rosenblum 2001) and some level\\nof discomfort exists even if the dose is reduced\\nslowly over months (Moolchan and Hoffman\\n1994). Patients should be assured that they\\ntemporarily can halt the reductions or return\\nto a previous methadone dosage if tapering\\ncauses problems.\\nAs medication is being tapered, intensified ser-\\nvices should be provided, including counseling\\nand monitoring of patientsí behavioral and\\nemotional conditions. Patients considered for', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='medication tapering should demonstrate suffi-\\ncient motivation to undertake this process,\\nincluding acceptance of the need for increased\\ncounseling. Tapering from medication can be\\ndifficult, and patients should understand the\\nadvantages and disadvantages of both tapering\\nfrom and continuing on medication mainte-\\nnance as they decide which path is best for\\nthem. Exhibit 7-5 presents treatment issues\\nduring the tapering phase, strategies to address', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='these issues, and indicators for return to a pre-\\nvious phase.\\nReasons for tapering\\nSometimes decisions to taper are motivated by\\nthe hardships of OTP attendance and other\\nrequirements or by the stigma often associated\\nwith MAT. The consensus panel urges OTPs to\\nidentify such situational motives and ensure\\nthat patients who choose medically supervised\\nwithdrawal from MAT are motivated instead by\\nlegitimate concerns about health and relapse.\\nPatients and treatment providers might fail to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='realize or understand that continuing or long-\\nterm MAT is the best choice for some patients.\\nOTP staff members consciously or inadvertent-\\nly might convey that tapering is more desirable\\nor expected than continuing opioid pharma-\\ncotherapy, through such practices as celebrat-\\ning patientsí tapering but not the accomplish-\\nments of others who successfully continue in\\nMAT. The consensus panel believes that a basic\\ngrounding in MAT pharmacology, the biology', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='of addiction, and the endorphin system helps\\npatients and treatment providers understand\\nthat both successful tapering from and contin-\\nued compliance with medical maintenance\\ntreatment are legitimate goals and commend-\\nable accomplishments.\\nRelapse after tapering\\nThe risk of relapse during and after tapering is\\nsignificant because of the physical and emotion-\\nal stress of attempting to discontinue medica-\\ntion (Magura and Rosenblum 2001). The con-\\nsensus panel recommends that patients be', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='encouraged to discuss any difficulties they\\nexperience with tapering and readjustment so\\nthat appropriate action can be taken to avoid\\nrelapse. Patients should be persuaded to\\nreturn to a previous phase if the need is indi-\\ncated at any time during tapering. Patients also\\nshould be told that they can taper at their own\\nrate, that successful tapering sometimes takes\\nmany months, and that they can stop tapering\\nor increase their dosage at any time without a', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='sense of failure. Patients should be educated\\nabout how to reenter MAT if they believe that\\nrelapse is imminent.\\nPhases of Treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 137}),\n",
       " Document(page_content='118\\nReadjustment\\nMany patients who complete tapering from \\nopioid medication continue to need support\\nand assistance, especially during the first 3 to\\n12 months, to readjust to a lifestyle that is \\nfree of both maintenance medication and \\nsubstances of abuse. During this period, treat-\\nment providers should focus on reinforcing\\npatientsí coping and relapse prevention skills.\\nPatientsí primary goals should be to increase\\nself-sufficiency and maintain balanced, stable,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 138}),\n",
       " Document(page_content='and productive lifestyles. Participation in \\n12-Step or other mutual-help groups is recom-\\nmended as reliance on the OTP is gradually\\nreduced. Motivated patients might be helped\\nby continued naltrexone therapy (see chapter\\n3), which blocks opioid effects for 2 to 3 days\\nin appropriate doses. Care must be taken \\nto initiate naltrexone well after tapering is \\ncompleted to avoid precipitating withdrawal\\nsymptoms. Other patients might benefit from\\ncontinued counseling to strengthen relapse', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 138}),\n",
       " Document(page_content='prevention skills. Some patients might find the\\nsupport of continued drug testing helpful after\\ntapering. Other recommended strategies\\ninclude problemsolving counseling approaches,\\nreinforcement of positive behaviors and atti-\\ntudes, an open-door policy to maximize avail-\\nability of counselors and providers, steps to\\nstrengthen patientsí own support systems, and\\ndevelopment of a relapse prevention plan,\\nincluding how to return to MAT if necessary.\\nChapter 7\\nExhibit 7-5 \\nTapering Phase of MAT', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 138}),\n",
       " Document(page_content='Treatment Issue Strategies To Address Issue\\nIndications for Return to a\\nPrevious Treatment Phase\\nAlcohol and drug use ï Monitor use\\nï Increase drug testing\\nï Increase counseling support\\nï Relapse or concern about\\nrelapse to opioid use\\nï Positive drug test for an illicit\\nsubstance\\nMedical and mental\\nhealth concerns\\nï Monitor compliance\\nï Maintain communication with\\nhealth care providers\\nï Continue education\\nï Unstable health issues\\nVocational and educa-\\ntional needs\\nï Monitor progress', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 138}),\n",
       " Document(page_content='ï Monitor progress\\nï Be available to address \\nworkplace problems \\nï Instability\\nï Loss of employment\\nFamily issues ï Monitor family stability\\nï Refer to family therapy as\\nneeded\\nï Instability\\nï Death or loss of loved one\\nï Unstable housing\\nLegal issues ï Monitor ongoing legal issues\\nï Provide support as needed\\nï New criminal involvement', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 138}),\n",
       " Document(page_content='Reversion to MAT\\nThe consensus panel recommends that all\\npatients attempting tapering be counseled that\\na return to medication and a previous phase\\ndoes not represent failure but simply that medi-\\ncal maintenance is more appropriate for some\\npatients in general and for others at particular\\ntimes in their lives.\\nIndicators for transition\\nSuccessful discontinuation of medication is a\\nkey indicator for transition from the tapering\\nphase to the continuing-care phase. Another', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='key indicator is a positive self-image as someone\\nwho feels and functions well without medica-\\ntion. Adoption of a socially productive lifestyle\\nwithout involvement with substances of abuse\\nalso is critical to completing this phase and to\\ncontinued recovery. The absence of signs and\\nsymptoms of abuse or dependence, as defined\\nby the Diagnostic and Statistical Manual of\\nMental Disorders, Fourth Edition, Text\\nRevision, (DSM-IV-TR) (American Psychiatric', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='Association 2000) indicates successful comple-\\ntion of tapering. \\nContinuing-Care Phase\\nContinuing care is the phase that follows suc-\\ncessful tapering and readjustment. Treatment\\nat this stage comprises ongoing medical fol-\\nlowup by a primary care physician, occasional\\ncheck-ins with an OTP counselor, and partici-\\npation in recovery groups. Ongoing treatment,\\nalthough less intense, often is necessary\\nbecause the chronic nature of opioid addiction\\ncan mean continuous potential for relapse to', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='opioid abuse for some patients.\\nPatients in continuing care should have a social-\\nly productive lifestyle, no involvement with\\ndrugs or problem involvement with alcohol, and\\nimproved coping skills demonstrated over at\\nleast 1 year. Significant co-occurring disorders\\nshould be well under control. People in this\\nphase should continue to participate regularly\\nin mutual-help groups, but regular attendance\\nat an OTP should be unnecessary, except to\\nreturn to a more intensive level of treatment if', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='necessary for continuation of recovery.\\nThe panel recommends that appointments with\\nthe OTP continue to be scheduled every 1 to 3\\nmonths, although many programs prefer that\\npatients in continuing care maintain at least\\nmonthly contact. Although many programs \\ncurtail this contact after 6 to 12 months, others\\nmaintain ongoing contact with patients to assist\\nthem in maintaining their medication-free\\nlifestyle. Some patients might not need \\ncontinuing-care services after tapering, prefer-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='ring instead a complete break from the OTP .\\nOthers might need more extensive continuing\\ncare, perhaps including referral to a non-MAT\\noutpatient program that more closely fits their\\nneeds.\\nTransition Between\\nTreatment Phases in\\nMAT\\nCharacteristics of the recommended treatment\\nphases are not immutable, and the criteria for\\ntransition between phases are not intended to\\nbe rigidly interpreted or enforced. The treat-\\nment system should be flexible enough to allow', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='for transition according to a patientís progress\\nand circumstances. The program should modify\\ntreatment based on the best interests of patients,\\nrather than infractions of program rules.\\nOccasional relapses to drug use might not\\nrequire that a patient return to the acute phase\\nbut instead that he or she receive intensified\\ncounseling, lose take-home privileges, or\\nreceive a dosage adjustment. If a patient is in\\nthe medical maintenance phase or the tapering', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='and readjustment phase, a relapse often\\nrequires a rapid response and change of phase.\\nIn these cases, the patient might be reclassified\\ninto the rehabilitative phase. After providing\\nevidence that problems are under control, the\\npatient might be able to return to the \\nsupportive-care or medical maintenance phase.\\n119Phases of Treatment', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 139}),\n",
       " Document(page_content='120\\nReadmission to the\\nOTP\\nThe consensus panel emphasizes that patients\\nalmost always should be encouraged to remain\\nin treatment at some level and that pharma-\\ncotherapy should be reinstituted unreservedly\\nfor most previously discharged patients if and\\nwhen relapse occurs or seems likely. Feelings of\\nshame, disappointment, and relapse-related\\nguilt, especially for rehabilitated patients who\\nhave close relationships with staff members,\\nshould not be allowed to inhibit patients from', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 140}),\n",
       " Document(page_content='seeking reentry to treatment. The consensus\\npanel recommends that all patients be informed\\nat entry to the OTP that subsequent reentry is\\ncommon and can be accomplished more quick-\\nly than initial intake because regulations waive\\ndocumentation of past addiction for returning\\npatients (42 CFR, Part 8 ß 12(e)(3)). All obsta-\\ncles to reentry should be minimized.\\nChapter 7', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 140}),\n",
       " Document(page_content='121\\n8 Approaches to\\nProviding \\nComprehensive Care\\nand Maximizing\\nPatient Retention\\nIn This\\nChapterÖ\\nCore Services\\nRetaining Patients\\nin MAT\\nCounseling and\\nCase Management,\\nBehavioral\\nTreatments, and\\nPsychotherapy\\nBenefits of Family\\nInvolvement\\nIntegrative\\nApproaches\\nRelapse Prevention\\nReferral to Social\\nServices\\nInvoluntary\\nDischarge From\\nMAT\\nPatient Advocacy\\nA core group of basic- and extended-care services is essential to the effec-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 141}),\n",
       " Document(page_content='tiveness of medication-assisted treatment for opioid addiction (MAT) in\\nopioid treatment programs (OTPs). Numerous studies support the belief\\nthat psychosocial interventions contribute to treatment retention and\\ncompliance by addressing the social and behavioral problems and co-\\noccurring disorders affecting patients in MAT (e.g., Brooner and Kidorf\\n2002; Joe et al. 2001). The consensus panel agrees that a well-planned\\nand well-supported comprehensive treatment program increases patient', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 141}),\n",
       " Document(page_content='retention in MAT and the likelihood of positive treatment outcomes.\\nCore Services\\nBasic-Care Services\\nThe minimum required services for MAT are outlined in Federal regula-\\ntions (42 Code of Federal Regulations [CFR], Part 8), but individual\\nprogram requirements vary according to State standards, accreditation\\nrequirements, and local factors. The consensus panel recommends that\\nOTPs offer at least the following services:\\nï Comprehensive psychosocial assessment (see chapter 4)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 141}),\n",
       " Document(page_content='ï Initial and yearly medical assessment (physical examination and labo-\\nratory testing [see chapter 10])\\nï Medication dispensing (see chapter 5)\\nï Drug tests (see chapter 9)\\nï Identification of co-occurring disorders and neuropsychological prob-\\nlems (see chapter 12)\\nï Counseling to stop substance abuse and manage drug craving and urges\\nï Evaluation of and interventions to address family problems\\nï HIV and hepatitis C virus (HCV) testing, education, counseling, and\\nreferral for care', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 141}),\n",
       " Document(page_content='referral for care\\nï Referral for additional services as needed.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 141}),\n",
       " Document(page_content='122\\nExtended-Care Services\\nMany patients in MAT have other problems\\naffecting their recovery, including medical,\\nsocial, family, vocational, and legal problems\\nand co-occurring disorders. Assessing and\\naddressing these problems are important to\\nfacilitate recovery from addiction. Various\\nstrategies have been developed, including psy-\\nchosocial and biomedical interventions and\\npeer-support approaches.\\nManaging an OTP To Meet\\nService Needs\\nSubstances of abuse', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='Substances of abuse\\nIncreasingly since the 1980s, patients have\\nentered OTPs with other addictions, particu-\\nlarly to alcohol, cocaine, marijuana, nicotine,\\nor other sedatives and stimulants. In addition,\\nadolescent and young adult patients often\\nsmoke or snort rather than inject heroin, and\\nmore patients are addicted to opioid analgesics,\\nsuch as oxycodone, taken orally (see chapter\\n11). To manage these developments, OTPs\\nshould evaluate and modify their core sub-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='stance abuse treatment services continuously,\\nbased on the changing needs of their patient\\npopulations.\\nMedical needs\\nPeople addicted to opioids are at greater risk\\nfor sexually transmitted diseases (STDs), pneu-\\nmonia, and other debilitating conditions that\\nrequire intensive medical services. Infected\\ninjection sites, cellulitis, and abscesses are\\nincreasingly common. Bacterial endocarditis\\nremains a concern. Long-term tobacco use con-\\ntributes to other diseases. Chapter 10 details', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='the medical problems of todayís patients in\\nMAT and the treatment approaches recom-\\nmended in OTPs.\\nStaffing needs\\nProgram administrators need to develop \\ncomprehensive patient population profiles for\\nplanning, staffing, and resource allocation.\\nManagers should provide an appropriate mix of\\nstaff for specific patient characteristics and\\nneeds and should determine the range of ser-\\nvices that can be provided with available funds.\\nUnfunded services should be covered by refer-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='ral to affiliated agencies. Positive, sustained\\noutcomes are more attainable in a therapeutic\\nenvironment with readily available, supportive,\\nqualified caregivers. It is difficult to provide\\nhigh-quality care and facilitate favorable treat-\\nment outcomes in a chaotic OTP environment\\nwith unqualified or overburdened staff and\\nmanagers and unreasonable caseloads.\\nOffsite treatment options\\nThe consensus panel urges OTPs to provide as\\nmany basic- and extended-care services as pos-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='sible on site. OTPs that lack the resources to\\nprovide or sponsor the comprehensive list of\\nservices recommended in this TIP should\\nengage in active case management while work-\\ning with other agencies and specialized service\\nproviders and educating these collaborators\\nabout MAT. Accreditation requirements\\nincreasingly are motivating OTPs to pursue\\nthese collaborations.\\nRetaining Patients \\nin MAT\\nImportance of Retention\\nStudies of patients who left MAT prematurely', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='have determined that length of retention was\\nthe most important indicator of treatment out-\\ncomes (e.g., Simpson, D.D., et al. 1997b).\\nPatients who stayed in treatment a year or\\nlonger abused substances less and were more\\nlikely to engage in constructive activities and\\navoid criminal involvement than those who left\\ntreatment earlier, although all patients benefit-\\ned from treatment, for instance, through less\\nexposure to and transmission of infectious dis-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='eases (Hartel and Schoenbaum 1998). Their\\ncommunities benefited as well.\\nChapter 8', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 142}),\n",
       " Document(page_content='Improving Patient Retention\\nFactors affecting patient\\nretention\\nPatient characteristics, behavior, and other\\nfactors unrelated to treatment have been found\\nto contribute relatively little to retention in\\nMAT. One comprehensive study found that\\nretention was determined almost entirely by\\nwhat happened during treatment, not before,\\nalthough two factors, older age and less\\ninvolvement with the criminal justice system,\\npredicted longer retention (Magura et al. 1998,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='1999). Another factor found to affect retention\\nwas motivation or readiness for treatment (Joe\\net al. 1998).\\nIn other studies, how patients entered OTPs,\\nwhether voluntarily or by a court referral, did\\nnot affect treatment retention (Brooner et al.\\n1998; Fallon 2001). Rhoades and colleagues\\n(1998) reported that patients who previously\\nreceived methadone were more likely to remain\\nin MAT than first-time patients. Some patients\\nrequire several attempts at treatment before', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='becoming stabilized for extended periods\\n(Koester et al. 1999). OTPs should not consider\\npatientsí prior failures indicative of future\\ncompliance or retention or use these failures as\\nreasons to reject those seeking readmission.\\nSome patients may need longer periods of\\nadjustment to MAT before making a long-term\\ncommitment.\\nRecommended steps to\\nimprove patient retention\\nIndividualize medication dosages. Adequate,\\nindividualized medication dosages are probably', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='the most important factor in patient retention\\n(Joseph et al. 2000) because they contribute to\\npatient comfort and satisfaction by reducing\\nwithdrawal symptoms and craving and enabling\\nmore attention to other concerns (reviewed in\\nLeavitt et al. 2000; Strain et al. 1999). (See\\nchapter 5 for further discussion of prescribing\\npractices in MAT.)\\nClarify program goals and treatment plans.\\nTreatment providers should explain program\\ngoals and treatment plans to every patient.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='Inconsistent messages adversely affect patient\\nretention, particular-\\nly when these mes-\\nsages are about the\\nadvisability of\\nremaining in MAT\\nversus tapering from\\nmedication (Magura\\nand Rosenblum\\n2001). Goals related\\nto medication should\\nbe individualized and\\nrespectful of patientís\\nwishes and goals, but\\nthey should incorpo-\\nrate knowledge and\\nresearch about reten-\\ntion in MAT.\\nTreatment planners\\nshould realize that,\\nregardless of OTP recommendations, some', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='patients want to taper from maintenance medi-\\ncation more quickly than seems advisable. Staff\\nshould work with these patients to achieve their\\ngoals in a reasonable timeframe.\\nOTP practices and communication with\\npatients should conform to best treatment prac-\\ntices. Setting maximum lengths of stay for all\\npatients or emphasizing low-dose medication\\ngoals can discourage retention and produce\\npoor outcomes (Magura and Rosenblum 2001).\\nRigid operating practices (e.g., requiring', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='extensive travel, inconvenient hours, long\\nwaits, frequent pickups) may lower retention\\nand disrupt treatment. Patients have cited\\nother factors that discourage retention, such as\\nstaff insensitivity, lack of treatment skills and\\nknowledge, and limited contact.\\nSimplify the entry process. Shortening \\nintake results in better program retention (see\\nchapter 4). \\nAttend to patients’ financial needs.Patientsí\\ninability to pay may limit both treatment entry', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='and retention, especially in States where MAT\\n123Providing Comprehensive Care and Maximizing Patient Retention\\n[R]etention was\\ndetermined almost\\nentirely by what\\nhappened during\\ntreatment, not\\nbefore...', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 143}),\n",
       " Document(page_content='124 Chapter 8\\nis not covered by Medicaid, State funds, or pri-\\nvate insurance. One study found that randomly\\noffering prospective patients either cost-free\\ntreatment or moderate fee rates significantly\\nincreased treatment entry and retention for the\\ncost-free patients (Kwiatkowski et al. 2000).\\nOTP staff members should work proactively\\nwith patients to apply for benefits covering\\ntreatment costs, investigate health insurance\\nand work with existing insurers, and develop\\nhardship payment plans.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='Reduce the atten-\\ndance burden.\\nAttendance require-\\nments can exert pow-\\nerful effects on\\nretention. Rhoades\\nand colleagues\\n(1998) found that\\npatients who were\\nrequired to visit an\\nOTP less frequently\\nwere less likely to\\ndrop out of treat-\\nment and no more\\nlikely to use other\\ndrugs than patients\\non a daily atten-\\ndance schedule.\\nProvide useful treatment services as early as\\npossible.Patients were more likely to stay in\\ntreatment when they were motivated strongly', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='and engaged earlier in useful activities\\n(Simpson, D.D., et al. 1997b). In the critical\\nfirst 90 days of treatment, higher service inten-\\nsities, especially for practical services that\\nhelped patients achieve basic goals, have been\\nassociated with higher retention. Examples\\ninclude attentive case management, psychiatric\\nservices, introduction to peer groups, and\\nassistance with insurance, transportation, and\\nhousing (Grella and Wugalter 1997).\\nEnhance staff–patient interactions. Good staff', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='attitudes and interactions with patients have\\nbeen associated with higher retention. In one\\nstudy, patientsí frequent contact with staff\\nmembers and the involvement and visibility of\\nOTP administrators increased patient retention\\n(Magura et al. 1999). Some treatment providers\\nhave found that patients are more likely to\\nremain in treatment when they are involved in\\nits planning and management. Increased inter-\\naction with staff increases communication and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='information flow, limits problems, and con-\\ntributes to patientsí sense of well-being.\\nUnfortunately, funding constraints often\\nreduce communication training for staff and\\nopportunities to improve patient-to-staff ratios.\\nImprove staff knowledge and attitudes about\\nMAT.OTP staff members should understand\\nMAT and appreciate the wealth of science sup-\\nporting it, and they should be aware of recom-\\nmended treatment practices so that they can\\ninteract effectively and constructively with', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='patients. However, Bell (2000) pointed to stud-\\nies showing that staff training, favorable\\npatient-to-staff ratios, and better facilities did\\nnot eliminate opioid abuse, and he concluded\\nthat staff attitudes contributed more directly to\\noutcomes. Staff members should express confi-\\ndence in MAT when communicating with\\npatients. Attitudes critical of extended pharma-\\ncotherapy have been found to be common (even\\ndominant) among many counselors (Kang et al.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='1997) and evoke frequent patient complaints.\\nCounseling and Case\\nManagement,\\nBehavioral Treatments,\\nand Psychotherapy\\nCounseling and Case\\nManagement\\nPatient counseling in individual, family, or\\ngroup sessions offers a venue for many treat-\\nment approaches and educational interven-\\ntions. It provides support for a substance-free\\nlifestyle and abstinence from substances of\\nabuse. Studies have found that OTPs providing\\nregular, structured, substance abuse-focused', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='counseling had better outcomes than OTPs\\nproviding little or no counseling (Kidorf et al.\\nStaff members\\nshould express\\nconfidence in \\nMAT when com-\\nmunicating with\\npatients.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 144}),\n",
       " Document(page_content='1999; Magura et al. 1999). Others have \\nconcluded that good counseling rapport was\\nrelated to improved abstinence and reductions\\nin criminality (e.g., Joe et al. 2001).\\nThe consensus panel recommends that counsel-\\ning in MAT focus on\\nï Providing support and guidance, especially to\\neliminate substance use\\nï Monitoring other problematic behaviors\\nï Helping patients comply with OTP rules\\nï Identifying problems that need extended ser-\\nvices and referring patients for these services', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='ï Identifying and removing barriers to full\\ntreatment participation and retention\\nï Providing motivational enhancement for \\npositive changes in lifestyle.\\nThe standard components of substance abuse\\ncounseling should include\\nï Assistance in locating and joining mutual-help\\ngroups or peer support groups such as\\nNarcotics Anonymous (NA) or Methadone\\nAnonymous (MA)\\nï Education about addiction and the effects of\\nsubstances of abuse\\nï Education about relapse prevention strategies', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='ï Identification of unexpected problems need-\\ning attention, such as sudden homelessness\\nï Assistance in complying with program rules\\nand regulations\\nï Information about stress- and time-\\nmanagement techniques\\nï Assistance in developing a healthy lifestyle\\ninvolving exercise, good nutrition, smoking\\ncessation, and avoidance of risky sexual\\npractices\\nï Assistance in joining socially constructive\\ngroups such as community organizations and\\nfaith-based groups', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='faith-based groups\\nï Continuing education on health issues (partic-\\nularly HIV/AIDS and hepatitis). \\nCounseling sessions to relieve patientsí anxiety\\nabout MAT and reassure them about its effica-\\ncy are of paramount importance during the\\nfirst weeks of treatment. Usually, individual\\nsessions during the acute phase (see chapter 7)\\nare more intensive than those that follow,\\nalthough individual needs should dictate the\\nfrequency and duration of counseling.\\nIndividual counseling', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='As MAT progresses, patients should continue\\nmeeting with counselors in individual sessions,\\nonce per month to several times per week\\ndepending on need, the phase of treatment,\\nand State regulations. In some States, Medicaid\\nregulations and contracts require or limit coun-\\nseling frequency. MAT counselors should con-\\ntinue to identify patientsí needs and refer them\\nto or arrange for other services (e.g., housing,\\nmedical and psychiatric care, legal services).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='A typical individual counseling session, as envi-\\nsioned by the consensus panel, might include\\nany of the following activities:\\nï Reviewing how a patient feels, is coping with\\ncravings, or is changing his or her lifestyle\\nï Reviewing drug test results and what they\\nmean\\nï Identifying emergencies and deciding how to\\naddress them\\nï Reviewing the treatment plan\\nï Identifying measurable goals and reasonable\\ntimeframes\\nï Reviewing progress in achieving goals, includ-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='ing abstinence and related behaviors\\nï Discussing dosage and take-home medications\\nï Discussing legal concerns, such as reporting\\nto probation officers and complying with the\\nterms of probation or parole\\nï Discussing family concerns\\nï Providing liaison services (e.g., with physi-\\ncians, courts, social service agencies)\\nï Addressing routine issues (e.g., transporta-\\ntion, childcare).\\nMedical staff should educate counselors about\\npatientsí medical problems so that counselors', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='can help patients understand the importance of\\nkeeping appointments for and complying with\\n125Providing Comprehensive Care and Maximizing Patient Retention', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 145}),\n",
       " Document(page_content='126\\nmedical treatment. Counselors should convey\\nobservations to medical staff about patientsí\\nconditions and information about other aspects\\nof patientsí lives that might clarify health prob-\\nlems. Although counselors are not expected to\\nunderstand medical treatments, pathophysiolo-\\ngy, or pharmacotherapy in the same way as\\nmedical professionals do, they should have gen-\\neral knowledge of common medical conditions\\naffecting patients in MAT and their treat-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='mentsóespecially how treatments for these\\nconditions can interact with addiction treat-\\nment medications. Counselors can help patients\\ncope with hepatitis C and adhere to its treat-\\nment regimens. Many patients have been\\nexposed to HCV infection (see chapter 10), and\\neffective treatment requires motivation and\\nsupport from the entire treatment team.\\nGroup counseling\\nGroup counseling has some advantages over\\nindividual counseling and therapy (see TIP 41,\\nSubstance Abuse Treatment: Group Therapy', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='[CSAT 2005c]). It can reduce patientsí sense of\\nisolation and help them cope with addiction\\nand other life problems by providing feedback\\nfrom peers, social skill training and practice,\\nstructure, discipline, and encouragement.\\nThrough peer interaction, patients contribute\\nto one anotherís recovery. Trained individuals\\nshould lead these groups. Some State agencies\\noffer courses in group process and dynamics.\\nThe following types of groups are used com-\\nmonly in MAT:\\nï Psychoeducational groups', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='ï Skill development groups, such as relapse\\nprevention, stress management, and sub-\\nstance use cessation groups, which help\\npatients learn skills to attain and maintain\\nabstinence\\nï Cognitive behavioral groups, in which\\npatients learn to alter pervasive thoughts and\\nactions\\nï Interpersonal-process groups, which delve\\ninto developmental issues contributing to\\naddiction or interfering with recovery\\nï Support groups, which buoy members and\\nprovide a forum to share pragmatic informa-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='tion about maintaining abstinence and man-\\naging a day-to-day substance-free lifestyle.\\nIn some OTPs, group membership is linked to\\nthe phase of a patientís treatment. Some groups\\nkeep the same membership but stay together\\nfor a short time; others are longer term and\\nhave a rolling membershipóthat is, frequent\\nmembership changes, with new members \\nentering when they are ready. Neither type of\\ngroup needs a predetermined end point or set\\ntimeframe. Using a manual with a structured', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='curriculum enables counselors and other staff\\nmembers to lead some groups (Exhibit 8-1).\\nManuals increase flexibility in resource-limited\\nOTPs and the likelihood that groups cover\\nstandard information. Manuals for group\\ncounseling in MAT are less common than for\\ngeneral substance abuse counseling. However,\\nthe consensus panel believes that the principles\\nused for non-MAT groups can be adapted \\neasily to groups in MAT.\\nSome patients resist group counseling and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='avoid sessions. Offering smaller groups might\\nease their concerns while therapists explore the\\nreasons for their resistance (e.g., fear of talking\\nin groups or confidentiality concerns). In gen-\\neral, an OTP should consider a groupís patient\\nmix. Some patients with co-occurring disorders\\ndo better in groups with members who have\\nsimilar conditions. However, some patients\\nwith severe co-occurring disorders cannot par-\\nticipate in groups, and some have problems\\nthat require individual counseling.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='A patientís gender or sexual orientation can be\\nimportant in choosing individual or group\\ncounseling. Some women are uncomfortable in\\nmale-dominated groups and do better in\\nwomen-only groups. Others feel embarrassed\\nabout personal subjects related to their addic-\\ntion. Gay men, lesbians, and bisexuals might\\nfeel isolated in predominantly heterosexual\\ngroups. In such cases, the consensus panel \\nrecommends individual, women-only, or \\nsexual-orientation-specific groups.\\nChapter 8', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 146}),\n",
       " Document(page_content='Social services case \\nmanagement \\nSome researchers have investigated the useful-\\nness of social service-focused case management\\nin addiction treatment settings such as OTPs.\\nMcLellan and coworkers (1999) described a\\nsystem with an active case management compo-\\nnent to help patients access services for hous-\\ning, medical care, and legal and parenting\\nassistance. Six months after the systemís imple-\\nmentation, patients receiving these services\\nshowed greater reduction in alcohol use and', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 147}),\n",
       " Document(page_content='improvement in medical conditions, family\\nrelations, and legal status than patients receiving\\nnone of these services. The authors concluded\\nthat social service-focused case management \\nwas an important and effective adjunct to \\naddiction treatment.\\nCognitive and Behavioral\\nTherapies\\nOther interventions, both in use and under\\nstudy, include cognitive-enhanced techniques to\\nincrease treatment participation, modify\\nbehavior, and address patientsí social, emo-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 147}),\n",
       " Document(page_content='tional, and behavioral problems, as well as any\\nco-occurring disorders. Behavioral treatments\\nsuch as contingency management (see below),\\n127Providing Comprehensive Care and Maximizing Patient Retention\\nExhibit 8-1\\nResource Materials for Psychoeducational, Skill-Building, and\\nGroup Counseling Sessions\\nï Anger Management for Substance Abuse and Mental Health Clients: A Cognitive\\nBehavioral Therapy Manual (Reilly and Shopshire 2002)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 147}),\n",
       " Document(page_content='ï Anger Management for Substance Abuse and Mental Health Clients: Participant\\nWorkbook(Reilly et al. 2002)\\nï Cognitive-Behavioral Coping Skills Therapy Manual(Kadden et al. 1992)\\nï Cognitive Therapy of Substance Abuse(Beck et al. 1993)\\nï A Family Like Yours: Breaking the Patterns of Drug Abuse (Sorensen and\\nBernal 1986)\\nï National Institute on Drug Abuseís Therapy Manuals for Drug Addiction Series\\n(www.drugabuse.gov)\\nï Recovery Training and Self-Help: Relapse Prevention and Aftercare for Drug', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 147}),\n",
       " Document(page_content='Addicts (National Institute on Drug Abuse 1993b)\\nï Relapse Prevention Workbook for Recovering Alcoholics and Drug-Dependent\\nPersons (Daley 2002)\\nï Seeking Safety: A Treatment Manual for PTSD and Substance Abuse(Najavits\\n2002)\\nï ìSupportive-expressive dynamic psychotherapy of opiate drug dependenceî\\n(Luborsky et al. 1995)\\nï Treatment of Opioid Addiction With Methadone: A Counselorís Manual\\n(McCann et al. 1994)', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 147}),\n",
       " Document(page_content='in which patients enter into agreements that\\nprovide positive incentives for treatment \\ncompliance, have been especially effective in\\nMAT (see Brooner and Kidorf 2002; Robles et\\nal. 1999). \\nBehavioral treatments in MAT are derived\\nfrom principles of cognitive learning and\\nbehavioral change developed by psychologists\\nand behavior scientists. The consensus panel\\nbelieves that substance abuse and addiction\\ninvolve major learning elements and are influ-\\nenced by patientsí environments and circum-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='stances. Many elements of cognitive behavioral\\ntherapy (CBT)ófor example, emphases on\\nidentifying high-risk circumstances that may\\ntrigger an event and developing coping re-\\nsponsesóare accepted and incorporated widely\\ninto substance abuse education and counseling\\n(Ryan 2002). CBT is associated with increased\\ntreatment compliance and improved treatment\\noutcomes.\\nNode-link mapping\\nNode-link mapping is a cognitive-enhanced\\ntechnique that uses flowcharts and other visual', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='aids to diagram relationships between patientsí\\nthoughts, actions, and feelings and their sub-\\nstance use and to increase patient participation\\nin counseling (Czuchry and Dansereau 2003).\\nStudies have found that node-link mapping\\nencouraged communication about topics such\\nas family, job, and substance use (Dees et al.\\n1997; Pitre et al. 1997) and improved partici-\\npantsí motivation, self-esteem, and rapport\\nwith counselors. Patients with poor attention', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='stamina were found to have greater success in\\nmapping-enhanced counseling than in standard\\ncounseling (Czuchry and Dansereau 2003).\\nLess educated patients exposed to mapping-\\nenhanced counseling also had better 12-month\\nfollowups than those in standard counseling\\n(Pitre et al. 1996). According to Dansereau and\\ncolleagues, ìThe use of node-link mapping\\nappears to reduce cultural, racial, and class\\nbarriers by providing a visual supplement and\\na common language that enhances counselorñ', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='client interchangesî (Dansereau et al. 1996, \\np. 363).\\nCommunity reinforcement\\napproach\\nThe community reinforcement approach\\n(CRA), originally developed to treat alco-\\nholism, is another effective model for MAT.\\nThis multicomponent treatment facilitates\\nchange in a patientís daily environment. CRA\\ncounselors work with patients to identify\\naspects of their lives that reinforce abstinence\\nand to understand how these reinforcers can\\nserve as alternatives to substance use. CRA has', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='been found to reduce opioid use and produce\\nother positive outcomes either with or without\\nvoucher-based incentives (Abbott et al. 2003;\\nHiggins and Abbott 2001).\\nContingency management\\nContingency management reinforces desired\\nbehavior with immediate incentives (Griffith et\\nal. 2000). Its efficacy has been demonstrated in\\nseveral well-designed studies (e.g., Rawson et\\nal. 2002; Robles et al. 1999). Incentives were\\nfound to increase such desirable outcomes in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='MAT as negative drug tests, attendance at\\ncounseling and medical appointments, working,\\nand volunteering. This approach is useful for\\ntreatment planning because it sets concrete\\ngoals and emphasizes positive behavioral\\nchanges. Exhibit 8-2 summarizes this strategy\\nin MAT.\\nThe consensus panel emphasizes that effective\\ncontingencies usually involve positive reinforce-\\nment. Positive contingencies or rewards are\\nmore effective than negative, punishing contin-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='gencies or threats (Gruber et al. 2000).\\nNegative consequences tend to drive patients\\nfrom treatment. In one study, a balance of posi-\\ntive and negative reinforcements, as part of a\\nwell-constructed contingency management\\nplan, helped patients reduce their drug use\\n(Crowley 1999). Tangible rewards, such as\\ntake-home medication privileges, should be\\npaired with social reinforcements, such as\\npraise from the counselor or other patients, to\\noptimize their value.\\n128 Chapter 8', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 148}),\n",
       " Document(page_content='A popular, effective reward in OTPs is the\\nmedication take-home privilege (Chutuape et\\nal. 1998). Other incentives may include special\\nscheduling for medication administration, meal\\nvouchers, gift certificates, entertainment tick-\\nets, or toys for patientsí children. Designing\\nsuch programs requires significant effort, yet\\nthe rewards can add an important dimension to\\nMAT. Kidorf and colleagues (1997, 1998, 1999)\\ndemonstrated the effectiveness of behavior-', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='contingent incentives in OTPs. They used \\ntake-home medication privileges to increase \\nthe involvement of significant others and\\nimprove patientsí job acquisition. They also\\nused behavior-contingent treatment availability\\nto improve drug test results and counseling\\nattendance.\\nTo be most effective, behavior contingencies\\nshould be defined clearly and implemented con-\\nsistently. Contingencies may be individualized\\nbased on each patientís targeted areas of', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='behavioral change or implemented on a uni-\\nform, programwide basis. Tailoring behavioral\\ncontingencies to patientsí needs has been found\\nto work better (Silverman et al. 1999). Piane\\n(2000) effectively combined contingency incen-\\ntives with systematic desensitization for patients\\nwhose anxiety blocked the benefits of contingen-\\ncy incentives alone. When combined with pro-\\ngressive muscle relaxation and desensitization,\\ncontingency management had a demonstrated', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='record of effectiveness, whereas systematic\\ndesensitization alone was less effective in \\neliminating opioid use but reduced fear of with-\\ndrawal and general anxiety (Piane 2000).\\nBrooner and Kidorf (2002) described a pro-\\ngram of motivational stepped-care levels in\\nwhich clear contingencies were matched with\\ntreatment responses. Patients who responded\\npoorly were moved to a more intensive level of\\ncare. Those who responded well received less\\nintensive care. The authors concluded that this', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='approach increased treatment participation\\nand that a stepped-care system was effective\\nand cost sensitive. In another study comparing\\ncontingency vouchers (which had monetary\\nvalue and were exchangeable for goods and ser-\\nvices) with methadone dosage increases, both\\nincentives increased negative drug test results,\\nbut only contingency vouchers increased dura-\\ntions of drug abstinence (Preston et al. 2000).\\nDosage increases should be based on evidence\\nof withdrawal symptoms and other medical', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='assessments, not good behavior.\\n129Providing Comprehensive Care and Maximizing Patient Retention\\nExhibit 8-2\\nStrategy for Contingency Management in MAT\\nï Pick a target behavior that can be measured easily (e.g., stopping opioid abuse).\\nï Select a reward that can be given as soon as the desired behavior (e.g., three con-\\nsecutive negative drug test results) is documented. The reward should be non-\\nmonetary (e.g., nonrefundable movie passes, take-home medication privileges).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='ï Specify the link between targeted behavior and the reward. For example, a nega-\\ntive drug test result might earn one take-home medication dose (other treatment\\nand program variables must be taken into account, including Federal and State\\nregulations).\\nï Put the contract in writing, specifying its duration and any changes over time in\\ncontingencies (e.g., after 3 substance-free weeks, the patient can receive take-\\nhome privileges).', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 149}),\n",
       " Document(page_content='The consensus panel emphasizes that, when\\ncontingency management is used to control use\\nof short-acting drugs, objective measures\\nshould provide the basis for withholding incen-\\ntives. Testing frequency (both randomly and,\\nwhen feasible, regularly at least once per week)\\nmust be adequate to detect short-acting drugs.\\n(See chapter 9 for a complete discussion of \\ndrug testing.)\\nMotivational enhancement\\nMotivational enhancement has emerged as a\\ncomponent of counseling in MAT, although the', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='effectiveness of motivational interviewing in\\nMAT needs more investigation. One study\\n(Saunders et al. 1995) found that brief motiva-\\ntional intervention improved outcomes in MAT.\\nPatients in this study demonstrated greater\\ncommitment to abstinence, reported more \\npositive outcomes and fewer opioid-related\\nproblems, and relapsed less quickly or fre-\\nquently than did the control group.\\nMotivational enhancement interventions influ-\\nence patients to give up secondary substances', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='of abuse, address health issues, and change\\ntheir social circumstances. TIP 35, Enhancing\\nMotivation for Change in Substance Abuse\\nTreatment (CSAT 1999a), provides a thorough\\ndiscussion of motivational therapy. Another\\nvaluable guide is Motivational Interviewing:\\nPreparing People for Change(Miller and\\nRollnick 2002).\\nPsychotherapy\\nPsychotherapy is a form of verbal-expressive\\ntherapy in which a trained therapist uses \\npsychological principles to modify or remove', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='problematic thoughts, feelings, and behaviors\\n(Kidorf et al. 1999). Whereas counseling focuses\\non the here-and-now, decisionmaking, values,\\nself-concept, strengths, and goal setting, psy-\\nchotherapy focuses on changes in personality,\\nand psychoanalytic psychotherapy attends to\\nthe subconscious. Both counseling and psy-\\nchotherapy can be short term and solution\\ndirected, but psychotherapy more often is used\\nto resolve chronic psychological and social\\nproblems.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='problems. \\nResearch has shown that psychotherapeutic\\ninterventions enhance the efficacy of MAT ó\\nparticularly for patients with co-occurring dis-\\norders who show little response to counseling\\nalone (OíBrien et al. 1995; Woody et al. 1995b).\\nPatients in MAT who have benefited from psy-\\nchotherapy include those whose anxiety or\\ndepression required more than routine, \\nbehavior-oriented counseling. Several authors\\nhave described effective psychotherapeutic\\napproaches for these patients (reviewed by', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='Woody [2003]).\\nBecause many patients are unstable during the\\nacute phase of MAT, providers usually delay\\npsychotherapy until later in the acute phase or\\nin the rehabilitative phase, but views differ on\\nwhen psychotherapy is appropriate. The con-\\nsensus panel believes that psychotherapy has\\nan important role in MAT but that it usually\\nshould be deferred until patients are stabilized.\\nExhibit 8-3 summarizes consensus panel recom-\\nmendations for psychotherapy in MAT.\\nStaff qualifications', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='Staff members responsible for psychotherapy\\nshould have more specialized training than\\nthose responsible for drug-focused counseling.\\nPsychotherapists should possess advanced\\ndegrees and undergo supervised training. If\\nOTPs lack staff or resources for psychotherapy,\\npatients should be referred elsewhere. OTPs\\nshould verify and document the degrees and\\nlicensure of those providing psychotherapeutic\\nservices.\\nGroup psychotherapy\\nGroup psychotherapy and group counseling', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='with an interpersonal, process, or psychody-\\nnamic focus can be effective interventions in\\nMAT. These groups should be flexibly struc-\\ntured and focus on interpersonal-relationship\\nbuilding, self-insight, reflection, and discussion\\n(Vannicelli 1992). Patients should be selected\\ncarefully for these groups and should be able to\\n130 Chapter 8', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 150}),\n",
       " Document(page_content='commit to the process. Group treatment can\\nprovide a sense that individuals are not alone\\nin addressing problems, even serious ones.\\nSuch normalization is often a first step toward\\nfeeling less isolated and developing new coping\\nstrategies. (For a thorough presentation of\\ngroup therapy in substance abuse treatment,\\nsee TIP 41, Substance Abuse Treatment:\\nGroup Therapy[CSAT 2005c].)\\nOther Topics\\nEffects of sexual abuse \\nThe consensus panel recommends specialized', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 151}),\n",
       " Document(page_content='training for counselors and therapists treating\\npatients who have been sexually abused or\\nreferral of these patients to qualified mental\\nhealth care providers. TIP 36, Substance\\nAbuse Treatment for Persons With Child Abuse\\nand Neglect Issues (CSAT 2000d), includes\\ninformation about the effects, symptoms, and\\ntreatment of sexual abuse for patients during\\nsubstance abuse treatment.\\nCounseling for HIV/AIDS and\\nhepatitis C\\nCounseling about the increased risks of HIV', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 151}),\n",
       " Document(page_content='and HCV infection arising from drug injection\\nand risky sexual behavior is essential for\\npatients in MAT. TIP 37, Substance Abuse\\nTreatment for Persons With HIV/AIDS(CSAT\\n2000e), thoroughly examines HIV education,\\nwhich is mandatory for MAT in some States.\\nMany States require that patients receive spe-\\ncialized HIV counseling before and after they\\nreceive HIV antibody tests and require that\\npatients be encouraged to ask questions about\\nHIV . Pretest HIV counseling should be factual', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 151}),\n",
       " Document(page_content='and medically based. For patients who test neg-\\native for HIV , posttest counseling should\\naddress how they can reduce infection risk.\\nPatients with positive HIV test results need\\n131Providing Comprehensive Care and Maximizing Patient Retention\\nExhibit 8-3\\nCommon Strategies for Psychotherapy in MAT\\nï Devote part of each session to addressing patientsí most recent successes and fail-\\nures regarding their substance use.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 151}),\n",
       " Document(page_content='ï Adopt a more active therapist role than typically required for co-occurring \\ndisorders.\\nï Strengthen patientsí resolve to stop substance use (help them visualize or recall\\nlife without drugs to replace memories of enjoyable drug use).\\nï Teach patients to recognize warning signs of relapse and develop coping skills.\\nï Support patientsí rearranging priorities so that they are not preoccupied with\\nsubstance use. This might involve their acquiring job skills, developing hobbies,', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 151}),\n",
       " Document(page_content='or rebuilding relationships.\\nï Assist patients in managing painful affects. (From a psychodynamic approach,\\nthis involves exploring the causes of such feelings.)\\nï Help patients enhance interpersonal functioning and social supports so that the\\nrewards of friendship and relationships replace those of substance use.\\nï Use psychotherapy only after a strong therapeutic alliance has developed with\\nthe patient or other supportive structures are in place to guard against relapse.', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 151}),\n",
       " Document(page_content='referrals for medical care and counseling about\\nwhat the tests mean, coping with problems and\\nissues raised by the results, treatment options,\\nparticipation in clinical trials if available, \\nsupport groups, and behaviors to prevent\\ninfecting others or contracting another HIV\\nstrain. Rapid HIV tests have been approved by\\nthe Food and Drug Administration and are rec-\\nommended by the U.S. Public Health Service\\nfor point-of-care diagnosis of HIV infection in', metadata={'source': 'data\\\\Medical_Book.pdf', 'page': 152}),\n",
       " ...]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text_chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7b5881bb",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "myenv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
